docetaxel anhydrous has been researched along with Local Neoplasm Recurrence in 636 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 18 (2.83) | 18.2507 |
| 2000's | 208 (32.70) | 29.6817 |
| 2010's | 323 (50.79) | 24.3611 |
| 2020's | 87 (13.68) | 2.80 |
| Authors | Studies |
|---|---|
| Bernstein, ML; Bomgaars, LR; Collier, AB; Dang, HM; DuBois, SG; Gorlick, RG; Hawkins, DS; Janeway, KA; Krailo, MD; Reed, DR | 1 |
| Grobet-Jeandin, E; Pinar, U; Rouprêt, M | 1 |
| Ahn, MJ; Chung, MK; Jeong, HS; Jung, HA; Kim, HR; Lee, SH; Lee, SJ; Park, S | 1 |
| Abdeddaim, C; Clatot, F; Even, C; Guiard, E; Johnson, A; Perréard, M; Rambeau, A; Vauléon, E | 1 |
| Aretin, MB; Czerny, C; Fuereder, T; Heller, G; Minichsdorfer, C; Mittlboeck, M; Müllauer, L; Oberndorfer, F; Putz, EM; Schwarz-Nemec, U; Wagner, C | 1 |
| Dietz, A; Fietkau, R; Frickhofen, N; Gauler, T; Goerling, U; Große-Thie, C; Grünwald, V; Guntinas-Lichius, O; Haxel, B; Keilholz, U; Klinghammer, K; Knipping, S; Knoedler, M; Lindeman, HW; Martus, P; Maschmeyer, G; Zipfel, M | 1 |
| Chen, Y; Katayose, T; Nagaoka, S; Sekine, N | 1 |
| Atz, J; Blau, W; Gleiber, W; Grohé, C; Haas, S; Hammerschmidt, S; Kaiser, R; Krüger, S; Müller-Huesmann, H; Schulze, M; Wehler, T | 1 |
| Belitsky, GA; Bokhyan, BY; Burov, DA; Fetisov, TI; Fomina, LY; Kirilin, EM; Kirsanov, KI; Kozlov, NA; Laletina, LA; Lesovaya, EA; Makhmudova, LF; Manikaylo, AE; Mekheda, LV; Moiseeva, NI; Scherbakov, AM; Vilkova, AS; Yakubovskaya, MG; Zinovieva, VY | 1 |
| Ahern, TP; Cronin-Fenton, D; Damkier, P; Ejlertsen, B; Feddersen, S; Hamilton-Dutoit, S; Hjorth, CF; Lash, TL; Rørth, M; Stage, TB; Sørensen, HT | 1 |
| Dewnani, K; diZerega, GS; Kates, M; Lamm, DL; Mansour, AM; Marin, A; Maulhardt, H; Shore, N; Verco, J; Verco, S; Wendt, A | 1 |
| Enokida, H; Harada, K; Hashine, K; Horikoshi, H; Ichikawa, T; Ito, A; Kamijima, T; Kamiyama, M; Matsuyama, H; Miyao, T; Mizokami, A; Nakajima, K; Nishimoto, K; Shiina, H; Sugiyama, Y; Takahashi, S; Yaegashi, H | 1 |
| Kumar, S; Pareek, T; Parmar, K; Sharma, AP | 1 |
| Lohynská, R; Pechačová, Z | 1 |
| Fujiwara, T; Hashimoto, M; Kunitomo, T; Maeda, N; Nishiwaki, N; Noma, K; Sakurama, K; Shirakawa, Y; Tanabe, S | 1 |
| Gellhaus, PT; McElree, IM; Mott, SL; Nepple, KG; O'Donnell, MA; Packiam, VT; Steinberg, RL | 1 |
| Goto, M; Kawakami, H; Kurokawa, Y; Sakai, D; Satoh, T; Shimokawa, T; Yamaguchi, T | 1 |
| Carlisle, J; Chen, Z; Dhodapkar, M; Leal, T; Liu, Y; Osta, BE; Owonikoko, T; Pakkala, S; Ramalingam, S; Steuer, C | 1 |
| Dong, MJ; Fu, JY; Li, J; Yue, XH; Zhang, CP | 1 |
| Gellhaus, PT; Martin, AC; McElree, IM; Mott, SL; Nepple, KG; O'Donnell, MA; Packiam, VT; Richards, J; Steinberg, RL | 1 |
| Bessho, A; Furuya, N; Goto, Y; Harada, T; Kawashima, Y; Misumi, T; Miura, S; Nakahara, Y; Nakamura, Y; Naoki, K; Okamoto, H; Seike, M; Shimokawa, T; Shiraishi, Y; Takiguchi, Y; Tanaka, H; Taniguchi, Y; Tokito, T; Uchiyama, A | 1 |
| Kavoussi, M; Nasrallah, AA; Williams, SB | 1 |
| Eckl, T; Grafe, A; Klare, P; Luedtke-Heckenkamp, K; Reichert, D; Schneeweiss, A; Thill, M; Wimberger, P; Zaiss, M; Ziegler-Löhr, K | 1 |
| Alone, M; Bhattacharjee, A; Dhumal, S; Kumar, S; Menon, N; Nawale, KP; Noronha, V; Patil, V; Prabhash, K; Waratkar, G | 1 |
| Chen, X; Fang, L; Guo, R; Liu, H; Pu, Y; Su, X; Yu, X; Zhang, H | 1 |
| Akita, H; Fujii, Y; Hara, H; Haraguchi, N; Hasegawa, S; Kanemura, T; Matsuda, C; Mikamori, M; Miyata, H; Mukai, Y; Nishimura, J; Omori, T; Shinno, N; Sugase, T; Sugimura, K; Takeoka, T; Wada, H; Yamamoto, M; Yasui, M | 1 |
| Fukuya, A; Kagemoto, K; Kawaguchi, T; Mitsui, Y; Miyamoto, H; Noda, K; Okamoto, K; Sato, Y; Takayama, T; Yamasaki, M | 1 |
| Chen, X; Dong, Q; Feng, J; Jiang, X; Li, Y; Liu, M; Nik Nabil, WN; Song, Z; Xi, Z; Xu, H; Zhou, H | 1 |
| Chevuru, PT; McElree, IM; Mott, SL; O'Donnell, MA; Packiam, VT; Steinberg, RL | 1 |
| Araki, M; Kawada, T; Pradere, B; Shariat, SF; Yanagisawa, T | 1 |
| Bernardo, MCC; Braojo, IMP; Caballero, BB; Carrasco, JM; Fernández, BM; Guerrero, OV; Gutiérrez, ZA; Medina, EAG; Miguel, KL; Montero, YC; Ortiz, MR; Prado, YID; Rodríguez, LEM; Rubio, MC; Torres, KP; Tul, LEA; Varela, IGS | 1 |
| Daiko, H; Honma, Y; Ishiyama, K; Kanematsu, K; Kato, K; Kubo, K; Kurita, D; Oguma, J; Utsunomiya, D; Yamamoto, S | 1 |
| Trapani, D | 1 |
| Balbach, ML; Bestvina, C; Camidge, DR; Hsu, R; Iams, WT; Kim, C; Leal, T; Marmarelis, ME; Mehta, K; Nieva, J; Patil, T; Phillips, S; Robinson, MA; Sacher, A; Sackstein, PE; Sethakorn, N; Velcheti, V; Wang, X | 1 |
| Chen, H; Huang, M; Jiang, R; Liu, W; Shi, Y; Wang, T; Yang, M; Zhang, S | 1 |
| Boere, I; Gennigens, C; Hanssen, R; Jalving, M; Ledermann, J; Mathijssen, RHJ; Ottevanger, P; Rijcken, CJF; van de Wouw, YJ; Vergote, I | 1 |
| Aaltomaa, S; Ahlgren, G; Andrén, O; Brasso, K; Castellanos, E; Damber, JE; de Wit, R; Holmberg, E; Jellvert, Å; Josefsson, A; Luukkaa, M; Meidahl Petersen, P; Seke, M; Verhagen, P; Widmark, A | 1 |
| Hosseinifard, H; Hua, Z; Ijaz, I; Imani, S; Kahloon, LE; Liu, S; Sefidan, MO; Shahzad, MN; Zhang, YQ | 1 |
| Aksoy, S; Arslan, C; Basaran, G; Bilici, A; Cakar, B; Cicin, I; Cubukcu, E; Demirci, U; Erdem, D; Gumus, M; Harputluoglu, H; Kaplan, MA; Karadag, I; Karadurmus, N; Oksuzoglu, B; Olmez, OF; Selcukbiricik, F; Sendur, MAN; Sezer, A; Sezgin Goksu, S; Shbair, ATM; Sumbul, AT | 1 |
| Akerley, WL; Burns, TF; Dragnev, KH; Gadgeel, SM; Gandara, DR; Gerstner, GJ; Gray, JE; Kelly, K; Laudi, N; Mack, PC; Miao, J; Moon, J; Redman, MW; Riess, JW; Taj, A | 1 |
| Akiyama, H; Endo, I; Kasahara, K; Kimura, J; Kondo, H; Kosaka, T; Kunisaki, C; Makino, H; Ono, H; Sato, K; Sato, S; Takahashi, M; Tamura, Y; Tanaka, Y; Tsuchiya, N | 1 |
| Baciuchka, M; Berdah, JF; Beuzeboc, P; Brihoum, M; Chinet-Charrot, P; Cojean-Zelek, I; Culine, S; Davin, JL; Delva, R; Deplanque, G; Drubay, D; Faivre, L; Ferrero, JM; Fizazi, K; Fléchon, A; Gravis, G; Grosse-Goupil, M; Houede, N; Krakowski, I; Labourey, JL; Lagrange, JL; Laguerre, B; Lavaud, P; Legouffe, E; Lesaunier, F; Linassier, C; Martin, AL; Mourey, L; Orlando, V; Oudard, S; Priou, F; Rolland, F; Teuff, GL; Theodore, C | 1 |
| Barwad, A; Bhatnagar, S; Bhoriwal, S; Dhamija, E; Kumar, A; Mridha, AR; Rastogi, S; Shamim, SA; Tansir, G | 1 |
| Aggarwal, C; Cantor, DJ | 1 |
| Carvalho, FLF; Clinton, TN; Feldman, A; Hirsch, M; Kibel, AS; Melnick, K; Mossanen, M; Mott, SL; Mouw, KW; O'Donnell, MA; Preston, MA; Rizzo, N; Salari, K; Steele, GS; Wszolek, M; Wu, CL; Yim, K; Zafar, A | 1 |
| Ahn, JS; Chae, BJ; Cho, WK; Im, YH; Kim, H; Kim, JY; Kim, N; Kim, SW; Kim, TG; Lee, JE; Lee, SK; Nam, SJ; Park, W; Park, YH; Ryu, JM; Yu, J | 1 |
| Ahn, MJ; Burtness, B; Cohen, EEW; Dinis, J; Ge, J; Harrington, KJ; Lerman, N; Licitra, L; Lin, J; Mach, N; Machiels, JP; Mehra, R; Soria, A; Soulières, D; Swaby, RF; Tourneau, CL | 1 |
| Atagi, S; Hirashima, T; Mitsudomi, T; Morita, S; Nakagawa, K; Okamoto, I; Saito, H; Satouchi, M; Seto, T; Shibata, K; Shimokawa, M; Toyooka, S; Tsurutani, J; Yamamoto, N; Yatabe, Y; Yoshioka, H | 1 |
| Abrams, J; Albain, KS; Badve, SS; Berenberg, JL; Brufsky, AM; Dees, EC; Desbiens, C; Ellis, MJ; Geyer, CE; Goetz, MP; Goggins, TF; Gomez, HL; Gray, RJ; Hayes, DF; Kaklamani, VG; Keane, MM; Lively, T; Mahalcioiu, C; Makower, DF; Mayer, IA; Olson, JA; Paik, S; Reddy, PS; Saphner, TJ; Sledge, GW; Sparano, JA; Toppmeyer, DL; Wagner, LI; Wood, WC | 1 |
| Bai, Z; Cai, Q; Cao, X; Liu, J; Ouyang, Y; Su, J; Wang, Y; Xu, Q | 1 |
| Gao, Y; Labhasetwar, V; Midura, RJ; Rahman, MT; Rozic, R; Sharifi, N; Vijayaraghavalu, S | 1 |
| Bajorin, D; Bellmunt, J; Enokida, H; Frenkl, T; Fujimoto, K; Fukasawa, S; Imai, K; Nishimura, K; Nishiyama, H; Perini, R; Sassa, N; Shimamoto, T; Takahashi, K; Tanaka, Y; Yamamoto, Y; Yokoyama, M | 1 |
| Hamasu, S; Ikeda, Y; Konishi, S; Kudo, R; Manaka, D; Nishitai, R; Ota, T | 1 |
| Chang, J; Chen, T; He, M; Hong, W; Li, F; Li, H; Li, J; Liu, L; Luo, D; Ran, L; Shan, L; Song, Y; Wang, B; Wang, H | 1 |
| Ackland, SP; Barbour, AP; Barnes, EH; Burge, M; Falk, GL; Finch, R; Gebski, V; Karapetis, CS; Lampe, G; Mai, GT; Martin, JM; Marx, G; Nott, LM; Oostendorp, M; Shannon, J; Simes, J; Smithers, BM; Thomas, J; Varma, S; Walpole, ET; Watson, DI; Wilson, K; Zalcberg, JR | 1 |
| Bi, J; Chen, S; Diao, C; Dong, Y; Fan, H; Fan, W; Feng, Q; Geng, D; Han, X; Huang, G; Li, F; Li, G; Li, P; Li, Q; Li, T; Li, W; Li, Y; Liu, B; Meng, M; Meng, Q; Ni, Y; Ren, H; Sheng, L; Sun, D; Sun, L; Sun, W; Sun, Y; Tian, H; Wang, C; Wang, J; Wei, Z; Xu, X; Xu, Y; Xue, G; Yang, X; Ye, X; Yu, G; Zhang, B; Zhang, K; Zhang, L; Zheng, A; Zou, Z | 1 |
| Chang, ED; Kim, JS; Kim, YS; Lee, DS; Na, SJ; Whang, IY; Won, HS | 1 |
| Endo, M; Hasegawa, H; Kaneko, T; Kanno, C; Kano, M; Kitabatake, T; Monma, T; Sato, E; Takeishi, E; Yamazaki, M | 1 |
| Albain, KS; Carlos, RC; Cella, D; Dees, EC; Garcia, SF; Geyer, CE; Goetz, MP; Gray, RJ; Hayes, DF; McCaskill-Stevens, WJ; Minasian, LM; Olson, JA; Pritchard, KI; Sledge, GW; Sparano, JA; Tevaarwerk, AJ; Wagner, LI; Whelan, TJ; Yanez, B | 1 |
| Abbasnezhad, A; Abd El-Ghafar, OA; Abhilash, L; Abouzid, KAM; Achberger, AM; Ackerman, S; Akhatayeva, Z; Akin, D; Al-Kaysi, RO; Alakhdar, AA; Alame, M; Aleksic Sabo, V; Alinezhadbalalami, N; Allen, JD; Alonso, JM; Alqatani, S; Alsayed, B; Álvarez Larraondo, M; Alvarez, M; Amini, SB; An, Z; Anasir, MI; Anderson, GH; Andremont, A; Andrés, S; Angel, S; Anigboro, AA; Anini, Y; Antonides, CFJ; Arafa, K; Arafa, RK; Aryal, UK; Asbaghi, O; Assefa, MK; Atyah, M; Avwioroko, OJ; Ayora-Talavera, G; Azpilikueta, A; Azyazov, VN; Ba, YF; Bachmann, KF; Badoual, J; Bae, SJ; Baek, SH; Bahrami, B; Bai, J; Baid-Agrawal, S; Bailey, MR; Baillie, JK; Balani, N; Balcar, VJ; Banica, T; Banks, L; Barb, J; Bardeen, CJ; Barrett, HE; Bartnikowski, N; Bashir, R; Battaglia, M; Bautista-Hernández, V; Becker, B; Beekman, FJ; Benidir, M; Benjelloun, M; Bentley, RF; Bergé, J; Berger, D; Bernsen, MR; Berraondo, P; Bhattacharya, R; Bhayani, SB; Bi, W; Bi, X; Bi, YL; Bi, Z; Bian, K; Biesecker, LG; Billadeau, DD; Blaszczyk, R; Blum, JL; Boachie, R; Boelte, K; Bogers, AJJC; Boileau, I; Bonduelle, C; Bonny, O; Bonsu, JM; Boos, LA; Borges-Argáez, R; Bouchard, PA; Boudot, C; Bourgeade-Delmas, S; Boutet-Robinet, E; Boyle, AJ; Branigan, D; Briones, S; Broniowska, KA; Brossas, JY; Brown, WA; Brzezinska, J; Buitron, G; Burnier, M; Bursulaya, B; Burton, PR; Bush, AA; Busuttil, RW; Cabello-Aguilar, S; Cáceres-Farfán, M; Cacheux, V; Caffrey, PJ; Cai, B; Cai, Q; Cai, S; Cai, Y; Calders, P; Cammarota, G; Campbell, DA; Cancelli, C; Cao, Q; Cao, WH; Cao, X; Capet, M; Capoluongo, E; Carey, ME; Carnero, M; Carrasco, LI; Carreno, J; Carrillo-Reyes, J; Casini, I; Cassar, M; Catalan, G; Cattamanchi, A; Cazares-Granillo, M; Celie, B; Cen, YK; Cena, H; Cerbo, RM; Ceron, E; Cetina-Montejo, L; Chaâbane-Banaoues, R; Chabanet, C; Chace-Donahue, F; Chalfun-Júnior, A; Chan-Balan, R; Chang, CS; Chen, CS; Chen, D; Chen, J; Chen, L; Chen, PN; Chen, Q; Chen, S; Chen, W; Chen, WP; Chen, X; Chen, Z; Cheng, H; Cheng, J; Cheng, Q; Cheng, T; Chi, T; Chianelli, D; Chieppa, M; Child, CJ; Cho, JH; Cho, JY; Chogtu, B; Choi, GH; Choi, J; Choi, M; Choi, NG; Cholu, CO; Chow, ES; Chowdhury, AH; Chu, PC; Chu, Q; Chu, S; Chua, H; Chung, T; Chunyan, L; Church, JS; Civardi, E; Cobiella, J; Colinge, J; Collado, CJ; Collins, TJ; Cong, LM; Conkrite, KL; Cope, SJ; Corbett, JA; Cornet, M; Cornillot, E; Corvaisier, S; Costes-Martineau, V; Courtioux, B; Coussens, M; Covino, M; Criado, A; Cui, J; Cui, Y; Cunitz, BW; Curry, AE; Cussó, L; D'Urzo, AD; D'Urzo, KA; Dabbous, S; Dahlgren, RA; Dai, H; Dai, T; Dai, W; Dalinghaus, M; Dang, S; Davalos, RV; Davidson, H; de Andrea, CE; De Angelis, M; de Blois, E; de Carvalho, PA; De Clercq, E; De Giuseppe, R; de Jong, M; De Langhe, S; De Oliveira, L; de Souza Pinto Lemgruber, R; de Souza, LB; de Swart, J; De Wandele, I; de Woestijne, PCV; Delaney, S; Delorme, M; Delvenne, P; Deng, L; Deng, Z; Denkinger, CM; der Meulen, MHV; Deraeve, C; Desco, M; DeSilva, S; Destere, A; Dhali, A; Di Ciano, P; Dias-Santagata, D; Diskin, SJ; Djè, MK; Doddipatla, S; Doerr, AJ; Dokla, EME; Domiciano, D; Domingo, N; Dong, C; Dong, J; Dong, Q; Dong, S; Dong, X; Dong, Z; Douair, I; Douglas, TA; Doyle, SM; Drain, PK; Du, K; Du, L; Du, Q; Du, S; Duan, C; Duan, H; Duan, J; Duan, S; Duan, W; Dueluzeau, R; Dukic, L; Dunmire, BL; Duvauchelle, T; Dymek, B; Dzwonek, K; Earnest, A; Eckardt, KU; El Ghadraoui, L; El Massoudi, S; Elloumi, F; Elnour, IE; Embarak, S; Ende, M; England, K; Enikeev, D; Enyedy, I; Epple, R; Erickson, GE; Eriksson, J; Erndt-Marino, J; Errachidi, F; Etxeberria, I; Evan, AP; Fairlamb, AH; Falahi, E; Fan, CC; Fan, H; Fan, M; Fan, MZ; Fan, S; Fan, Y; Fang, CS; Fang, J; Fang, X; Fang, Z; Farmany, A; Farooqi, A; Farouk, HO; Fazelipour, S; Feng, D; Feng, J; Feng, JX; Feng, YL; Ferraz, SL; Ferreira, CR; Figenshau, RS; Finn, AV; Fiseha, T; Fleischer, AS; Fogleman, AD; Fontaine, O; Ford, CR; Fouladvand, F; Four, M; Fousteri, G; Francis, JR; Fraser, JF; Frazier, RP; Fu, H; Fu, P; Fu, YJ; Fujishima, A; Fuster, V; Gabilan, JC; Gagliani, N; Gai, QY; Galán-Arriola, C; Gale, P; Galimova, GR; Galkin, A; Gallo, A; Gallo, AA; Gang, DD; Ganschow, S; Gao, C; Gao, F; Gao, GP; Gao, H; Gao, K; Gao, M; Gao, MY; Gao, P; Gao, R; Gao, S; Gao, WJ; Gao, Y; Garbacz, P; García Ruiz, L; Garcia, EM; Garofoli, F; Gasbarrini, A; Gattinoni, L; Gaudig, M; Gbureck, U; Ge, X; Genko, N; Gentile, GL; George, MW; Gerety, GF; Gestwicki, JE; Geusens, PP; Ghassemi, M; Giardina, JD; Giebultowicz, JM; Gifford, CA; Gijsen, FJH; Gilfillan, R; Gilson, E; Gingl, K; Giuliano, C; Glybochko, P; Goessler, W; Gofflot, S; Golab, J; Goldstein, A; Golebiowski, A; Gómez, L; Gómez-Carballo, J; Gonçalves, PEO; Gonzales, R; Gonzalez-Cotto, M; González-Fernández, D; Gonzalez-Lopez de Turiso, F; Goodman, JM; Govinda Raju, S; Grimm, J; Gross, AJ; Gruenheid, S; Gu, C; Gu, FF; Gu, S; Gu, Z; Guest, RL; Gui, C; Gui, J; Guillem, A; Guo, G; Guo, L; Guo, Q; Guo, S; Guo, SW; Guo, W; Guo, Y; Guo, YG; Guo, Z; Guretzky, JA; Haenggi, M; Hahn, MS; Hakkola, J; Halim, AA; Hampel, D; Han, B; Han, BH; Han, D; Han, G; Han, J; Han, LZ; Han, R; Han, S; Han, X; Han, Z; Handley, MA; Hanke, I; Hannongbua, S; Hao, P; Happ, JT; Hara, M; Haraux, F; Hare, JL; Harper, JD; Hartley, AM; Harvey, E; Hashimoto, K; Hassan, HM; Hautajärvi, H; Hayton, TW; He, C; He, H; He, HJ; He, WP; He, Y; He, Z; Hedrick, V; Heffernan, JK; Hegrová, J; Heidarimoghadam, R; Helms, K; Hengphasatporn, K; Henry, D; Herrmann, TRW; Hesson, T; Himmelbauer, MK; Hindle, A; Hoffmann, R; Hogg, N; Hong, KB; Hong, SK; Honjol, Y; Hood, C; Hsi, RS; Hsu, JL; Hu, B; Hu, BC; Hu, D; Hu, H; Hu, J; Hu, K; Hu, M; Hu, MK; Hu, T; Hu, W; Hu, Y; Hu, Z; Hua, S; Huang, H; Huang, J; Huang, L; Huang, M; Huang, P; Huang, X; Huang, Y; Huang, Z; Hukkanen, J; Hung, MC; Huo, X; Hyötyläinen, T; Ianiro, G; Ibanez, B; Imran, M; Ireland, S; Irwin, MS; Ishiguro, H; Jackowski, K; Jackson, C; Jacob, SI; Jahromy, MH; Jakob, SM; Jang, J; Javvaji, PK; Jefferson, KK; Jena, P; Ji, H; Jiang, F; Jiang, GH; Jiang, H; Jiang, J; Jiang, X; Jiang, Z; Jiao, J; Jiménez, A; Jin, X; Jincai, W; Jintao, X; Jo, K; Jofra, T; Johari, Y; Johnson, ACM; Jones, JH; Josephine Fauci, A; Juhl, AK; Jun, S; Kaiser, RI; Kajioka, J; Kajiyama, H; Kalliyil, A; Kalthur, SG; Kamalanathan, M; Kamaldinov, T; Kanaani, L; Kang, D; Kang, J; Kang, S; Känsäkoski, P; Kaplan, DL; Karwan, M; Kasibhatla, S; Kaur, A; Kawazoe, Y; Ke, C; Keyser, J; Khalique, A; Khan, IT; Kharshoum, RM; Kher, R; Kherani, J; Ki, KK; Kikkawa, F; Kikkawa, R; Kim, BT; Kim, EH; Kim, GA; Kim, GD; Kim, HB; Kim, HG; Kim, JS; Kim, MJ; Kim, SI; Kim, SJ; Kim, Y; King, K; Kinyamu-Akunda, J; Kirkkala, T; Kjaer-Sorensen, K; Kleppinger, EL; Kloner, RA; Klopfenstein, TJ; Knappe, D; Knezevic, P; Kobos, LM; Kohli, M; Kolano, L; Kolodgie, FD; Kolte, AP; Koneru, B; Kong, D; Kong, F; Kong, X; Konggidinata, MI; Köpke, M; Koski, KG; Kotsis, F; Köttgen, A; Kouakou-Kouamé, CA; Kraemer, US; Krane, V; Krehbiel, CR; Krenning, BJ; Kretzschmar, D; Ku, KB; Kubota, Y; Kulich, P; Kumar, NG; Kupiec-Weglinski, JW; Lalani, SS; Lan, X; Landfeldt, E; Langenberg, E; Lapauw, B; Larkin, J; Lassoued, MA; Laukhtina, E; Laura Martinez, J; Laveillé, A; Lavela, P; Law, AD; Lazraq, A; Le Foll, B; Lee, BK; Lee, C; Lee, CS; Lee, EJ; Lee, EY; Lee, G; Lee, HY; Lee, JH; Lee, JJ; Lee, JO; Lee, JS; Lee, R; Lei, H; Lei, P; Lellouche, F; Lennerz, JK; Leong, W; Leslie, I; Lessem, E; Levin, M; Levinger, I; Li, C; Li, CW; Li, CX; Li, CY; Li, D; Li, H; Li, HM; Li, J; Li, L; Li, LM; Li, N; Li, S; Li, W; Li, X; Li, XX; Li, Y; Li, Z; Li, ZL; Li, ZX; Lian, Q; Liang, C; Liang, GH; Liang, H; Liang, J; Liang, X; Liao, CX; Liao, R; Ličbinský, R; Lim, YS; Lima, HK; Lin, JG; Lin, L; Lin, S; Lin, WP; Lin, Z; Liso, M; Liu, BX; Liu, C; Liu, H; Liu, J; Liu, M; Liu, Q; Liu, S; Liu, SF; Liu, SL; Liu, T; Liu, W; Liu, X; Liu, XB; Liu, Y; Liu, YY; Liu, Z; Liu, ZQ; Lobo, M; Loitzenbauer, M; López, F; Lopez, G; López, GJ; Lou, Z; Lu, IC; Lu, J; Lu, M; Lu, W; Lu, X; Lu, Y; Luhovyy, BL; Luna-Abanto, J; Luo, J; Luo, K; Luo, L; Luo, M; Luo, W; Luo, X; Luo, XM; Lv, Y; Lv, YQ; Lyu, HD; Lyu, J; Ma, C; Ma, G; Ma, L; Ma, Q; Ma, X; Ma, Y; Macha, SJ; MacLean, E; Mahalapbutr, P; Maina, T; Malfait, F; Malfertheiner, MV; Malzert-Fréon, A; Mansouri, E; Mao, C; Marcellin, E; Marchiori, PER; Marcotte, DJ; Maréchal, A; Maric, N; Maris, JM; Maron, L; Marti, CN; Martínez-Milla, J; Mateo, J; Mather, K; Mathison, CJN; Matthay, MA; Maxwell, CL; Mazier, D; Mazumder, D; Mazurkiewicz, M; Mazzucchelli, TG; McAuley, DF; Mccoy, K; McVicar, DW; Mebel, AM; Mech, A; Meester, EJ; Meiselbach, H; Melero, I; Ménard, G; Meng, X; Mengya, Y; Merle, G; Meunier, B; Mfarrej, B; Mi, K; Migueliz, I; Mikuška, P; Miladi, K; Miletich, R; Millar, JE; Mills, MR; Milne, R; Minute, L; Misiak, M; Mo, F; Modi, A; Mok, F; Molina, C; Mollen, CJ; Molteni, V; Montalto, M; Montet, D; Monti, MC; Moor, MB; Moravec, P; Morsiani, C; Murillo, E; Murugan, P; Muslem, R; Myers, RK; N'guessan, FK; Nabil, H; Nadal, J; Nadeem, M; Nafady, MM; Nafie, MS; Nair, HP; Nakano, R; Nance, J; Naren, N; Neil, CJ; Nelson, J; Nery, FC; Netsch, C; Nguyen, TH; Ni, L; Ni, YX; Nie, W; Nielsen, LK; Nigam, K; Nikolayev, AA; Nishiyama, M; Niu, LL; Niu, PP; Nock, BA; Noer, PR; Noll, G; Noll, S; Norenberg, JP; Nowicka, J; Nutho, B; O'Connor, M; Obonyo, NG; Ochiai, T; Ochoa, MC; Oh, BL; Oh, S; Olczak, J; Olivares, X; Ommurugan, B; Oosthuizen, MC; Operario, D; Orešič, M; Oshima, K; Otano, I; Ou, Y; Owen, TW; Oxvig, C; Pacey, V; Pai, M; Paik, H; Paiva, R; Palmieri, EM; Palpant, N; Pan, L; Pan, Q; Panahi, S; Pang, B; Pang, ZC; Pannecouque, C; Paris, L; Park, D; Park, DJ; Park, E; Park, EC; Park, IH; Park, JH; Park, JI; Park, S; Passmore, MR; Pattaranggoon, NC; Paun, M; Pedersen, S; Pedron, J; Peng, M; Peng, X; Penzhorn, BL; Pérez-Camargo, D; Perez-Maldonado, R; Pérez-Vicente, C; Pham, TD; Pickering, L; Pickersgill, NA; Pinault, E; Pinotsis, N; Plan, M; Pocino, K; Poh, CL; Pons, EDC; Popoff, MR; Porri, D; Pourmand, A; Pratviel, G; Prudente, DO; Qi, H; Qi, N; Qian, LY; Qiao, L; Qiao, Q; Qin, QP; Qiu, N; Qiu, SW; Qu, F; Quan, M; Quigg, A; Raee, E; Raibaud, P; Ramanitrahasimbola, D; Rapoport, L; Rasby, RJ; Rasoanirina, BNV; Raspini, B; Ratner, JR; Razafindrakoto, Z; Redd, MA; Ren, H; Ren, N; Rey, J; Reynolds, CP; Rich, PR; Richards, CJ; Rigol, M; Rimoldi, S; Robert, P; Rodrigues, AE; Roe, JH; Rohde, S; Rokita, JL; Roland, J; Rombaut, L; Ronkainen, J; Rothenberg, SM; Roy, SC; Ruan, Z; Rucker, PV; Rueda, D; Ruhwald, M; Rungrotmongkol, T; Rupert, AS; Rusjan, P; Ryabov, AD; Rysä, J; Saad, NES; Sabioni, P; Sadow, PM; Sahai, N; Salem, HF; Salinas, B; Salonurmi, T; Samé Guerra, D; Sánchez, J; Sanchez-González, J; Sanmamed, MF; Sansores-Peraza, P; Santoro, JC; Santschi, PH; Saritas, T; Sarkisova, Y; Savolainen, MJ; Scherberich, JE; Schlom, DG; Schmelz, EM; Schmid, MC; Schneider, MP; Schumacher, S; Schwartz, JC; Schwartzer, JJ; Schwehr, K; Schweitzer, DH; Scott, ME; Sedky, NK; See Hoe, L; Sejian, V; Selvaraju, S; Sen, SK; Seo, G; Šerý, O; Settles, JA; Sfar, S; Shaffer, J; Shan, GL; Shang, Q; Shannahan, JH; Shao, B; Shao, H; Shao, J; Shao, ZH; Shasha, Y; Shaw, K; Sheeba, V; Shekar, K; Shen, G; Shen, H; Shen, XD; Shen, Y; Sherrell, PC; Shete, PB; Shi, AX; Shi, J; Shi, JH; Shi, S; Shi, X; Shigeta, Y; Shimbo, A; Shin, E; Sikka, N; Silhavy, TJ; Simanon, N; Simard, S; Simon, J; Simon, M; Simpson, SD; Simundic, AM; Since, M; Singh, B; Singhroy, DN; Sinisterra, OT; Smith, EH; Sobreira, TJP; Solanes, N; Somasundar, Y; Sommerer, C; Sonei, A; Song, B; Song, E; Song, J; Song, M; Song, Y; Soo Lee, M; Sorensen, MD; Sournia-Saquet, A; Spaepen, E; Spirk, D; Srivastava, S; Stancill, JS; Stanczak, PS; Starenki, D; Starr, F; Step, DL; Steubl, D; Stigliani, JL; Stráská, J; Sträter, N; Su, ZZ; Sudano, I; Suen, JY; Suh, HJ; Sui, ZY; Suico, JG; Suleiman, K; Sumon, K; Sun, HB; Sun, J; Sun, L; Sun, LL; Sun, M; Sun, Q; Sun, W; Sun, X; Sun, XF; Sun, Y; Sun, YB; Sun, YH; Sun, YN; Sun, Z; Sunada, K; Suzuki, S; Sylvan, JB; Takala, J; Talla, D; Tamir, Z; Tan, SJ; Tanda, S; Tang, H; Tang, J; Tang, LF; Tang, SJ; Tang, Y; Tao, FB; Tappel, R; Taratkin, M; Teijeira, Á; Tellew, JE; Thomas, AM; Thomas, SG; Thomson, SR; Tian, J; Tie, Y; Tirado, JL; Tolonen, A; Tosato, G; Tronnet, A; Tsai, S; Turtoi, A; Turtoi, E; Tvrdoňová, M; Tyagi, A; Tzou, DT; Uddin Ahmad, Z; Urias, E; Usawachintachit, M; Ustriyana, P; Utsumi, F; Vacca, M; Vaculovič, T; Vaidya, SS; Valentin, A; Valgepea, K; van den Berg, P; van den Bergh, JP; van der Heiden, K; van Gaalen, K; Van Gemert, W; van Haard, PMM; van Hest, JCM; Vecchiarelli, E; Večeřa, Z; Venkatesh, R; Verhaeghe, P; Verhagen, HJ; Vetter, JM; Vieira, D; Vilchez-Tschischke, JP; Villena-Gutierrez, R; Villoslada Terrones, V; Vital-Jacome, M; Voelkl, J; Vogel, K; Vogrin, S; Volke, D; von Bahr, V; Vysloužil, J; Wade, TL; Wagner-Gillespie, M; Walsh, SW; Wan, LJ; Wan, SP; Wang, AL; Wang, B; Wang, BY; Wang, C; Wang, D; Wang, F; Wang, H; Wang, HR; Wang, HY; Wang, J; Wang, JY; Wang, K; Wang, L; Wang, LF; Wang, P; Wang, Q; Wang, R; Wang, SF; Wang, SP; Wang, SR; Wang, T; Wang, W; Wang, WP; Wang, X; Wang, XJ; Wang, Y; Wang, YL; Wang, YN; Wáng, YXJ; Wang, Z; Wang, ZF; Wang, ZY; Waning, B; Warner, JM; Washington, SL; Watson, AK; Wei, B; Wei, C; Wei, F; Wei, X; Wei, Y; Wemhoff, AP; Wen, Z; Weng, TT; Wesdemiotis, C; Wheeler, DA; Wildner, M; Wilson, BK; Wirth, LJ; Wissler, M; Wu, F; Wu, G; Wu, J; Wu, KH; Wu, MC; Wu, P; Wu, PK; Wu, S; Wu, W; Wu, X; Wu, XP; Wu, Y; Wyatt, E; Wyllie, S; Xia, Y; Xiao, BH; Xiao, SZ; Xiao, W; Xiao, X; Xiao, Z; Xie, D; Xie, K; Xie, X; Xie, Y; Xie, YF; Xin, S; Xin, Z; Xing, Q; Xing, WQ; Xiong, D; Xiong, X; Xu, C; Xu, D; Xu, F; Xu, G; Xu, H; Xu, J; Xu, JY; Xu, L; Xu, N; Xu, W; Xu, X; Xu, Y; Xu, YM; Xue, H; Xue, J; Xue, Z; Yan, R; Yan, SQ; Yan, W; Yan, X; Yan, Z; Yang, C; Yang, D; Yang, F; Yang, FC; Yang, G; Yang, J; Yang, M; Yang, P; Yang, Q; Yang, R; Yang, S; Yang, SJ; Yang, TWW; Yang, X; Yang, Y; Yang, Z; Yao, C; Yao, L; Yao, LP; Yao, M; Yao, T; Yao, W; Yao, Y; Yaseen, T; Yazdani, V; Ye, J; Ye, S; Yerys, BE; Yi, HWL; Yi, JL; Yin, F; Yin, J; Yin, Y; Yin, Z; Yong, ZP; Yongli, S; Yoo, JS; Yoshikawa, N; You, Q; Yu, B; Yu, CQ; Yu, H; Yu, HG; Yu, J; Yu, L; Yu, Q; Yu, X; Yu, Y; Yu, YK; Yu, Z; Yuan, Q; Yuan, R; Yuan, W; Yuan, X; Yuan, Y; Zager, RA; Zagozdzon, A; Zaller, N; Zang, YP; Zappi, ME; Zelikoff, JT; Zeman, T; Zhai, X; Zhan, P; Zhang, B; Zhang, C; Zhang, G; Zhang, H; Zhang, HB; Zhang, J; Zhang, JS; Zhang, L; Zhang, M; Zhang, Q; Zhang, RX; Zhang, S; Zhang, T; Zhang, W; Zhang, WH; Zhang, X; Zhang, XX; Zhang, Y; Zhang, YQ; Zhang, YW; Zhang, Z; Zhang, ZH; Zhao, D; Zhao, FL; Zhao, K; Zhao, L; Zhao, M; Zhao, R; Zhao, S; Zhao, W; Zhao, WG; Zhao, X; Zhao, Y; Zheng, G; Zheng, J; Zheng, S; Zheng, W; Zheng, Y; Zheng, YG; Zhong, Z; Zhou, C; Zhou, D; Zhou, H; Zhou, HY; Zhou, L; Zhou, Q; Zhou, X; Zhou, Y; Zhou, YL; Zhou, Z; Zhu, J; Zhu, L; Zhu, N; Zhu, X; Zhu, XF; Zhu, Y; Zhu, Z | 1 |
| André, T; Baba-Hamed, N; Bidard, FC; Borg, C; Bouché, O; Buecher, B; Dahan, L; de la Fouchardière, C; Desramé, J; El Hajbi, F; François, É; Ghiringhelli, F; Jacquin, M; Jary, M; Kim, S; Parzy, A; Rebucci-Peixoto, M; Samalin, E; Smith, D; Spehner, L; Taieb, J; Tougeron, D; Vendrely, V; Vernerey, D | 1 |
| Albiges, L; Baciarello, G; Blanchard, P; Bosset, PO; Bossi, A; Colomba, E; Dumont, C; Fizazi, K; Lavaud, P; Loriot, Y; Massard, C; Nenan, S | 1 |
| Ahn, MJ; Burtness, B; Cheng, JD; Chirovsky, DR; Cohen, EEW; Dinis, J; Ellison, MC; Harrington, KJ; Le Tourneau, C; Licitra, LF; Mach, N; Machiels, JH; Mehra, R; Soria, A; Soulières, D; Swaby, RF | 1 |
| Ando, M; Gemma, A; Hagiwara, K; Hino, M; Kobayashi, K; Kubota, K; Miyanaga, A; Nishitsuji, M; Noro, R; Seike, M; Shimokawa, T; Usuki, J; Yomota, M | 1 |
| Adnet, J; Bertaut, A; Coudert, B; Favier, L; Foucher, P; Kaderbhaï, CG; Lagrange, A; Martin, E; Mettey, L; Peignaux-Casasnovas, K; Tharin, Z | 1 |
| Bergan, R; Cao, M; Liu, B; Liu, Y; Luoh, SW; Mori, M; Zhang, X; Zhang, Z | 1 |
| Adachi, T; Eguchi, S; Hidaka, M; Inoue, Y; Isagawa, Y; Ito, S; Kanetaka, K; Kawaguchi, Y; Kobayashi, K; Kobayashi, S; Kosaka, T; Kuba, S; Maruya, Y; Migita, K; Morita, M; Okada, S; Takatsuki, M; Torashima, Y; Yamaguchi, S; Yoneda, A; Yoshimoto, T | 1 |
| Beltran, H; Clinton, SK; Coleman, J; Eastham, JA; Evans, CP; George, S; Gleave, M; Hahn, OM; Halabi, S; Heller, G; Hillman, DW; Mohler, JL; Monk, JP; Morris, MJ; Parsons, JK; Sanda, MG; Small, EJ; Szmulewitz, RZ; Taplin, ME; Watt, CR | 1 |
| Brizel, DM; Choudhury, KR; Das, S; Mowery, YM; Niedzwiecki, D; Rushing, CN; Vergalasova, I; Wong, TZ; Wu, Q; Yoo, DS | 1 |
| Argiris, A; Cella, D; Forastiere, AA; Lee, JW; Oswald, LB; Webster, KA | 1 |
| Chung, H; Kim, HS; Kim, JW; Kim, SI; Lee, EJ; Lee, M; Park, NH; Song, YS | 1 |
| Anzellini, D; De Sanctis, V; Marinelli, L; Massaro, M; Montalto, A; Osti, MF; Reverberi, C; Valeriani, M | 1 |
| Doyama, H; Kito, Y; Kubo, A; Miyajima, S; Tsuji, K; Ushijima, K; Yonezawa, M | 1 |
| An, X; Feng, K; Li, S; Liao, H; Mei, T; Zhan, J; Zhao, C | 1 |
| Chang Lee, R; Hsieh, AH; Moldovan, M; Price, T; Tomita, Y; Townsend, A | 1 |
| Nemoto, H; Tanaka, K | 1 |
| Harada, D; Hosomi, Y; Kasai, T; Kato, T; Kishi, K; Kubota, K; Misumi, T; Nakamura, Y; Okamoto, H; Otani, S; Saito, H; Shimokawa, T; Takiguchi, Y; Tanaka, H; Yamada, K; Yamanaka, T | 1 |
| Igai, H; Iwashita, H; Kamiyoshihara, M; Matsuura, N; Ohsawa, F; Yazawa, T | 1 |
| Arigami, T; Kurahara, H; Matsushita, D; Mori, S; Noda, M; Ohtsuka, T; Okubo, K; Sasaki, K; Tanaka, T; Tsuruda, Y | 1 |
| Kigawa, J; Nagao, S; Nakamura, K; Sato, S; Shimada, M; Shoji, T; Sueoka, K; Takehara, K; Tokunaga, H; Yamaguchi, S | 1 |
| Arén Frontera, O; Bajars, M; Barlesi, F; Calabrò, L; de Marinis, F; Garassino, M; Ishii, H; Krzakowski, M; Lee, JS; Özgüroğlu, M; Park, K; Polychronis, A; Ruisi, M; Spigel, D; Szczesna, A; Uslu, R; Vansteenkiste, J; Xiong, H; Yang, JCH | 1 |
| Liao, K; Qiu, WZ; Tao, HY; Yuan, YW; Zhan, ZJ; Zheng, RH | 1 |
| Baas, P; Boyer, M; Cho, BC; Forster, MD; Garon, EB; Gervais, R; Gubens, MA; Han, JY; Herbst, RS; Jensen, EH; Kim, DW; Kobie, J; Majem, M; Monnet, I; Novello, S; Perez-Gracia, JL; Piperdi, B; Samkari, A; Su, WC | 1 |
| Girgis-Gabardo, A; Gwynne, WD; Hassell, JA; Shakeel, MS | 1 |
| Bivalacqua, TJ; Brooks, N; Crump, T; DeWolf, WC; Hyndman, ME; Kamat, AM; Kates, M; Lamm, DL; Mott, SL; Nepple, KG; O'Donnell, MA; Packiam, VT; Steinberg, RL; Thomas, LJ; Vitale, A; Wang, J | 1 |
| Guo, S; He, B; Jiang, T; Liu, C; Ma, Y | 1 |
| Ademuyiwa, FO; Akintola-Ogunremi, O; Anurag, M; Bagegni, N; Basu, A; Bose, R; Chen, I; Church, SE; Clifton, K; Davis, J; Ellis, MJ; Ferrando-Martinez, S; Fisk, B; Frith, A; Gao, F; Gillanders, W; Griffith, M; Griffith, OL; Hagemann, IS; Hernandez-Aya, LF; Jeffers, G; Lee, BH; Luo, J; Ma, CX; Opyrchal, M; Peterson, LL; Rearden, TP; Richters, M; Rigden, CE; Rimawi, MF; Roshal, A; Skidmore, ZL; Suresh, R; Weilbaecher, K | 1 |
| Akabane, S; Babasaki, T; Hayashi, T; Katsuya, N; Kobayashi, G; Matsubara, A; Oue, N; Sekino, Y; Sentani, K; Shiota, M; Taniyama, D; Teishima, J; Thang Pham, Q; Yasui, W | 1 |
| Cho, SG; Choi, YJ; Hwang, HH; Jeong, MS; Joo, YJ; Jung, SE; Kim, YG; Ko, SG; Lee, JH; Lee, KW; Lee, SY; Park, SA | 1 |
| Aneja, R; Choi, DH; Donthamsetty, S; Gupta, MV; Kaur, R; Mittal, K; Reid, MD; Rida, PCG; Yang, C | 1 |
| Chiba, N; Imai, H; Ishioka, C; Komine, K; Mori, T; Ohori, H; Okada, Y; Saijo, K; Shimodaira, H; Shirota, H; Takahashi, M; Takahashi, S | 1 |
| Bonnefoi, H; Breton-Callu, C; Cameron, D; Gillon, P; Slaets, L; Touati, N | 1 |
| Hoshino, A; Kawada, K; Kawano, T; Nakajima, Y; Okada, T; Tokairin, Y | 1 |
| Izumi, K; Kadono, Y; Kitagawa, Y; Konaka, H; Mizokami, A | 1 |
| Amin, M; Chiorean, EG; Gandhi, J; Harris, WP; Kim, R; Portnoy, D; Rocha-Lima, CMS; Song, T | 1 |
| Embry-Schubert, J; Lentz, SE; Littell, RD; Neugebauer, R; Palen, TE; Raine-Bennett, T; Tucker, LY; Zaritsky, E | 1 |
| Abdelghani, MB; André, T; Aparicio, T; Baba-Hamed, N; Bachet, JB; Bennouna, J; Bidard, FC; Bonnetain, F; Borg, C; Bouché, O; Buecher, B; De La Fouchardière, C; Desrame, J; Dumont, S; El Hajbi, F; François, E; Gornet, JM; Jacquin, M; Jary, M; Kim, S; Louvet, C; Nguyen, T; Parzy, A; Peiffert, D; Pernot, S; Samalin, E; Smith, D; Vendrely, V; Zoubir, M | 1 |
| Castelnau, O; Cohen, C; Mouroux, J; Otto, J; Pop, D; Poudenx, M; Venissac, N | 1 |
| Joensuu, H; Lindman, H | 1 |
| Altundag, K | 1 |
| Bunger, D; Gupta, S; Pawar, SS | 1 |
| Alseidi, A; Badiozamani, K; Biehl, TR; Edwards, AM; Helton, WS; Kanji, ZS; Kozarek, RA; Lin, BS; Mandelson, MT; Picozzi, VJ; Rocha, FG; Sahar, N; Song, G | 1 |
| Bilhim, T; Costa, NV; Fernandes, L; Oliveira, AG; Pisco, J; Ribeiro, MP | 1 |
| Chan, LLK; Kam, MKM; Kwong, DLW; Lee, AWM; Lung, ML; Ng, WT; Ngan, RKC; Sze, HCK; Tung, SY; Yiu, HHY; Yuen, KT | 1 |
| Borel, C; Burgy, M; Leblanc, J | 1 |
| Patel, JA; Piper, JB; Wang, BG | 1 |
| Chen, LT; Chin, YY; Chu, NS; Wu, IC | 1 |
| Hida, T; Horiike, A; Ikeda, N; Kaji, R; Kawakami, T; Kubo, T; Nakagawa, S; Nokihara, H; Satouchi, M; Seto, T | 1 |
| Bouzguenda, R; Daoud, J; Fourati, N; Frikha, M; Ghorbel, A; Mnejja, W; Siala, W; Toumi, N | 1 |
| Bora, C; Candiloro, KM; Coleman, TP; Connolly, DC; Davis, B; Galati, CA; Ganta, S; Litwin, S; Maglaty, MA; Morse, AB; Nack, AH; O'Brien, SW; Patel, NR; Piroyan, A; Solon, AL | 1 |
| Kawamata, O; Murata, T; Uda, M | 1 |
| Ahn, MJ; Chang, WJ; Choi, MK; Hong, JY; Jung, HA; Kim, HS; Kim, MJ; Kim, SM; Park, K; Sun, JM | 1 |
| Ferrari, M; Holder, AM; Liu, X; Mai, J; Mu, C; Shen, H; Shen, J; Wolfram, J; Wu, X; Xia, X; Zhang, D; Zhou, X | 1 |
| Arakawa, A; Asai-Sato, M; Hongo, A; Inokuchi, Y; Kamiura, S; Kato, K; Komiyama, S; Matsumoto, T; Sugiyama, T; Tabata, T; Takano, H; Takeshima, N | 1 |
| Sclafani, F | 1 |
| Hofer, MD | 1 |
| Benítez, J; Caronia, D; de la Torre-Montero, JC; García-Sáenz, JÁ; González-Neira, A; Martin, M; Moreno, F; Moreno, LT; Pita, G; Ruiz-Pinto, S | 1 |
| Akazawa, K; Fushimi, C; Hirai, H; Kamata, SE; Kawakita, D; Masubuchi, T; Matsuki, T; Miura, K; Nagao, T; Ojiri, H; Osamura, RY; Saotome, T; Tada, Y; Takahashi, H; Tani, K; Yamada, S | 1 |
| Eto, M; Inokuchi, J; Kobayashi, T; Namitome, R; Shiota, M; Tatsugami, K | 1 |
| Ahn, MJ; Burtness, B; Cheng, J; Cohen, EEW; Dinis, J; Harrington, KJ; Le Tourneau, C; Licitra, L; Mach, N; Machiels, JP; Mehra, R; Soria, A; Soulières, D; Swaby, RF; Zhang, P | 1 |
| Daido, W; Funaishi, K; Hattori, N; Kawamoto, K; Matsumoto, N; Matsumoto, Y; Ohashi, N; Taniwaki, M; Yamasaki, M | 1 |
| Chen, QY; Guo, L; Guo, SS; Li, XY; Liang, YJ; Lin, C; Lin, HX; Liu, LT; Liu, SL; Mai, HQ; Sun, XS; Tang, LQ; Tang, QN; Wen, YF; Xie, HJ; Yan, JJ; Yang, ZC | 1 |
| Blumenschein, GR; Garden, AS; Ginsberg, LE; Glisson, BS; Gold, KA; Haddad, RI; Hutcheson, K; Johnson, FM; Kies, MS; Lee, JJ; Lewis, J; Lin, HY; Massarelli, E; Myers, J; Papadimitrakopoulou, V; Pharaon, RR; Pickering, C; Rabinowits, G; Tishler, RB; William, WN; Williams, MD | 1 |
| Adachi, S; Hayashida, H; Higaki, N; Kawanaka, S; Nezu, R; Oka, Y; Okada, K; Taniguchi, S; Ueshima, S; Yoshioka, S | 1 |
| Kim, S; Kim, SW; Kim, YT; Lee, J; Li, LY; Nam, EJ | 1 |
| Chon, HJ; Chung, HC; Jung, M; Kang, B; Kim, C; Kim, HS; Kim, JH; Nam, CM; Rha, SY | 1 |
| Cocks, K; Contente, M; DeRosa, M; Shaw, JW; Simpson, S; Taylor, FC | 1 |
| Chinnakotla, S; Eidenschink, B; Luquette, M; Neglia, J; Pilbeam, K; Sulciner, M | 1 |
| Awasthi, A; Bill, KLJ; Brock, GN; Bupathi, M; Chen, JL; Demoret, B; Duggan, MC; Hays, JL; Millis, SZ; Pollock, RE; Seligson, ND; Shakya, R; Stets, CW; Timmers, CD; Wakely, PE | 1 |
| Bajorin, DF; Bellmunt, J; Choueiri, TK; Climent, MA; Culine, S; de Wit, R; Fong, L; Fradet, Y; Frenkl, TL; Gerritsen, W; Gurney, H; Lee, JL; Nam, K; Necchi, A; Perini, RF; Petrylak, DP; Quinn, DI; Sternberg, CN; Vaughn, DJ; Vogelzang, NJ | 1 |
| Alzouebi, M; Attard, G; Birtle, AJ; Brock, S; Cathomas, R; Chakraborti, PR; Cook, A; Cross, WR; Dearnaley, DP; Gale, J; Gannon, MR; Gibbs, S; Graham, JD; Hughes, R; James, ND; Jones, RJ; Laing, R; Mason, MD; Matheson, D; McLaren, DB; Millman, R; O'Sullivan, JM; Parikh, O; Parker, CC; Parmar, MKB; Peedell, C; Protheroe, A; Ritchie, AWS; Robinson, A; Russell, JM; Sculpher, MJ; Sideris, E; Simms, MS; Srihari, NN; Srinivasan, R; Staffurth, JN; Sundar, S; Sydes, MR; Thalmann, GN; Tolan, S; Tran, ATH; Tsang, D; Wagstaff, J; Woods, BS | 1 |
| Asai, Y; Gon, Y; Nakagawa, Y; Shimizu, T; Takahashi, N; Tsujino, I | 1 |
| Kazuno, A; Koyanagi, K; Ninomiya, Y; Oguma, J; Ozawa, S; Yamamoto, M; Yatabe, K | 1 |
| Barangi, M; Bouvet, M; Chawla, SP; Endo, I; Higuchi, T; Hiroshima, Y; Hoffman, RM; Homma, Y; Katsuya, Y; Li, Y; Matsuyama, R; Miyake, K; Murakami, T; Nelson, SD; Oshiro, H; Park, JH; Razmjooei, S; Singh, SR; Sugisawa, N; Zhang, Z | 1 |
| Asai, K; Chiba, Y; Hayashi, H; Kasai, T; Kawaguchi, T; Kijima, T; Kimura, T; Kogure, Y; Nakagawa, K; Nakanishi, Y; Niwa, T; Oguri, T; Ono, A; Tanaka, H; Watanabe, K; Yamamoto, N; Yano, S; Yoshimura, N; Yoshioka, H | 1 |
| Fukushima, H; Mitani, H; Nakano, K; Sasaki, T; Seto, A; Shimbashi, W; Takahashi, S; Yonekawa, H | 1 |
| Akutsu, Y; Chin, K; Hamamoto, Y; Hara, H; Hironaka, S; Ito, Y; Kato, K; Kawakami, K; Kii, T; Kitagawa, Y; Kojima, T; Kojima, Y; Makiuchi, T; Matsushita, H; Mori, K; Nagumo, R; Ogawa, H; Tsubosa, Y; Ura, T; Yokota, T | 1 |
| Lin, B; Shao, L; Song, Z; Zhang, Y | 1 |
| Arnold, D; Dietz, A; Eberhardt, W; Gauler, TC; Gruenwald, V; Hennemann, B; Hofele, C; Jordan, WO; Keilholz, U; Knoedler, M; Matzdorff, A; Schroeder, M; Weissinger, F | 1 |
| Bubley, G; Buckle, G; Ernstoff, MS; Kantoff, PW; Morganstern, DE; Nakabayashi, M; Taplin, ME; Walsh, W; Xie, W | 1 |
| Argiris, A; Burtness, B; Forastiere, AA; Ghebremichael, M; Gilbert, J; Kolesar, JM; Lee, JW; Sachidanandam, K | 1 |
| Fleitas, T; Gómez-Codina, J; Martín, M; Martínez-Sales, V; Mesado, D; Montalar, J; Reganon, E; Reynés, G; Vila, V | 1 |
| Hanai, N; Harata, I; Hasegawa, Y; Hirakawa, H; Miyazaki, T; Okamoto, H; Ozawa, T; Suzuki, A | 1 |
| Armstrong, DK; Coleman, RL; Phillips, M; Weil, SC; White, AJ | 1 |
| Han, W; Im, SA; Moon, HG; Moon, WK; Noh, DY; Park, IA; Park, SJ; Shin, HC | 1 |
| Cheng, J; Gao, J; Liu, X; Wang, J; Wang, L; Xiong, L | 1 |
| Allen, P; Buchholz, TA; Buzdar, AU; Gonzalez-Angulo, AM; Hortobagyi, GN; Hunt, KK; Kim, MM; Kuerer, HM; Litton, JK; Meric-Bernstam, F; Mittendorf, EA; Woodward, WA | 1 |
| Andre, F; Chan, A; Chan, S; Gianni, L; Greil, R; Lichinitser, M; Lipatov, O; Mansutti, M; Mariani, P; Moore, N; Pallaud, C; Pivot, X; Prot, S; Romieu, GH; Semiglazov, V; Serrano, SV; Wardley, A | 1 |
| Cai, RG; Li, Q; Wang, JY; Wang, X; Xu, BH; Xu, XZ; Yin, Y; Yuan, P; Zhang, BL; Zhang, P | 1 |
| Wang, B; Wang, XD; Yue, K; Zhang, S | 1 |
| Apte, SM; Gonzalez-Bosquet, J; Havrilesky, LJ; Herschberger, A; Judson, PL; Lancaster, JM; Lapolla, J; Lin, HY; Secord, AA; Wenham, RM | 1 |
| Backes, FJ; Cohn, DE; Copeland, LJ; Eisenhauer, EL; Fowler, JM; McCann, GA; O'Malley, DM; Richardson, DL; Salani, R; Smith, B | 1 |
| Chen, CS; Chiou, HY; Hung, CS; Pan, CK; Tai, CJ; Wu, CH | 1 |
| Cho, JY | 1 |
| Kim, HJ; Kim, SH; Lee, H; Lee, HJ; Lee, JH; Lee, S; Oh, SY | 1 |
| Choueiri, TK; Fennessy, FM; Galsky, MD; Kantoff, PW; Khine, K; Nakabayashi, M; Oh, WK; Ross, RW; Taplin, ME; Tempany, CM; Xie, W | 1 |
| Ahn, JS; Ahn, MJ; Ahn, Y; Chang, WJ; Choi, YS; Kim, H; Kim, J; Kim, K; Kwon, OJ; Lee, SJ; Park, K; Park, S; Shim, YM; Shin, S; Sun, JM | 1 |
| Adkins, D; Clark, J; Haddad, R; Jaffa, Z; Limaye, S; O'Neill, A; Posner, M; Riley, S; Zhao, S | 1 |
| Chou, H; Mekata, E; Nagasawa, Y; Shimizu, T; Sonoda, H; Tani, T | 1 |
| Fujitani, K; Furukawa, H; Iijima, S; Imamura, H; Inoue, K; Kimura, Y; Kobayashi, K; Kurokawa, Y; Matsuyama, J; Shimokawa, T; Tamura, S; Tsuji, T; Tsujinaka, T | 1 |
| Evans, CP; Gao, AC; Liu, C; Lou, W; Nadiminty, N; Tummala, R; Zhu, Y | 1 |
| Baek, SK; Kim, HJ; Kim, HS; Kim, SY; Kim, TY; Lee, KW; Nam, BH; Ryu, MH; Zang, DY | 1 |
| Cataruozolo, PE; Cesari, R; Collier, M; Cortés, J; Curigliano, G; Elias, A; Goldhirsch, A; Huang, X; Kern, KA; Khosravan, R; Pivot, X | 1 |
| Alley, WR; Goetz, JA; Jacobson, SC; Mitra, I; Novotny, MV; Vasseur, JA | 1 |
| Hosono, MN; Kamo, R; Miki, Y; Ogino, R; Shimatani, Y; Tada, T; Tamiya, H; Tsutsumi, S | 1 |
| Celano, P; Eisenhauer, E; Fader, AN; Frasure, H; Gehrig, PA; Giuntoli, RL; Havrilesky, LJ; Krill, L; Levinson, K; Lopez, MA; Ricci, S; Secord, AA; Tanner, EJ | 1 |
| Button, MR; Evans, J; Kumar, S; Lester, JF; Palaniappan, N; Smith, C; Staffurth, J; Tanguay, JS; Thomas, BM | 1 |
| Daiko, H; Ebihara, M; Fujii, S; Hayashi, R; Miyazaki, M; Sakuraba, M; Shinozaki, T; Suzuki, K; Tahara, M; Zenda, S | 1 |
| Al-Sakaff, N; Bell, R; Chang, J; Feng, FY; Heinzmann, D; Jassem, J; Láng, I; Lopez, RI; Semiglazov, V | 1 |
| Ozdemir, O; Ozdemir, P; Ozhan, MH; Uluer, H; Veral, A | 1 |
| Benzidane, B; Bonnetain, F; Borg, C; Bosset, JF; Cazorla, A; Delabrousse, E; Demarchi, M; Jary, M; Kaliski, A; Kim, S; Letondal, P; Mansi, L; Nguyen, T; Valmary-Degano, S | 1 |
| Fajdiga, I; Gale, N; Grašič Kuhar, C; Jančar, B; Kadivec, M; Karner, K; Kocjan, BJ; Poljak, M; Strojan, P; Zakotnik, B; Žumer, B | 1 |
| Caton, J; Chittoor, S; Cohn, A; Garbo, L; Katz, T; Kim, ES; Neubauer, M; Reynolds, C; Robert, F; Saxman, S; Schwartzberg, L; Simms, L | 1 |
| Ansari, J; Bahl, A; Birtle, A; Butt, M; Chowdhury, S; Eswar, CV; Hughes, S; Malik, Z; Payne, H; Sundar, S | 1 |
| Bai, B; Cai, QC; Cai, QQ; Gao, Y; Huang, HQ; Wang, XX | 1 |
| Guo, CY; Han, SH; Song, HP; Yu, L; Zhang, PJ; Zhang, Z | 1 |
| Inoue, K; Kobayashi, H; Murata, S; Naitoh, H; Tani, T; Yamamoto, H | 1 |
| Ando, T; Fujinami, H; Hosokawa, A; Kajiura, S; Mihara, H; Minemura, M; Nishikawa, J; Ogawa, K; Sugiyama, T; Ueda, A; Ueda, Y; Yoshita, H | 1 |
| Adams, JW; Berger, MS; Chiappori, A; Edelman, MJ; Haura, EB; Malik, S; Northfelt, DW; Rosen, P; Van Echo, DA; Williams, C | 1 |
| Canbay, E; Hirano, M; Ichinose, M; Ishibashi, H; Mizumoto, A; Sako, S; Takao, N; Yonemura, Y | 1 |
| Cho, JY; Chung, HC; Fujii, M; Hara, T; Hosaka, H; Imamura, H; Inokuchi, M; Kim, HK; Kim, YH; Koizumi, W; Lee, KH; Nakajima, T; Ogura, M; Okuno, T; Satoh, T; Takagane, A; Takeuchi, M; Tanabe, K; Tsuji, A; Yoshida, K | 1 |
| Fusi, A; Keilholz, U; Klinghammer, K; Knödler, M; Nonnenmacher, A; Pfisterer, K | 1 |
| Hori, A; Hori, S; Seki, A; Sueyoshi, S | 1 |
| Christopoulou, A; Emmanouilidis, C; Georgoulias, V; Kalbakis, K; Kalykaki, A; Koinis, F; Papadimitraki, E; Polyzos, A; Samonis, G; Zafeiriou, Z | 1 |
| Hayashi, N; Kajiura, Y; Matsuda, N; Nakamura, S; Ohde, S; Suzuki, K; Tsunoda, H; Yagata, H; Yamauchi, H; Yoshida, A | 1 |
| Barron, R; Chandler, DB; Fust, K; Li, X; Lyman, GH; Maschio, M; Parthan, A; Walli-Attaei, M; Weinstein, MC | 1 |
| Alcaraz, A; Bermudo, R; Codony-Servat, J; Donovan, M; Fernández, PL; Font, A; Gallardo, E; Gascón, P; Jiménez, N; Lozano, JJ; Marín-Aguilera, M; Mellado, B; Mengual, L; Pereira, MV; Puig, P; Reig, Ò; Ribal, MJ | 1 |
| Anderson, GL; Bonebrake, AJ; Chambers, SK; Coleman, RL; Delmore, JE; Hu, W; Markman, M; Moon, J; Sood, AK | 1 |
| Deo, SV; Gogia, A; Mohanti, BK; Raina, V; Sharma, DN; Shukla, NK | 1 |
| Fujimoto, M; Fujisawa, Y; Kadono, T; Miyagawa, T; Nakamura, Y; Yoshino, K | 1 |
| Belot, A; Céruse, P; Cosmidis, A; Favrel, V; Fayette, J; Fuchsmann, C; Pommier, P; Poupart, M; Rabilloud, M; Ramade, A; Tartas, S; Zrounba, P | 1 |
| Behrman, SW; Chauhan, SC; Ganju, A; Jaggi, M; Khan, S; Yallapu, MM | 1 |
| Guan, Y; Liu, J; Liu, S; Liu, X; Niu, Y; Wang, L; Wang, Y; Zhang, W | 1 |
| Bauman, JE; Becker, D; Bowles, DW; Camidge, DR; Evans, T; Halmos, B; Hausman, D; Levy, B; Nemunaitis, J; Rudin, CM; Schnadig, I; Spira, A; Walker, L | 1 |
| Caffo, O; Creppy, L; Hansen, S; Holmberg, M; Krainer, M; Kramer, G; Loriot, Y; Machiels, JP; Oudard, S; Rolland, F | 1 |
| Feng, Q; Gao, S; He, J; Huang, J; Jiang, Y; Liu, Y; Lyu, X; Mao, Y; Shao, K; Wang, J | 1 |
| Eskander, RN; Tewari, KS | 1 |
| Chen, CH; Lin, SF; Liu, YC; Sun, Y; Tang, JY; Wu, CF; Yang, WC | 1 |
| Ades, S; Alcindor, T; Aloraini, A; Asselah, J; Brisson, S; David, M; Ferri, L; Frechette, D; Sudarshan, M; Thirlwell, M; van Huyse, M | 1 |
| Cai, XY; Chen, XX; Guo, GF; He, WZ; Jiang, C; Liao, FX; Qiu, HJ; Rong, YM; Xia, LP; Yang, Q; Yin, CX; Zhang, B | 1 |
| Dang, J; Li, G; Yao, L; Zang, S; Zhang, S | 1 |
| Joo, J; Kwon, MM; Lim, KY; Park, BK; Park, HJ; Park, SY; Yoon, JH | 1 |
| Abi Gerges, D; Buyse, M; Fung, H; Gelmon, KA; Gorbunova, V; Hegg, R; Ibrahim, A; Konecny, GE; Krasnozhon, D; Lipatov, O; Mackey, JR; Manikhas, A; Martin, M; McCarthy, N; Ramos-Vazquez, M; Semiglazov, V; Simms, L; Thireau, F; Verma, S; Webster, M | 1 |
| Arnold, KM; Davis, J; Flynn, D; Opdenaker, LM; Sims-Mourtada, J | 1 |
| Hamaguchi, T; Honma, Y; Iwasa, S; Kato, K; Nagashima, K; Nishikawa, A; Okita, N; Sasaki, Y; Sawada, R; Shimada, Y; Shirakawa, T; Shoji, H; Takahashi, N; Takashima, A; Yamada, Y | 1 |
| Arrondeau, J; Huguet, F; Lacau St Guily, J; Le Nagat, S; Lefèvre, M; Tassart, M; Touboul, E | 1 |
| Cho, H; Kim, JH; Kim, S; Kim, SW; Kim, YT; Lee, M; Nam, EJ | 1 |
| Guo, H; Liu, Y; Yang, S; Yao, S; Yao, Z; Zhao, Y | 1 |
| Nahta, R; O'Regan, RM; Paplomata, E | 1 |
| Wang, W; Wang, Z; Xiao, X | 1 |
| Boni, C; Clemens, M; Cohn, A; Dane, F; Ecstein-Fraisse, E; Follana, P; Harrison, M; Hitier, S; Massuti, B; Middleton, G; Moiseyenko, V; Pernot, S; Pimentel, FL; Prenen, H; Reichardt, P; Richards, DA; Rougier, P; Tabernero, J; Van Cutsem, E; Zaniboni, A | 1 |
| Amarillo, I; Fisher, SI; Rashidi, A | 1 |
| Li, X; Li, Y | 1 |
| Agüero, A; Farré, N; García, J; León, X; López, M; López-Pousa, A; Quer, M | 1 |
| Barni, S; Botti, G; Colantuoni, G; D'Aiuto, M; Daniele, B; Daniele, G; De Laurentiis, M; De Maio, E; de Matteis, A; De Placido, S; Di Maio, M; Di Rella, F; Forestieri, V; Gallo, C; Gori, S; Gravina, A; Iodice, G; Labonia, V; Landi, G; Lauria, R; Montanino, A; Morabito, A; Nuzzo, F; Pacilio, C; Perrone, F; Piccirillo, MC; Riccardi, F; Rossi, E; Signoriello, S; Tinessa, V | 1 |
| Addeo, G; Allendorf, J; Chabot, J; Chu, K; Fine, RL; Hecht, E; Jin, B; Leung, D; Postolov, I; Remotti, H; Schrope, BA; Sherman, WH; Tsai, W | 1 |
| DePoint Christensen, R; Havsteen, H; Herrstedt, J; Kristensen, G; Lund, B; Maenpaa, J; Mirza, MR; Wang, Y | 1 |
| Aktas, B; Aydogdu, M; Feisel-Schwickardi, G; Höffkes, HG; Illmer, T; Janni, W; Loibl, S; Lübbe, K; Lück, HJ; Maass, N; Mehta, K; Nekljudova, V; Neunhöffer, T; Ober, A; Park-Simon, TW; Reinisch, M; Schumacher, C; Tomé, O; von Minckwitz, G; Wagner, H | 1 |
| Ba, Y; Bai, Y; Chen, W; Dai, G; Fan, N; Jiao, S; Li, J; Liu, T; Liu, Y; Ma, D; Qin, S; Shen, L; Shu, Y; Wang, J; Xu, J; Xu, R; Zheng, L | 1 |
| Autret, D; Capitain, O; Cellier, P; El Alouani, C; Gustin, P; Jadaud, É; Laccourreye, L; Peyraga, G; Pointreau, Y; Septans, AL; Tuchais, C; Vinchon-Petit, S; Yossi, S | 1 |
| Chin, K; Fukuda, H; Hironaka, S; Kataoka, K; Katayama, H; Kato, K; Kii, T; Kitagawa, Y; Mizusawa, J; Shibuya, Y; Tsubosa, Y; Tsushima, T | 1 |
| Dreicer, R; Gao, T; Klein, EA; Yerram, NK; Zhao, B | 1 |
| Beer, TM; Efstathiou, E; Forer, D; Higano, CS; Hirmand, M; Scher, HI; Taplin, ME | 1 |
| Cho, H; Hanamoto, A; Inohara, H; Nakahara, S; Nishiike, S; Takenaka, Y; Yamamoto, Y; Yasui, T | 1 |
| Bubley, GJ; Gray, KP; Hayes, JH; Hussain, A; Kantoff, PW; McKay, RR; Rosenberg, JE; Taplin, ME | 1 |
| Albiges, L; Fizazi, K; Loriot, Y; Massard, C | 1 |
| Baciuchka, M; Berdah, JF; Beuzeboc, P; Chinet-Charrot, P; Cojean-Zelek, I; Culine, S; Davin, JL; Delva, R; Deplanque, G; Faivre, L; Ferrero, JM; Fizazi, K; Fléchon, A; Gravis, G; Habibian, M; Houede, N; Krakowski, I; Labourey, JL; Lagrange, JL; Laguerre, B; Laplanche, A; Legouffe, E; Lesaunier, F; Linassier, C; Martin, AL; Mourey, L; Oudard, S; Priou, F; Ravaud, A; Rolland, F; Theodore, C | 1 |
| Blum, JL; Brooks, R; Brownstein, C; Hoersch, S; Holmes, FA; Jones, S; Koeppen, H; Krekow, L; Lackner, MR; Lindquist, D; McIntyre, K; O'Shaughnessy, J; Paul, D; Pippen, J; Rivera, R; Sedlacek, S; Stokoe, C; Vukelja, S; Xiao, Y | 1 |
| Carp, L; Corthouts, B; Specenier, P; Szturz, P; Van Den Weyngaert, D; Van Laer, C; Van Marck, E; Vanderveken, O; Vermorken, JB | 1 |
| Kawakami, H; Nakagawa, K; Nishina, S; Nonagase, Y; Okabe, T; Sakiyama, T; Tamura, T; Ueda, S | 1 |
| Fujiwara, K; Hasegawa, T; Hasumi, Y; Kigawa, J; Matsumoto, T; Nagao, S; Nakamura, K; Nishio, S; Okada, S; Otsuki, T; Shimada, M; Suzuki, M; Takano, M; Takei, Y; Takekuma, M; Tanabe, H | 1 |
| Abe, T; Andoh, M; Ishihara, M; Kadowaki, S; Kawai, R; Komori, A; Masuishi, T; Muro, K; Muto, M; Narita, Y; Niwa, Y; Nomura, M; Oze, I; Tajika, M; Tanaka, T; Taniguchi, H; Uemura, N; Ura, T | 1 |
| Kyprianou, N; Martin, SK | 1 |
| Bourhis, J; Bozec Le Moal, L; Dillies, AF; Fayette, J; Guigay, J; Henry, S; Kerger, JN; Machiels, JP; Pointreau, Y; Schilf, A; Sire, C; Tennevet, I; Zanetta, S | 1 |
| Donovan, H; Edwards, RP; Keeler, AW; Li, R; O'Neal, S; Petschauer, JS; Taylor, SE; Zamboni, WC; Zorn, KK | 1 |
| Nishimura, H; Senda, N; Shiozaki, T; Tsuyuki, S; Yamaguchi, A | 1 |
| Antonarakis, ES; Carducci, MA; Chen, Y; Eisenberger, MA; Lu, C; Luo, J; Nakazawa, M; Paller, CJ | 1 |
| Cai, YL; Guo, W; He, Y; Hong, CS; Hu, YJ; Ji, T; Lee, JJ; Li, J; Myers, JN; Ren, GX; Sun, J; Tu, WY; Wang, LZ; Wang, YA; Wang, ZH; William, WN; Xu, LQ; Yang, WJ; Ye, WM; Yin, QM; Zhang, CP; Zhang, ZY; Zhong, LP; Zhu, HG; Zhuang, Z | 1 |
| Cao, L; Cheng, HR; Li, RQ; Long, HL; Mao, WK; Xiao, BR; Zhai, XJ | 1 |
| Chen, Z; Ding, Q; Guo, G; Li, Z; Luo, F; Qian, Z; Shi, S; Yang, Y | 1 |
| Feifan, Z; Kun, M; Lin, M; Xinxin, Z | 1 |
| Adams, PT; Baez-Diaz, L; Bear, HD; Brufsky, AM; Costantino, JP; Fehrenbacher, L; Gaur, R; Geyer, CE; Gross, HM; Liu, Q; Mamounas, EP; Margolese, RG; Mehta, RS; Paik, S; Rastogi, P; Robidoux, A; Senecal, FM; Swain, SM; Tang, G; Wolmark, N; Young, JA | 1 |
| Fizazi, K; Saad, F | 1 |
| Choi, DH; Huh, SJ; Keum, KC; Kim, KH; Kim, YB; Noh, JM; Park, W; Suh, CO | 1 |
| Rexer, H | 2 |
| Bradley, WH; Eng, KH; Hanlon, BM; Szender, JB | 1 |
| Airoldi, M; Di Muzio, J; Fasolis, M; Franco, P; Garzaro, M; Garzino Demo, P; Melano, M; Moretto, F; Pecorari, G; Potenza, I; Ragona, R; Rampino, M; Ricardi, U; Riva, G; Schena, M | 1 |
| Spicer, J; Wu, Y | 1 |
| Daga, H; Goto, K; Hattori, Y; Iwamoto, Y; Kaneda, H; Kawaguchi, T; Nagase, S; Nakagawa, K; Nakanishi, Y; Nishimura, T; Oguri, T; Saka, H; Seto, T; Shukuya, T; Sugawara, S; Takahashi, T; Yamamoto, N; Yamanaka, T; Yokota, S | 1 |
| Cho, S; Ham, HS; Han, SW; Han, W; Im, SA; Keam, B; Kim, H; Kim, TY; Lee, KH; Min, A; Noh, DY; Oh, DY; Park, IA; Ryu, HS; Yang, Y; Youk, J | 1 |
| de Boer, JP; de Jong, MA; Driessen, CM; Gelderblom, H; Kaanders, JH; Melchers, WJ; Rasch, CR; Tesselaar, ME; van der Graaf, WT; van Herpen, CM; Verbist, BM | 1 |
| Cheng, ZB; Liao, H; Lin, Z; Liu, YM; Lv, BJ; Peng, PJ; Tang, C; Wang, SY; Wang, ZH | 1 |
| Du, C; Guo, C; Wang, J; Xu, Q; Zhou, A | 1 |
| Hayata, K; Iwahashi, M; Katsuda, M; Matsumura, S; Nakamori, M; Nakamura, M; Ojima, T; Yamaue, H | 1 |
| Anand, M; Armstrong, AJ; Bratt, L; Carducci, MA; Creel, P; Davis, K; George, DJ; Halabi, S; Healy, P; Hobbs, C; Kim, S; Koontz, BF; Lee, WR; Moul, JW; Mundy, K; Nguyen, M; Reimer, B; Stein, M; Tran, PT; Wood, S | 1 |
| Gehrig, PA; Kim, KH; Milam, B; Palisoul, M; Raker, C; Robison, K; Roque, DR; Taylor, KN; Wysham, WZ | 1 |
| Hayata, K; Iwahashi, M; Kato, T; Katsuda, M; Kitadani, J; Nakamori, M; Nakamura, M; Ojima, T; Tabata, H; Takeuchi, A; Yamaue, H | 1 |
| Hou, MF; Kim, SB; Nguyen Ba, D; Sayeed, A; Shah, MA; Shen, ZZ; Villalon, AH | 1 |
| Ba, DN; Chao, TY; Hou, MF; Kim, SB; Sayeed, A; Shah, MA; Shen, ZZ; Thuan, TV; Villalon, AH; Yau, TK | 1 |
| Kawada, K; Kawano, T; Miyawaki, Y; Nakajima, Y; Okada, T; Tokairin, Y | 1 |
| Azami, Y; Fuwa, N; Hareyama, M; Hatayama, Y; Hayashi, Y; Kikuchi, Y; Mitsudo, K; Nakamura, T; Ono, T; Suzuki, M; Takayama, K; Tohnai, I; Tsukiyama, I; Yamaguchi, H | 1 |
| Albanell, J; Campone, M; Chang, JC; de Haas, SL; Dewar, JA; Fumoleau, P; Garcia-Saenz, JA; Limentani, SA; Martin, M; Patre, M; Strasak, A; Xu, J | 1 |
| Aoki, D; Banno, K; Chiyoda, T; Hirasawa, A; Kataoka, F; Makabe, T; Ninomiya, T; Nomura, H; Sakai, K; Susumu, N; Takigawa, A; Wada, M; Yamagami, W | 1 |
| Abe, T; Hazama, S; Kanekiyo, S; Kitahara, M; Michihisa, I; Nagano, H; Nakajima, M; Nishiyama, M; Shindou, Y; Takeda, S; Yoshino, S | 1 |
| Asaftei, S; Cesari, M; Coccoli, L; Fagioli, F; Ferrari, S; Grignani, G; Jones, RL; Longhi, A; Marchesi, E; Meazza, C; Paioli, A; Palmerini, E; Picci, P; Pollack, SM; Tamburini, A | 1 |
| Alpert, Y; Bruchim, I; Fishman, A; Piura, E; Sade, D; Weeg, N | 1 |
| Huang, CQ; Ji, ZH; Li, Y; Peng, KW; Sun, JH; Wu, HT; Yang, XJ; Zhang, Q | 1 |
| Bellile, E; Bradford, C; Carey, TE; Chepeha, DB; Eisbruch, A; Jackson, TL; Malloy, K; McKean, E; McLean, S; Moyer, J; Nör, JE; Pearson, AT; Prince, M; Sacco, AG; Shuman, A; Spector, ME; Sukari, A; Swiecicki, PL; Taylor, JM; Wang, S; Wolf, GT; Worden, FP | 1 |
| Pugliano, L; Ryan, C; Tsoi, D; White, M; Woodward, N | 1 |
| Cheon, GJ; Chung, JK; Kang, KW; Kim, EE; Kim, YI; Lee, DS; Moon, WK; Paeng, JC; Yoon, HJ | 1 |
| Früh, M; Gautschi, O; Mirimanoff, RO; Peters, S; Pless, M; Ris, HB; Stupp, R; Xyrafas, A | 1 |
| Gill, HS; Mody, MD; Saba, NF | 1 |
| Cordero, A; Dougall, WC; Gomez-Miragaya, J; González-Suárez, E; Muñoz, P; Pellegrini, P; Planelles, L; Pujana, MA; Serra-Musach, J; Trinidad, EM; Yoldi, G | 1 |
| Aretin, MB; Fuchs, H; Fuereder, T; Grah, A; Kornek, G; Pammer, J; Posch, D | 1 |
| Bristow, R; Joshua, AM; Milosevic, MF; Smith, AD; Truong, M; Yip, P | 1 |
| Alunni-Fabbroni, M; Andergassen, U; Fasching, P; Fehm, T; Friedl, TW; Hecker, N; Hepp, P; Jäger, B; Janni, W; Lorenz, R; Rack, B; Schneeweiss, A; Trapp, E | 1 |
| Adkins, D; Axelrod, R; Dakhil, S; Debruyne, PR; Dong, J; Kornek, G; Murugappan, S; O'Brien, P; Oliner, KS; Pant, S; Wirth, LJ | 1 |
| Bolton, D; Corfield, J; Crozier, J; Joshua, AM; Lawrentschuk, N | 1 |
| Fujiwara, Y; Goto, K; Horinouchi, H; Hozumi, H; Kanda, S; Kitazono, S; Kubo, E; Mizugaki, H; Nokihara, H; Shiraishi, H; Sunami, K; Tamura, T; Tanaka, A; Utsumi, H; Yamamoto, N | 1 |
| Doihara, H; Hamada, A; Hinotsu, S; Hirata, T; Iwamoto, T; Matsuoka, J; Mizoo, T; Motoki, T; Nogami, T; Shien, T; Tabata, M; Taira, N; Tamura, T | 1 |
| Anderson, H; Bengtsson, NO; Bergh, J; Brandberg, Y; Carlsson, L; Egle, D; Fornander, T; Foukakis, T; Gnant, M; Greil, R; Hellström, M; Johansson, H; Karlsson, E; Loibl, S; Malmström, P; Mlineritsch, B; Möbus, V; Schmatloch, S; Singer, CF; Steger, G; Untch, M; von Minckwitz, G; Wallberg, B | 1 |
| Egashira, S; Fukushima, S; Ihn, H; Inoue, Y; Jinnin, M; Kajihara, I; Kanemaru, H; Nagamoto, E; Nakahara, S; Uemura-Kiyohara, M; Yamada-Kanazawa, S | 1 |
| Jiang, W; Luo, S; Pan, H; Shi, M; Wang, J; Xu, M; Zang, J; Zhao, L; Zhou, Y | 1 |
| Albiges, L; Attard, G; Bianchini, D; de Bono, J; Fizazi, K; Loriot, Y; Massard, C; Mateo, J; Mehra, N; Petrylak, DP; Pezaro, C; Ryan, CJ; Shen, L; Varga, A | 1 |
| Bhandari, M; Jones, RG; Kang, SY; Seim, NB; Teknos, TN | 1 |
| Allaoui, M; Elm'hadi, C; Errihani, H; Ichou, M; Khmamouche, MR; Mahtat, E; Messaoudi, N; Oukabli, M; Tanz, R; Toreis, M | 1 |
| Adkins, D; Daly, K; Ley, J; Oppelt, P; Wildes, TM | 1 |
| Hosoda, K; Katada, C; Katada, N; Komori, S; Mieno, H; Moriya, H; Sugawara, M; Watanabe, M; Yamashita, K | 1 |
| Furue, M; Uchi, H; Wada, N | 1 |
| Hayasaka, T; Honda, T; Imai, N; Kagabu, S; Kin, S; Matsui, T; Nishigori, H; Oishi, T; Otsuki, T; Sato, H; Sato, K; Shimokawa, H; Shoji, T; Sugiyama, T; Takahashi, F; Tando, T; Tokunaga, H; Wagatsuma, S; Watanabe, T; Watanabe, Y; Yaegashi, N; Yamada, H; Yamamoto, H; Yokoyama, Y; Yoshida, Y; Yoshinaga, K | 1 |
| Bajorin, DF; Bellmunt, J; Choueiri, TK; Climent, MA; Culine, S; de Wit, R; Fong, L; Fradet, Y; Gerritsen, W; Gurney, H; Lee, JL; Mai, Y; Necchi, A; Perini, RF; Petrylak, DP; Poehlein, CH; Quinn, DI; Sternberg, CN; Vaughn, DJ; Vogelzang, NJ | 1 |
| Atagi, S; Fujita, S; Hida, T; Kato, T; Masuda, N; Nakanishi, Y; Namba, Y; Sakai, H; Satouchi, M; Takahashi, M; Takeda, K; Tamura, T; Tanaka, H | 1 |
| Bacich, DJ; Cummings, JL; O'Keefe, DS; Sobek, KM | 1 |
| Andre, F; Broglio, K; Hortobagyi, GN; Mackey, JR; Martin, M; Penault-Llorca, F; Pusztai, L; Roche, H | 1 |
| Bachelot, T; Blay, JY; Dufresne, A | 1 |
| Eisenkop, SM; McAlpine, JN; Spirtos, NM | 1 |
| Blessing, JA; Garcia, AA; Mannel, RS; Nolte, S | 1 |
| Hamada, Y; Horikoshi, N; Ichinose, I; Ikeda, T; Ishikawa, E; Kobayashi, S; Mitsuyama, S; Tamura, K | 1 |
| Borghaei, H; Cohen, RB; Huang, CH; Langer, CJ; Millenson, MM; Mintzer, DM; Ruth, KJ; Seldomridge, J; Sherman, EJ; Staddon, AP; Treat, OJ; Tuttle, H | 1 |
| Choi, IK; Kim, AR; Kim, JS; Kim, YH; Koo, BH; Lee, JB; Oh, SC; Park, KH; Seo, JH; Shin, SW; Sung, HJ | 1 |
| Bu, Q; Cai, QQ; Guan, ZZ; Hu, XH; Huang, HQ; Li, YH; Lin, XB; Pan, ZH; Shuang, YR; Wang, AL | 1 |
| Fujita, Y; Hiramatsu, M; Kawai, M; Nishimura, H; Sumiyoshi, K; Tanigawa, N | 1 |
| Chen, Z; Guo, J; Li, CZ; Liu, B; Liu, J; Sheng, LJ; Wang, QC; Wang, ZH; Zhang, EN; Zhou, DG | 1 |
| Kim, JH; Lee, YC | 1 |
| Leminen, A; Mäenpää, J | 1 |
| Chen, W; Gadgeel, SM; Kalemkerian, GP; Kraut, MJ; Schneider, BJ; Smith, DW; Worden, FP; Wozniak, AJ | 1 |
| Shao, ZY; Zhang, JD | 1 |
| Herbst, RS; Hong, WK; Kim, ES; Lee, JJ; Liu, D; Mauer, AM; Tran, HT; Vokes, EE; William, WN; Windt, P | 1 |
| Chang, JW; Chen, CH; Lin, CM; Tsao, TC | 1 |
| Shinden, S; Shiotani, A; Watabe, T; Yamashita, T | 1 |
| Cho, BC; Choi, EC; Choi, HJ; Keum, KC; Kim, JH; Kim, SH; Lee, YJ; Shin, SJ | 1 |
| Barlow, L; Benson, M; McKiernan, J; Sawczuk, I | 1 |
| Al Hasan, SA; Cher, ML; Dickow, B; Eliason, J; Heilbrun, LK; Marur, S; Smith, DW; Vaishampayan, UN | 1 |
| Fouret, P; Handra-Luca, A; Planchard, D | 1 |
| Cao, Z; Jin, J; Li, X; Liu, J; Lu, W; Tucker, SJ; Wang, D; Wang, F; Xu, X; Yan, G; Zhong, B | 1 |
| Egashira, A; Emi, Y; Kakeji, Y; Maehara, Y; Morita, M; Oki, E; Sadanaga, N; Takahashi, I | 1 |
| Chilcott, J; Lloyd Jones, M; Wilkinson, A | 1 |
| Anderson, DM; Bernath, AM; Gamini, SS; Hillman, DW; Niedringhaus, R; Northfelt, DW; Palmieri, F; Perez, EA; Salim, M; Stella, PJ; Tan, WW | 1 |
| Argiris, A; Axelrod, R; Brockstein, B; Buchanan, A; Forastiere, A; Ghebremichael, M; Hahn, K; Kolesar, J; Pins, M | 1 |
| Habuchi, T; Numakura, K; Takahashi, N; Tsuchiya, N | 1 |
| Hanai, N; Hasegawa, Y; Hirakawa, H; Ozawa, T; Terada, A; Yokoi, H | 1 |
| Endou, Y; Hirano, M; Ichinose, M; Ikeda, M; Ikeda, S; Kimura, H; Masuda, S; Matsuda, T; Matsuki, N; Miura, M; Mizumoto, A; Mizuno, M; Nakajima, G; Sasaki, T; Shinbo, M; Takao, N; Yonemura, J; Yonemura, Y; Yuuba, T | 1 |
| Candeloro, G; Di Orio, F; Guerriero, G; Piazze, J; Rea, S; Recchia, F | 1 |
| Ju, JH; Kang, JH; Kang, MH; Kim, HG; Kim, JP; Lee, GW; Park, JJ | 1 |
| Alanko, T; Asola, R; Auvinen, P; Bono, P; Helle, L; Huusko, M; Ingalsuo, S; Isola, J; Joensuu, H; Jyrkkiö, S; Kataja, V; Kellokumpu-Lehtinen, PL; Kokko, R; Leinonen, H; Leinonen, M; Möykkynen, K; Pajunen, M; Salminen, T; Turpeenniemi-Hujanen, T; Utriainen, T | 1 |
| Arimura, Y; Hokari, K; Hosokawa, M; Kodaira, J; Okahara, S; Shinomura, Y; Takahashi, H; Tanuma, T; Tsukagoshi, H; Yamashita, K | 1 |
| Fan, QX; Han, N; Wang, HL; Wang, J; Zhang, ZM | 1 |
| Gelmon, K; Mackey, J; Martin, M; McCarthy, N; Pinter, T; Rupin, M; Youssoufian, H | 1 |
| Ami, K; Andou, M; Arai, K; Fukuda, A; Ganno, H; Hataji, K; Kurokawa, T; Nagahama, T; Ohara, T; Tei, S | 1 |
| Bibeau, F; Bleuse, JP; Colombo, PE; Gourgou-Bourgade, S; Gutowski, M; Jacot, W; Kramar, A; Romieu, G | 1 |
| Hataya, K; Kimura, M; Kobayashi, O; Koizumi, W; Nabeshima, K; Sato, A; Shimada, K; Takahashi, M; Tsuburaya, A; Yoshikawa, T; Yoshizawa, Y | 1 |
| Baba, K; Hasegawa, Y; Ichikawa, M; Imaizumi, K; Kataoka, K; Kondo, M; Kume, H; Matsumoto, S; Noda, Y; Shindo, Y; Shindoh, J; Suzuki, K; Suzuki, R; Takagi, K; Taniguchi, H; Tanikawa, Y | 1 |
| Goto, K; Kim, YH; Kubota, K; Nagano, T; Naito, Y; Niho, S; Nishiwaki, Y; Ohmatsu, H; Saijo, N; Yoh, K | 1 |
| Fujimoto, N; Fujiwara, Y; Kiura, K; Tabata, M; Takigawa, N; Tanimoto, M; Toyooka, S; Ueoka, H; Umemura, S | 1 |
| Bamberg, M; Belka, C; Berger, B; Budach, W; Hehr, T; Weinmann, M | 1 |
| Abulafia, O; Blessing, JA; Miller, BE; Richards, WE; Secord, AA; Shahin, MS; Stehman, FB; Van Le, L; Warshal, DP; Yamada, SD | 1 |
| Hozumi, Y; Masuda, N; Mitsuyama, S; Mukai, H; Murakami, S; Ohashi, Y; Ohmura, T; Takashima, T; Watanabe, T; Yajima, T | 1 |
| Ohdan, H; Suzuki, T; Tanabe, K; Tokumoto, N; Yamamoto, H; Yoshida, K | 1 |
| Hosojima, Y; Miura, T; Nakamura, J; Nakazawa, Y; Ozeki, Y; Takahashi, T; Yamada, S; Yamazaki, H; Yanagi, M | 1 |
| Chan, A; Chlistalla, A; Cortés, J; Delozier, T; Dirix, LY; Harbeck, N; Miles, DW; Pivot, X; Provencher, L; Puglisi, F; Romieu, G; Schneeweiss, A; Sohn, JH; Steger, GG; Tomczak, P; Wardley, AM | 1 |
| Araki, K; Doi, T; Fuse, N; Hayashi, R; Kawashima, M; Kiyota, N; Minami, H; Minashi, K; Ogino, T; Ohtsu, A; Okano, S; Tahara, M; Yoshino, T; Zenda, S | 1 |
| Cameron, DA; Coleman, RE; Crown, J; Earl, HM; Evans, TR; Gallagher, CJ; Highley, M; Jones, AL; Leonard, RC; Lipscombe, J; Mansi, JL; Perren, T; Quigley, M; Yellowlees, A | 1 |
| Foster, J; Lee, J; Urba, S; Worden, F; Zhang, J | 1 |
| Bradley, D; Daignault, S; Dunn, R; Egorin, MJ; Hussain, M; Kalemkerian, GP; Schneider, BJ; Smith, DC | 1 |
| Aoki, D; Hatae, M; Hiura, M; Jobo, T; Katsumata, N; Konishi, I; Nomura, H; Takahashi, F; Watanabe, Y; Yaegashi, N | 1 |
| Baker, LH; Chenevert, T; Chugh, R; Karantza, V; Mehnert, J; Moss, RA; Poplin, EA; Saraiya, B; Savkina, N; Stein, MN | 1 |
| Akiyama, H; Endo, I; Fujii, S; Kameda, K; Kimura, J; Kito, F; Kosaka, T; Kunisaki, C; Makino, H; Morita, S; Ono, HA; Oshima, T; Takagawa, R; Takahashi, M | 1 |
| Chang, HM; Kang, YK; Kim, BS; Kim, TW; Oh, ST; Ryu, MH; Yoo, C; Yook, JH | 1 |
| Han, B; Kang, WK; Kim, JA; Lee, J; Lim, HY; Park, JO; Park, SH; Park, YS | 1 |
| Ahn, EH; Eno, ML; Im, DD; Matsuo, K; Rosenshein, NB; Shahzad, MM; Sood, AK | 1 |
| Dyck, J; Huizing, MT; Rasschaert, M; Schrijvers, D; Specenier, P; Van den Brande, J; Vermorken, JB; Vroman, P | 1 |
| Bai, YX; Cheng, Y; Jiang, ZF; Jiao, SC; Li, X; Liu, DQ; Liu, JW; Liu, WC; Ren, J; Sun, Q; Tang, LL; Wang, HQ; Wang, Y; Wang, YS; Wei, Y; Xiao, JX; Xie, XD; Zhang, SH | 1 |
| de Vries, A; Gastl, G; Lukas, P; Mühlmann, G; Öfner, D; Pluschnig, U; Spizzo, G; Steger, G; Widder, J; Zabernigg, A; Zacherl, J | 1 |
| Buekers, TE; Fracasso, PM; Kunos, CA; Mohiuddin, M; Schilder, JM; Sill, MW; Waggoner, SE; Walker, JL; Yamada, SD | 1 |
| Chen, ZW; Jian, H; Li, ZM; Lu, S; Song, ZB; Yu, YF; Zhang, YF; Zhou, Z | 1 |
| Bonebrake, AJ; De Geest, K; Edwards, R; Hanjani, P; Monk, BJ; Rotmensch, J; Sill, MW; Walker, JL | 1 |
| Allen, A; Hsueh, CT; Huang, CH; Kelly, K; Mayo, M; Smith, H; Tawfik, O; Uypeckcuat, AM; Van Veldhuizen, PJ; Wick, J; Williamson, SK | 1 |
| Chang, SY; Chang, YC; Chu, PY; Hsieh, SL; Li, WY; Tai, SK; Tsai, TL; Wang, YF; Yang, MH | 1 |
| Amano, R; Hirakawa, K; Ishikawa, T; Kubo, N; Maeda, K; Morimoto, J; Muguruma, K; Nagahara, H; Nakata, B; Noda, E; Ohira, M; Onoda, N; Sakurai, K; Sawada, T; Takashima, T; Tanaka, H; Yamada, N; Yashiro, M | 1 |
| Amagasa, H; Ami, K; Ando, M; Arai, K; Fukuda, A; Ganno, H; Hataji, K; Kawasaki, Y; Kurokawa, T; Nagahama, T; Tei, S; Watayou, Y | 1 |
| Aoyagi, H; Hamada, S; Hasegawa, K; Kaneko, J; Katsuta, E; Maejima, S; Ohkubo, T; Saguchi, M; Someno, Y; Takahata, T | 1 |
| Cullen, K; Fasciano, J; Goloubeva, O; Haddad, RI; Lorch, JH; Posner, MR; Sammartino, DE; Sarlis, N; Tan, M; Tishler, R | 1 |
| Argenta, PA; Boente, MP; Carson, LF; Downs, LS; Dusenbery, K; Geller, MA; Ghebre, R; Ivy, JJ; Jonson, AL; Judson, PL; Vogel, RI | 1 |
| Kajiura, Y; Yagata, H; Yamauchi, H | 1 |
| Fujiwara, K; Kigawa, J; Kitada, F; Nagao, S; Nishimura, R; Takekida, S; Terakawa, N; Yamaguchi, S; Yoshida, N | 1 |
| del Valle, ML; Sanz, A | 1 |
| Belzer, K; Burger, AM; Chen, W; Gadgeel, SM; Hackstock, D; Konski, A; Marquette, L; Patel, BB; Ruckdeschel, JC; Turrisi, A; Valdivieso, M; Wozniak, A | 1 |
| Corrado, G; di Stefano, A; Ferrandina, G; Lucidi, A; Margaritora, S; Piraino, A; Salutari, V; Scambia, G | 1 |
| Chang, PM; Chang, SY; Chang, YF; Chen, MH; Hwang, WS; Su, WC; Tsao, CJ; Tzeng, CH; Yang, MH | 1 |
| Amano, S; Enomoto, K; Matsuo, S; Sakurai, K; Shiono, M | 1 |
| Doki, Y; Fujiwara, Y; Kurokawa, Y; Miyata, H; Mori, M; Nakajima, K; Okada, K; Takiguchi, S; Yamasaki, M | 1 |
| Markman, M | 1 |
| Catanzaro, M; Colecchia, M; Necchi, A; Nicolai, N; Piva, L; Salvioni, R; Torelli, T | 1 |
| Andrieu, JM; Bats, AS; Eme, D; Hofmann, H; Huchon, C; Le Frere-Belda, MA; Lecuru, F; Levy, E; Medioni, J; Oudard, S | 1 |
| Buyse, ME; Dy, PA; Geyer, CE; Jacobs, SA; Liepman, MK; Mamounas, EP; Melnik, MK; Pajon, ER; Piette, F; Posada, JG; Rastogi, P; Robidoux, A; Swain, SM; Wolmark, N | 1 |
| Bennouna, J; de Castro, J; Dingemans, AM; Gridelli, C; Griesinger, F; Grossi, F; Langer, C; Rossi, A; Thatcher, N; Wong, EK | 1 |
| Armstrong, AJ; Berry, WR; Brookes, M; de Wit, R; Eisenberger, MA; Leopold, L; Pond, GR; Sonpavde, G; Tannock, IF; Wood, BA | 1 |
| Chan, S; Davidson, SE; Harden, S; McMahon, T; Paul, J; Rai, D; Reed, NS; Symonds, RP | 1 |
| Benedetti, G; Chang, HT; Ciruelos, E; Duenne, AA; Miles, DW; Passos-Coelho, JL; Pivot, X; Schneeweiss, A; Thomssen, C; Verma, S; von Moos, R | 1 |
| Ae, T; Azuma, M; Higuchi, K; Ishido, K; Katada, C; Koizumi, W; Nakatani, K; Nakayama, N; Naruke, A; Nishimura, K; Sasaki, T; Takagi, S; Tanabe, S | 1 |
| Guancial, EA; Taplin, ME | 1 |
| Chen, I; Chow Maneval, E; George, DJ; Harmon, CS; Hutson, TE; Kozloff, M; Liu, G; Logothetis, CJ; Mathew, P; Shore, ND; Wang, SL; Wilding, G; Zurita, AJ | 1 |
| Asahina, H; Horinouchi, H; Kubota, K; Nokihara, H; Sekine, I; Tamura, T; Yamamoto, N | 1 |
| Coleman, RL; Duska, LR; Garcia, ME; Heymach, JV; Iyer, RB; Jackson, EF; Jaffe, R; Kamat, AA; Kundra, V; Miller, DL; Modesitt, SC; Ng, CS; Ramirez, PT; Schmeler, KM; Sood, AK | 1 |
| Ariga, H; Jingu, K; Koto, M; Kubozono, M; Miyata, G; Narazaki, K; Nemoto, K; Onodera, K; Sugawara, T; Takeda, K; Umezawa, R; Yamada, S | 1 |
| Kondo, C; Mizota, A; Muro, K; Nomura, M; Shitara, K; Takahari, D; Ura, T; Yokota, T | 1 |
| Börgermann, C; Molitor, B | 1 |
| Ayala de la Peña, F; Chaves Benito, A; Garcia Garcia, T; Garcia-Martinez, E; Gonzalez Billalabeitia, E; Vicente Conesa, MA; Vicente Garcia, V | 1 |
| Kamura, T; Kuzuya, K; Noda, K; Ochiai, K; Sugiyama, T; Tamura, K; Ushijima, K | 1 |
| Enomoto, T; Fujita, M; Kimura, T; Kobayashi, E; Tsutsui, T; Ueda, Y; Yoshino, K | 1 |
| Cengiz, M; Kotek, A; Ozsahin, M; Parlak, C; Pehlivan, B; Topkan, E; Yuksel, O | 1 |
| Fu, S; Jiang, R; Liu, T; Lu, JJ; Peng, L; Tey, J; Xiong, F; Yang, Z; Zhang, Q | 1 |
| Habuchi, T; Horikawa, Y; Inoue, T; Kumazawa, T; Maita, S; Nanjyo, H; Narita, S; Numakura, K; Obara, T; Saito, M; Satoh, S; Tsuchiya, N; Tsuruta, H | 1 |
| Ben-Ami, T; Gosiengfiao, Y; Reichek, J; Walterhouse, D; Woodman, J | 1 |
| Fu, X; Hsia, Y; Li, J; Long, X; Luo, S; Shi, M; Wang, J; Xiao, F; Xu, M; Zhao, L; Zhou, B | 1 |
| Furuya, T; Hirowatari, H; Ito, K; Izawa, H; Karasawa, K; Mitsuhashi, N; Ozawa, S; Saito, M; Suzuki, T | 1 |
| Chen, Y; Shi, Y; Wang, C; Yang, Y | 1 |
| Mahmood, A; Rahman, A | 1 |
| Awada, A; Bergh, J; Cardoso, F; Gianni, L; Giorgetti, C; Huang, X; Kern, KA; Liljegren, A; Mariani, G; Verkh, L; Viganò, L | 1 |
| Date, H; Fujiwara, T; Kiura, K; Miyoshi, S; Oto, T; Takemoto, M; Takigawa, N; Toyooka, S | 1 |
| Baeuerle, PA; Eiermann, W; Göppel, G; Hanusch, CA; Lang, A; Marschner, N; Oruzio, D; Rüttinger, D; Schlimok, G; Schmidt, M; Schuler, M; Sebastian, M; Steger, GG; Wolf, A; Wolf, C | 1 |
| Imholz, ALT; Laddach, N; Lips, EH; Mulder, L; Oonk, AMM; Rodenhuis, S; Savola, SP; Smits, MM; van Rijn, C; Wesseling, J | 1 |
| Benjamin, RS; Chawla, S; Chugh, R; Fox, E; Harmon, D; Helman, LJ; Patel, S; Reinke, D; Schuetze, S; Wathen, JK | 1 |
| Iitsuka, C; Iwase, H; Nomura, H; Omatsu, K; Sakamoto, K; Takada, T; Takeshima, N; Takizawa, K | 1 |
| Perry, CJ; Sundar, S | 1 |
| He, AN; Lin, F; Qi, WX; Shen, Z; Tang, LN; Yao, Y | 1 |
| Facio, G; Garcia, AA; Muderspach, L; Pham, H; Roman, L; Yessaian, A | 1 |
| Du, C; Hu, C; Ying, H; Zhang, Y; Zhou, J | 1 |
| Haruma, K; Higashida, M; Hirabayashi, Y; Hirai, T; Hiratsuka, J; Kubota, H; Matsumoto, H; Murakami, H; Nakamura, M | 1 |
| Arsenijevic, L; Atanackovic, J; Jeftovic, M; Jeremic, K; Stefanovic, A; Stojnic, J; Zecevic, N | 1 |
| Dalenc, F; Filleron, T; Fumoleau, P; Kerbrat, P; Kramar, A; Martin, AL; Roché, H; Spielmann, M | 1 |
| Antonarakis, ES; Carducci, MA; De Marzo, AM; Eisenberger, MA; Fedor, HL; Gurel, B; Hicks, JL; Keizman, D; Lotan, TL; Zhang, Z | 1 |
| Fukuoka, M; Katakami, N; Kudoh, S; Kurata, T; Matsui, K; Mitsudomi, T; Nishimura, Y; Saka, H; Senba, H; Tada, H | 1 |
| Fujiwara, H; Ichikawa, D; Iitaka, D; Ikoma, H; Kokuba, Y; Komatsu, S; Kuriu, Y; Murayama, Y; Nakanishi, M; Ochiai, T; Okamoto, K; Otsuji, E; Shiozaki, A; Sonoyama, T | 1 |
| Ahn, MJ; Cho, IS; Heo, DS; Hwang, DW; Jang, JS; Ji, JH; Kang, JH; Kim, SB; Park, JC; Park, K; Shin, SW; Sohn, CH; Sun, JM; Yun, T | 1 |
| Bando, Y; Furukita, Y; Goto, M; Minato, T; Seike, J; Takechi, H; Tangoku, A; Yamai, H; Yamamoto, Y; Yoshida, T; Yuasa, Y | 1 |
| Aoki, Y; Emi, M; Hamai, Y; Hihara, J; Kushitani, K; Okada, M; Tanabe, K | 1 |
| Chang, JC; Dave, B; Dobrolecki, LE; Hilsenbeck, SG; Landis, MD; Lewis, MT; Liu, D; Tweardy, DJ; Westbrook, TF; Wu, MF; Zhang, X | 1 |
| Abgral, R; Gouders, D; Keromnes, N; Le Roux, PY; Leleu, C; Mollon, D; Nowak, E; Querellou, S; Rousset, J; Salaün, PY; Valette, G | 1 |
| Blay, JY; Bompas, E; Cioffi, A; Collin, F; Cupissol, D; Delcambre, C; Duffaud, F; Floquet, A; Isambert, N; Jimenez, M; Pautier, P; Penel, N; Piperno-Neumann, S; Rey, A | 1 |
| Burnside, N; MacGowan, SW | 1 |
| Baek, JH; Cho, SH; Choi, YH; Chung, IJ; Hong, YS; Jeung, HC; Kang, HJ; Kim, BS; Kim, JS; Nam, SH; Oh, SC; Song, EK; Yang, SH; Yim, CY | 1 |
| Date, H; Hotta, K; Kanazawa, S; Katsui, K; Kiura, K; Miyoshi, S; Shien, K; Toyooka, S | 1 |
| Aldrighetti, D; Amadori, D; Bouko, Y; Canon, JL; Cardoso, F; Dirix, L; Giorgetti, C; Kern, KA; Machiels, JP; Usari, T; Verkh, L | 1 |
| Anderson, SJ; Bear, HD; Dignam, JJ; Geyer, CE; Julian, TB; Mamounas, EP; Taghian, A; Wickerham, DL; Wolmark, N | 1 |
| Al-Batran, SE; Bokemeyer, C; Hartmann, JT; Hofheinz, RD; Hollerbach, S; Homann, N; Jäger, E; Kullmann, F; Luley, K; Mahlberg, R; Moehler, M; Pauligk, C; Prasnikar, N; Probst, S; Rethwisch, V; Stoehlmacher-Williams, J | 1 |
| Chen, Y; Cui, Y; Feng, Y; Li, Q; Liu, T; Wang, Y; Yu, Y | 1 |
| Biesma, B; Heideman, D; Smit, EF; Thunnissen, E; van Riel, S | 1 |
| Cheng, HH; Lin, DW; Yu, EY | 1 |
| Ben-Harim, Z; Bruchim, I; Fishman, A; Shavit, T | 1 |
| Date, M; Fujiwara-Honjo, N; Haba, R; Hashimoto, S; Houchi, H; Kontani, K; Kuroda, N; Kushida, Y; Murazawa, C; Norimura, S; Ohtani, M; Tanaka, H; Yamauchi, A; Yokomise, H | 1 |
| Barlow, LJ; Benson, MC; McKiernan, JM | 1 |
| Jonkers, J; Rottenberg, S | 1 |
| Baek, SK; Jung, KY; Kim, CY; Kim, DS; Kim, IS; Kim, JS; Kim, YH; Kwon, SY; Lee, NJ; Park, KH; Park, Y; Shin, SW | 1 |
| Chen, JH; Chen, KY; Ho, CC; Liao, WY; Shih, JY; Wu, M; Yang, JC; Yu, CJ | 1 |
| Fietkau, R; Iro, H; Kuwert, T; Lell, M; Lettmaier, S; Schmidt, D; Semrau, S; Waldfahrer, F | 1 |
| Ding, JX; Han, JH; Ji, FZ; Ji, YL; Li, T; Pu, J; Qin, SS; Sun, JX; Tao, GZ; Yu, CH; Zhang, Y; Zhou, XL; Zhu, WG | 1 |
| Chen, J; Huan, Y; Jia, Q; Jiang, W; Wang, L; Wei, M; Xu, J; Zheng, M | 1 |
| Araujo, DM; Baker, LH; George, S; Hensley, ML; Maki, RG; Priebat, DA; Soslow, RA; Sutton, G; Wathen, JK | 1 |
| Fujiwara, T; Gochi, A; Kagawa, S; Kimura, T; Kishimoto, H; Ninomiya, M; Nishizaki, M; Nonaka, Y; Shigeyasu, K; Takahata, T; Uno, F | 1 |
| Ardizzoni, A; Bisagni, G; Boni, C; De Matteis, A; Gamucci, T; Gnoni, R; Gori, S; Moretti, G; Musolino, A; Nuzzo, F; Panebianco, M; Passalacqua, R | 1 |
| Glisson, BS | 1 |
| Baur, M; DeSantis, M; Dittrich, C; Gerber, E; Hudec, M; Kienzer, HR; Pont, J; Schratter-Sehn, AU; Schweiger, J; Wicke, W | 1 |
| Degendorfer, P; Furlan, M; McCarthy, JS; Panzarella, T; Siu, LL; Tannock, IF | 1 |
| Adjei, AA; Baron, AT; Geeraerts, L; Hatfield, AK; Ingle, JN; Kugler, JW; Kuross, SA; Lafky, JM; Maihle, N; Michalak, JC; Perez, EA; Suman, VJ | 1 |
| Petrylak, DP | 2 |
| Bang, YJ; Boudraa, Y; Daglish, B; Heo, DS; Jacques, C; Kang, WK; Kang, YK; Kim, HC; Kim, NK; Kim, WS; Zuber, E | 1 |
| Hyodo, I; Katsu, K; Mitachi, Y; Miyata, Y; Ohtsu, A; Sairenji, M; Saitoh, S; Sakata, Y; Sato, T; Suwa, T | 1 |
| Blohmer, JU; Breidenbach, M; Göhring, UJ; König, E; Kurbacher, CM; Mallmann, P; Rein, DT; Schmidt, T; Schöndorf, T | 1 |
| Fossella, FV; Lynch, T; Shepherd, FA | 1 |
| Kurihara, M; Matsukawa, M; Nakamachi, M; Sato, A; Shimada, K; Ushio, J; Yamamoto, W | 1 |
| Budd, GT; Bukowski, RM; Elson, P; Hutson, TE; Mekhail, T; Olencki, T; Peereboom, D; Pelley, R; Srkalovic, G | 1 |
| Andre, F; Fandi, A; Fossella, F; Herbst, RS; Le Chevalier, T; Lee, JJ; Liu, DD; Massarelli, E; Ochs, J; Wolf, M | 1 |
| Antman, K; Brafman, L; Fine, R; Nelsen, C; Petrylak, DP; Shriberg, L; Talbot, S; Tiersten, AD; Troxel, A; Vahdat, L | 1 |
| Aoki, Y; Fujita, K; Kurata, H; Matsushita, H; Obata, H; Tanaka, K; Watanabe, M; Yahata, T | 1 |
| Dörken, B; Krenn, V; Kretzschmar, A; Reichardt, P; Thuss-Patience, PC | 1 |
| Airoldi, M; Bumma, C; Cortesina, G; Gabriele, P; Giordano, C; Pedani, F | 1 |
| Enomoto, K; Fukuda, M; Haga, S; Iino, Y; Ikeda, T; Shimizu, T; Taguchi, T | 1 |
| Aravantinos, G; Bafaloukos, D; Christodoulou, C; Dimopoulos, MA; Fountzilas, G; Gogas, H; Kalofonos, HP; Kosmidis, P; Papadimitriou, C; Pavlidis, N | 1 |
| Heys, SD; Hutcheon, AW; Sarkar, TK | 1 |
| Aotani, E; Fujiwara, K; Fujiwara, M; Kato, H; Katsumata, N; Kigawa, J; Kohno, I; Numa, F; Oishi, T; Terakawa, N | 1 |
| Airoldi, M; Beatrice, F; Bumma, C; Cattel, L; Marchionatti, S; Maria Gabriele, A; Pedani, F; Recalenda, V; Succo, G; Tagini, V | 1 |
| Bernhard, H; Bredenkamp, R; Hennig, M; Lordick, F; Peschel, C; von Schilling, C | 1 |
| Liu, WW; Yu, QW; Zeng, J; Zeng, ZY | 1 |
| Ahiskali, R; Celikel, T; Ceyhan, BB; Duman, D; Duman, DG | 1 |
| Bessho, A; Eguchi, K; Harada, M; Harita, S; Hiraki, S; Hiraki, Y; Kamei, H; Kiura, K; Okimoto, N; Segawa, Y; Tabata, M; Takemoto, M; Takigawa, N; Tanimoto, M; Ueoka, H; Watanabe, Y | 1 |
| Haga, S; Hanyu, N; Karasawa, K; Katsui, K; Kimura, T; Kohno, M; Maebayashi, K; Mitsuhashi, N; Muramatsu, H; Nasu, S; Seki, K; Takahashi, I | 1 |
| Gamoh, M; Kanamaru, R; Mitachi, Y; Saitoh, S; Sakata, Y; Sekikawa, K; Terashima, M; Yoshioka, T | 1 |
| Hirata, Y; Imanishi, K; Kaku, M; Kobayashi, A; Murao, S; Ohara, N; Seima, Y; Tomura, N; Yamasaki, M | 1 |
| Anderson, S; Bear, HD; Brown, A; Fisher, B; Mamounas, EP; Margolese, R; Smith, R; Soran, A; Theoret, H; Wickerham, DL; Wolmark, N | 1 |
| Kawaguchi, Y; Saji, S; Sugiyama, Y | 1 |
| Fujita, H; Matono, S; Sasahara, H; Shirouzu, K; Sueyoshi, S; Tanaka, T; Yamana, H | 1 |
| Kuzuya, K; Mizutani, S; Nakanishi, T; Nawa, A; Niwa, Y | 1 |
| Brechot, JM; Breton, JL; Clouet, P; Debieuvre, D; Depierre, A; Ducolone, A; Lebeau, B; Lemarie, E; Milleron, B; Moro-Sibilot, D; Pujol, JL; Quoix, E; Vaylet, F; Vergnenegre, A; Zalcman, G | 1 |
| Asai Go, Go; Fukuoka, M; Kaneda, H; Kurata, T; Nakagawa, K; Nogami, T; Tamura, K; Uejima, H | 1 |
| Kawamoto, K; Kuroiwa, T; Ochiai, N; Tajima, T; Tomita, K; Yabuuchi, H | 1 |
| Alfonsi, M; Auvray, H; Bardet, E; Bourhis, J; Calais, G; Garaud, P; Man, YT; Rhein, B; Sire, C; Tortochaux, J | 1 |
| Manegold, C | 1 |
| Akashi-Tanaka, S; Ando, M; Fukutomi, T; Hasegawa, T; Iwamoto, E; Katsumata, N; Miyakawa, K; Sato, N; Watanabe, T | 1 |
| Bayouth, J; Culp, LR; Jones, DV; Pou, AM; Sanguineti, G | 1 |
| Aoe, M; Date, H; Fujiwara, T; Hiraki, Y; Katayama, H; Kiura, K; Kozuki, T; Shimizu, N; Tabata, M; Takemoto, M; Tanaka, N; Tanimoto, M; Ueoka, H | 1 |
| Bergh, J; Linderholm, B | 1 |
| Hanna, NH | 1 |
| Hirono, M; Ikeda, M; Kurebayashi, J; Nakashima, K; Nomura, N; Okubo, S; Sonoo, H; Tanaka, K; Udagawa, K; Yamamoto, Y | 1 |
| Aragane, Y; Isogai, R; Kawada, A; Tezuka, T | 1 |
| Ajani, JA; Andrassy, RJ; Blakely, ML; Harting, MT; Herzog, CE; Lally, KP | 1 |
| Adak, S; Aisner, S; Belani, CP; Johnson, DH; Levitan, N; Stella, PJ | 1 |
| Blay, JY; Bleuze, JP; Bompas, E; Chaigneau, L; Cupissol, D; Guardiola, E; Madroszyk, A; Peyrade, F; Pivot, X; Ronchin, P; Schneider, M; Tchiknavorian, X | 1 |
| Fujita, S; Inoue, Y; Katsura, H; Nomura, M; Sakao, J; Souda, S; Yokotani, H | 1 |
| Hatae, M; Nakamura, T; Onishi, Y | 1 |
| Toge, T; Yoshida, K | 1 |
| Bendahmane, B; Bontemps, P; Bourgeois, H; Calais, G; Cupissol, D; Dutin, JP; Genet, D; Mallard-Carre, M; Philippi, MH; Tubiana-Mathieu, N | 1 |
| Chung, CW; Im, YH; Kang, WK; Kim, K; Kim, WS; Lee, HR; Lee, KE; Lee, MH; Lee, SH; Park, CH; Park, J; Park, JO; Park, K; Park, SH | 1 |
| El-Sheemy, M; Eremin, J; Eremin, O; Griffiths, PA; Marshall, C | 1 |
| Asaga, T; Fukuda, M; Fukuma, E; Hamaguchi, Y; Inaba, M; Ishida, K; Ishikawa, T; Ishiyama, A; Katayama, K; Shimada, H; Shimizu, S; Suda, T; Tokuda, Y | 1 |
| Achiwa, H; Kato, D; Maeda, H; Niimi, T; Oguri, T; Sato, S; Ueda, R | 1 |
| Nortier, JW; Rodenburg, CJ; Slee, PH; van Bochove, A | 1 |
| Kim, SJ; Miyoshi, Y; Noguchi, S; Taguchi, T; Tamaki, Y | 1 |
| Economopoulos, T; Farmakis, D; Gaglia, A; Kostopoulou, V; Koumpou, M; Mylonakis, N; Nikolaou, M; Pectasides, D; Pectasides, M; Raptis, SA; Xiros, N | 1 |
| Fujiwara, K; Ishikawa, H; Kohno, I; Koike, H; Nagao, S; Oda, T; Tanaka, H | 1 |
| Bamberg, M; Belka, C; Budach, W; Classen, J; Hehr, T; Koitschev, A; Schäfer, J; Welz, S | 1 |
| Ryan, CJ; Small, EJ | 1 |
| Anderson, L; Anzai, Y; Boyd, C; Buelna, R; Canby, R; Donahue, M; Hutson, J; Keegan, K; Montgomery, RB; Schwartz, DL; Yueh, B | 1 |
| Cameron, DA; Coleman, RE; Crown, J; Earl, H; Evans, TR; Foster, E; Gallagher, CJ; Highley, M; Hutcheon, AW; Jones, AL; Leonard, RC; Mansi, JL; Perren, T; Quigley, M; Yellowlees, A | 1 |
| Blagden, SP; Kaye, SB | 1 |
| Bagaméri, A; Lehoczky, O; Pulay, T; Sárosi, Z; Thurzó, L; Udvary, J | 1 |
| Fujii, K; Fujino, S; Higashide, S; Hori, T; Inamoto, T; Kan, N; Lee, CJ; Maruhashi, K; Mise, K; Mitsumori, M; Nishimura, S; Okamoto, M; Okamura, T; Sawai, S; Takemoto, Y; Yamauchi, A | 1 |
| Asai, S; Dokoh, J; Ishikawa, M; Komiyama, S; Mikami, M; Tsuji, H | 1 |
| Ando, A; Hasegawa, Y; Hyodo, I; Ogawa, T; Ozawa, T; Suzuki, Y; Terada, A | 1 |
| Broglio, KR; Buzdar, AU; Cristofanilli, M; Hanrahan, EO; Hortobagyi, GN; Kau, SW; Rivera, E; Theriault, RL; Valero, V; Yin, G | 1 |
| Busse, PM; Goguen, L; Guadagnolo, BA; Haddad, RI; Norris, CM; Posner, MR; Sullivan, CA; Tishler, R; Weeks, L; Wirth, LJ | 1 |
| Carbone, DP; Csiki, I; Dang, T; Johnson, DH; Morrow, JD; Oates, J; Sandler, A; Shyr, Y; Williams, MK | 1 |
| Aoki, D; Eguchi, F; Fujiwara, K; Jobo, T; Katsumata, N; Kitagawa, R; Kohno, I; Kuramoto, H; Nishimura, R; Noda, K; Nozawa, S; Sohda, Y; Susumu, N; Ueki, K; Ueki, M; Yamaguchi, S | 1 |
| Alexopoulos, A; Ardavanis, A; Karamouzis, M; Orfanos, G; Rigatos, G; Scorilas, A; Tryfonopoulos, D | 1 |
| De Lena, M; Leone, B; Lorusso, V; Numico, G; Silvestris, N | 1 |
| Amador, ML; Cortes-Funes, H; del Val, O; Hernando, S; Hitt, R; Jimeno, A; Quintela-Fandino, M | 1 |
| Bang, SJ; Cho, HR; Kim, DH; Kim, GY; Kim, H; Min, YJ; Park, JH | 1 |
| Bonhoure, E; Calvet, C; Cuvillier, O; Doumerc, N; Garcia, V; Golzio, M; Malavaud, B; Mazerolles, C; Pchejetski, D; Rischmann, P; Teissié, J | 1 |
| Baltas, D; Filipowicz, I; Hoffmann, G; Kolotas, C; Kontova, M; Kuner, RP; Kurek, R; Martin, T; Pollow, B; Roddiger, SJ; Rogge, B; Zamboglou, N | 1 |
| Akimoto, T; Chikamatsu, K; Furuya, N; Hayakawa, K; Ishikawa, H; Kitamoto, Y; Mitsuhashi, N; Nakano, T; Ninomiya, H; Nonaka, T | 1 |
| André, T; Bennamoun, M; Carola, E; Flesch, M; Gamelin, E; Louvet, C; Nguyen, S; Rebischung, C; Van Ongeval, J; Ychou, M | 1 |
| Boku, N; Fukutomi, A | 1 |
| Cohn, DE; Copeland, LJ; Eaton, LA; Fowler, JM; Resnick, KE; Valmadre, S | 1 |
| Byrd, R; Chen, Z; Dunaway, R; Krailo, M; Monteleone, P; Reaman, G; Sato, J; Seibel, N; Strain, J; Zwerdling, T | 1 |
| Nakabayashi, M; Oh, WK | 1 |
| Cirillo, I; de Bruijn, P; de Jonge, MJ; Felici, A; Loos, WJ; Mathijssen, RH; Nooter, K; Verweij, J | 1 |
| Gilbert, DC; Parker, C | 1 |
| Appenrodt, S; Guntinas-Lichius, O; Krug, B; Veelken, F | 1 |
| Asmar, L; Ilegbodu, D; Khandelwal, P; O'Shaughnessy, JA; Pluenneke, R; Sternberg, J | 1 |
| Lehoczky, O; Pulay, T | 1 |
| Betticher, DC; Cerny, T; Egli, F; Furrer, M; Habicht, J; Hansen, E; Honegger, H; Hsu Schmitz, SF; Joss, C; Pless, M; Ris, HB; Roth, AD; Schmid, RA; Spiliopoulos, A; Stahel, R; Stupp, R; Tötsch, M; von Briel, C; Weder, W; Wernli, M | 1 |
| Botti, G; Chiodini, P; D'Aiuto, G; De Maio, E; de Matteis, A; Di Maio, M; Gallo, C; Gravina, A; Labonia, V; Landi, G; Morabito, A; Normanno, N; Nuzzo, F; Pacilio, C; Perrone, F; Rossi, E | 1 |
| Abratt, RP; Dane, G; Dharan, B; Gervais, R; Grotzinger, KM; Kaukel, E; Krzakowski, M; Ramlau, R; Ross, G; Shepherd, FA; von Pawel, J | 1 |
| Gotoh, M; Hirabayashi, N; Ninomiya, M; Nishiyama, M; Sakamoto, J; Sato, Y; Takakura, N; Takiyama, W; Terashima, M; Todo, S; Yoshida, K | 1 |
| Antoniou, D; Chaimala, D; Chondrou, E; Dariotaki, F; Karydis, I; Papageorgiou, C; Pavlakou, G; Stathopoulos, GP; Veslemes, M | 1 |
| Ikeda, M; Ishiguro, K; Kataoka, T; Komaki, K; Kurebayashi, J; Morimoto, T; Sonoo, H; Tanaka, K; Tangoku, A; Yoshizawa, K | 1 |
| Basler, JW | 1 |
| Kato, K; Noguchi, S; Ooe, A | 1 |
| Hihara, J; Tanabe, K; Ukon, K; Wada, Y; Yoshida, K | 1 |
| James, J; Miller, KD; Murry, DJ; Sidor, C; Sledge, GW; Storniolo, AM; Treston, AM | 1 |
| Ackermann, S; Beckmann, MW; Camara, O; Emons, G; Günthert, AR; Kiesel, L; Rensing, K; Schröder, W; Steiner, E | 1 |
| Gemba, K; Harita, S; Hiraki, S; Kishino, D; Kiura, K; Kozuki, T; Segawa, Y; Shibayama, T; Tabata, M; Tada, A; Tada, S; Takigawa, N; Tanimoto, M; Ueoka, H; Yonei, T | 1 |
| Calabrò, F; Sternberg, CN | 1 |
| Akamatsu, H; Imazu, Y; Koshida, Y; Motegi, K; Murayama, T; Ohyama, R; Toeda, H; Toriumi, F; Yoneyama, K | 1 |
| Aoki, T; Hoshino, S; Osaka, Y; Tachibana, S; Takagi, Y; Tsuchida, A | 1 |
| Baumgart, A; Henze, A; Karbe, I; Koelbl, H; Strauss, HG; Teichmann, A; Thomssen, C | 1 |
| Akerley, W; Axelrod, R; Belt, R; Carbone, DP; Crawford, J; Fanucchi, MP; Fidias, P; Fossella, FV; Govindan, R; Kashala, O; Kelly, K; Limentani, SA; Natale, R; Raez, LE; Reimers, HJ; Ribeiro, M; Robert, F; Schiller, JH; Sheng, S | 1 |
| Boswell, JS; Flam, MS; Tashjian, DN; Tschang, TP | 1 |
| Mohagheghi, MA; Montazeri, A; Sadighi, S; Sadighi, Z | 1 |
| Feng, FY; Guan, ZZ; Guo, Y; Hu, XH; Liu, DG; Peng, RJ; Tang, GD; Xiong, JP; Zhao, HY | 1 |
| Chiba, N; Ishioka, C; Kakudo, Y; Kato, S; Miyazaki, S; Nemoto, K; Ohtsuka, K; Sakata, Y; Sakayori, M; Shibata, H; Shimodaira, H; Yoshioka, T | 1 |
| Azzouzi, AR; Capron, F; Charlotte, F; Chartier-Kastler, E; Compérat, E; Ménégaux, F; Richard, F | 1 |
| Ami, K; Ando, M; Ganno, H; Ito, T; Nagahama, T; Ohbu, M; Taira, M | 1 |
| Bailey, HH; Connor, JP; Fine, J; Harris, LS; Hartenbach, EM; Kushner, DM; Sanchez, F; Schink, JC; Stewart, SL; Volk, M | 1 |
| Alcaide, J; Alés, I; Benavides, M; Bretón, JJ; Carabantes, F; Cobo, M; Durán, G; Gil, S; Gutiérrez, V; Martínez, J; Villar, E | 1 |
| Coleman, RL; Crotzer, DR; Gershenson, DM; Levenback, CF; Sun, CC; Wolf, JK | 1 |
| Ellis, PM; Evans, WK; Mackay, JA; Noble, J | 1 |
| Beer, TM; Benson, MC; Chatta, GS; Cookson, MS; DiPaola, RS; Dreicer, R; Eisenberger, MA; Garrett-Mayer, E; Jarrard, DF; Kattan, MW; Kibel, AS; Klein, EA; Nelson, JB; Partin, AW; Petrylak, DP; Picus, J; Rosenbaum, E; Roth, BJ; Ryan, CW; Wilding, G | 1 |
| Colangelo, M; De Vincenzo, R; Ferrandina, G; Lorusso, D; Ludovisi, M; Prantera, T; Salutari, V; Scambia, G; Valerio, MR | 1 |
| Higashida, M; Hirabayashi, Y; Hirai, T; Kawabe, Y; Matsumoto, H; Murakami, H; Tsunoda, T; Urakami, A; Yamashita, K | 1 |
| Bilancia, D; Dinota, A; Germano, D; Manzione, L; Reggiardo, G; Romano, R; Rosati, G | 1 |
| Hamai, Y; Oue, N; Sentani, K; Suzuki, T; Wada, Y; Yasui, W; Yoshida, K | 1 |
| Johnston, CM; McMeekin, DS; Pearl, ML | 1 |
| Masuda, N | 1 |
| Boku, N; Ebihara, M; Iida, Y; Onitsuka, T; Onozawa, Y; Zenda, S | 1 |
| Blessing, JA; Garcia, AA; Roman, LD; Vaccarello, L | 1 |
| Goh, PG; Hwang, SW; Jeong, HY; Kang, HM; Kang, SH; Kang, YS; Kim, JI; Kim, SH; Kwon, DS; Lee, BS; Moon, HS; Nam, KW; Seong, JK | 1 |
| Davis, S; Hind, D; Rees, A; Simpson, E; Ward, S; Wilkinson, A | 1 |
| Faerber, GJ; Weizer, AZ; Wolf, JS | 1 |
| Belani, CP; Bonomi, PD; Fehrenbacher, L; Hart, L; Herbst, RS; Lin, M; Melnyk, O; O'Neill, VJ; Ramies, D; Sandler, A | 1 |
| Ashley, S; Barbachano, Y; Norton, A; O'Brien, M; Popat, S | 1 |
| Govindan, R; Morgensztern, D; Perry, MC | 1 |
| Barduagni, M; Belli, F; D'Ottavio, AM; Gamucci, T; Magnolfi, E; Meliffi, L; Moscetti, L; Sperduti, I; Vaccaro, A | 1 |
| Fujita, H; Mori, N; Nagano, T; Sasahara, H; Shirouzu, K; Sueyoshi, S; Tanaka, T; Tanaka, Y; Yamana, H | 1 |
| Assmann, M; Deist, T; Fahlke, J; Hribaschek, K; Keilholz, U; Kettner, E; Lippert, H; Quietzsch, D; Ridwelski, K; Schmidt, C; Stuebs, P | 1 |
| Copeman, M; Gurney, H; Rosenthal, MA; Woo, H; Zingarelli, G | 1 |
| Akashi-Tanaka, S; Ando, M; Fujiwara, Y; Hojo, T; Katsumata, N; Kinoshita, T; Kohno, T; Seki, K; Shibata, T; Shien, T; Shimizu, C | 1 |
| Barlesi, F; Debieuvre, D; Fournel, P; Gervais, R; Mazieres, J; Milleron, B; Morin, F; Moro-Sibilot, D; Perol, M; Soria, JC; Souquet, PJ; Timsit, JF; Vergnenègre, A; Zalcman, G | 1 |
| Aksu, G; Binici, A; Cicin, I; Fayda, M; Karagol, H; Kocak, Z; Uygun, K; Uzunoglu, F | 1 |
| Cho, JY; Choi, SH; Lee, DK; Lee, KS; Lee, SI; Lee, SJ; Lim, JY; Paik, YH; Park, HJ; Yoon, DS | 1 |
| Bisegna, R; Bratta, M; Candeloro, G; Di Staso, M; Necozione, S; Rea, S; Recchia, F; Tombolini, V | 1 |
| Abulafia, O; Blessing, JA; Degeest, K; Hensley, ML; Homesley, HD; Rose, PG | 1 |
| Casasola, RJ; Nashed, M | 1 |
| Arima, N; Iwase, H; Kai, K; Miyayama, H; Nishimura, R; Yamamoto, Y | 1 |
| Benner, S; Calayag, M; Chasen, M; Fossella, FV; Glisson, B; Lee, JS; Lippman, SM; Murphy, WK; Pang, A; Shin, DM | 1 |
| Abe, R; Enomoto, K; Fujita, M; Hamano, K; Hasegawa, K; Mori, S; Morishita, Y; Sasaki, Y; Tabei, T; Taguchi, T | 1 |
| Adachi, I; Aoyama, H; Horikoshi, N; Narabayashi, M; Taguchi, T; Takashima, S; Watanabe, T | 1 |
| Busse, PM; Clark, JR; Costello, R; Dreyfuss, AI; Lucarini, JW; Norris, CM; Posner, MR; Poulin, MD; Rossi, RM; Thornhill, L | 1 |
| Edwards, CL; Ende, K; Fishman, A; Freedman, RS; Kaplan, A; Kavanagh, JJ; Kieback, DG; Kudelka, AP; Levy, T; Mante, R; Steger, M; Verschraegen, CF | 1 |
| Cairncross, G; Eisenhauer, E; Forsyth, P; Goodyear, M; Stewart, D; Wainman, N | 1 |
| Schrijvers, D; van Dam, P; van Oosterom, A | 1 |
| Davison, JD; Francis, PA; Ganju, V; Michael, M; Millward, MJ; Rischin, D; Shapiro, JD; Toner, GC | 1 |
| Fossella, FV; Hong, WK; Lee, JS | 1 |
| Kokawa, Y; Oura, S; Sakurai, T; Tamaki, T; Umemura, T; Yoshimura, G | 2 |
| Adachi, I; Ando, M; Fujii, H; Igarashi, T; Itoh, K; Katsumata, N; Narabayashi, M; Ohtsu, T; Omuro, Y; Sasaki, Y; Taguchi, T; Tokue, Y; Wakita, H; Watanabe, T; Ying, DF | 1 |
| Hirabayashi, N; Kanamaru, R; Kurihara, M; Ota, J; Sakata, Y; Suminaga, M; Taguchi, T | 1 |
| Baba, S; Ebihara, S; Horiuchi, M; Ichikawa, G; Inuyama, Y; Kamata, S; Kanzaki, J; Kataura, A; Kida, A; Konno, A; Kono, N; Kubota, A; Matsunaga, T; Matsuura, H; Miyake, H; Moriyama, H; Saijo, S; Saito, H; Sakai, M; Sasaki, Y; Satake, B; Taguchi, T; Takeoda, S; Togawa, K; Tsukuda, M | 1 |
| Catimel, G; Droz, JP; Gras, L; Hanauske, AR; Planting, AS; Schöffski, P; Schrijvers, A; Schrijvers, D; Verweij, J; Wanders, J | 1 |
| Aritake, N; Fukunaga, M; Gotoh, K; Hasegawa, S; Imamoto, H; Kan, K; Kim, Y; Maruyama, H; Oozato, H; Takatsuka, Y; Touno, T; Yamazaki, K | 1 |
| Funahashi, H; Hayashi, H; Imai, T; Itoh, T; Kikumori, T; Mase, T; Oiwa, M; Sekiya, M; Shibata, A | 1 |
| Forastiere, AA | 1 |
| Naito, Y; Oura, S; Sakurai, T; Suzuma, T; Tanino, H; Yamamiti, N; Yoshimasu, T | 1 |
| Gen, T; Hara, Y; Igarashi, K; Jibiki, M; Kawasaki, T; Kikuchi, M; Kudoh, A; Noguchi, N; Yabata, E | 1 |
| Glisson, BS; Hong, WK; Khuri, FR; Lippman, SM; Shin, DM | 1 |
| Buccheri, G; Ferrigno, D | 1 |
| Austin Seymour, MM; Bellon, JR; Ellis, GK; Gralow, JR; Lindsley, KL; Livingston, RB | 1 |
| Hansen, HS; Larsen, SK; Specht, L | 1 |
| Naito, Y; Oura, S; Tanino, H | 1 |
| Endo, M; Kadou, T; Kotani, Y; Ohbayashi, K; Satouchi, M; Takada, Y | 1 |
| Belani, CP; Calvo, AR | 1 |
| Doihara, H; Hino, M; Ishibe, Y; Nagahiro, I; Ogasawara, Y; Sano, Y; Shimizu, N; Teramoto, A; Yoshitomi, S | 1 |
| Blair, S; Carman, L; Colborn, D; George, C; Jones, J; Kuebler, JP; Laufman, LR; Moore, T; Patel, T; Roach, R; Rupert, R; Spiridonidis, CH; Zangmeister, J | 1 |
| Broët, P; Delattre, JY; Hoang-Xuan, K; Keime-Guibert, F; Napolitano, M; Sanson, M; Yaya, R | 1 |
| Avallone, A; Biglietto, M; Caponigro, F; Comella, G; Comella, P; De Lucia, L; Mantovani, G; Manzione, L; Massa, E; Rosati, G; Sganga, P; Sguotti, C | 1 |
| Ohtsu, A; Yoshida, M | 1 |
| Bando, H; Hayashi, K; Kuroi, K; Nagai, S; Tanaka, C; Toi, M | 1 |
| Aoyama, H; Asaga, T; Iwase, H; Kimura, M; Mitsuyama, S; Nishimura, R; Tominaga, T | 1 |
| Hada, M; Koshizuka, K; Mouri, N; Muto, S; Nakagomi, H; Serizawa, M; Tada, Y; Takano, K | 1 |
| Belette, F; Blaustein, A; Davila, E; Lilenbaum, RC; Schwartz, MA; Seigel, L; Wittlin, FN | 1 |
| Amin, P; Chen, T; Dawson, N; Engstrom, C; Hussain, A; Naslund, M | 1 |
| Bubley, GJ; Ko, YJ; Morganstern, DE; Rajeshkumar, B; Shuster, T; Taplin, ME | 1 |
| Leyland-Jones, B; Smith, I | 1 |
| Amann, G; Attems, Y; Brodowicz, T; Fiebiger, WC; Hejna, M; Köstler, WJ; Krainer, M; Tomek, S; Wiltschke, CH; Zielinski, CC | 1 |
| Kalofonos, HP; Kosmas, C; Koutras, A; Malamos, N; Onyenadum, A; Polyzos, A; Rokana, S; Stavroyianni, N; Tsavaris, N; Vadiaka, M | 1 |
| Forastiere, AA; Frenette, G; Glisson, BS; Khuri, FR; Murphy, BA | 1 |
| Inaji, H; Kobayashi, H; Motomura, K; Noguchi, S; Taguchi, T; Takamura, Y | 1 |
| Hensley, ML | 1 |
| Kovács, AF; Schiemann, M; Turowski, B | 1 |
57 review(s) available for docetaxel anhydrous and Local Neoplasm Recurrence
| Article | Year |
|---|---|
Efficacy of first-line systemic treatment regimens for recurrent/metastatic head and neck squamous cell carcinoma: a network meta-analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cetuximab; Docetaxel; Fluorouracil; Head and Neck Neoplasms; Humans; Neoplasm Recurrence, Local; Network Meta-Analysis; Squamous Cell Carcinoma of Head and Neck | 2023 |
Sequential intravesical gemcitabine and docetaxel therapy in patients with nonmuscle invasive bladder cancer: a systematic review and meta-analysis.
Topics: Adjuvants, Immunologic; Administration, Intravesical; BCG Vaccine; Docetaxel; Gemcitabine; Humans; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Urinary Bladder Neoplasms | 2023 |
Adjuvant Chemotherapy in Older Women With Early Breast Cancer.
Topics: Aged; Breast Neoplasms; Capecitabine; Chemotherapy, Adjuvant; Docetaxel; Female; Humans; Neoplasm Recurrence, Local | 2023 |
Anthracycline-containing and taxane-containing chemotherapy for early-stage operable breast cancer: a patient-level meta-analysis of 100 000 women from 86 randomised trials.
Topics: Anthracyclines; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Docetaxel; Female; Humans; Neoplasm Recurrence, Local; Randomized Controlled Trials as Topic; Receptors, Estrogen | 2023 |
Evaluation of the efficacy of systemic therapy for advanced uterine leiomyosarcoma: A systematic review, meta-analysis, and meta-regression analysis.
Topics: Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Female; Gemcitabine; Humans; Leiomyosarcoma; Neoplasm Recurrence, Local; Proportional Hazards Models; Uterine Neoplasms | 2023 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor Proteins, Signal Transducing; Adenine; Adenocarcinoma; Adipogenesis; Administration, Cutaneous; Administration, Ophthalmic; Adolescent; Adsorption; Adult; Aeromonas hydrophila; Aerosols; Aged; Aged, 80 and over; Aging; Agriculture; Air Pollutants; Air Pollution; Airway Remodeling; Alanine Transaminase; Albuminuria; Aldehyde Dehydrogenase 1 Family; Algorithms; AlkB Homolog 2, Alpha-Ketoglutarate-Dependent Dioxygenase; Alzheimer Disease; Amino Acid Sequence; Ammonia; Ammonium Compounds; Anaerobiosis; Anesthetics, Dissociative; Anesthetics, Inhalation; Animals; Anti-Bacterial Agents; Anti-HIV Agents; Anti-Infective Agents; Anti-Inflammatory Agents; Antibiotics, Antineoplastic; Antibodies, Antineutrophil Cytoplasmic; Antibodies, Monoclonal, Humanized; Antifungal Agents; Antigens, Bacterial; Antigens, CD; Antigens, Differentiation, Myelomonocytic; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Antioxidants; Antitubercular Agents; Antiviral Agents; Apolipoproteins E; Apoptosis; Arabidopsis; Arabidopsis Proteins; Arsenic; Arthritis, Rheumatoid; Asthma; Atherosclerosis; ATP-Dependent Proteases; Attitude of Health Personnel; Australia; Austria; Autophagy; Axitinib; Bacteria; Bacterial Outer Membrane Proteins; Bacterial Proteins; Bacterial Toxins; Bacterial Typing Techniques; Bariatric Surgery; Base Composition; Bayes Theorem; Benzoxazoles; Benzylamines; beta Catenin; Betacoronavirus; Betula; Binding Sites; Biological Availability; Biological Oxygen Demand Analysis; Biomarkers; Biomarkers, Tumor; Biopsy; Bioreactors; Biosensing Techniques; Birth Weight; Blindness; Blood Chemical Analysis; Blood Gas Analysis; Blood Glucose; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Blood-Brain Barrier; Blotting, Western; Body Mass Index; Body Weight; Bone and Bones; Bone Density; Bone Resorption; Borates; Brain; Brain Infarction; Brain Injuries, Traumatic; Brain Neoplasms; Breakfast; Breast Milk Expression; Breast Neoplasms; Bronchi; Bronchoalveolar Lavage Fluid; Buffaloes; Cadherins; Calcification, Physiologic; Calcium Compounds; Calcium, Dietary; Cannula; Caprolactam; Carbon; Carbon Dioxide; Carboplatin; Carcinogenesis; Carcinoma, Ductal; Carcinoma, Ehrlich Tumor; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Pancreatic Ductal; Carcinoma, Renal Cell; Cardiovascular Diseases; Carps; Carrageenan; Case-Control Studies; Catalysis; Catalytic Domain; Cattle; CD8-Positive T-Lymphocytes; Cell Adhesion; Cell Cycle Proteins; Cell Death; Cell Differentiation; Cell Line; Cell Line, Tumor; Cell Movement; Cell Nucleus; Cell Phone Use; Cell Proliferation; Cell Survival; Cell Transformation, Neoplastic; Cell Transformation, Viral; Cells, Cultured; Cellulose; Chemical Phenomena; Chemoradiotherapy; Child; Child Development; Child, Preschool; China; Chitosan; Chlorocebus aethiops; Cholecalciferol; Chromatography, Liquid; Circadian Clocks; Circadian Rhythm; Circular Dichroism; Cisplatin; Citric Acid; Clinical Competence; Clinical Laboratory Techniques; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Clostridioides difficile; Clostridium Infections; Coculture Techniques; Cohort Studies; Cold Temperature; Colitis; Collagen Type I; Collagen Type I, alpha 1 Chain; Collagen Type XI; Color; Connective Tissue Diseases; Copper; Coronary Angiography; Coronavirus 3C Proteases; Coronavirus Infections; Cost of Illness; Counselors; COVID-19; COVID-19 Testing; Creatine Kinase; Creatinine; Cross-Over Studies; Cross-Sectional Studies; Cryoelectron Microscopy; Cryosurgery; Crystallography, X-Ray; Cues; Cultural Competency; Cultural Diversity; Curriculum; Cyclic AMP Response Element-Binding Protein; Cyclin-Dependent Kinase Inhibitor p21; Cycloparaffins; Cysteine Endopeptidases; Cytokines; Cytoplasm; Cytoprotection; Databases, Factual; Denitrification; Deoxycytidine; Diabetes Complications; Diabetes Mellitus; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Diagnosis, Differential; Diatoms; Diet; Diet, High-Fat; Dietary Exposure; Diffusion Magnetic Resonance Imaging; Diketopiperazines; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Disease Models, Animal; Disease Progression; Disease-Free Survival; DNA; DNA Damage; DNA Glycosylases; DNA Repair; DNA-Binding Proteins; DNA, Bacterial; DNA, Viral; Docetaxel; Dose Fractionation, Radiation; Dose-Response Relationship, Drug; Down-Regulation; Doxorubicin; Drosophila; Drosophila melanogaster; Drug Carriers; Drug Delivery Systems; Drug Liberation; Drug Repositioning; Drug Resistance, Bacterial; Drug Resistance, Multiple, Bacterial; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Drug Synergism; Drug Therapy, Combination; Edema; Edible Grain; Education, Graduate; Education, Medical, Graduate; Education, Pharmacy; Ehlers-Danlos Syndrome; Electron Transport Complex III; Electron Transport Complex IV; Electronic Nicotine Delivery Systems; Emergency Service, Hospital; Empathy; Emulsions; Endothelial Cells; Endurance Training; Energy Intake; Enterovirus A, Human; Environment; Environmental Monitoring; Enzyme Assays; Enzyme Inhibitors; Epithelial Cells; Epithelial-Mesenchymal Transition; Epoxide Hydrolases; Epoxy Compounds; Erythrocyte Count; Erythrocytes; Escherichia coli; Escherichia coli Infections; Escherichia coli Proteins; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Esophagectomy; Estrogens; Etanercept; Ethiopia; Ethnicity; Ethylenes; Exanthema; Exercise; Exercise Test; Exercise Tolerance; Extracellular Matrix; Extracorporeal Membrane Oxygenation; Eye Infections, Fungal; False Negative Reactions; Fatty Acids; Fecal Microbiota Transplantation; Feces; Female; Femur Neck; Fermentation; Ferritins; Fetal Development; Fibroblast Growth Factor-23; Fibroblast Growth Factors; Fibroblasts; Fibroins; Fish Proteins; Flavanones; Flavonoids; Focus Groups; Follow-Up Studies; Food Handling; Food Supply; Food, Formulated; Forced Expiratory Volume; Forests; Fractures, Bone; Fruit and Vegetable Juices; Fusobacteria; G1 Phase Cell Cycle Checkpoints; G2 Phase Cell Cycle Checkpoints; Gamma Rays; Gastrectomy; Gastrointestinal Microbiome; Gastrointestinal Stromal Tumors; Gefitinib; Gels; Gemcitabine; Gene Amplification; Gene Expression; Gene Expression Regulation; Gene Expression Regulation, Bacterial; Gene Expression Regulation, Neoplastic; Gene Expression Regulation, Plant; Gene Knockdown Techniques; Gene-Environment Interaction; Genotype; Germany; Glioma; Glomerular Filtration Rate; Glucagon; Glucocorticoids; Glycemic Control; Glycerol; Glycogen Synthase Kinase 3 beta; Glycolipids; Glycolysis; Goblet Cells; Gram-Negative Bacterial Infections; Granulocyte Colony-Stimulating Factor; Graphite; Greenhouse Effect; Guanidines; Haemophilus influenzae; HCT116 Cells; Health Knowledge, Attitudes, Practice; Health Personnel; Health Services Accessibility; Health Services Needs and Demand; Health Status Disparities; Healthy Volunteers; Heart Failure; Heart Rate; Heart Transplantation; Heart-Assist Devices; HEK293 Cells; Heme; Heme Oxygenase-1; Hemolysis; Hemorrhage; Hepatitis B; Hepatitis B e Antigens; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Hepatocytes; Hexoses; High-Throughput Nucleotide Sequencing; Hippo Signaling Pathway; Histamine; Histamine Agonists; Histidine; Histone Deacetylase 2; HIV Infections; HIV Reverse Transcriptase; HIV-1; Homebound Persons; Homeodomain Proteins; Homosexuality, Male; Hospice and Palliative Care Nursing; HSP70 Heat-Shock Proteins; Humans; Hyaluronan Receptors; Hydrogen; Hydrogen Peroxide; Hydrogen-Ion Concentration; Hydrolysis; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypoglycemia; Hypoglycemic Agents; Hypoxia; Idiopathic Interstitial Pneumonias; Imaging, Three-Dimensional; Imatinib Mesylate; Immunotherapy; Implementation Science; Incidence; INDEL Mutation; Induced Pluripotent Stem Cells; Industrial Waste; Infant; Infant, Newborn; Inflammation; Inflammation Mediators; Infliximab; Infusions, Intravenous; Inhibitory Concentration 50; Injections; Insecticides; Insulin-Like Growth Factor Binding Protein 5; Insulin-Secreting Cells; Interleukin-1; Interleukin-17; Interleukin-8; Internship and Residency; Intestines; Intracellular Signaling Peptides and Proteins; Ion Transport; Iridaceae; Iridoid Glucosides; Islets of Langerhans Transplantation; Isodon; Isoflurane; Isotopes; Italy; Joint Instability; Ketamine; Kidney; Kidney Failure, Chronic; Kidney Function Tests; Kidney Neoplasms; Kinetics; Klebsiella pneumoniae; Knee Joint; Kruppel-Like Factor 4; Kruppel-Like Transcription Factors; Lactate Dehydrogenase 5; Laparoscopy; Laser Therapy; Lasers, Semiconductor; Lasers, Solid-State; Laurates; Lead; Leukocyte L1 Antigen Complex; Leukocytes, Mononuclear; Light; Lipid Peroxidation; Lipopolysaccharides; Liposomes; Liver; Liver Cirrhosis; Liver Neoplasms; Liver Transplantation; Locomotion; Longitudinal Studies; Lopinavir; Lower Urinary Tract Symptoms; Lubricants; Lung; Lung Diseases, Interstitial; Lung Neoplasms; Lymphocyte Activation; Lymphocytes, Tumor-Infiltrating; Lymphoma, Mantle-Cell; Lysosomes; Macrophages; Male; Manganese Compounds; MAP Kinase Kinase 4; Mass Screening; Maternal Health; Medicine, Chinese Traditional; Melanoma, Experimental; Memantine; Membrane Glycoproteins; Membrane Proteins; Mesenchymal Stem Cell Transplantation; Metal Nanoparticles; Metalloendopeptidases; Metalloporphyrins; Methadone; Methane; Methicillin-Resistant Staphylococcus aureus; Mexico; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Mice, Inbred ICR; Mice, Knockout; Mice, Nude; Mice, SCID; Mice, Transgenic; Microarray Analysis; Microbial Sensitivity Tests; Microbiota; Micronutrients; MicroRNAs; Microscopy, Confocal; Microsomes, Liver; Middle Aged; Milk; Milk, Human; Minority Groups; Mitochondria; Mitochondrial Membranes; Mitochondrial Proteins; Models, Animal; Models, Molecular; Molecular Conformation; Molecular Docking Simulation; Molecular Dynamics Simulation; Molecular Epidemiology; Molecular Structure; Molecular Weight; Multilocus Sequence Typing; Multimodal Imaging; Muscle Strength; Muscle, Skeletal; Muscular Diseases; Mutation; Mycobacterium tuberculosis; Myocardial Stunning; Myristates; NAD(P)H Dehydrogenase (Quinone); Nanocomposites; Nanogels; Nanoparticles; Nanotechnology; Naphthalenes; Nasal Cavity; National Health Programs; Necrosis; Needs Assessment; Neoadjuvant Therapy; Neonicotinoids; Neoplasm Invasiveness; Neoplasm Metastasis; Neoplasm Proteins; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplasm Transplantation; Neoplasms; Neoplastic Stem Cells; Netherlands; Neuroblastoma; Neuroprotective Agents; Neutrophils; NF-kappa B; NFATC Transcription Factors; Nicotiana; Nicotine; Nitrates; Nitrification; Nitrites; Nitro Compounds; Nitrogen; Nitrogen Dioxide; North Carolina; Nuclear Magnetic Resonance, Biomolecular; Nuclear Proteins; Nucleic Acid Hybridization; Nucleosomes; Nutrients; Obesity; Obesity, Morbid; Oceans and Seas; Oncogene Protein v-akt; Oncogenes; Oocytes; Open Reading Frames; Osteoclasts; Osteogenesis; Osteoporosis; Osteoporosis, Postmenopausal; Outpatients; Ovarian Neoplasms; Ovariectomy; Overweight; Oxazines; Oxidants; Oxidation-Reduction; Oxidative Stress; Oxides; Oxidoreductases; Oxygen; Oxygen Inhalation Therapy; Oxygenators, Membrane; Ozone; Paclitaxel; Paenibacillus; Pain Measurement; Palliative Care; Pancreatic Neoplasms; Pandemics; Parasympathetic Nervous System; Particulate Matter; Pasteurization; Patient Preference; Patient Satisfaction; Pediatric Obesity; Permeability; Peroxiredoxins; Peroxynitrous Acid; Pharmaceutical Services; Pharmacists; Pharmacy; Phaseolus; Phenotype; Phoeniceae; Phosphates; Phosphatidylinositol 3-Kinases; Phospholipid Transfer Proteins; Phospholipids; Phosphorus; Phosphorylation; Photoperiod; Photosynthesis; Phylogeny; Physical Endurance; Physicians; Pilot Projects; Piperidines; Pituitary Adenylate Cyclase-Activating Polypeptide; Plant Extracts; Plant Leaves; Plant Proteins; Plant Roots; Plaque, Atherosclerotic; Pneumonia; Pneumonia, Viral; Point-of-Care Testing; Polyethylene Glycols; Polymers; Polysorbates; Pore Forming Cytotoxic Proteins; Positron Emission Tomography Computed Tomography; Positron-Emission Tomography; Postprandial Period; Poverty; Pre-Exposure Prophylaxis; Prediabetic State; Predictive Value of Tests; Pregnancy; Pregnancy Trimester, First; Pregnancy, High-Risk; Prenatal Exposure Delayed Effects; Pressure; Prevalence; Primary Graft Dysfunction; Primary Health Care; Professional Role; Professionalism; Prognosis; Progression-Free Survival; Prolactin; Promoter Regions, Genetic; Proof of Concept Study; Proportional Hazards Models; Propylene Glycol; Prospective Studies; Prostate; Protein Binding; Protein Biosynthesis; Protein Isoforms; Protein Kinase Inhibitors; Protein Phosphatase 2; Protein Processing, Post-Translational; Protein Serine-Threonine Kinases; Protein Structure, Tertiary; Protein Transport; Proteoglycans; Proteome; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-myc; Proto-Oncogene Proteins c-ret; Proto-Oncogene Proteins p21(ras); Proton Pumps; Protons; Protoporphyrins; Pseudomonas aeruginosa; Pseudomonas fluorescens; Pulmonary Artery; Pulmonary Disease, Chronic Obstructive; Pulmonary Gas Exchange; Pulmonary Veins; Pyrazoles; Pyridines; Pyrimidines; Qualitative Research; Quinoxalines; Rabbits; Random Allocation; Rats; Rats, Sprague-Dawley; Rats, Wistar; Receptors, Histamine H3; Receptors, Immunologic; Receptors, Transferrin; Recombinant Proteins; Recurrence; Reference Values; Referral and Consultation; Regional Blood Flow; Registries; Regulon; Renal Insufficiency, Chronic; Reperfusion Injury; Repressor Proteins; Reproducibility of Results; Republic of Korea; Research Design; Resistance Training; Respiration, Artificial; Respiratory Distress Syndrome; Respiratory Insufficiency; Resuscitation; Retinal Dehydrogenase; Retreatment; Retrospective Studies; Reverse Transcriptase Inhibitors; Rhinitis, Allergic; Ribosomal Proteins; Ribosomes; Risk Assessment; Risk Factors; Ritonavir; Rivers; RNA Interference; RNA-Seq; RNA, Messenger; RNA, Ribosomal, 16S; RNA, Small Interfering; Rosuvastatin Calcium; Rural Population; Saccharomyces cerevisiae; Saccharomyces cerevisiae Proteins; Salivary Ducts; Salivary Gland Neoplasms; San Francisco; SARS-CoV-2; Satiation; Satiety Response; Schools; Schools, Pharmacy; Seasons; Seawater; Selection, Genetic; Sequence Analysis, DNA; Serine-Threonine Kinase 3; Sewage; Sheep; Sheep, Domestic; Shock, Hemorrhagic; Signal Transduction; Silver; Silymarin; Single Photon Emission Computed Tomography Computed Tomography; Sirolimus; Sirtuin 1; Skin; Skin Neoplasms; Skin Physiological Phenomena; Sleep Initiation and Maintenance Disorders; Social Class; Social Participation; Social Support; Soil; Soil Microbiology; Solutions; Somatomedins; Soot; Specimen Handling; Spectrophotometry, Ultraviolet; Spectroscopy, Fourier Transform Infrared; Spectrum Analysis; Spinal Fractures; Spirometry; Staphylococcus aureus; STAT1 Transcription Factor; STAT3 Transcription Factor; Streptomyces coelicolor; Stress, Psychological; Stroke; Stroke Volume; Structure-Activity Relationship; Students, Medical; Students, Pharmacy; Substance Abuse Treatment Centers; Sulfur Dioxide; Surface Properties; Surface-Active Agents; Surveys and Questionnaires; Survival Analysis; Survival Rate; Survivin; Sweden; Swine; Swine, Miniature; Sympathetic Nervous System; T-Lymphocytes, Regulatory; Talaromyces; Tandem Mass Spectrometry; tau Proteins; Telemedicine; Telomerase; Telomere; Telomere Homeostasis; Temperature; Terminally Ill; Th1 Cells; Thiamethoxam; Thiazoles; Thiophenes; Thioredoxin Reductase 1; Thrombosis; Thulium; Thyroid Cancer, Papillary; Thyroid Carcinoma, Anaplastic; Thyroid Neoplasms; Time Factors; Titanium; Tomography, Emission-Computed, Single-Photon; Tomography, X-Ray Computed; TOR Serine-Threonine Kinases; Transcription Factor AP-1; Transcription Factors; Transcription, Genetic; Transcriptional Activation; Transcriptome; Transforming Growth Factor beta1; Transistors, Electronic; Translational Research, Biomedical; Transplantation Tolerance; Transplantation, Homologous; Transportation; Treatment Outcome; Tretinoin; Tuberculosis, Multidrug-Resistant; Tuberculosis, Pulmonary; Tubulin Modulators; Tumor Microenvironment; Tumor Necrosis Factor Inhibitors; Tumor Necrosis Factor-alpha; Twins; Ultrasonic Therapy; Ultrasonography; Ultraviolet Rays; United States; Up-Regulation; Uranium; Urethra; Urinary Bladder; Urodynamics; Uromodulin; Uveitis; Vasoconstrictor Agents; Ventricular Function, Left; Vero Cells; Vesicular Transport Proteins; Viral Nonstructural Proteins; Visual Acuity; Vital Capacity; Vitamin D; Vitamin D Deficiency; Vitamin K 2; Vitamins; Volatilization; Voriconazole; Waiting Lists; Waste Disposal, Fluid; Wastewater; Water Pollutants, Chemical; Whole Genome Sequencing; Wine; Wnt Signaling Pathway; Wound Healing; Wounds and Injuries; WW Domains; X-linked Nuclear Protein; X-Ray Diffraction; Xanthines; Xenograft Model Antitumor Assays; YAP-Signaling Proteins; Yogurt; Young Adult; Zebrafish; Zebrafish Proteins; Ziziphus | 2016 |
Salvage systemic therapy for advanced gastric and oesophago-gastric junction adenocarcinoma.
Topics: Adenocarcinoma; Antineoplastic Agents; Combined Modality Therapy; Docetaxel; Esophageal Neoplasms; Esophagogastric Junction; Humans; Immunotherapy; Irinotecan; Neoplasm Recurrence, Local; Paclitaxel; Placebos; Progression-Free Survival; Quality of Life; Randomized Controlled Trials as Topic; Salvage Therapy; Stomach Neoplasms | 2020 |
The Role of Serotonin in Breast Cancer Stem Cells.
Topics: Animals; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Cell Survival; Disease Models, Animal; Docetaxel; Epithelial-Mesenchymal Transition; Female; Humans; Mice; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neoplasm Transplantation; Neoplastic Stem Cells; Phenotype; Receptors, Serotonin; Remission Induction; Serotonin; Sertraline; Signal Transduction | 2021 |
Therapies for castration-resistant prostate cancer in a new era: The indication of vintage hormonal therapy, chemotherapy and the new medicines.
Topics: Abiraterone Acetate; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Bone Neoplasms; Disease Progression; Docetaxel; Humans; Japan; Male; Neoplasm Recurrence, Local; Nitriles; Phenylthiohydantoin; Prognosis; Progression-Free Survival; Prostatic Neoplasms, Castration-Resistant; Radium; Taxoids | 2017 |
Any place left for induction chemotherapy for locally advanced head and neck squamous cell carcinoma?
Topics: Antineoplastic Agents, Phytogenic; Carboplatin; Chemoradiotherapy; Cisplatin; Clinical Trials, Phase III as Topic; Combined Modality Therapy; Docetaxel; Fluorouracil; Head and Neck Neoplasms; Humans; Induction Chemotherapy; Lymph Nodes; Lymphatic Metastasis; Neoplasm Recurrence, Local; Paclitaxel; Squamous Cell Carcinoma of Head and Neck; Survival Rate | 2018 |
Second-line chemotherapy versus supportive cancer treatment in advanced gastric cancer: a meta-analysis.
Topics: Antineoplastic Agents; Camptothecin; Clinical Trials, Phase III as Topic; Docetaxel; Fluorouracil; Humans; Irinotecan; Neoplasm Recurrence, Local; Neoplasm Staging; Randomized Controlled Trials as Topic; Stomach Neoplasms; Taxoids | 2013 |
Evolution of the treatment paradigm for patients with metastatic castration-resistant prostate cancer.
Topics: Aged; Algorithms; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Disease-Free Survival; Docetaxel; Drug Resistance, Neoplasm; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Recurrence, Local; Nitriles; Phenylthiohydantoin; Prognosis; Prostatic Neoplasms, Castration-Resistant; Quality Improvement; Randomized Controlled Trials as Topic; Risk Assessment; Survival Analysis; Taxoids; Treatment Outcome; United Kingdom | 2013 |
Nanoways to overcome docetaxel resistance in prostate cancer.
Topics: Animals; Antineoplastic Agents; Apoptosis; ATP Binding Cassette Transporter, Subfamily B, Member 1; Biological Transport; Docetaxel; Drug Carriers; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Humans; Male; MicroRNAs; Molecular Targeted Therapy; Nanoparticles; Neoplasm Recurrence, Local; Prostatic Neoplasms; Taxoids | 2014 |
Chemotherapy in the treatment of metastatic, persistent, and recurrent cervical cancer.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Cisplatin; Deoxycytidine; Docetaxel; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Mass Screening; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Taxoids; Topotecan; Uterine Cervical Neoplasms | 2014 |
Systemic therapy for early-stage HER2-positive breast cancers: time for a less-is-more approach?
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Chemotherapy, Adjuvant; Clinical Trials as Topic; Docetaxel; Female; Humans; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Taxoids; Trastuzumab; Treatment Outcome | 2015 |
The role of chemotherapy for metastatic, relapsed and refractory osteosarcoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Cyclophosphamide; Deoxycytidine; Docetaxel; Etoposide; Gemcitabine; Humans; Ifosfamide; Methotrexate; Neoplasm Recurrence, Local; Osteosarcoma; Taxoids | 2014 |
Exploitation of the Androgen Receptor to Overcome Taxane Resistance in Advanced Prostate Cancer.
Topics: Androgen Antagonists; Animals; Cell Cycle Checkpoints; Docetaxel; Drug Resistance, Neoplasm; G2 Phase Cell Cycle Checkpoints; Humans; Male; Neoplasm Recurrence, Local; Prostatic Neoplasms, Castration-Resistant; Receptors, Androgen; Signal Transduction; Taxoids | 2015 |
Unresectable Recurrent Squamous Cell Carcinoma of the Temporal Bone Treated by Induction Chemotherapy Followed by Concurrent Chemo-Reirradiation: A Case Report and Review of the Literature.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cetuximab; Chemoradiotherapy; Cisplatin; Docetaxel; Fluorouracil; Head and Neck Neoplasms; Humans; Induction Chemotherapy; Male; Middle Aged; Neoplasm Recurrence, Local; Re-Irradiation; Skull Neoplasms; Squamous Cell Carcinoma of Head and Neck; Taxoids; Temporal Bone | 2015 |
Androgen Deprivation Therapy and Secondary Hormone Therapy in the Management of Hormone-sensitive and Castration-resistant Prostate Cancer.
Topics: Androgen Antagonists; Antineoplastic Agents, Hormonal; Disease-Free Survival; Docetaxel; Humans; Male; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Prostatectomy; Prostatic Neoplasms, Castration-Resistant; Risk Assessment; Secondary Prevention; Survival Analysis; Taxoids; Treatment Outcome | 2015 |
Management of patients treated with pertuzumab in the Australian clinical practice setting.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Australia; Breast Neoplasms; Bridged-Ring Compounds; Disease Management; Disease Progression; Docetaxel; Female; Humans; Neoplasm Recurrence, Local; Paclitaxel; Receptor, ErbB-2; Taxoids; Trastuzumab | 2016 |
The Evolving and Future Role of Taxanes in Squamous Cell Carcinomas of the Head and Neck: A Review.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Squamous Cell; Chemoradiotherapy; Clinical Trials as Topic; Docetaxel; Head and Neck Neoplasms; Humans; Immunotherapy; Neoplasm Metastasis; Neoplasm Recurrence, Local; Paclitaxel; Radiotherapy, Adjuvant; Taxoids | 2016 |
Understanding the role of new systemic agents in the treatment of prostate cancer.
Topics: Abiraterone Acetate; Antineoplastic Agents, Hormonal; Docetaxel; Humans; Immunotherapy; Male; Neoplasm Metastasis; Neoplasm Recurrence, Local; Precision Medicine; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Radium; Randomized Controlled Trials as Topic; Taxoids; Tissue Extracts | 2016 |
[Therapy related leukemia with 11q23 abnormality induced by chemotherapy consisted of docetaxel for advanced prostatic carcinoma: case report].
Topics: Aged; Antineoplastic Agents; Carcinoma; Chromosomes, Human, Pair 11; Combined Modality Therapy; Docetaxel; Humans; Leukemia, Myelomonocytic, Acute; Liver Neoplasms; Male; Neoplasm Recurrence, Local; Neoplasms, Second Primary; Prostatectomy; Prostatic Neoplasms; Taxoids; Translocation, Genetic | 2009 |
Current strategy for triple-negative breast cancer: appropriate combination of surgery, radiation, and chemotherapy.
Topics: Adult; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Chemotherapy, Adjuvant; Cyclophosphamide; Docetaxel; Epirubicin; Female; Fluorouracil; Humans; Mastectomy, Segmental; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Platinum; Receptors, Estrogen; Taxoids | 2011 |
[Second line therapy for castration-resistant prostate cancer (CRPC)].
Topics: Androstenes; Androstenols; Antineoplastic Combined Chemotherapy Protocols; Cancer Vaccines; Clinical Trials as Topic; Combined Modality Therapy; Docetaxel; Humans; Male; Mitoxantrone; Neoplasm Recurrence, Local; Orchiectomy; Prostatic Neoplasms; Receptors, Androgen; Signal Transduction; Survival Rate; Taxoids; Tissue Extracts | 2012 |
Malignant primary cardiac tumours.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cardiac Surgical Procedures; Chemotherapy, Adjuvant; Deoxycytidine; Docetaxel; Doxorubicin; Fatal Outcome; Female; Gemcitabine; Heart Neoplasms; Humans; Ifosfamide; Male; Middle Aged; Myxoma; Neoplasm Recurrence, Local; Reoperation; Sarcoma; Taxoids; Time Factors; Treatment Outcome | 2012 |
Predictors of locoregional recurrence after neoadjuvant chemotherapy: results from combined analysis of National Surgical Adjuvant Breast and Bowel Project B-18 and B-27.
Topics: Adult; Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials as Topic; Cyclophosphamide; Docetaxel; Doxorubicin; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Lymph Nodes; Lymphatic Metastasis; Mastectomy; Middle Aged; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Nomograms; Predictive Value of Tests; Risk Factors; Sentinel Lymph Node Biopsy; Taxoids; Treatment Outcome | 2012 |
Advanced clinical states in prostate cancer.
Topics: Androgen Antagonists; Antineoplastic Agents; Bone Neoplasms; Cancer Vaccines; Disease Progression; Docetaxel; Gonadotropin-Releasing Hormone; Humans; Male; Neoplasm Recurrence, Local; Neoplasms, Hormone-Dependent; Orchiectomy; Prognosis; Prostate-Specific Antigen; Prostatic Neoplasms; Taxoids; Tissue Extracts | 2012 |
The role of docetaxel in the management of squamous cell cancer of the head and neck.
Topics: Antineoplastic Agents, Phytogenic; Clinical Trials as Topic; Docetaxel; Head and Neck Neoplasms; Humans; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Neoplasms, Squamous Cell; Paclitaxel; Radiation-Sensitizing Agents; Taxoids | 2002 |
Chemotherapy for androgen-independent prostate cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Docetaxel; Drug Resistance, Neoplasm; Estramustine; Humans; Male; Neoplasm Recurrence, Local; Paclitaxel; Palliative Care; Prostatic Neoplasms; Taxoids | 2002 |
Second line chemotherapy for NSCLC: establishing a gold standard.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Docetaxel; Humans; Lung Neoplasms; Neoplasm Recurrence, Local; Paclitaxel; Prognosis; Quality of Life; Taxoids; Treatment Outcome | 2002 |
Neoadjuvant docetaxel in locally advanced breast cancer.
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Disease-Free Survival; Docetaxel; Female; Humans; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Paclitaxel; Randomized Controlled Trials as Topic; Research Design; Survival Analysis; Taxoids | 2003 |
[Docetaxel (Taxotere) as first-line therapy of advanced non-small cell lung cancer (NSCLC)].
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Docetaxel; Humans; Lung Neoplasms; Neoplasm Recurrence, Local; Neoplasm Staging; Randomized Controlled Trials as Topic; Survival Rate; Taxoids | 2003 |
Second-line chemotherapy for non-small-cell lung cancer: recent data with pemetrexed.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Glutamates; Guanine; Humans; Lung Neoplasms; Neoplasm Recurrence, Local; Pemetrexed; Taxoids | 2004 |
Current data and ongoing trials in patients with recurrent non-small-cell lung cancer.
Topics: Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Cytotoxins; Docetaxel; ErbB Receptors; Erlotinib Hydrochloride; Glutamates; Glutathione; Guanine; Humans; Lung Neoplasms; Neoplasm Recurrence, Local; Paclitaxel; Pemetrexed; Prodrugs; Prognosis; Quinazolines; Taxoids | 2004 |
[Treatment of platinum-resistant ovarian cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Clinical Trials as Topic; DNA Damage; Docetaxel; Drug Resistance, Neoplasm; Etoposide; Female; Gynecologic Surgical Procedures; Humans; Irinotecan; Neoplasm Recurrence, Local; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Taxoids; Treatment Outcome | 2004 |
[Combination chemotherapy of TS-1 and docetaxel on advanced and recurrent gastric cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Drug Administration Schedule; Drug Combinations; Humans; Maximum Tolerated Dose; Neoplasm Recurrence, Local; Oxonic Acid; Pyridines; Stomach Neoplasms; Taxoids; Tegafur | 2004 |
Progress in detection and treatment of prostate cancer.
Topics: Antineoplastic Agents, Hormonal; Antineoplastic Agents, Phytogenic; Docetaxel; Humans; Male; Medical Oncology; Neoplasm Recurrence, Local; Prostate-Specific Antigen; Prostatectomy; Prostatic Neoplasms; Salvage Therapy; Taxoids | 2005 |
Docetaxel in the management of ovarian cancer.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Docetaxel; Drug Approval; Female; Humans; Neoplasm Recurrence, Local; Neoplasm Staging; Ovarian Neoplasms; Taxoids; United Kingdom; United States | 2005 |
Present status and perspectives in the treatment of hormone-refractory prostate cancer.
Topics: Androgens; Antineoplastic Combined Chemotherapy Protocols; Bone Density Conservation Agents; Bone Neoplasms; Chemotherapy, Adjuvant; Clinical Trials, Phase III as Topic; Diphosphonates; Docetaxel; Humans; Male; Neoplasm Recurrence, Local; Palliative Care; Prostate-Specific Antigen; Prostatic Neoplasms; Radiopharmaceuticals; Radiotherapy, Adjuvant; Survival Analysis; Taxoids; Treatment Outcome | 2005 |
[Activity of Taxanes for advanced and recurrent pancreatic cancer].
Topics: Antineoplastic Agents, Phytogenic; Clinical Trials as Topic; Combined Modality Therapy; Docetaxel; Drug Administration Schedule; Humans; Neoplasm Recurrence, Local; Paclitaxel; Pancreatic Neoplasms; Taxoids | 2006 |
Chemotherapy for high-risk localized prostate cancer.
Topics: Antineoplastic Agents; Chemotherapy, Adjuvant; Docetaxel; Humans; Male; Mitoxantrone; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Prostatic Neoplasms; Taxoids | 2006 |
Docetaxel for the treatment of prostate cancer.
Topics: Antineoplastic Agents, Phytogenic; Docetaxel; Drug Resistance, Neoplasm; Humans; Male; Neoplasm Recurrence, Local; Prostatic Neoplasms; Taxoids | 2005 |
State-of-the-art management of metastatic disease at initial presentation or recurrence.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Deoxycytidine; Disease-Free Survival; Docetaxel; Gemcitabine; Humans; Neoplasm Metastasis; Neoplasm Recurrence, Local; Paclitaxel; Prognosis; Taxoids; Urinary Bladder Neoplasms | 2006 |
Second-line or subsequent systemic therapy for recurrent or progressive non-small cell lung cancer: a systematic review and practice guideline.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase III as Topic; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Maximum Tolerated Dose; Neoplasm Recurrence, Local; Neoplasm Staging; Ontario; Palliative Care; Practice Guidelines as Topic; Quality of Life; Randomized Controlled Trials as Topic; Risk Assessment; Survival Analysis; Taxoids; Time Factors | 2006 |
[Optimal chemotherapy for advanced and recurrent breast cancer patients].
Topics: Anthracyclines; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Bone Neoplasms; Breast Neoplasms; Capecitabine; Deoxycytidine; Diphosphonates; Docetaxel; Female; Fluorouracil; Humans; Informed Consent; Neoplasm Recurrence, Local; Paclitaxel; Palliative Care; Patient Care Team; Quality of Life; Receptor, ErbB-2; Receptors, Estrogen; Silicates; Taxoids; Titanium; Trastuzumab | 2007 |
Taxanes for the adjuvant treatment of early breast cancer: systematic review and economic evaluation.
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Chemotherapy, Adjuvant; Cost-Benefit Analysis; Disease-Free Survival; Docetaxel; Female; Humans; Models, Biological; Neoplasm Recurrence, Local; Paclitaxel; Quality of Life; Randomized Controlled Trials as Topic; Taxoids | 2007 |
Management strategies for recurrent non-small cell lung cancer.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Docetaxel; Humans; Lung Neoplasms; Neoplasm Recurrence, Local; Paclitaxel; Survival Rate; Taxoids; Treatment Failure | 1997 |
Taxoids in head and neck cancer: the American approach.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Clinical Trials as Topic; Docetaxel; Head and Neck Neoplasms; Humans; Neoplasm Recurrence, Local; Paclitaxel; Taxoids; United States | 1999 |
Docetaxel (Taxotere) in hormone-refractory prostate cancer.
Topics: Antineoplastic Agents, Hormonal; Antineoplastic Agents, Phytogenic; Clinical Trials as Topic; Docetaxel; Drug Resistance, Neoplasm; Drug Therapy, Combination; Humans; Male; Neoplasm Recurrence, Local; Paclitaxel; Prognosis; Prostate-Specific Antigen; Prostatic Neoplasms; Taxoids | 2000 |
Treatment of patients with recurrent or metastatic squamous cell carcinoma of the head and neck: current status and future directions.
Topics: Antineoplastic Agents; Carcinoma, Squamous Cell; Deoxycytidine; Docetaxel; Gemcitabine; Head and Neck Neoplasms; Humans; Ifosfamide; Neoplasm Recurrence, Local; Paclitaxel; Taxoids; Vinblastine; Vinorelbine | 2000 |
Second-line chemotherapy for recurrent non-small cell lung cancer: do new agents make a difference?
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Camptothecin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Docetaxel; Drugs, Investigational; Gemcitabine; Humans; Irinotecan; Lung Neoplasms; Neoplasm Recurrence, Local; Paclitaxel; Randomized Controlled Trials as Topic; Salvage Therapy; Taxoids; Vinblastine; Vinorelbine | 2000 |
[Chemosensitivity test of breast cancer].
Topics: Antineoplastic Agents; Breast Neoplasms; Docetaxel; Doxorubicin; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Female; Humans; Lymphatic Metastasis; Neoplasm Recurrence, Local; Paclitaxel; Predictive Value of Tests; Taxoids; Tumor Cells, Cultured | 2000 |
Lung cancer: therapeutic options for stage IV and recurrent NSCLC.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Combined Modality Therapy; Deoxycytidine; Docetaxel; Etoposide; Gemcitabine; Humans; Irinotecan; Lung Neoplasms; Multicenter Studies as Topic; Neoplasm Recurrence, Local; Paclitaxel; Prognosis; Randomized Controlled Trials as Topic; Risk Factors; Survival Rate; Taxoids; Teniposide; Treatment Outcome; Vinblastine; Vinorelbine | 2001 |
[New drugs for unresectable or recurrent gastric cancer--paclitaxel and docetaxel].
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Clinical Trials as Topic; Docetaxel; Humans; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Stomach Neoplasms; Taxoids; Treatment Outcome | 2001 |
Role of Herceptin in primary breast cancer: views from North America and Europe.
Topics: Adult; Aged; Aged, 80 and over; Antibiotics, Antineoplastic; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Chemotherapy, Adjuvant; Clinical Trials as Topic; Combined Modality Therapy; Disease-Free Survival; Docetaxel; Drug Interactions; Europe; Female; Humans; Middle Aged; Multicenter Studies as Topic; Neoplasm Metastasis; Neoplasm Proteins; Neoplasm Recurrence, Local; North America; Paclitaxel; Palliative Care; Pilot Projects; Randomized Controlled Trials as Topic; Receptor, ErbB-2; Receptors, Estrogen; Research Design; Safety; Survival Analysis; Tamoxifen; Taxoids; Trastuzumab; Treatment Outcome | 2001 |
Epithelial ovarian cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bridged-Ring Compounds; Combined Modality Therapy; Deoxycytidine; Docetaxel; Doxorubicin; Etoposide; Female; Gemcitabine; Humans; Ifosfamide; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Platinum Compounds; Practice Guidelines as Topic; Tamoxifen; Taxoids; Topotecan; Vinblastine; Vinorelbine | 2002 |
294 trial(s) available for docetaxel anhydrous and Local Neoplasm Recurrence
| Article | Year |
|---|---|
Outcome of patients with relapsed or progressive Ewing sarcoma enrolled on cooperative group phase 2 clinical trials: A report from the Children's Oncology Group.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Child; Docetaxel; Humans; Neoplasm Recurrence, Local; Neuroectodermal Tumors, Primitive, Peripheral; Sarcoma, Ewing | 2021 |
A Single-Arm, Prospective, Phase II Study of Cisplatin Plus Weekly Docetaxel as First-Line Therapy in Patients with Metastatic or Recurrent Salivary Gland Cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Adenoid Cystic; Carcinoma, Ductal; Cisplatin; Docetaxel; Humans; Middle Aged; Neoplasm Recurrence, Local; Prospective Studies; Salivary Gland Neoplasms; Treatment Outcome | 2022 |
Pembrolizumab plus docetaxel for the treatment of recurrent/metastatic head and neck cancer: A prospective phase I/II study.
Topics: Antibodies, Monoclonal, Humanized; Docetaxel; Head and Neck Neoplasms; Humans; Neoplasm Recurrence, Local; Prospective Studies; Squamous Cell Carcinoma of Head and Neck | 2022 |
Quality of Life of Patients with Head and Neck Cancer Receiving Cetuximab, Fluorouracil, Cisplatin Comparing to Cetuximab, Fluorouracil, Cisplatin, and Docetaxel within the CEFCID Trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cetuximab; Cisplatin; Docetaxel; Fatigue; Fluorouracil; Head and Neck Neoplasms; Humans; Neoplasm Recurrence, Local; Quality of Life; Squamous Cell Carcinoma of Head and Neck | 2022 |
Phase 1/2 Trial Results of a Large Surface Area Microparticle Docetaxel for the Treatment of High-Risk Nonmuscle-Invasive Bladder Cancer.
Topics: Administration, Intravesical; BCG Vaccine; Docetaxel; Humans; Immune Checkpoint Inhibitors; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Treatment Outcome; Tumor Microenvironment; Urinary Bladder Neoplasms | 2022 |
Protocol of OGSG 1901: a phase II trial of ramucirumab plus irinotecan for patients with early relapsed gastric cancer during or after adjuvant docetaxel plus S - 1 therapy.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Clinical Trials, Phase II as Topic; Docetaxel; Humans; Irinotecan; Multicenter Studies as Topic; Neoplasm Recurrence, Local; Prospective Studies; Ramucirumab; Stomach Neoplasms | 2022 |
A Phase 2 Study of Docetaxel, Ramucirumab, and Pembrolizumab for Patients With Metastatic or Recurrent Non-Small-Cell Lung Cancer (NSCLC) who Progressed on Platinum-Doublet and PD-1/PD-L1 Blockade.
Topics: Antineoplastic Combined Chemotherapy Protocols; B7-H1 Antigen; Carcinoma, Non-Small-Cell Lung; Docetaxel; Humans; Immune Checkpoint Inhibitors; Lung Neoplasms; Neoplasm Recurrence, Local; Platinum; Programmed Cell Death 1 Receptor; Ramucirumab | 2022 |
A Randomized Comparison of Nivolumab versus Nivolumab + Docetaxel for Previously Treated Advanced or Recurrent ICI-Naïve Non-Small Cell Lung Cancer: TORG1630.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Docetaxel; Humans; Immune Checkpoint Inhibitors; Lung Neoplasms; Neoplasm Recurrence, Local; Nivolumab; Platinum | 2022 |
Long term outcomes of a randomized controlled clinical trial comparing the efficacy of Cabazitaxel versus docetaxel as second-line or above therapy in recurrent head and neck cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Head and Neck Neoplasms; Humans; Neoplasm Recurrence, Local; Taxoids; Treatment Outcome | 2022 |
CINOVA: a phase II study of CPC634 (nanoparticulate docetaxel) in patients with platinum resistant recurrent ovarian cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Ovarian Epithelial; Docetaxel; Drug Resistance, Neoplasm; Fatigue; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Young Adult | 2023 |
Effect of docetaxel added to bicalutamide in Hormone-Naïve non-metastatic prostate cancer with rising PSA, a randomized clinical trial (SPCG-14).
Topics: Androgen Antagonists; Antineoplastic Combined Chemotherapy Protocols; Chronic Disease; Disease-Free Survival; Docetaxel; Hormones; Humans; Male; Neoplasm Recurrence, Local; Prostate-Specific Antigen; Prostatic Neoplasms; Treatment Outcome | 2023 |
Very Long-Term Complete Remission Can Be Achieved in Men With High-Risk Localized Prostate Cancer and a Very High PSA Value: An Analysis of the GETUG 12 Phase 3 Trial.
Topics: Androgen Antagonists; Docetaxel; Estramustine; Humans; Male; Neoplasm Recurrence, Local; Prostate-Specific Antigen; Prostatic Neoplasms; Treatment Outcome | 2023 |
A phase II study of gemcitabine and docetaxel combination in relapsed metastatic or unresectable locally advanced synovial sarcoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Neoplasm Recurrence, Local; Neutropenia; Prospective Studies; Quality of Life; Sarcoma; Sarcoma, Synovial; Soft Tissue Neoplasms; Treatment Outcome | 2023 |
Pembrolizumab versus methotrexate, docetaxel, or cetuximab in recurrent or metastatic head and neck squamous cell carcinoma (KEYNOTE-040): Subgroup analysis by pattern of disease recurrence.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cetuximab; Docetaxel; Head and Neck Neoplasms; Humans; Methotrexate; Neoplasm Recurrence, Local; Platinum; Squamous Cell Carcinoma of Head and Neck | 2023 |
Final overall survival results of WJTOG3405, a randomized phase III trial comparing gefitinib versus cisplatin with docetaxel as the first-line treatment for patients with stage IIIB/IV or postoperative recurrent EGFR mutation-positive non-small-cell lung
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Disease-Free Survival; Docetaxel; ErbB Receptors; Female; Gefitinib; Humans; Japan; Kaplan-Meier Estimate; Male; Middle Aged; Mutation; Neoplasm Recurrence, Local; Neoplasm Staging; Proportional Hazards Models; Protein Kinase Inhibitors; Treatment Outcome | 2019 |
Clinical Outcomes in Early Breast Cancer With a High 21-Gene Recurrence Score of 26 to 100 Assigned to Adjuvant Chemotherapy Plus Endocrine Therapy: A Secondary Analysis of the TAILORx Randomized Clinical Trial.
Topics: Adult; Aged; Anthracyclines; Antineoplastic Agents; Breast Neoplasms; Bridged-Ring Compounds; Chemotherapy, Adjuvant; Cyclophosphamide; Docetaxel; Female; Fluorouracil; Humans; Methotrexate; Middle Aged; Neoplasm Recurrence, Local; Taxoids; Treatment Outcome; Young Adult | 2020 |
Multicentre, randomised controlled trial of adjuvant chemotherapy in cervical cancer with residual human papilloma virus DNA following primary radiotherapy or chemoradiotherapy: a study protocol.
Topics: Adult; Antineoplastic Agents; Chemotherapy, Adjuvant; Disease-Free Survival; DNA, Viral; Docetaxel; Female; Humans; Multicenter Studies as Topic; Neoplasm Recurrence, Local; Neoplasm Staging; Organoplatinum Compounds; Papillomaviridae; Radiotherapy; Randomized Controlled Trials as Topic; Uterine Cervical Neoplasms | 2019 |
Pembrolizumab versus chemotherapy in recurrent, advanced urothelial cancer in Japanese patients: a subgroup analysis of the phase 3 KEYNOTE-045 trial.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Docetaxel; Female; Humans; Japan; Male; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Survival Rate; Treatment Outcome; Urinary Bladder Neoplasms; Urologic Neoplasms; Vinblastine | 2020 |
Pilot study of docetaxel combined with lobaplatin or gemcitabine for recurrent and metastatic breast cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclobutanes; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Recurrence, Local; Organoplatinum Compounds; Pilot Projects; Survival Analysis | 2019 |
Preoperative cisplatin, fluorouracil, and docetaxel with or without radiotherapy after poor early response to cisplatin and fluorouracil for resectable oesophageal adenocarcinoma (AGITG DOCTOR): results from a multicentre, randomised controlled phase II t
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; Esophageal Neoplasms; Fluorouracil; Humans; Neoplasm Recurrence, Local; Positron Emission Tomography Computed Tomography; Treatment Outcome | 2020 |
Microwave ablation plus chemotherapy versus chemotherapy in advanced non-small cell lung cancer: a multicenter, randomized, controlled, phase III clinical trial.
Topics: Adenocarcinoma of Lung; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Combined Modality Therapy; Deoxycytidine; Disease-Free Survival; Docetaxel; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Microwaves; Middle Aged; Neoplasm Recurrence, Local; Organoplatinum Compounds; Paclitaxel; Pemetrexed; Progression-Free Survival; Prospective Studies; Radiofrequency Ablation; Treatment Outcome; Vinorelbine | 2020 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor Proteins, Signal Transducing; Adenine; Adenocarcinoma; Adipogenesis; Administration, Cutaneous; Administration, Ophthalmic; Adolescent; Adsorption; Adult; Aeromonas hydrophila; Aerosols; Aged; Aged, 80 and over; Aging; Agriculture; Air Pollutants; Air Pollution; Airway Remodeling; Alanine Transaminase; Albuminuria; Aldehyde Dehydrogenase 1 Family; Algorithms; AlkB Homolog 2, Alpha-Ketoglutarate-Dependent Dioxygenase; Alzheimer Disease; Amino Acid Sequence; Ammonia; Ammonium Compounds; Anaerobiosis; Anesthetics, Dissociative; Anesthetics, Inhalation; Animals; Anti-Bacterial Agents; Anti-HIV Agents; Anti-Infective Agents; Anti-Inflammatory Agents; Antibiotics, Antineoplastic; Antibodies, Antineutrophil Cytoplasmic; Antibodies, Monoclonal, Humanized; Antifungal Agents; Antigens, Bacterial; Antigens, CD; Antigens, Differentiation, Myelomonocytic; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Antioxidants; Antitubercular Agents; Antiviral Agents; Apolipoproteins E; Apoptosis; Arabidopsis; Arabidopsis Proteins; Arsenic; Arthritis, Rheumatoid; Asthma; Atherosclerosis; ATP-Dependent Proteases; Attitude of Health Personnel; Australia; Austria; Autophagy; Axitinib; Bacteria; Bacterial Outer Membrane Proteins; Bacterial Proteins; Bacterial Toxins; Bacterial Typing Techniques; Bariatric Surgery; Base Composition; Bayes Theorem; Benzoxazoles; Benzylamines; beta Catenin; Betacoronavirus; Betula; Binding Sites; Biological Availability; Biological Oxygen Demand Analysis; Biomarkers; Biomarkers, Tumor; Biopsy; Bioreactors; Biosensing Techniques; Birth Weight; Blindness; Blood Chemical Analysis; Blood Gas Analysis; Blood Glucose; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Blood-Brain Barrier; Blotting, Western; Body Mass Index; Body Weight; Bone and Bones; Bone Density; Bone Resorption; Borates; Brain; Brain Infarction; Brain Injuries, Traumatic; Brain Neoplasms; Breakfast; Breast Milk Expression; Breast Neoplasms; Bronchi; Bronchoalveolar Lavage Fluid; Buffaloes; Cadherins; Calcification, Physiologic; Calcium Compounds; Calcium, Dietary; Cannula; Caprolactam; Carbon; Carbon Dioxide; Carboplatin; Carcinogenesis; Carcinoma, Ductal; Carcinoma, Ehrlich Tumor; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Pancreatic Ductal; Carcinoma, Renal Cell; Cardiovascular Diseases; Carps; Carrageenan; Case-Control Studies; Catalysis; Catalytic Domain; Cattle; CD8-Positive T-Lymphocytes; Cell Adhesion; Cell Cycle Proteins; Cell Death; Cell Differentiation; Cell Line; Cell Line, Tumor; Cell Movement; Cell Nucleus; Cell Phone Use; Cell Proliferation; Cell Survival; Cell Transformation, Neoplastic; Cell Transformation, Viral; Cells, Cultured; Cellulose; Chemical Phenomena; Chemoradiotherapy; Child; Child Development; Child, Preschool; China; Chitosan; Chlorocebus aethiops; Cholecalciferol; Chromatography, Liquid; Circadian Clocks; Circadian Rhythm; Circular Dichroism; Cisplatin; Citric Acid; Clinical Competence; Clinical Laboratory Techniques; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Clostridioides difficile; Clostridium Infections; Coculture Techniques; Cohort Studies; Cold Temperature; Colitis; Collagen Type I; Collagen Type I, alpha 1 Chain; Collagen Type XI; Color; Connective Tissue Diseases; Copper; Coronary Angiography; Coronavirus 3C Proteases; Coronavirus Infections; Cost of Illness; Counselors; COVID-19; COVID-19 Testing; Creatine Kinase; Creatinine; Cross-Over Studies; Cross-Sectional Studies; Cryoelectron Microscopy; Cryosurgery; Crystallography, X-Ray; Cues; Cultural Competency; Cultural Diversity; Curriculum; Cyclic AMP Response Element-Binding Protein; Cyclin-Dependent Kinase Inhibitor p21; Cycloparaffins; Cysteine Endopeptidases; Cytokines; Cytoplasm; Cytoprotection; Databases, Factual; Denitrification; Deoxycytidine; Diabetes Complications; Diabetes Mellitus; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Diagnosis, Differential; Diatoms; Diet; Diet, High-Fat; Dietary Exposure; Diffusion Magnetic Resonance Imaging; Diketopiperazines; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Disease Models, Animal; Disease Progression; Disease-Free Survival; DNA; DNA Damage; DNA Glycosylases; DNA Repair; DNA-Binding Proteins; DNA, Bacterial; DNA, Viral; Docetaxel; Dose Fractionation, Radiation; Dose-Response Relationship, Drug; Down-Regulation; Doxorubicin; Drosophila; Drosophila melanogaster; Drug Carriers; Drug Delivery Systems; Drug Liberation; Drug Repositioning; Drug Resistance, Bacterial; Drug Resistance, Multiple, Bacterial; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Drug Synergism; Drug Therapy, Combination; Edema; Edible Grain; Education, Graduate; Education, Medical, Graduate; Education, Pharmacy; Ehlers-Danlos Syndrome; Electron Transport Complex III; Electron Transport Complex IV; Electronic Nicotine Delivery Systems; Emergency Service, Hospital; Empathy; Emulsions; Endothelial Cells; Endurance Training; Energy Intake; Enterovirus A, Human; Environment; Environmental Monitoring; Enzyme Assays; Enzyme Inhibitors; Epithelial Cells; Epithelial-Mesenchymal Transition; Epoxide Hydrolases; Epoxy Compounds; Erythrocyte Count; Erythrocytes; Escherichia coli; Escherichia coli Infections; Escherichia coli Proteins; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Esophagectomy; Estrogens; Etanercept; Ethiopia; Ethnicity; Ethylenes; Exanthema; Exercise; Exercise Test; Exercise Tolerance; Extracellular Matrix; Extracorporeal Membrane Oxygenation; Eye Infections, Fungal; False Negative Reactions; Fatty Acids; Fecal Microbiota Transplantation; Feces; Female; Femur Neck; Fermentation; Ferritins; Fetal Development; Fibroblast Growth Factor-23; Fibroblast Growth Factors; Fibroblasts; Fibroins; Fish Proteins; Flavanones; Flavonoids; Focus Groups; Follow-Up Studies; Food Handling; Food Supply; Food, Formulated; Forced Expiratory Volume; Forests; Fractures, Bone; Fruit and Vegetable Juices; Fusobacteria; G1 Phase Cell Cycle Checkpoints; G2 Phase Cell Cycle Checkpoints; Gamma Rays; Gastrectomy; Gastrointestinal Microbiome; Gastrointestinal Stromal Tumors; Gefitinib; Gels; Gemcitabine; Gene Amplification; Gene Expression; Gene Expression Regulation; Gene Expression Regulation, Bacterial; Gene Expression Regulation, Neoplastic; Gene Expression Regulation, Plant; Gene Knockdown Techniques; Gene-Environment Interaction; Genotype; Germany; Glioma; Glomerular Filtration Rate; Glucagon; Glucocorticoids; Glycemic Control; Glycerol; Glycogen Synthase Kinase 3 beta; Glycolipids; Glycolysis; Goblet Cells; Gram-Negative Bacterial Infections; Granulocyte Colony-Stimulating Factor; Graphite; Greenhouse Effect; Guanidines; Haemophilus influenzae; HCT116 Cells; Health Knowledge, Attitudes, Practice; Health Personnel; Health Services Accessibility; Health Services Needs and Demand; Health Status Disparities; Healthy Volunteers; Heart Failure; Heart Rate; Heart Transplantation; Heart-Assist Devices; HEK293 Cells; Heme; Heme Oxygenase-1; Hemolysis; Hemorrhage; Hepatitis B; Hepatitis B e Antigens; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Hepatocytes; Hexoses; High-Throughput Nucleotide Sequencing; Hippo Signaling Pathway; Histamine; Histamine Agonists; Histidine; Histone Deacetylase 2; HIV Infections; HIV Reverse Transcriptase; HIV-1; Homebound Persons; Homeodomain Proteins; Homosexuality, Male; Hospice and Palliative Care Nursing; HSP70 Heat-Shock Proteins; Humans; Hyaluronan Receptors; Hydrogen; Hydrogen Peroxide; Hydrogen-Ion Concentration; Hydrolysis; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypoglycemia; Hypoglycemic Agents; Hypoxia; Idiopathic Interstitial Pneumonias; Imaging, Three-Dimensional; Imatinib Mesylate; Immunotherapy; Implementation Science; Incidence; INDEL Mutation; Induced Pluripotent Stem Cells; Industrial Waste; Infant; Infant, Newborn; Inflammation; Inflammation Mediators; Infliximab; Infusions, Intravenous; Inhibitory Concentration 50; Injections; Insecticides; Insulin-Like Growth Factor Binding Protein 5; Insulin-Secreting Cells; Interleukin-1; Interleukin-17; Interleukin-8; Internship and Residency; Intestines; Intracellular Signaling Peptides and Proteins; Ion Transport; Iridaceae; Iridoid Glucosides; Islets of Langerhans Transplantation; Isodon; Isoflurane; Isotopes; Italy; Joint Instability; Ketamine; Kidney; Kidney Failure, Chronic; Kidney Function Tests; Kidney Neoplasms; Kinetics; Klebsiella pneumoniae; Knee Joint; Kruppel-Like Factor 4; Kruppel-Like Transcription Factors; Lactate Dehydrogenase 5; Laparoscopy; Laser Therapy; Lasers, Semiconductor; Lasers, Solid-State; Laurates; Lead; Leukocyte L1 Antigen Complex; Leukocytes, Mononuclear; Light; Lipid Peroxidation; Lipopolysaccharides; Liposomes; Liver; Liver Cirrhosis; Liver Neoplasms; Liver Transplantation; Locomotion; Longitudinal Studies; Lopinavir; Lower Urinary Tract Symptoms; Lubricants; Lung; Lung Diseases, Interstitial; Lung Neoplasms; Lymphocyte Activation; Lymphocytes, Tumor-Infiltrating; Lymphoma, Mantle-Cell; Lysosomes; Macrophages; Male; Manganese Compounds; MAP Kinase Kinase 4; Mass Screening; Maternal Health; Medicine, Chinese Traditional; Melanoma, Experimental; Memantine; Membrane Glycoproteins; Membrane Proteins; Mesenchymal Stem Cell Transplantation; Metal Nanoparticles; Metalloendopeptidases; Metalloporphyrins; Methadone; Methane; Methicillin-Resistant Staphylococcus aureus; Mexico; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Mice, Inbred ICR; Mice, Knockout; Mice, Nude; Mice, SCID; Mice, Transgenic; Microarray Analysis; Microbial Sensitivity Tests; Microbiota; Micronutrients; MicroRNAs; Microscopy, Confocal; Microsomes, Liver; Middle Aged; Milk; Milk, Human; Minority Groups; Mitochondria; Mitochondrial Membranes; Mitochondrial Proteins; Models, Animal; Models, Molecular; Molecular Conformation; Molecular Docking Simulation; Molecular Dynamics Simulation; Molecular Epidemiology; Molecular Structure; Molecular Weight; Multilocus Sequence Typing; Multimodal Imaging; Muscle Strength; Muscle, Skeletal; Muscular Diseases; Mutation; Mycobacterium tuberculosis; Myocardial Stunning; Myristates; NAD(P)H Dehydrogenase (Quinone); Nanocomposites; Nanogels; Nanoparticles; Nanotechnology; Naphthalenes; Nasal Cavity; National Health Programs; Necrosis; Needs Assessment; Neoadjuvant Therapy; Neonicotinoids; Neoplasm Invasiveness; Neoplasm Metastasis; Neoplasm Proteins; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplasm Transplantation; Neoplasms; Neoplastic Stem Cells; Netherlands; Neuroblastoma; Neuroprotective Agents; Neutrophils; NF-kappa B; NFATC Transcription Factors; Nicotiana; Nicotine; Nitrates; Nitrification; Nitrites; Nitro Compounds; Nitrogen; Nitrogen Dioxide; North Carolina; Nuclear Magnetic Resonance, Biomolecular; Nuclear Proteins; Nucleic Acid Hybridization; Nucleosomes; Nutrients; Obesity; Obesity, Morbid; Oceans and Seas; Oncogene Protein v-akt; Oncogenes; Oocytes; Open Reading Frames; Osteoclasts; Osteogenesis; Osteoporosis; Osteoporosis, Postmenopausal; Outpatients; Ovarian Neoplasms; Ovariectomy; Overweight; Oxazines; Oxidants; Oxidation-Reduction; Oxidative Stress; Oxides; Oxidoreductases; Oxygen; Oxygen Inhalation Therapy; Oxygenators, Membrane; Ozone; Paclitaxel; Paenibacillus; Pain Measurement; Palliative Care; Pancreatic Neoplasms; Pandemics; Parasympathetic Nervous System; Particulate Matter; Pasteurization; Patient Preference; Patient Satisfaction; Pediatric Obesity; Permeability; Peroxiredoxins; Peroxynitrous Acid; Pharmaceutical Services; Pharmacists; Pharmacy; Phaseolus; Phenotype; Phoeniceae; Phosphates; Phosphatidylinositol 3-Kinases; Phospholipid Transfer Proteins; Phospholipids; Phosphorus; Phosphorylation; Photoperiod; Photosynthesis; Phylogeny; Physical Endurance; Physicians; Pilot Projects; Piperidines; Pituitary Adenylate Cyclase-Activating Polypeptide; Plant Extracts; Plant Leaves; Plant Proteins; Plant Roots; Plaque, Atherosclerotic; Pneumonia; Pneumonia, Viral; Point-of-Care Testing; Polyethylene Glycols; Polymers; Polysorbates; Pore Forming Cytotoxic Proteins; Positron Emission Tomography Computed Tomography; Positron-Emission Tomography; Postprandial Period; Poverty; Pre-Exposure Prophylaxis; Prediabetic State; Predictive Value of Tests; Pregnancy; Pregnancy Trimester, First; Pregnancy, High-Risk; Prenatal Exposure Delayed Effects; Pressure; Prevalence; Primary Graft Dysfunction; Primary Health Care; Professional Role; Professionalism; Prognosis; Progression-Free Survival; Prolactin; Promoter Regions, Genetic; Proof of Concept Study; Proportional Hazards Models; Propylene Glycol; Prospective Studies; Prostate; Protein Binding; Protein Biosynthesis; Protein Isoforms; Protein Kinase Inhibitors; Protein Phosphatase 2; Protein Processing, Post-Translational; Protein Serine-Threonine Kinases; Protein Structure, Tertiary; Protein Transport; Proteoglycans; Proteome; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-myc; Proto-Oncogene Proteins c-ret; Proto-Oncogene Proteins p21(ras); Proton Pumps; Protons; Protoporphyrins; Pseudomonas aeruginosa; Pseudomonas fluorescens; Pulmonary Artery; Pulmonary Disease, Chronic Obstructive; Pulmonary Gas Exchange; Pulmonary Veins; Pyrazoles; Pyridines; Pyrimidines; Qualitative Research; Quinoxalines; Rabbits; Random Allocation; Rats; Rats, Sprague-Dawley; Rats, Wistar; Receptors, Histamine H3; Receptors, Immunologic; Receptors, Transferrin; Recombinant Proteins; Recurrence; Reference Values; Referral and Consultation; Regional Blood Flow; Registries; Regulon; Renal Insufficiency, Chronic; Reperfusion Injury; Repressor Proteins; Reproducibility of Results; Republic of Korea; Research Design; Resistance Training; Respiration, Artificial; Respiratory Distress Syndrome; Respiratory Insufficiency; Resuscitation; Retinal Dehydrogenase; Retreatment; Retrospective Studies; Reverse Transcriptase Inhibitors; Rhinitis, Allergic; Ribosomal Proteins; Ribosomes; Risk Assessment; Risk Factors; Ritonavir; Rivers; RNA Interference; RNA-Seq; RNA, Messenger; RNA, Ribosomal, 16S; RNA, Small Interfering; Rosuvastatin Calcium; Rural Population; Saccharomyces cerevisiae; Saccharomyces cerevisiae Proteins; Salivary Ducts; Salivary Gland Neoplasms; San Francisco; SARS-CoV-2; Satiation; Satiety Response; Schools; Schools, Pharmacy; Seasons; Seawater; Selection, Genetic; Sequence Analysis, DNA; Serine-Threonine Kinase 3; Sewage; Sheep; Sheep, Domestic; Shock, Hemorrhagic; Signal Transduction; Silver; Silymarin; Single Photon Emission Computed Tomography Computed Tomography; Sirolimus; Sirtuin 1; Skin; Skin Neoplasms; Skin Physiological Phenomena; Sleep Initiation and Maintenance Disorders; Social Class; Social Participation; Social Support; Soil; Soil Microbiology; Solutions; Somatomedins; Soot; Specimen Handling; Spectrophotometry, Ultraviolet; Spectroscopy, Fourier Transform Infrared; Spectrum Analysis; Spinal Fractures; Spirometry; Staphylococcus aureus; STAT1 Transcription Factor; STAT3 Transcription Factor; Streptomyces coelicolor; Stress, Psychological; Stroke; Stroke Volume; Structure-Activity Relationship; Students, Medical; Students, Pharmacy; Substance Abuse Treatment Centers; Sulfur Dioxide; Surface Properties; Surface-Active Agents; Surveys and Questionnaires; Survival Analysis; Survival Rate; Survivin; Sweden; Swine; Swine, Miniature; Sympathetic Nervous System; T-Lymphocytes, Regulatory; Talaromyces; Tandem Mass Spectrometry; tau Proteins; Telemedicine; Telomerase; Telomere; Telomere Homeostasis; Temperature; Terminally Ill; Th1 Cells; Thiamethoxam; Thiazoles; Thiophenes; Thioredoxin Reductase 1; Thrombosis; Thulium; Thyroid Cancer, Papillary; Thyroid Carcinoma, Anaplastic; Thyroid Neoplasms; Time Factors; Titanium; Tomography, Emission-Computed, Single-Photon; Tomography, X-Ray Computed; TOR Serine-Threonine Kinases; Transcription Factor AP-1; Transcription Factors; Transcription, Genetic; Transcriptional Activation; Transcriptome; Transforming Growth Factor beta1; Transistors, Electronic; Translational Research, Biomedical; Transplantation Tolerance; Transplantation, Homologous; Transportation; Treatment Outcome; Tretinoin; Tuberculosis, Multidrug-Resistant; Tuberculosis, Pulmonary; Tubulin Modulators; Tumor Microenvironment; Tumor Necrosis Factor Inhibitors; Tumor Necrosis Factor-alpha; Twins; Ultrasonic Therapy; Ultrasonography; Ultraviolet Rays; United States; Up-Regulation; Uranium; Urethra; Urinary Bladder; Urodynamics; Uromodulin; Uveitis; Vasoconstrictor Agents; Ventricular Function, Left; Vero Cells; Vesicular Transport Proteins; Viral Nonstructural Proteins; Visual Acuity; Vital Capacity; Vitamin D; Vitamin D Deficiency; Vitamin K 2; Vitamins; Volatilization; Voriconazole; Waiting Lists; Waste Disposal, Fluid; Wastewater; Water Pollutants, Chemical; Whole Genome Sequencing; Wine; Wnt Signaling Pathway; Wound Healing; Wounds and Injuries; WW Domains; X-linked Nuclear Protein; X-Ray Diffraction; Xanthines; Xenograft Model Antitumor Assays; YAP-Signaling Proteins; Yogurt; Young Adult; Zebrafish; Zebrafish Proteins; Ziziphus | 2016 |
Atezolizumab plus modified docetaxel-cisplatin-5-fluorouracil (mDCF) regimen versus mDCF in patients with metastatic or unresectable locally advanced recurrent anal squamous cell carcinoma: a randomized, non-comparative phase II SCARCE GERCOR trial.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carcinoma, Squamous Cell; Cisplatin; Docetaxel; Female; Fluorouracil; Follow-Up Studies; Humans; Lymphatic Metastasis; Male; Neoplasm Recurrence, Local; Prognosis; Survival Rate | 2020 |
Long-term Castration-related Outcomes in Patients With High-risk Localized Prostate Cancer Treated With Androgen Deprivation Therapy With or Without Docetaxel and Estramustine in the UNICANCER GETUG-12 Trial.
Topics: Androgen Antagonists; Androgens; Docetaxel; Estramustine; Humans; Male; Neoplasm Recurrence, Local; Orchiectomy; Prostatic Neoplasms | 2020 |
Bevacizumab plus chemotherapy in nonsquamous non-small cell lung cancer patients with malignant pleural effusion uncontrolled by tube drainage or pleurodesis: A phase II study North East Japan Study group trial NEJ013B.
Topics: Adenocarcinoma of Lung; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Carcinoma, Non-Small-Cell Lung; Docetaxel; Erlotinib Hydrochloride; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Pemetrexed; Pleural Effusion, Malignant; Pleurodesis; Prognosis; Survival Rate | 2020 |
A Randomized Parallel Controlled Phase II Trial of Recombinant Human Endostatin Added to Neoadjuvant Chemotherapy for Stage III Breast Cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Disease-Free Survival; Docetaxel; Endostatins; Epirubicin; Female; Follow-Up Studies; Humans; Mastectomy; Middle Aged; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Neoplasm Staging; Radiotherapy, Adjuvant; Recombinant Proteins | 2020 |
Cancer and Leukemia Group B 90203 (Alliance): Radical Prostatectomy With or Without Neoadjuvant Chemohormonal Therapy in Localized, High-Risk Prostate Cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Disease Progression; Docetaxel; Humans; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Neoplasm Staging; Progression-Free Survival; Prostatectomy; Prostatic Neoplasms; Risk Assessment; Risk Factors; Time Factors; United States | 2020 |
Early
Topics: Analysis of Variance; Antineoplastic Agents; Cisplatin; Docetaxel; Female; Fluorodeoxyglucose F18; Human papillomavirus 16; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Recurrence, Local; Oropharyngeal Neoplasms; Papillomavirus Infections; Positron Emission Tomography Computed Tomography; Proportional Hazards Models; Prospective Studies; Radiopharmaceuticals; Treatment Outcome; Tumor Burden | 2020 |
Validation of brief symptom indexes among patients with recurrent or metastatic squamous cell carcinoma of the head and neck: A trial of the ECOG-ACRIN Cancer Research Group (E1302).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Female; Gefitinib; Head and Neck Neoplasms; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Patient Reported Outcome Measures; Predictive Value of Tests; Reproducibility of Results; Squamous Cell Carcinoma of Head and Neck; Symptom Assessment; Treatment Outcome | 2020 |
Randomized phase II trial of S-1 plus cisplatin or docetaxel plus cisplatin with concurrent thoracic radiotherapy for inoperable stage III non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Chemoradiotherapy; Cisplatin; Docetaxel; Drug Combinations; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Oxonic Acid; Prognosis; Survival Rate; Tegafur; Thoracic Neoplasms | 2021 |
Docetaxel and carboplatin chemotherapy for treating patients with stage IVB or recurrent non-squamous cell carcinoma of the uterine cervix: a phase II study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Docetaxel; Female; Humans; Neoplasm Recurrence, Local; Neoplasm Staging; Uterine Cervical Neoplasms | 2021 |
Avelumab Versus Docetaxel in Patients With Platinum-Treated Advanced NSCLC: 2-Year Follow-Up From the JAVELIN Lung 200 Phase 3 Trial.
Topics: Antibodies, Monoclonal, Humanized; B7-H1 Antigen; Docetaxel; Follow-Up Studies; Humans; Lung; Lung Neoplasms; Neoplasm Recurrence, Local; Platinum | 2021 |
Five Year Survival Update From KEYNOTE-010: Pembrolizumab Versus Docetaxel for Previously Treated, Programmed Death-Ligand 1-Positive Advanced NSCLC.
Topics: Antibodies, Monoclonal, Humanized; B7-H1 Antigen; Carcinoma, Non-Small-Cell Lung; Docetaxel; Humans; Lung Neoplasms; Neoplasm Recurrence, Local | 2021 |
Immunogenomic profiling and pathological response results from a clinical trial of docetaxel and carboplatin in triple-negative breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Docetaxel; Female; Humans; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Treatment Outcome; Triple Negative Breast Neoplasms | 2021 |
Factors predictive of locoregional recurrence following neoadjuvant chemotherapy in patients with large operable or locally advanced breast cancer: An analysis of the EORTC 10994/BIG 1-00 study.
Topics: Adult; Age of Onset; Aged; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Docetaxel; Epirubicin; Female; Fluorouracil; Humans; Mastectomy; Middle Aged; Neoplasm Recurrence, Local; Taxoids; Trastuzumab; Treatment Outcome | 2017 |
Phase 2 study of combination SPI-1620 with docetaxel as second-line advanced biliary tract cancer treatment.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Disease-Free Survival; Docetaxel; Drug-Related Side Effects and Adverse Reactions; Endothelins; Female; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Peptide Fragments; Taxoids; Treatment Outcome | 2017 |
Docetaxel, Cisplatin, and 5-fluorouracil (DCF) chemotherapy in the treatment of metastatic or unresectable locally recurrent anal squamous cell carcinoma: a phase II study of French interdisciplinary GERCOR and FFCD groups (Epitopes-HPV02 study).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carcinoma, Squamous Cell; Cisplatin; Docetaxel; Fluorouracil; France; Humans; Middle Aged; Neoplasm Recurrence, Local; Prognosis; Research Design; Taxoids; Young Adult | 2017 |
Prospective, Multicenter, Phase 2 Trial of Induction Chemotherapy Followed by Bio-Chemoradiotherapy for Locally Advanced Recurrent Nasopharyngeal Carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cause of Death; Cetuximab; Chemoradiotherapy; Cisplatin; Docetaxel; Female; Fluorouracil; Humans; Induction Chemotherapy; Male; Middle Aged; Nasopharyngeal Carcinoma; Nasopharyngeal Neoplasms; Necrosis; Neoplasm Recurrence, Local; Progression-Free Survival; Prospective Studies; Radiotherapy, Intensity-Modulated; Salvage Therapy; Temporal Lobe; Treatment Outcome | 2018 |
Atezolizumab in Japanese Patients With Previously Treated Advanced Non-Small-Cell Lung Cancer: A Subgroup Analysis of the Phase 3 OAK Study.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Asian People; Carcinoma, Non-Small-Cell Lung; Docetaxel; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Progression-Free Survival; Treatment Outcome | 2018 |
Phase II Trial of Trastuzumab and Docetaxel in Patients With Human Epidermal Growth Factor Receptor 2-Positive Salivary Duct Carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Drug Administration Schedule; Female; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Progression-Free Survival; Receptor, ErbB-2; Salivary Gland Neoplasms; Trastuzumab; Treatment Outcome | 2019 |
Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Cetuximab; Disease Progression; Docetaxel; Drug Administration Schedule; Female; Head and Neck Neoplasms; Humans; Kaplan-Meier Estimate; Male; Methotrexate; Middle Aged; Neoplasm Recurrence, Local; Squamous Cell Carcinoma of Head and Neck | 2019 |
Weekly paclitaxel, carboplatin, cetuximab, and cetuximab, docetaxel, cisplatin, and fluorouracil, followed by local therapy in previously untreated, locally advanced head and neck squamous cell carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cetuximab; Cisplatin; Docetaxel; Female; Fluorouracil; Humans; Induction Chemotherapy; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Papillomaviridae; Papillomavirus Infections; Progression-Free Survival; Squamous Cell Carcinoma of Head and Neck | 2019 |
Randomised phase II trial comparing four front-line doublets in Asian patients with metastatic gastric cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Asian People; Bridged-Ring Compounds; Cisplatin; Disease-Free Survival; Docetaxel; Female; Fluorouracil; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Organoplatinum Compounds; Paclitaxel; Prospective Studies; Stomach Neoplasms; Taxoids | 2019 |
A Q-TWiST Analysis Comparing Nivolumab and Therapy of Investigator's Choice in Patients with Recurrent/Metastatic Platinum-Refractory Squamous Cell Carcinoma of the Head and Neck.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cetuximab; Disease Progression; Docetaxel; Follow-Up Studies; Head and Neck Neoplasms; Humans; Methotrexate; Neoplasm Recurrence, Local; Nivolumab; Quality of Life; Squamous Cell Carcinoma of Head and Neck; Survival | 2019 |
Randomized phase III KEYNOTE-045 trial of pembrolizumab versus paclitaxel, docetaxel, or vinflunine in recurrent advanced urothelial cancer: results of >2 years of follow-up.
Topics: Adult; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Follow-Up Studies; Humans; Neoplasm Recurrence, Local; Paclitaxel; Prognosis; Response Evaluation Criteria in Solid Tumors; Survival Rate; Urologic Neoplasms; Vinblastine | 2019 |
Addition of Docetaxel to First-line Long-term Hormone Therapy in Prostate Cancer (STAMPEDE): Modelling to Estimate Long-term Survival, Quality-adjusted Survival, and Cost-effectiveness.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cost-Benefit Analysis; Docetaxel; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Prognosis; Prostatic Neoplasms; Quality-Adjusted Life Years; Standard of Care; United Kingdom | 2018 |
A phase II study of the combination of docetaxel and bevacizumab for previously treated non-small cell lung cancer.
Topics: Adenocarcinoma of Lung; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Docetaxel; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Prognosis; Salvage Therapy; Survival Rate | 2019 |
Phase I/II study of intermitted erlotinib in combination with docetaxel in patients with recurrent non-small cell lung cancer (WJOG4708L).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Docetaxel; Erlotinib Hydrochloride; Female; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Protein Kinase Inhibitors; Treatment Outcome | 2019 |
A 3-Year Overall Survival Update From a Phase 2 Study of Chemoselection With DCF and Subsequent Conversion Surgery for Locally Advanced Unresectable Esophageal Cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Cisplatin; Docetaxel; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Esophagectomy; Female; Fluorouracil; Follow-Up Studies; Humans; Induction Chemotherapy; Male; Middle Aged; Neoplasm Recurrence, Local; Prognosis; Survival Rate | 2020 |
Phase II study of cetuximab in combination with docetaxel in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck after platinum-containing therapy: a multicenter study of the Arbeitsgemeinschaft Internistische Onkologie.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cetuximab; Cisplatin; Disease-Free Survival; Docetaxel; Female; Head and Neck Neoplasms; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Taxoids; Time Factors; Treatment Outcome | 2013 |
Long-term follow-up of a phase II trial of chemotherapy plus hormone therapy for biochemical relapse after definitive local therapy for prostate cancer.
Topics: Aged; Androgen Antagonists; Anilides; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Drug Therapy, Combination; Estramustine; Follow-Up Studies; Goserelin; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Nitriles; Prostatic Neoplasms; Retrospective Studies; Taxoids; Time Factors; Tosyl Compounds; Treatment Outcome | 2013 |
Phase III randomized, placebo-controlled trial of docetaxel with or without gefitinib in recurrent or metastatic head and neck cancer: an eastern cooperative oncology group trial.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Diarrhea; Docetaxel; Drug Administration Schedule; ErbB Receptors; Fatigue; Female; Gefitinib; Genotype; Head and Neck Neoplasms; Humans; Kaplan-Meier Estimate; Leukopenia; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-met; Proto-Oncogene Proteins p21(ras); Quinazolines; ras Proteins; Taxoids; Treatment Outcome | 2013 |
Farletuzumab (a monoclonal antibody against folate receptor alpha) in relapsed platinum-sensitive ovarian cancer.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Ovarian Epithelial; Disease-Free Survival; Docetaxel; Drug Hypersensitivity; Fallopian Tube Neoplasms; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Taxoids | 2013 |
AVEREL: a randomized phase III Trial evaluating bevacizumab in combination with docetaxel and trastuzumab as first-line therapy for HER2-positive locally recurrent/metastatic breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers, Tumor; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Disease-Free Survival; Docetaxel; Drug Administration Schedule; Female; Humans; Hypertension; Inflammatory Breast Neoplasms; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Neutropenia; Quality of Life; Receptor, ErbB-2; Surveys and Questionnaires; Taxoids; Trastuzumab; Treatment Outcome; Vascular Endothelial Growth Factor A | 2013 |
Unfavorable pathological complete response rate of neoadjuvant chemotherapy epirubicin plus taxanes for locally advanced triple-negative breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy, Adjuvant; Disease-Free Survival; Docetaxel; Epirubicin; Female; Humans; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Neoplasm, Residual; Paclitaxel; Taxoids; Treatment Failure; Treatment Outcome; Triple Negative Breast Neoplasms | 2013 |
A phase II trial of docetaxel and bevacizumab in recurrent ovarian cancer within 12 months of prior platinum-based chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Ovarian Epithelial; Disease-Free Survival; Docetaxel; Drug Resistance, Neoplasm; Drug Synergism; Fallopian Tube Neoplasms; Female; Humans; Infusions, Intravenous; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Glandular and Epithelial; Organoplatinum Compounds; Ovarian Neoplasms; Peritoneal Neoplasms; Taxoids | 2013 |
Third-line docetaxel chemotherapy for recurrent and metastatic gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Antineoplastic Protocols; Docetaxel; Female; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Republic of Korea; Salvage Therapy; Stomach Neoplasms; Taxoids | 2013 |
A prospective phase II trial of induction chemotherapy with docetaxel/cisplatin for Masaoka stage III/IV thymic epithelial tumors.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; Female; Follow-Up Studies; Humans; Induction Chemotherapy; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplasms, Glandular and Epithelial; Prognosis; Prospective Studies; Survival Rate; Taxoids; Thymus Neoplasms; Young Adult | 2013 |
A randomized phase II study of docetaxel with or without vandetanib in recurrent or metastatic squamous cell carcinoma of head and neck (SCCHN).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Docetaxel; Female; Head and Neck Neoplasms; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Piperidines; Quinazolines; Taxoids | 2013 |
Three-year outcomes of a phase II study of adjuvant chemotherapy with S-1 plus docetaxel for stage III gastric cancer after curative D2 gastrectomy.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Combined Modality Therapy; Docetaxel; Drug Combinations; Female; Follow-Up Studies; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Oxonic Acid; Prognosis; Prospective Studies; Salvage Therapy; Stomach Neoplasms; Survival Rate; Taxoids; Tegafur; Time Factors | 2014 |
Randomized phase II study of sunitinib versus standard of care for patients with previously treated advanced triple-negative breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Anthracyclines; Antineoplastic Agents; Capecitabine; Chemotherapy, Adjuvant; Deoxycytidine; Disease-Free Survival; Docetaxel; Fatigue; Female; Fluorouracil; Gemcitabine; Hand-Foot Syndrome; Humans; Indoles; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neutropenia; Paclitaxel; Pyrroles; Sunitinib; Survival Rate; Taxoids; Thrombocytopenia; Triple Negative Breast Neoplasms | 2013 |
Trastuzumab retreatment after relapse on adjuvant trastuzumab therapy for human epidermal growth factor receptor 2-positive breast cancer: final results of the Retreatment after HErceptin Adjuvant trial.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cohort Studies; Docetaxel; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Receptor, ErbB-2; Taxoids; Trastuzumab | 2014 |
Docetaxel or pemetrexed with or without cetuximab in recurrent or progressive non-small-cell lung cancer after platinum-based therapy: a phase 3, open-label, randomised trial.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Canada; Carcinoma, Non-Small-Cell Lung; Cetuximab; Disease Progression; Disease-Free Survival; Docetaxel; Drug Administration Schedule; Female; Glutamates; Guanine; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Pemetrexed; Platinum Compounds; Severity of Illness Index; Taxoids; Treatment Failure; United States | 2013 |
Treatment outcome of docetaxel, capecitabine and cisplatin regimen for patients with refractory and relapsed nasopharyngeal carcinoma who failed previous platinum-based chemotherapy.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma; Cisplatin; Deoxycytidine; Disease-Free Survival; DNA, Viral; Docetaxel; Female; Fluorouracil; Follow-Up Studies; Herpesvirus 4, Human; Humans; Male; Middle Aged; Multivariate Analysis; Nasopharyngeal Carcinoma; Nasopharyngeal Neoplasms; Neoplasm Recurrence, Local; Remission Induction; Survival Rate; Taxoids; Treatment Outcome; Young Adult | 2014 |
[Evaluation of induction chemotherapy with vinorelbine plus cisplatin (NP) or docetaxel plus cisplatin (TP) combined with concurrent chemoradiotherapy for patients with locally advanced nasopharyngeal carcinoma].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Carcinoma; Chemoradiotherapy; Cisplatin; Disease-Free Survival; Docetaxel; Female; Follow-Up Studies; Humans; Induction Chemotherapy; Leukopenia; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Mucositis; Nasopharyngeal Carcinoma; Nasopharyngeal Neoplasms; Neoplasm Recurrence, Local; Neoplasm Staging; Radiotherapy, Intensity-Modulated; Remission Induction; Survival Rate; Taxoids; Vinblastine; Vinorelbine; Young Adult | 2013 |
Stratified phase II trial to establish the usefulness of the collagen gel droplet embedded culture-drug sensitivity test (CD-DST) for advanced gastric cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Collagen; Docetaxel; Drug Combinations; Drug Resistance, Neoplasm; Female; Humans; Irinotecan; Male; Middle Aged; Neoplasm Recurrence, Local; Oxonic Acid; Stomach Neoplasms; Taxoids; Tegafur; Treatment Outcome | 2014 |
Phase I Study of Docetaxel Plus Nedaplatin in Patients With Metastatic or Recurrent Esophageal Squamous Cell Carcinoma After Cisplatin Plus 5-Fluorouracil Treatment.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Carcinoma, Squamous Cell; Cisplatin; Disease-Free Survival; Docetaxel; Dose-Response Relationship, Drug; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Female; Fluorouracil; Humans; Leukopenia; Liver Neoplasms; Lung Neoplasms; Lymph Nodes; Male; Middle Aged; Nausea; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neutropenia; Organoplatinum Compounds; Taxoids; Treatment Failure; Vomiting | 2016 |
Obatoclax mesylate, a pan-bcl-2 inhibitor, in combination with docetaxel in a phase 1/2 trial in relapsed non-small-cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Docetaxel; Humans; Indoles; Lung Neoplasms; Maximum Tolerated Dose; Neoplasm Recurrence, Local; Pyrroles; Taxoids | 2014 |
Addition of docetaxel to S-1 without platinum prolongs survival of patients with advanced gastric cancer: a randomized study (START).
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; Drug Combinations; Female; Follow-Up Studies; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neoplasm Staging; Oxonic Acid; Prognosis; Prospective Studies; Stomach Neoplasms; Survival Rate; Taxoids; Tegafur; Young Adult | 2014 |
Salvage chemotherapy with docetaxel and pegylated liposomal doxorubicin in pretreated patients with platinum- and taxane-sensitive ovarian cancer: a multicenter phase II trial of the Hellenic Oncology Research Group (HORG).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Ovarian Epithelial; Docetaxel; Doxorubicin; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Polyethylene Glycols; Prospective Studies; Salvage Therapy; Taxoids | 2014 |
Randomised phase II study of docetaxel plus vandetanib versus docetaxel followed by vandetanib in patients with persistent or recurrent epithelial ovarian, fallopian tube or primary peritoneal carcinoma: SWOG S0904.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Ovarian Epithelial; Disease-Free Survival; Docetaxel; Fallopian Tube Neoplasms; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Peritoneal Neoplasms; Piperidines; Quinazolines; Taxoids; Treatment Outcome | 2014 |
A randomized, phase 2 trial of Docetaxel with or without PX-866, an irreversible oral phosphatidylinositol 3-kinase inhibitor, in patients with relapsed or metastatic non-small-cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Class I Phosphatidylinositol 3-Kinases; Disease-Free Survival; Docetaxel; Female; Gonanes; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; PTEN Phosphohydrolase; Survival Rate; Taxoids | 2014 |
A study of docetaxel and irinotecan in children and young adults with recurrent or refractory Ewing sarcoma family of tumors.
Topics: Adolescent; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Camptothecin; Child; Child, Preschool; Disease-Free Survival; Docetaxel; Drug Administration Schedule; Female; Humans; Irinotecan; Male; Neoplasm Recurrence, Local; Prospective Studies; Sarcoma, Ewing; Taxoids; Young Adult | 2014 |
Primary results of ROSE/TRIO-12, a randomized placebo-controlled phase III trial evaluating the addition of ramucirumab to first-line docetaxel chemotherapy in metastatic breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease-Free Survival; Docetaxel; Double-Blind Method; Drug Administration Schedule; Fatigue; Febrile Neutropenia; Female; Hand-Foot Syndrome; Humans; Hypertension; Immunoglobulin G; Kaplan-Meier Estimate; Middle Aged; Neoplasm Recurrence, Local; Ramucirumab; Stomatitis; Taxoids; Treatment Outcome | 2015 |
Docetaxel plus oxaliplatin with or without fluorouracil or capecitabine in metastatic or locally recurrent gastric cancer: a randomized phase II study.
Topics: Adenocarcinoma; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Disease-Free Survival; Docetaxel; Drug Administration Schedule; Female; Fluorouracil; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Organoplatinum Compounds; Oxaliplatin; Prospective Studies; Stomach Neoplasms; Taxoids; Treatment Outcome | 2015 |
[Clinical study on chemotherapy of lobaplatin combined with docetaxel in patients with relapsed ovarian cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Ovarian Epithelial; Cisplatin; Cyclobutanes; Disease-Free Survival; Docetaxel; Female; Humans; Neoplasm Recurrence, Local; Neoplasms, Glandular and Epithelial; Organoplatinum Compounds; Ovarian Neoplasms; Taxoids | 2014 |
Weekly docetaxel versus CMF as adjuvant chemotherapy for older women with early breast cancer: final results of the randomized phase III ELDA trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Chemotherapy, Adjuvant; Cyclophosphamide; Docetaxel; Female; Fluorouracil; Follow-Up Studies; Humans; Methotrexate; Neoplasm Grading; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Survival Rate; Taxoids | 2015 |
Neoadjuvant gemcitabine, docetaxel, and capecitabine followed by gemcitabine and capecitabine/radiation therapy and surgery in locally advanced, unresectable pancreatic adenocarcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Combined Modality Therapy; Deoxycytidine; Docetaxel; Female; Fluorouracil; Gemcitabine; Humans; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Pancreatic Neoplasms; Prospective Studies; Taxoids; Treatment Outcome | 2015 |
A multicenter, non-randomized, phase II study of docetaxel and carboplatin administered every 3 weeks as second line chemotherapy in patients with first relapse of platinum sensitive epithelial ovarian, peritoneal or fallopian tube cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma; Carcinoma, Ovarian Epithelial; Chemotherapy-Induced Febrile Neutropenia; Disease Progression; Disease-Free Survival; Docetaxel; Drug Screening Assays, Antitumor; Fallopian Tube Neoplasms; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Peritoneal Neoplasms; Prospective Studies; Somatosensory Disorders; Taxoids; Treatment Outcome; Young Adult | 2014 |
Phase III study on efficacy of taxanes plus bevacizumab with or without capecitabine as first-line chemotherapy in metastatic breast cancer.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Capecitabine; Deoxycytidine; Disease-Free Survival; Docetaxel; Drug-Related Side Effects and Adverse Reactions; Female; Fluorouracil; Humans; Middle Aged; Neoplasm Recurrence, Local; Taxoids | 2015 |
Randomized multicenter phase III study of a modified docetaxel and cisplatin plus fluorouracil regimen compared with cisplatin and fluorouracil as first-line therapy for advanced or locally recurrent gastric cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; Female; Fluorouracil; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Stomach Neoplasms; Survival Rate; Taxoids; Treatment Outcome; Young Adult | 2016 |
A randomized controlled Phase III trial comparing 2-weekly docetaxel combined with cisplatin plus fluorouracil (2-weekly DCF) with cisplatin plus fluorouracil (CF) in patients with metastatic or recurrent esophageal cancer: rationale, design and methods o
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Disease-Free Survival; Docetaxel; Drug Administration Schedule; Esophageal Neoplasms; Female; Fluorouracil; Humans; Japan; Middle Aged; Neoplasm Recurrence, Local; Patient Selection; Research Design; Survival Analysis; Taxoids; Treatment Outcome | 2015 |
Long-term survival of patients with locally advanced prostate cancer managed with neoadjuvant docetaxel and radical prostatectomy.
Topics: Aged; Antineoplastic Agents; Chemotherapy, Adjuvant; Combined Modality Therapy; Docetaxel; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Proportional Hazards Models; Prostate-Specific Antigen; Prostatectomy; Prostatic Neoplasms; Taxoids; Treatment Outcome | 2015 |
Long-term Safety and Antitumor Activity in the Phase 1-2 Study of Enzalutamide in Pre- and Post-docetaxel Castration-Resistant Prostate Cancer.
Topics: Adult; Aged; Aged, 80 and over; Androgen Receptor Antagonists; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Benzamides; Bone Neoplasms; Disease-Free Survival; Docetaxel; Humans; Kallikreins; Lymph Nodes; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Nitriles; Phenylthiohydantoin; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Taxoids | 2015 |
Docetaxel, bevacizumab, and androgen deprivation therapy for biochemical disease recurrence after definitive local therapy for prostate cancer.
Topics: Adenocarcinoma; Androgen Antagonists; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers, Tumor; Chemotherapy, Adjuvant; Docetaxel; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Prostate-Specific Antigen; Prostatic Neoplasms; Taxoids; Treatment Outcome | 2015 |
Androgen deprivation therapy plus docetaxel and estramustine versus androgen deprivation therapy alone for high-risk localised prostate cancer (GETUG 12): a phase 3 randomised controlled trial.
Topics: Aged; Androgen Antagonists; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Estramustine; Follow-Up Studies; France; Humans; Kaplan-Meier Estimate; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Neoplasm Staging; Proportional Hazards Models; Prostate-Specific Antigen; Prostatic Neoplasms; Survival Analysis; Taxoids; Treatment Outcome | 2015 |
Patients with Slowly Proliferative Early Breast Cancer Have Low Five-Year Recurrence Rates in a Phase III Adjuvant Trial of Capecitabine.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Capecitabine; Chemotherapy, Adjuvant; Docetaxel; Female; Follow-Up Studies; Humans; Kaplan-Meier Estimate; Ki-67 Antigen; Middle Aged; Neoplasm Grading; Neoplasm Recurrence, Local; Neoplasm Staging; Taxoids; Treatment Outcome | 2015 |
Phase I trial of 5-FU, docetaxel, and nedaplatin (UDON) combination therapy for recurrent or metastatic esophageal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Esophageal Neoplasms; Female; Fluorouracil; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Organoplatinum Compounds; Taxoids; Young Adult | 2015 |
Cetuximab, docetaxel, and cisplatin as first-line treatment in patients with recurrent or metastatic head and neck squamous cell carcinoma: a multicenter, phase II GORTEC study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cetuximab; Cisplatin; Disease Progression; Disease-Free Survival; Docetaxel; Drug Administration Schedule; Female; Granulocyte Colony-Stimulating Factor; Head and Neck Neoplasms; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Squamous Cell Carcinoma of Head and Neck; Taxoids | 2015 |
Phase I study of intravenous (IV) docetaxel and intraperitoneal (IP) oxaliplatin in recurrent ovarian and fallopian tube cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Fallopian Tube Neoplasms; Female; Humans; Infusions, Intravenous; Infusions, Parenteral; Middle Aged; Neoplasm Recurrence, Local; Organoplatinum Compounds; Ovarian Neoplasms; Oxaliplatin; Taxoids | 2015 |
Long-term results of a randomized phase III trial of TPF induction chemotherapy followed by surgery and radiation in locally advanced oral squamous cell carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therapy; Disease-Free Survival; Docetaxel; Female; Fluorouracil; Follow-Up Studies; Humans; Induction Chemotherapy; Male; Middle Aged; Mouth Neoplasms; Neoplasm Metastasis; Neoplasm Recurrence, Local; Prospective Studies; Radiotherapy; Surgical Procedures, Operative; Taxoids; Treatment Outcome; Young Adult | 2015 |
Effects of docetaxel plus three-dimensional conformal radiation therapy on microvessel density and apoptosis expression in local advanced squamous non-small-cell lung cancer.
Topics: Aged; Apoptosis; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Docetaxel; Female; Humans; Male; Microvessels; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Squamous Cell; Prognosis; Quality of Life; Radiotherapy, Conformal; Survival Rate; Taxoids | 2015 |
Neoadjuvant plus adjuvant bevacizumab in early breast cancer (NSABP B-40 [NRG Oncology]): secondary outcomes of a phase 3, randomised controlled trial.
Topics: Adult; Aged; Bevacizumab; Breast Neoplasms; Capecitabine; Deoxycytidine; Disease-Free Survival; Docetaxel; Female; Gemcitabine; Humans; Middle Aged; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Neoplasm Staging; Taxoids; United States | 2015 |
[Study on therapy of metastasized or locally advanced urothelial cancer: A phase III randomized clinical trial of pembrolizumab (MK-3475) versus paclitaxel, docetaxel or vinflunine in subjects with recurrent or progressive metastatic urothelial cancer (Ke
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Docetaxel; Europe; Germany; Humans; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Paclitaxel; Taxoids; Treatment Outcome; United States; Vinblastine | 2015 |
Nedaplatin plus docetaxel versus cisplatin plus docetaxel for advanced or relapsed squamous cell carcinoma of the lung (WJOG5208L): a randomised, open-label, phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Disease Progression; Disease-Free Survival; Docetaxel; Female; Humans; Intention to Treat Analysis; Japan; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Organoplatinum Compounds; Proportional Hazards Models; Risk Factors; Taxoids; Time Factors; Treatment Outcome | 2015 |
Induction chemotherapy with docetaxel/cisplatin/5-fluorouracil followed by randomization to two cisplatin-based concomitant chemoradiotherapy schedules in patients with locally advanced head and neck cancer (CONDOR study) (Dutch Head and Neck Society 08-0
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Cisplatin; Disease Progression; Disease-Free Survival; Docetaxel; Early Termination of Clinical Trials; Feasibility Studies; Female; Fluorouracil; Head and Neck Neoplasms; Humans; Induction Chemotherapy; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Netherlands; Radiotherapy Dosage; Risk Factors; Taxoids; Time Factors; Treatment Outcome | 2016 |
Phase II trial of docetaxel combined with nedaplatin for patients with recurrent and metastatic nasopharyngeal carcinoma.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Docetaxel; Drug Design; Female; Humans; Injections, Intravenous; Male; Middle Aged; Nasopharyngeal Carcinoma; Nasopharyngeal Neoplasms; Neoplasm Recurrence, Local; Organoplatinum Compounds; Taxoids; Young Adult | 2015 |
Phase I/II study of divided-dose docetaxel, cisplatin and fluorouracil for patients with recurrent or metastatic squamous cell carcinoma of the esophagus.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Disease-Free Survival; Docetaxel; Drug Administration Schedule; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Esophagus; Fluorouracil; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Neutropenia; Research Design; Taxoids; Treatment Outcome | 2017 |
A phase 2 multimodality trial of docetaxel/prednisone with sunitinib followed by salvage radiation therapy in men with PSA recurrent prostate cancer after radical prostatectomy.
Topics: Adult; Aged; Disease-Free Survival; Docetaxel; Humans; Indoles; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Grading; Neoplasm Recurrence, Local; Prednisone; Prostate-Specific Antigen; Prostatectomy; Prostatic Neoplasms; Pyrroles; Quality of Life; Salvage Therapy; Sunitinib; Taxoids | 2016 |
Neoadjuvant Chemotherapy with Divided-dose Docetaxel, Cisplatin and Fluorouracil for Patients with Squamous Cell Carcinoma of the Esophagus.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Cisplatin; Disease-Free Survival; Docetaxel; Drug Administration Schedule; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Feasibility Studies; Female; Fluorouracil; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Neoplasm Staging; Neutropenia; Risk Factors; Taxoids; Time Factors; Treatment Outcome | 2016 |
Trastuzumab emtansine (T-DM1) plus docetaxel with or without pertuzumab in patients with HER2-positive locally advanced or metastatic breast cancer: results from a phase Ib/IIa study.
Topics: Ado-Trastuzumab Emtansine; Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease-Free Survival; Docetaxel; Female; Granulocyte Colony-Stimulating Factor; Humans; Maytansine; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neoplasm Staging; Receptor, ErbB-2; Taxoids; Trastuzumab | 2016 |
Efficacy and Safety of Biweekly Docetaxel in Combination with Nedaplatin as Second-line Chemotherapy for Unresectable or Recurrent Esophageal Cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Drug Administration Schedule; Esophageal Neoplasms; Female; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Organoplatinum Compounds; Taxoids; Treatment Outcome | 2016 |
High Efficacy and Low Toxicity of the Modified Docetaxel and Carboplatin Protocol in Patients with Recurrent Ovarian Cancer-A Phase 2 Cohort Study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Case-Control Studies; Cohort Studies; Cystadenocarcinoma, Serous; Docetaxel; Endometrial Neoplasms; Fallopian Tube Neoplasms; Female; Follow-Up Studies; Humans; Middle Aged; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Prognosis; Survival Rate; Taxoids | 2016 |
A phase II trial of the BCL-2 homolog domain 3 mimetic AT-101 in combination with docetaxel for recurrent, locally advanced, or metastatic head and neck cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Disease-Free Survival; Docetaxel; Drug Administration Schedule; Female; Gossypol; Head and Neck Neoplasms; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Taxoids; Treatment Outcome | 2016 |
Preoperative chemoradiotherapy with cisplatin and docetaxel for stage IIIB non-small-cell lung cancer: 10-year follow-up of the SAKK 16/01 trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Chemoradiotherapy; Cisplatin; Docetaxel; Follow-Up Studies; Humans; Lung Neoplasms; Neoplasm Recurrence, Local; Neoplasm Staging; Preoperative Care; Switzerland; Taxoids; Time Factors | 2016 |
Docetaxel plus cetuximab biweekly is an active regimen for the first-line treatment of patients with recurrent/metastatic head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cetuximab; Docetaxel; Female; Follow-Up Studies; Head and Neck Neoplasms; Humans; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Prognosis; Remission Induction; Retrospective Studies; Survival Rate; Taxoids | 2016 |
Association of CA27.29 and Circulating Tumor Cells Before and at Different Times After Adjuvant Chemotherapy in Patients with Early-stage Breast Cancer - The SUCCESS Trial.
Topics: Adult; Aged; Biomarkers, Tumor; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Deoxycytidine; Disease-Free Survival; Docetaxel; Epirubicin; Female; Fluorouracil; Gemcitabine; Humans; Middle Aged; Mucin-1; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplastic Cells, Circulating; Prognosis; Taxoids | 2016 |
PARTNER: An open-label, randomized, phase 2 study of docetaxel/cisplatin chemotherapy with or without panitumumab as first-line treatment for recurrent or metastatic squamous cell carcinoma of the head and neck.
Topics: Adult; Aged; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Docetaxel; Female; Head and Neck Neoplasms; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Panitumumab; Squamous Cell Carcinoma of Head and Neck; Taxoids | 2016 |
Safety and efficacy of nivolumab and standard chemotherapy drug combination in patients with advanced non-small-cell lung cancer: a four arms phase Ib study.
Topics: Adult; Aged; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Disease-Free Survival; Docetaxel; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Nivolumab; Paclitaxel; Pemetrexed; Taxoids | 2016 |
A Phase I Trial of 100 mg/m2 Docetaxel in Patients with Advanced or Recurrent Breast Cancer.
Topics: Adult; Antineoplastic Agents; Breast Neoplasms; Clinical Protocols; Docetaxel; Dose-Response Relationship, Drug; Female; Humans; Neoplasm Recurrence, Local; Taxoids; Young Adult | 2016 |
Effect of Tailored Dose-Dense Chemotherapy vs Standard 3-Weekly Adjuvant Chemotherapy on Recurrence-Free Survival Among Women With High-Risk Early Breast Cancer: A Randomized Clinical Trial.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Austria; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Disease-Free Survival; Docetaxel; Drug Administration Schedule; Epirubicin; Female; Fluorouracil; Germany; Humans; Middle Aged; Neoplasm Recurrence, Local; Quality of Life; Sweden; Taxoids | 2016 |
Phase I/II trial of cabazitaxel plus abiraterone in patients with metastatic castration-resistant prostate cancer (mCRPC) progressing after docetaxel and abiraterone.
Topics: Aged; Androstenes; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Disease-Free Survival; Docetaxel; Humans; Kaplan-Meier Estimate; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Taxoids; Treatment Outcome | 2017 |
Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Docetaxel; Female; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Platinum Compounds; Programmed Cell Death 1 Receptor; Survival Analysis; Taxoids; Urologic Neoplasms; Urothelium; Vinblastine | 2017 |
Nivolumab-induced interstitial lung disease analysis of two phase II studies patients with recurrent or advanced non-small-cell lung cancer.
Topics: Aged; Antibodies, Monoclonal; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Disease Progression; Docetaxel; Female; Humans; Japan; Lung Diseases, Interstitial; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Nivolumab; Risk Factors; Smoking; Taxoids; Tomography, X-Ray Computed; Tubulin Modulators | 2017 |
A phase II evaluation of weekly docetaxel in the treatment of recurrent or persistent endometrial carcinoma: a study by the Gynecologic Oncology Group.
Topics: Aged; Antineoplastic Agents; Disease-Free Survival; Docetaxel; Drug Administration Schedule; Endometrial Neoplasms; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Taxoids | 2008 |
Dose escalation study of epirubicin and docetaxel in patients with advanced or recurrent breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Dose-Response Relationship, Drug; Epirubicin; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Taxoids | 2008 |
Promising survival in patients with recurrent non-small cell lung cancer treated with docetaxel and gemcitabine in combination as second-line therapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Salvage Therapy; Survival Rate; Taxoids | 2008 |
Docetaxel and epirubicin salvage regimen in relapsed anthracycline-sensitive metastatic breast cancer patients after anthracycline-containing adjuvant therapy.
Topics: Adult; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Docetaxel; Drug Resistance, Neoplasm; Epirubicin; Female; Humans; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Recurrence; Salvage Therapy; Survival Analysis; Taxoids | 2009 |
[Preliminary result of multi-center clinical trial on the docetaxel, 5-Fu and DDP in the treatment of advanced, recurrent or metastatic nasopharyngeal carcinoma].
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Docetaxel; Female; Fluorouracil; Follow-Up Studies; Humans; Leukopenia; Male; Middle Aged; Nasopharyngeal Neoplasms; Nausea; Neoplasm Recurrence, Local; Neoplasm Staging; Remission Induction; Taxoids; Young Adult | 2008 |
[Preliminary study of biweekly regimen of docetaxel, oxaliplatin, 5-fluorouracil and leucovorin for advanced gastric cancer].
Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Female; Fluorouracil; Follow-Up Studies; Humans; Leucovorin; Leukopenia; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Remission Induction; Stomach Neoplasms; Taxoids; Vomiting; Young Adult | 2008 |
Biweekly docetaxel in recurrent ovarian cancer: a phase I dose finding study.
Topics: Aged; Antineoplastic Agents; Carcinoma, Endometrioid; Cystadenocarcinoma, Serous; Docetaxel; Dose-Response Relationship, Drug; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Ovarian Neoplasms; Prognosis; Survival Rate; Taxoids; Treatment Outcome | 2009 |
Phase II study of celecoxib and docetaxel in non-small cell lung cancer (NSCLC) patients with progression after platinum-based therapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Celecoxib; Disease Progression; Disease-Free Survival; Docetaxel; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Female; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Organoplatinum Compounds; Pyrazoles; Salvage Therapy; Sulfonamides; Survival Rate; Taxoids; Treatment Outcome | 2008 |
A phase 2 study of cetuximab in combination with docetaxel in chemotherapy-refractory/resistant patients with advanced nonsmall cell lung cancer.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cetuximab; Disease Progression; Docetaxel; Drug Administration Schedule; ErbB Receptors; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Taxoids | 2009 |
Phase II study of epirubicin in combination with weekly docetaxel for patients with advanced NSCLC who have failed or relapsed after the frontline platinum-based chemotherapy.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Docetaxel; Epirubicin; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Salvage Therapy; Survival Rate; Taxoids; Treatment Failure | 2009 |
Outpatient chemotherapy with S-1 for recurrent head and neck cancer.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Docetaxel; Drug Combinations; Female; Head and Neck Neoplasms; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Oxonic Acid; Taxoids; Tegafur | 2009 |
Weekly docetaxel in patients with platinum-refractory metastatic or recurrent squamous cell carcinoma of the head and neck.
Topics: Adult; Aged; Anemia; Antineoplastic Agents; Carcinoma, Squamous Cell; Disease-Free Survival; Docetaxel; Female; Head and Neck Neoplasms; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Survival Rate; Taxoids | 2009 |
A single-institution experience with induction and maintenance intravesical docetaxel in the management of non-muscle-invasive bladder cancer refractory to bacille Calmette-Guérin therapy.
Topics: Administration, Intravesical; Aged; Aged, 80 and over; Antineoplastic Agents; BCG Vaccine; Docetaxel; Drug Resistance, Neoplasm; Female; Humans; Male; Middle Aged; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Retrospective Studies; Risk Factors; Taxoids; Treatment Outcome; Urinary Bladder Neoplasms | 2009 |
Phase II trial of capecitabine and weekly docetaxel for metastatic castrate resistant prostate cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Confidence Intervals; Deoxycytidine; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Fluorouracil; Humans; Kaplan-Meier Estimate; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Neoplasm Staging; Probability; Prognosis; Prostatectomy; Prostatic Neoplasms; Statistics, Nonparametric; Survival Analysis; Taxoids; Treatment Failure; Treatment Outcome | 2009 |
Phase II study of biweekly docetaxel and S-1 combination therapy for advanced or recurrent gastric cancer.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Drug Combinations; Female; Follow-Up Studies; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Oxonic Acid; Prognosis; Stomach Neoplasms; Survival Rate; Taxoids; Tegafur; Treatment Outcome; Young Adult | 2009 |
N0332 phase 2 trial of weekly irinotecan hydrochloride and docetaxel in refractory metastatic breast cancer: a North Central Cancer Treatment Group (NCCTG) Trial.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Camptothecin; Docetaxel; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Humans; Irinotecan; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Salvage Therapy; Survival Rate; Taxoids; Treatment Outcome | 2010 |
Docetaxel and irinotecan in recurrent or metastatic head and neck cancer: a phase 2 trial of the Eastern Cooperative Oncology Group.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Squamous Cell; Cyclooxygenase 2; Docetaxel; Drug Administration Schedule; Female; Glucuronosyltransferase; Head and Neck Neoplasms; Humans; Irinotecan; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Taxoids; Vascular Endothelial Growth Factor A | 2009 |
[A Phase II study of docetaxel and cisplatin in patients with recurrent or unresectable squamous cell carcinoma of the head and neck].
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Docetaxel; Female; Head and Neck Neoplasms; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Taxoids | 2009 |
Maintenance immunotherapy in recurrent ovarian cancer: long term follow-up of a phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Disease-Free Survival; Docetaxel; Female; Follow-Up Studies; Humans; Immunotherapy; Interleukin-2; Isotretinoin; Killer Cells, Natural; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; T-Lymphocytes, Regulatory; Taxoids; Vascular Endothelial Growth Factor A; Young Adult | 2010 |
Fluorouracil, epirubicin, and cyclophosphamide with either docetaxel or vinorelbine, with or without trastuzumab, as adjuvant treatments of breast cancer: final results of the FinHer Trial.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Disease-Free Survival; Docetaxel; Epirubicin; Female; Humans; Lymphatic Metastasis; Middle Aged; Neoplasm Recurrence, Local; Receptor, ErbB-2; Survival Rate; Taxoids; Trastuzumab; Vinblastine; Vinorelbine | 2009 |
Phase I/II study of docetaxel/cisplatin/fluorouracil combination chemotherapy against metastatic esophageal squamous cell carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Docetaxel; Esophageal Neoplasms; Female; Fluorouracil; Humans; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Survival Rate; Taxoids; Treatment Outcome; Young Adult | 2010 |
[Therapeutic effect of docetaxel combined with oxaliplatin for treatment of recurrent epithelial ovarian cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cystadenoma, Mucinous; Cystadenoma, Serous; Docetaxel; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Organoplatinum Compounds; Ovarian Neoplasms; Oxaliplatin; Taxoids | 2009 |
TRIO-012: a multicenter, multinational, randomized, double-blind phase III study of IMC-1121B plus docetaxel versus placebo plus docetaxel in previously untreated patients with HER2-negative, unresectable, locally recurrent or metastatic breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease-Free Survival; Docetaxel; Double-Blind Method; Female; Humans; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neoplasm Staging; Ramucirumab; Taxoids; Treatment Outcome | 2009 |
Phase II trial of dose dense docetaxel followed by FEC100 as neoadjuvant chemotherapy in patients with operable breast cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease-Free Survival; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fluorouracil; Follow-Up Studies; Humans; Infusions, Intravenous; Mastectomy; Maximum Tolerated Dose; Middle Aged; Neoadjuvant Therapy; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Neoplasm Staging; Risk Assessment; Survival Analysis; Taxoids; Time Factors; Treatment Outcome | 2010 |
A phase II study of doxifluridine and docetaxel combination chemotherapy for advanced or recurrent gastric cancer.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Docetaxel; Female; Floxuridine; Humans; Infusions, Intravenous; Male; Middle Aged; Neoplasm Recurrence, Local; Stomach Neoplasms; Survival Rate; Taxoids; Treatment Outcome | 2009 |
Second-line weekly paclitaxel in resistant or relapsed non-small cell lung cancer treated with docetaxel and carboplatin: a multi-center phase II study.
Topics: Adult; Aged; Anemia; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Disease Progression; Docetaxel; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Humans; Leukopenia; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Survival Analysis; Taxoids | 2010 |
A phase II evaluation of weekly gemcitabine and docetaxel for second-line treatment of recurrent carcinosarcoma of the uterus: a gynecologic oncology group study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinosarcoma; Deoxycytidine; Disease-Free Survival; Docetaxel; Drug Administration Schedule; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Recurrence, Local; Taxoids; Uterine Neoplasms | 2010 |
Randomized study of taxane versus TS-1 in women with metastatic or recurrent breast cancer (SELECT BC).
Topics: Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Breast Neoplasms; Cost-Benefit Analysis; Disease Progression; Disease-Free Survival; Docetaxel; Drug Administration Schedule; Drug Combinations; Female; Humans; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Oxonic Acid; Paclitaxel; Quality of Life; Survival Rate; Taxoids; Tegafur | 2010 |
Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Docetaxel; Drug Administration Schedule; ErbB Receptors; Female; Humans; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Placebos; Taxoids | 2010 |
Phase I trial of combination chemotherapy with docetaxel, cisplatin and S-1 (TPS) in patients with locally advanced or recurrent/metastatic head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; Dose-Response Relationship, Drug; Drug Combinations; Female; Head and Neck Neoplasms; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Oxonic Acid; Taxoids; Tegafur; Young Adult | 2011 |
Five-year outcome for women randomised in a phase III trial comparing doxorubicin and cyclophosphamide with doxorubicin and docetaxel as primary medical therapy in early breast cancer: an Anglo-Celtic Cooperative Oncology Group study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Docetaxel; Doxorubicin; Female; Follow-Up Studies; Humans; Lymph Nodes; Middle Aged; Neoplasm Recurrence, Local; Survival Rate; Taxoids; Treatment Outcome | 2010 |
A phase II trial evaluating weekly docetaxel and capecitabine in patients with metastatic or advanced, locally recurrent head and neck cancers.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Case-Control Studies; Deoxycytidine; Disease-Free Survival; Docetaxel; Drug Administration Schedule; Fatigue; Female; Fluorouracil; Head and Neck Neoplasms; Humans; Lymphopenia; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Taxoids; Treatment Outcome | 2010 |
Phase I study of vorinostat (suberoylanilide hydroxamic acid, NSC 701852) in combination with docetaxel in patients with advanced and relapsed solid malignancies.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Docetaxel; Drug Administration Schedule; Female; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Prostatic Neoplasms; Taxoids; Time Factors; Treatment Outcome; Tubulin Modulators; Urologic Neoplasms; Vorinostat | 2012 |
Randomized phase II study comparing docetaxel plus cisplatin, docetaxel plus carboplatin, and paclitaxel plus carboplatin in patients with advanced or recurrent endometrial carcinoma: a Japanese Gynecologic Oncology Group study (JGOG2041).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma; Cisplatin; Docetaxel; Endometrial Neoplasms; Female; Humans; Kaplan-Meier Estimate; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Taxoids; Treatment Outcome | 2011 |
Phase I study of gemcitabine, docetaxel and imatinib in refractory and relapsed solid tumors.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Deoxycytidine; Diffusion Magnetic Resonance Imaging; Docetaxel; Drug Administration Schedule; Drug Interactions; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Imatinib Mesylate; Male; Maximum Tolerated Dose; Michigan; Middle Aged; Neoplasm Recurrence, Local; Neoplasms; New Jersey; Perfusion Imaging; Piperazines; Pyrimidines; Taxoids; Time Factors; Treatment Outcome | 2012 |
Phase II study of biweekly docetaxel and S-1 combination chemotherapy as first-line treatment for advanced gastric cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Docetaxel; Drug Administration Schedule; Drug Combinations; Female; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Oxonic Acid; Stomach Neoplasms; Survival Rate; Taxoids; Tegafur | 2011 |
Phase I/II study of a combination of docetaxel, capecitabine, and cisplatin (DXP) as first-line chemotherapy in patients with advanced gastric cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin; Deoxycytidine; Docetaxel; Female; Fluorouracil; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Stomach Neoplasms; Taxoids; Young Adult | 2011 |
Docetaxel/cisplatin followed by FOLFIRI versus the reverse sequence in metastatic gastric cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Disease-Free Survival; Docetaxel; Drug Administration Schedule; Female; Fluorouracil; Humans; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Stomach Neoplasms; Survival Rate; Taxoids; Treatment Outcome | 2011 |
Weekly docetaxel in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck.
Topics: Adult; Aged; Antineoplastic Agents; Bone Neoplasms; Carcinoma, Squamous Cell; Cohort Studies; Docetaxel; Female; Follow-Up Studies; Head and Neck Neoplasms; Humans; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Recurrence, Local; Survival Rate; Taxoids; Treatment Outcome | 2011 |
[A pilot study of weekly versus 3-week docetaxel in combination with capecitabine in patients with anthracycline-pretreated metastatic breast cancer].
Topics: Adult; Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Docetaxel; Female; Fluorouracil; Humans; Middle Aged; Neoplasm Recurrence, Local; Pilot Projects; Taxoids; Treatment Failure; Treatment Outcome | 2010 |
Preoperative chemotherapy with cisplatin and docetaxel followed by surgery and clip-oriented postoperative chemoradiation in patients with localized gastric or gastroesophageal junction adenocarcinoma: results from a phase II feasibility study.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therapy; Docetaxel; Esophageal Neoplasms; Esophagogastric Junction; Feasibility Studies; Female; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Postoperative Care; Preoperative Care; Radiotherapy Dosage; Stomach Neoplasms; Survival Rate; Taxoids; Treatment Outcome | 2011 |
Low-dose abdominal radiation as a docetaxel chemosensitizer for recurrent epithelial ovarian cancer: a phase I study of the Gynecologic Oncology Group.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Ovarian Epithelial; Combined Modality Therapy; Disease-Free Survival; Docetaxel; Dose-Response Relationship, Drug; Dose-Response Relationship, Radiation; Drug Administration Schedule; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Taxoids; Treatment Outcome | 2011 |
Docetaxel plus trabectedin appears active in recurrent or persistent ovarian and primary peritoneal cancer after up to three prior regimens: a phase II study of the Gynecologic Oncology Group.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dioxoles; Docetaxel; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Peritoneal Neoplasms; Taxoids; Tetrahydroisoquinolines; Trabectedin | 2011 |
Induction chemotherapy with cisplatin and fluorouracil alone or in combination with docetaxel in locally advanced squamous-cell cancer of the head and neck: long-term results of the TAX 324 randomised phase 3 trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Disease-Free Survival; Docetaxel; Fluorouracil; Follow-Up Studies; Head and Neck Neoplasms; Humans; Neoplasm Recurrence, Local; Neoplasm Staging; Taxoids | 2011 |
A phase II trial of carboplatin and docetaxel followed by radiotherapy given in a "Sandwich" method for stage III, IV, and recurrent endometrial cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; Carboplatin; Carcinoma, Endometrioid; Combined Modality Therapy; Disease-Free Survival; Docetaxel; Dose Fractionation, Radiation; Endometrial Neoplasms; Female; Follow-Up Studies; Humans; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Taxoids; Young Adult | 2011 |
Phase II study of combination chemotherapy with docetaxel and carboplatin for locally advanced or recurrent cervical cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma; Disease Progression; Docetaxel; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Taxoids; Treatment Outcome; Uterine Cervical Neoplasms | 2010 |
Phase II study of pemetrexed and cisplatin, with chest radiotherapy followed by docetaxel in patients with stage III non-small cell lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therapy; DNA-Binding Proteins; Docetaxel; Endonucleases; Feasibility Studies; Female; Follow-Up Studies; Glutamates; Guanine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Pemetrexed; Survival Rate; Taxoids; Thymidylate Synthase; Treatment Outcome | 2011 |
Triweekly reduced-dose docetaxel combined with cisplatin in recurrent/metastatic head and neck squamous cell carcinoma: a multicenter phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Docetaxel; Drug Administration Schedule; Female; Head and Neck Neoplasms; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Squamous Cell Carcinoma of Head and Neck; Taxoids | 2011 |
Docetaxel plus trabectedin appears active in recurrent or persistent ovarian and primary peritoneal cancer after up to three prior regimes: a phase II study of the Gynecologic Oncology Group.
Topics: Antineoplastic Combined Chemotherapy Protocols; Dioxoles; Docetaxel; Female; Humans; Neoplasm Recurrence, Local; Ovarian Neoplasms; Peritoneal Neoplasms; Taxoids; Tetrahydroisoquinolines; Trabectedin | 2011 |
Neoadjuvant dose-dense gemcitabine plus docetaxel and vinorelbine plus epirubicin for operable breast cancer: improved prognosis in triple-negative tumors.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Deoxycytidine; Docetaxel; Epirubicin; Female; Gemcitabine; Humans; Lymphatic Metastasis; Middle Aged; Neoadjuvant Therapy; Neoplasm Grading; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Survival Analysis; Taxoids; Treatment Outcome; Vinblastine; Vinorelbine; Young Adult | 2011 |
Concurrent bevacizumab with a sequential regimen of doxorubicin and cyclophosphamide followed by docetaxel and capecitabine as neoadjuvant therapy for HER2- locally advanced breast cancer: a phase II trial of the NSABP Foundation Research Group.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Capecitabine; Cyclophosphamide; Deoxycytidine; Docetaxel; Doxorubicin; Female; Fluorouracil; Follow-Up Studies; Humans; Immunoenzyme Techniques; Middle Aged; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Neoplasm Staging; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Survival Rate; Taxoids; Treatment Outcome | 2011 |
Randomized phase IIIb trial evaluating the continuation of bevacizumab beyond disease progression in patients with advanced non-squamous non-small-cell lung cancer after first-line treatment with bevacizumab plus platinum-based chemotherapy: treatment rat
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Docetaxel; Erlotinib Hydrochloride; Female; Follow-Up Studies; Glutamates; Guanine; Humans; International Agencies; Lung Neoplasms; Maintenance Chemotherapy; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Pemetrexed; Platinum; Quality of Life; Quinazolines; Survival Rate; Taxoids; Treatment Outcome; Young Adult | 2011 |
SCOTCERV: a phase II trial of docetaxel and gemcitabine as second line chemotherapy in cervical cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Docetaxel; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Middle Aged; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Quality of Life; Taxoids; Uterine Cervical Neoplasms | 2011 |
Efficacy and safety of bevacizumab in combination with docetaxel for the first-line treatment of elderly patients with locally recurrent or metastatic breast cancer: results from AVADO.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Breast Neoplasms; Disease-Free Survival; Docetaxel; Drug Therapy, Combination; Female; Humans; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Taxoids | 2011 |
A multicenter phase II study of combined chemotherapy with docetaxel, cisplatin, and S-1 in patients with unresectable or recurrent gastric cancer (KDOG 0601).
Topics: Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; Drug Administration Schedule; Female; Humans; Kaplan-Meier Estimate; Leukopenia; Male; Middle Aged; Neoplasm Recurrence, Local; Neutropenia; Oxonic Acid; Stomach Neoplasms; Taxoids; Tegafur; Treatment Outcome | 2012 |
Sunitinib in combination with docetaxel and prednisone in chemotherapy-naive patients with metastatic, castration-resistant prostate cancer: a phase 1/2 clinical trial.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Docetaxel; Drug Resistance, Neoplasm; Humans; Indoles; Kaplan-Meier Estimate; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Prednisone; Prostate-Specific Antigen; Prostatic Neoplasms; Pyrroles; Sunitinib; Taxoids | 2012 |
Phase 1-2 study of docetaxel plus aflibercept in patients with recurrent ovarian, primary peritoneal, or fallopian tube cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Fallopian Tube Neoplasms; Female; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Peritoneal Neoplasms; Receptors, Vascular Endothelial Growth Factor; Recombinant Fusion Proteins; Taxoids; Time Factors; Treatment Outcome; United States | 2011 |
Docetaxel/irinotecan combination chemotherapy in platinum/taxane-refractory and -resistant ovarian cancer: JGOG/WJGOG Intergroup Study.
Topics: Adult; Aged; Bridged-Ring Compounds; Camptothecin; Disease-Free Survival; Docetaxel; Drug Resistance, Neoplasm; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Irinotecan; Japan; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Ovarian Neoplasms; Platinum; Taxoids | 2013 |
Clinical and pharmacokinetic study of sunitinib and docetaxel in women with advanced breast cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Docetaxel; Drug Administration Schedule; Drug Interactions; Feasibility Studies; Female; Humans; Indoles; Middle Aged; Neoplasm Recurrence, Local; Pyrroles; Receptor, ErbB-2; Sunitinib; Taxoids; Treatment Outcome | 2012 |
Phase IB study of the EpCAM antibody adecatumumab combined with docetaxel in patients with EpCAM-positive relapsed or refractory advanced-stage breast cancer.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antigens, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cell Adhesion Molecules; Docetaxel; Drug Administration Schedule; Drug Resistance, Neoplasm; Epithelial Cell Adhesion Molecule; Female; Humans; Leukocyte Disorders; Liver Neoplasms; Middle Aged; Neoplasm Recurrence, Local; Taxoids; Treatment Outcome | 2012 |
Phase II study of sequential gemcitabine followed by docetaxel for recurrent Ewing sarcoma, osteosarcoma, or unresectable or locally recurrent chondrosarcoma: results of Sarcoma Alliance for Research Through Collaboration Study 003.
Topics: Adolescent; Adult; Aged; Bone Neoplasms; Chondrosarcoma; Deoxycytidine; Docetaxel; Drug Administration Schedule; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Osteosarcoma; Sarcoma, Ewing; Taxoids | 2012 |
Phase II study of gemcitabine and docetaxel in recurrent platinum resistant ovarian cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Docetaxel; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Taxoids | 2012 |
A phase 3 study of induction treatment with concurrent chemoradiotherapy versus chemotherapy before surgery in patients with pathologically confirmed N2 stage IIIA nonsmall cell lung cancer (WJTOG9903).
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Chemoradiotherapy; Docetaxel; Female; Follow-Up Studies; Humans; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Remission Induction; Survival Rate; Taxoids | 2012 |
A prospective multicentre phase II study of cisplatin and weekly docetaxel as first-line treatment for recurrent or metastatic nasopharyngeal cancer (KCSG HN07-01).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Disease-Free Survival; Docetaxel; Female; Humans; Male; Middle Aged; Nasopharyngeal Neoplasms; Neoplasm Metastasis; Neoplasm Recurrence, Local; Prospective Studies; Taxoids | 2012 |
Early prediction of survival following induction chemotherapy with DCF (docetaxel, cisplatin, 5-fluorouracil) using FDG PET/CT imaging in patients with locally advanced head and neck squamous cell carcinoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Disease-Free Survival; Docetaxel; Female; Fluorodeoxyglucose F18; Fluorouracil; Head and Neck Neoplasms; Humans; Induction Chemotherapy; Male; Middle Aged; Multimodal Imaging; Neoplasm Recurrence, Local; Positron-Emission Tomography; Radiopharmaceuticals; Squamous Cell Carcinoma of Head and Neck; Taxoids; Tomography, X-Ray Computed; Treatment Outcome | 2012 |
Randomized multicenter and stratified phase II study of gemcitabine alone versus gemcitabine and docetaxel in patients with metastatic or relapsed leiomyosarcomas: a Federation Nationale des Centres de Lutte Contre le Cancer (FNCLCC) French Sarcoma Group
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease-Free Survival; Docetaxel; Dose-Response Relationship, Drug; Female; France; Gemcitabine; Granulocyte Colony-Stimulating Factor; Humans; Leiomyosarcoma; Lenograstim; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Recombinant Proteins; Taxoids; Uterine Neoplasms | 2012 |
A phase II study of docetaxel and oxaliplatin combination in recurrent gastric cancer patients after fluoropyrimidine and/or cisplatin adjuvant treatment: a Korean Cancer Study Group Protocol ST06-02.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; Cisplatin; Combined Modality Therapy; Deoxycytidine; Disease-Free Survival; Docetaxel; Drug Combinations; Female; Fluorouracil; Follow-Up Studies; Humans; Korea; Male; Middle Aged; Neoplasm Recurrence, Local; Organoplatinum Compounds; Oxaliplatin; Oxonic Acid; Stomach Neoplasms; Survival Rate; Taxoids; Tegafur; Treatment Outcome | 2012 |
An exploratory study of sunitinib in combination with docetaxel and trastuzumab as first-line therapy for HER2-positive metastatic breast cancer.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease-Free Survival; Docetaxel; Drug Administration Schedule; Feasibility Studies; Female; Humans; Indoles; Infusions, Intravenous; Kaplan-Meier Estimate; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Pyrroles; Receptor, ErbB-2; Sunitinib; Taxoids; Trastuzumab; Treatment Outcome | 2012 |
The feasibility of triple-drug chemotherapy combination in older adult patients with oesophagogastric cancer: a randomised trial of the Arbeitsgemeinschaft Internistische Onkologie (FLOT65+).
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Esophageal Neoplasms; Feasibility Studies; Female; Follow-Up Studies; Humans; Leucovorin; Male; Neoplasm Recurrence, Local; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Prognosis; Prospective Studies; Quality of Life; Survival Rate; Taxoids | 2013 |
Combination of low-dose docetaxel and standard-dose S-1 for the treatment of advanced gastric cancer: efficacy, toxicity, and potential predictive factor.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dihydrouracil Dehydrogenase (NADP); Docetaxel; Dose-Response Relationship, Drug; Drug Combinations; Enzyme-Linked Immunosorbent Assay; Female; Gene Expression Regulation, Neoplastic; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Oxonic Acid; Peritoneal Neoplasms; Stomach Neoplasms; Survival Rate; Taxoids; Tegafur; Treatment Outcome | 2013 |
RASSF1A and ERCC1 expression levels might be predictive of prognosis in advanced, recurrent, and metastatic squamous cell carcinoma of the head and neck treated with docetaxel and cisplatin.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; DNA-Binding Proteins; Docetaxel; Endonucleases; Female; Head and Neck Neoplasms; Humans; Incidence; Male; Neoplasm Recurrence, Local; Prognosis; Republic of Korea; Risk Factors; Survival Analysis; Survival Rate; Taxoids; Treatment Outcome; Tumor Suppressor Proteins | 2012 |
A randomized controlled study of single-agent cisplatin and radiotherapy versus docetaxel/cisplatin and radiotherapy in high-risk early-stage cervical cancer after radical surgery.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplatin; Docetaxel; Female; Follow-Up Studies; Humans; Hysterectomy; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Radiotherapy, Intensity-Modulated; Survival Rate; Taxoids; Uterine Cervical Neoplasms; Young Adult | 2013 |
Dynamic contrast-enhanced MR imaging in a phase Ⅱ study on neoadjuvant chemotherapy combining Rh-endostatin with docetaxel and epirubicin for locally advanced breast cancer.
Topics: Adolescent; Adult; Aged; Breast Neoplasms; Docetaxel; Endostatins; Epirubicin; Female; Humans; Magnetic Resonance Imaging; Microvessels; Middle Aged; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Neovascularization, Pathologic; Radiography; Taxoids | 2013 |
Adjuvant therapy for high-grade, uterus-limited leiomyosarcoma: results of a phase 2 trial (SARC 005).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cohort Studies; Deoxycytidine; Disease-Free Survival; Docetaxel; Doxorubicin; Female; Gemcitabine; Humans; Leiomyosarcoma; Middle Aged; Neoplasm Grading; Neoplasm Recurrence, Local; Prospective Studies; Taxoids; Treatment Outcome; Uterine Neoplasms | 2013 |
Multicenter phase II study of S-1 and docetaxel combination chemotherapy for advanced or recurrent gastric cancer patients with peritoneal dissemination.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Drug Combinations; Female; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Oxonic Acid; Peritoneum; Stomach Neoplasms; Taxoids; Tegafur | 2013 |
The Breast Avastin Trial: phase II study of bevacizumab maintenance therapy after induction chemotherapy with docetaxel and capecitabine for the first-line treatment of patients with locally recurrent or metastatic breast cancer.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Capecitabine; Deoxycytidine; Docetaxel; Female; Fluorouracil; Humans; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Patient Compliance; Taxoids | 2013 |
Docetaxel/cisplatin as first-line chemotherapy in patients with head and neck carcinoma: a phase II trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Disease Progression; Docetaxel; Female; Head and Neck Neoplasms; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Survival Rate; Taxoids; Treatment Outcome | 2002 |
A Phase II trial of docetaxel and cisplatin in patients with recurrent or metastatic nasopharyngeal carcinoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; Female; Humans; Male; Middle Aged; Nasopharyngeal Neoplasms; Neoplasm Recurrence, Local; Neutropenia; Paclitaxel; Taxoids; Treatment Outcome | 2002 |
A randomized phase II study of sequential docetaxel and doxorubicin/cyclophosphamide in patients with metastatic breast cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Case-Control Studies; Cyclophosphamide; Disease Progression; Docetaxel; Doxorubicin; ErbB Receptors; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Receptor, ErbB-2; Remission Induction; Survival Rate; Taxoids | 2002 |
Docetaxel 75 mg/m(2) is active and well tolerated in patients with metastatic or recurrent gastric cancer: a phase II trial.
Topics: Adenocarcinoma; Adult; Aged; Docetaxel; Drug Administration Schedule; Drug Evaluation; Female; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neutropenia; Paclitaxel; Stomach Neoplasms; Taxoids | 2002 |
Docetaxel and cisplatin in patients with advanced or recurrent gastric cancer: a multicenter phase I/II study.
Topics: Adult; Aged; Alkyl and Aryl Transferases; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Humans; Incidence; Japan; Male; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Severity of Illness Index; Stomach Neoplasms; Survival Analysis; Taxoids; Transferases (Other Substituted Phosphate Groups); Treatment Outcome | 2002 |
Weekly carboplatin and docetaxel for locally advanced primary and recurrent cervical cancer: a phase I study.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Docetaxel; Drug Administration Schedule; Female; Hematologic Diseases; Humans; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Taxoids; Uterine Cervical Neoplasms | 2002 |
Phase I trial of weekly docetaxel and gemcitabine in patients with refractory malignancies.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Docetaxel; Female; Gastrointestinal Diseases; Gemcitabine; Hematologic Diseases; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Neoplasms; Paclitaxel; Taxoids; Treatment Outcome | 2003 |
A phase II trial of docetaxel and estramustine in patients with refractory metastatic breast carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Estramustine; Humans; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Paclitaxel; Quality of Life; Remission Induction; Survival Analysis; Taxoids | 2003 |
Recurrent gastric adenocarcinoma with unusual metastatic localization and excellent response to docetaxel and 5-FU continuous infusion.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Biopsy, Needle; Cisplatin; Docetaxel; Epirubicin; Fluorouracil; Humans; Infusions, Intravenous; Lymphatic Metastasis; Male; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Spleen; Splenic Neoplasms; Stomach Neoplasms; Taxoids; Treatment Outcome | 2003 |
Docetaxel and vinorelbine: an effective regimen in recurrent squamous cell esophageal carcinoma.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Docetaxel; Drug Administration Schedule; Drug Synergism; Esophageal Neoplasms; Female; Follow-Up Studies; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Taxoids; Treatment Outcome; Vinblastine; Vinorelbine | 2003 |
Phase I study of docetaxel and cyclophosphamide in patients with advanced or recurrent breast cancer.
Topics: Adult; Aged; Antineoplastic Agents; Breast Neoplasms; Carcinoma, Ductal, Breast; Cyclophosphamide; Docetaxel; Drug Therapy, Combination; Female; Hematologic Diseases; Humans; Incidence; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Taxoids | 2003 |
Phase II study of docetaxel-vinorelbine in platinum-resistant, paclitaxel-pretreated ovarian cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Disease Progression; Disease-Free Survival; Docetaxel; Drug Resistance, Neoplasm; Female; Granulocyte Colony-Stimulating Factor; Humans; Leukopenia; Middle Aged; Neoplasm Recurrence, Local; Neutropenia; Ovarian Neoplasms; Paclitaxel; Prospective Studies; Taxoids; Treatment Outcome; Vinblastine; Vinorelbine | 2003 |
Neoadjuvant docetaxel in locally advanced breast cancer.
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Disease-Free Survival; Docetaxel; Female; Humans; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Paclitaxel; Randomized Controlled Trials as Topic; Research Design; Survival Analysis; Taxoids | 2003 |
A feasibility study on biweekly administration of docetaxel for patients with recurrent ovarian cancer.
Topics: Aged; Antineoplastic Agents, Phytogenic; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Granulocyte Colony-Stimulating Factor; Humans; Infusions, Intravenous; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Taxoids | 2003 |
Docetaxel and vinorelbine in recurrent head and neck cancer: pharmacokinetic and clinical results.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Carcinoma, Squamous Cell; Docetaxel; Female; Head and Neck Neoplasms; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Remission Induction; Survival Analysis; Taxoids; Vinblastine; Vinorelbine | 2003 |
Phase II trial of irinotecan plus docetaxel in cisplatin-pretreated relapsed or refractory oesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Squamous Cell; Cisplatin; Docetaxel; Dose-Response Relationship, Drug; Esophageal Neoplasms; Female; Humans; Infusions, Intravenous; Irinotecan; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Salvage Therapy; Survival Rate; Taxoids; Treatment Outcome | 2003 |
Phase I/II study of docetaxel and cisplatin with concurrent thoracic radiation therapy for locally advanced non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Combined Modality Therapy; Docetaxel; Dose-Response Relationship, Drug; Female; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Paclitaxel; Radiation-Sensitizing Agents; Survival Rate; Taxoids | 2003 |
Radiotherapy with concurrent docetaxel for advanced and recurrent breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Combined Modality Therapy; Docetaxel; Drug Administration Schedule; Female; Humans; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Palliative Care; Radiation Dosage; Radiation-Sensitizing Agents; Radiography; Taxoids; Treatment Outcome | 2003 |
Biweekly administration regimen of docetaxel combined with CPT-11 in patients with inoperable or recurrent gastric cancer.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Irinotecan; Male; Middle Aged; Neoplasm Recurrence, Local; Stomach Neoplasms; Taxoids | 2003 |
The effect on tumor response of adding sequential preoperative docetaxel to preoperative doxorubicin and cyclophosphamide: preliminary results from National Surgical Adjuvant Breast and Bowel Project Protocol B-27.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Docetaxel; Doxorubicin; Female; Humans; Mastectomy; Middle Aged; Neoplasm Recurrence, Local; Preoperative Care; Survival Rate; Taxoids; Treatment Outcome | 2003 |
Salvage treatment with docetaxel for recurrent epithelial ovarian cancer.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Asthenia; Docetaxel; Fatigue; Female; Humans; Infusions, Intravenous; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Retrospective Studies; Salvage Therapy; Survival Analysis; Taxoids; Treatment Outcome | 2003 |
Randomised, multicentre phase II study assessing two doses of docetaxel (75 or 100 mg/m2) as second-line monotherapy for non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Disease Progression; Docetaxel; Dose-Response Relationship, Drug; Female; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neutropenia; Safety; Survival Analysis; Taxoids; Time Factors; Treatment Failure; Treatment Outcome | 2004 |
Efficacy of intra-arterial infusion therapy using a combination of cisplatin and docetaxel for recurrent head and neck cancers compared with cisplatin alone.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; Female; Head and Neck Neoplasms; Humans; Infusions, Intra-Arterial; Male; Middle Aged; Neoplasm Recurrence, Local; Taxoids; Treatment Outcome | 2003 |
Radiotherapy with concomitant weekly docetaxel for Stages III/IV oropharynx carcinoma. Results of the 98-02 GORTEC Phase II trial.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Carcinoma, Squamous Cell; Combined Modality Therapy; Docetaxel; Dose Fractionation, Radiation; Female; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Oropharyngeal Neoplasms; Prospective Studies; Radiation-Sensitizing Agents; Survival Analysis; Taxoids | 2004 |
Docetaxel for malignant mesothelioma: phase II study of the Eastern Cooperative Oncology Group.
Topics: Aged; Aged, 80 and over; Agranulocytosis; Antineoplastic Agents, Phytogenic; Docetaxel; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Leukopenia; Lung Neoplasms; Male; Mesothelioma; Middle Aged; Neoplasm Recurrence, Local; Survival Rate; Taxoids; United States | 2004 |
Results of a randomised phase II study comparing docetaxel with methotrexate in patients with recurrent head and neck cancer.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Carcinoma, Squamous Cell; Docetaxel; Female; Head and Neck Neoplasms; Humans; Male; Methotrexate; Middle Aged; Neoplasm Recurrence, Local; Survival Analysis; Taxoids; Treatment Outcome | 2004 |
Docetaxel plus 5-fluorouracil in locally recurrent and/or metastatic squamous cell carcinoma of the head and neck: a phase II multicenter study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Docetaxel; Female; Fluorouracil; Head and Neck Neoplasms; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Survival Analysis; Taxoids | 2004 |
Docetaxel plus cisplatin as second-line therapy in metastatic or recurrent advanced gastric cancer progressing on 5-fluorouracil-based regimen.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; Drug Resistance, Neoplasm; Female; Fluorouracil; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Stomach Neoplasms; Survival Analysis; Taxoids | 2004 |
Monitoring the response of large (>3 cm) and locally advanced (T3-4, N0-2) breast cancer to neoadjuvant chemotherapy using (99m)Tc-Sestamibi uptake.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Docetaxel; Doxorubicin; Female; Humans; Image Interpretation, Computer-Assisted; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Radionuclide Imaging; Radiopharmaceuticals; Reproducibility of Results; Sensitivity and Specificity; Severity of Illness Index; Taxoids; Technetium Tc 99m Sestamibi; Treatment Outcome | 2005 |
A multicenter phase II study of docetaxel 60 mg/m2 as first-line chemotherapy in patients with advanced or recurrent breast cancer.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Disease-Free Survival; Docetaxel; Drug Administration Schedule; Female; Humans; Japan; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Palliative Care; Survival Analysis; Taxoids; Treatment Outcome | 2004 |
A phase I dose-escalating study of docetaxel plus folinic acid and 5-fluorouracil in anthracycline-pretreated patients with metastatic breast cancer.
Topics: Adult; Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Drug Resistance, Neoplasm; Female; Fluorouracil; Humans; Leucovorin; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Taxoids | 2004 |
Comparison of docetaxel and docetaxel-irinotecan combination as second-line chemotherapy in advanced non-small-cell lung cancer: a randomized phase II trial.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Docetaxel; Female; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Survival Analysis; Taxoids; Treatment Outcome | 2005 |
Combination chemotherapy of docetaxel and carboplatin in advanced or recurrent cervix cancer. A pilot study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Docetaxel; Female; Humans; Middle Aged; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Neoplasm Staging; Pilot Projects; Taxoids; Uterine Cervical Neoplasms | 2005 |
Reirradiation alternating with docetaxel and cisplatin in inoperable recurrence of head-and-neck cancer: a prospective phase I/II trial.
Topics: Adult; Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therapy; Docetaxel; Drug Administration Schedule; Female; Head and Neck Neoplasms; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Radiotherapy Dosage; Taxoids | 2005 |
Phase I and initial phase II results from a trial investigating weekly docetaxel and carboplatin given neoadjuvantly and then concurrently with concomitant boost radiotherapy for locally advanced squamous cell carcinoma of the head and neck.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; Combined Modality Therapy; Docetaxel; Feasibility Studies; Female; Head and Neck Neoplasms; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Neoplasm Staging; Prospective Studies; Radiotherapy Dosage; Survival Rate; Taxoids; Treatment Outcome | 2005 |
Phase III randomized trial of doxorubicin and docetaxel versus doxorubicin and cyclophosphamide as primary medical therapy in women with breast cancer: an anglo-celtic cooperative oncology group study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Docetaxel; Doxorubicin; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Middle Aged; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Taxoids; Treatment Outcome | 2005 |
[Results of docetaxel therapy in patients with relapsed ovarian cancer].
Topics: Adult; Aged; Alopecia; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Docetaxel; Drug Administration Schedule; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Taxoids; Treatment Outcome | 2005 |
[Bi-weekly chemotherapy with medium-dose docetaxel for advanced and recurrent breast cancers (The 15th study of Keiji Breast Cancer Study Group)].
Topics: Adult; Aged; Alopecia; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Bone Marrow; Breast Neoplasms; Docetaxel; Drug Administration Schedule; Female; Floxuridine; Humans; Middle Aged; Neoplasm Recurrence, Local; Taxoids | 2005 |
[A Phase I study of docetaxel and cisplatin for advanced squamous cell carcinoma of the head and neck].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Docetaxel; Drug Administration Schedule; Female; Head and Neck Neoplasms; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Taxoids | 2005 |
Organ preservation and treatment toxicity with induction chemotherapy followed by radiation therapy or chemoradiation for advanced laryngeal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; Cisplatin; Docetaxel; Dose Fractionation, Radiation; Esophageal Stenosis; Female; Fluorouracil; Follow-Up Studies; Humans; Laryngeal Neoplasms; Laryngectomy; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Radiotherapy, Adjuvant; Salvage Therapy; Survival Rate; Taxoids | 2005 |
Targeting cyclooxygenase-2 in recurrent non-small cell lung cancer: a phase II trial of celecoxib and docetaxel.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inducing Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Celecoxib; Cohort Studies; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Dinoprostone; Docetaxel; Endostatins; Female; Hematologic Diseases; Humans; Lung Neoplasms; Male; Membrane Proteins; Middle Aged; Nausea; Neoplasm Recurrence, Local; Prostaglandin-Endoperoxide Synthases; Prostaglandins; Pyrazoles; Sulfonamides; Survival Analysis; Taxoids; Treatment Outcome; Vascular Endothelial Growth Factor A; Vomiting | 2005 |
Phase II trial of docetaxel in advanced or metastatic endometrial cancer: a Japanese Cooperative Study.
Topics: Adenocarcinoma; Adenocarcinoma, Papillary; Adult; Aged; Antineoplastic Agents, Phytogenic; Carcinoma, Squamous Cell; Cystadenocarcinoma, Serous; Docetaxel; Endometrial Neoplasms; Female; Humans; Japan; Middle Aged; Neoplasm Recurrence, Local; Salvage Therapy; Survival Rate; Taxoids | 2005 |
Safety and efficacy of trastuzumab every 3 weeks combined with cytotoxic chemotherapy in patients with HER2-positive recurrent breast cancer: findings from a case series.
Topics: Adult; Age Distribution; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Disease-Free Survival; Docetaxel; Drug Administration Schedule; Drug-Related Side Effects and Adverse Reactions; Female; Fluorouracil; Greece; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Receptor, ErbB-2; Risk Assessment; Risk Factors; Sex Distribution; Survival Rate; Taxoids; Trastuzumab; Treatment Outcome; Vinblastine; Vinorelbine | 2005 |
Weekly docetaxel in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Phytogenic; Carcinoma, Squamous Cell; Docetaxel; Drug Administration Schedule; Female; Head and Neck Neoplasms; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Survival Rate; Taxoids; Treatment Outcome | 2006 |
A phase II study of docetaxel and cisplatin in patients with gastric cancer recurring after or progressing during 5-FU/platinum treatment.
Topics: Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Docetaxel; Drug Administration Schedule; Female; Gastrectomy; Humans; Leukopenia; Male; Middle Aged; Neoplasm Recurrence, Local; Neutropenia; Stomach Neoplasms; Survival Analysis; Taxoids; Treatment Outcome | 2005 |
Epirubicin-docetaxel in advanced gastric cancer: two phase II studies as second and first line treatment.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Docetaxel; Epirubicin; Female; Humans; Infusions, Intravenous; Male; Middle Aged; Neoplasm Recurrence, Local; Neutropenia; Stomach Neoplasms; Survival Analysis; Taxoids; Treatment Outcome | 2006 |
Phase II investigation of docetaxel in pediatric patients with recurrent solid tumors: a report from the Children's Oncology Group.
Topics: Adolescent; Antineoplastic Agents, Phytogenic; Child; Child, Preschool; Docetaxel; Female; Glioma; Humans; Infant; Male; Neoplasm Recurrence, Local; Sarcoma; Taxoids | 2006 |
A pharmacokinetic interaction study of docetaxel and cisplatin plus or minus 5-fluorouracil in the treatment of patients with recurrent or metastatic solid tumors.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Cisplatin; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fluorouracil; Half-Life; Humans; Infusions, Intravenous; Leukopenia; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neoplasms; Neutropenia; Taxoids; Treatment Outcome | 2006 |
Phase II study of weekly docetaxel and cisplatin in patients with advanced recurrent and metastatic head and neck cancer.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Cisplatin; Docetaxel; Drug Administration Schedule; Drug Therapy, Combination; Female; Follow-Up Studies; Head and Neck Neoplasms; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Prospective Studies; Quality of Life; Survival Rate; Taxoids; Treatment Outcome | 2006 |
Phase II trial of weekly docetaxel/ gemcitabine as first-line chemotherapy in patients with locally recurrent or metastatic breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Infusions, Intravenous; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Survival Analysis; Taxoids; Treatment Outcome | 2006 |
Prognostic factors affecting long-term outcomes in patients with resected stage IIIA pN2 non-small-cell lung cancer: 5-year follow-up of a phase II study.
Topics: Adult; Aged; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Cisplatin; Combined Modality Therapy; Disease-Free Survival; Docetaxel; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Recurrence; Risk Assessment; Survival Rate; Taxoids; Time Factors; Treatment Outcome | 2006 |
Is epirubicin effective in first-line chemotherapy of metastatic breast cancer (MBC) after an epirubicin-containing adjuvant treatment? A single centre phase III trial.
Topics: Adult; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Epirubicin; Female; Humans; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Survival Analysis; Taxoids | 2006 |
Phase III study comparing oral topotecan to intravenous docetaxel in patients with pretreated advanced non-small-cell lung cancer.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Docetaxel; Female; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Survival Analysis; Taxoids; Topotecan | 2006 |
Phase II study of docetaxel and S-1 combination therapy for advanced or recurrent gastric cancer.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Combinations; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Injections, Intravenous; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Recurrence, Local; Oxonic Acid; Stomach Neoplasms; Survival Rate; Taxoids; Tegafur; Treatment Outcome | 2006 |
[Evaluation of safety and efficacy for bi-weekly Docetaxel and 5'-DFUR combination therapy in patients with advanced or recurrent breast cancer--Phase I study].
Topics: Administration, Oral; Aged; Ambulatory Care; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Floxuridine; Humans; Lung Neoplasms; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Taxoids | 2006 |
Possible involvement of CCT5, RGS3, and YKT6 genes up-regulated in p53-mutated tumors in resistance to docetaxel in human breast cancers.
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Carcinoma, Ductal, Breast; Cell Line; Chaperonin Containing TCP-1; Chaperonins; Chemotherapy, Adjuvant; DNA Mutational Analysis; DNA, Neoplasm; Docetaxel; Drug Resistance, Neoplasm; Female; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Gene Silencing; Genes, p53; GTP-Binding Proteins; GTPase-Activating Proteins; Humans; Molecular Chaperones; Neoplasm Proteins; Neoplasm Recurrence, Local; R-SNARE Proteins; RGS Proteins; RNA, Small Interfering; Taxoids; Treatment Outcome; Tumor Cells, Cultured; Tumor Suppressor Protein p53 | 2007 |
[Combination chemotherapy of S-1 and docetaxel on advanced and recurrent gastric cancer].
Topics: Adult; Aged; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Drug Administration Schedule; Drug Combinations; Humans; Infusions, Intravenous; Leukopenia; Middle Aged; Neoplasm Recurrence, Local; Neutropenia; Oxonic Acid; Stomach Neoplasms; Survival Rate; Taxoids; Tegafur | 2006 |
Phase I safety, pharmacokinetic and pharmacodynamic studies of 2-methoxyestradiol alone or in combination with docetaxel in patients with locally recurrent or metastatic breast cancer.
Topics: 2-Methoxyestradiol; Administration, Oral; Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Breast Neoplasms; Docetaxel; Drug Administration Schedule; Estradiol; Fatigue; Female; Half-Life; Humans; Matrix Metalloproteinase 2; Matrix Metalloproteinase 9; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Taxoids; Treatment Outcome; Tubulin Modulators; Urinalysis; Vascular Cell Adhesion Molecule-1; Vascular Endothelial Growth Factor A | 2007 |
Phase II study of weekly docetaxel in patients with recurrent or metastatic endometrial cancer: AGO Uterus-4.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Docetaxel; Drug Administration Schedule; Endometrial Neoplasms; Female; Humans; Infusions, Intravenous; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Taxoids | 2007 |
A triplet chemotherapy with cisplatin, docetaxel and gemcitabine in patients with advanced non-small-cell lung cancer: a phase I/II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Docetaxel; Dose-Response Relationship, Drug; Female; Gemcitabine; Humans; Leukopenia; Lung Neoplasms; Male; Metabolic Clearance Rate; Middle Aged; Nausea; Neoplasm Recurrence, Local; Neoplasm Staging; Pregnancy; Survival Analysis; Taxoids; Treatment Outcome; Vomiting | 2007 |
Phase II trial of docetaxel and carboplatin in recurrent platinum-sensitive ovarian, peritoneal and tubal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Disease-Free Survival; Docetaxel; Drug Resistance, Neoplasm; Fallopian Tube Neoplasms; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Peritoneal Neoplasms; Taxoids | 2007 |
Randomized phase II study of bortezomib alone and bortezomib in combination with docetaxel in previously treated advanced non-small-cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Carcinoma, Non-Small-Cell Lung; Docetaxel; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Pyrazines; Taxoids; Treatment Outcome; United States | 2006 |
Quality of life in patients with advanced gastric cancer: a randomized trial comparing docetaxel, cisplatin, 5-FU (TCF) with epirubicin, cisplatin, 5-FU (ECF).
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Disease-Free Survival; Docetaxel; Epirubicin; Female; Fluorouracil; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Quality of Life; Stomach Neoplasms; Survival Rate; Taxoids | 2006 |
[Randomized controlled trial of two kinds of home-produced docetaxel in China for advanced breast cancer].
Topics: Adult; Aged; Alopecia; Antineoplastic Agents; Breast Neoplasms; Disease-Free Survival; Docetaxel; Female; Follow-Up Studies; Humans; Infusions, Intravenous; Leukopenia; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Remission Induction; Survival Rate; Taxoids | 2006 |
Weekly docetaxel and carboplatin for recurrent ovarian and peritoneal cancer: a phase II trial.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Docetaxel; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Peritoneal Neoplasms; Quality of Life; Taxoids | 2007 |
A phase II study of days 1 and 8 combination of docetaxel plus gemcitabine for the second-line treatment of patients with advanced non-small-cell lung cancer and good performance status.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Survival Analysis; Survival Rate; Taxoids | 2007 |
Adjuvant weekly docetaxel for patients with high risk prostate cancer after radical prostatectomy: a multi-institutional pilot study.
Topics: Adult; Aged; Antineoplastic Agents; Biomarkers, Tumor; Chemotherapy, Adjuvant; Disease-Free Survival; Docetaxel; Drug Administration Schedule; Follow-Up Studies; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Pilot Projects; Prospective Studies; Prostate-Specific Antigen; Prostatectomy; Prostatic Neoplasms; Radiation-Sensitizing Agents; Risk Factors; Survival Rate; Taxoids; Treatment Outcome | 2007 |
Docetaxel and oxaliplatin in the second-line treatment of platinum-sensitive recurrent ovarian cancer: a phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Docetaxel; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Organoplatinum Compounds; Ovarian Neoplasms; Oxaliplatin; Taxoids; Treatment Outcome | 2007 |
Reduced dose intensity of docetaxel plus capecitabine as second-line palliative chemotherapy in patients with metastatic gastric cancer: a phase II study.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fluorouracil; Humans; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Recurrence, Local; Palliative Care; Peritoneal Neoplasms; Stomach Neoplasms; Taxoids | 2007 |
A phase II study of weekly docetaxel for patients with advanced or recurrent cancer of the cervix.
Topics: Adenocarcinoma; Adult; Antineoplastic Agents; Carcinoma, Adenosquamous; Carcinoma, Squamous Cell; Disease-Free Survival; Docetaxel; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Middle Aged; Neoplasm Recurrence, Local; Oklahoma; Survival Analysis; Taxoids; Treatment Outcome; Uterine Cervical Neoplasms | 2007 |
Phase II clinical trial of docetaxel in refractory squamous cell carcinoma of the cervix: a Gynecologic Oncology Group Study.
Topics: Adult; Antineoplastic Agents; Carcinoma, Squamous Cell; Docetaxel; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Salvage Therapy; Survival Rate; Taxoids; Uterine Cervical Neoplasms | 2007 |
Phase II study of efficacy and safety of bevacizumab in combination with chemotherapy or erlotinib compared with chemotherapy alone for treatment of recurrent or refractory non small-cell lung cancer.
Topics: Adenocarcinoma; Adenocarcinoma, Bronchiolo-Alveolar; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Docetaxel; Erlotinib Hydrochloride; Female; Glutamates; Guanine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Pemetrexed; Quinazolines; Survival Rate; Taxoids; Treatment Outcome | 2007 |
A phase II study of topotecan and docetaxel in patients with sensitive relapse small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Docetaxel; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Recombinant Proteins; Taxoids; Topotecan; Treatment Failure | 2008 |
A multicentre phase II study of docetaxel plus cisplatin for the treatment of advanced gastric cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; Female; Humans; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Peritoneal Neoplasms; Prospective Studies; Stomach Neoplasms; Survival Rate; Taxoids; Treatment Outcome | 2007 |
[How to treat the relapse of NSCLC after surgery and chemotherapy? IFTC 0702 randomized phase III study].
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Docetaxel; Humans; Lung Neoplasms; Middle Aged; Neoplasm Recurrence, Local; Taxoids | 2008 |
The efficiency of single agent docetaxel in patients with platinum-refractory non-small cell lung carcinoma.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Docetaxel; Drug Resistance, Neoplasm; Female; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Platinum Compounds; Salvage Therapy; Taxoids | 2008 |
Salvage chemotherapy with docetaxel and epirubicin for advanced/metastatic gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Disease-Free Survival; Docetaxel; Drug Administration Schedule; Epirubicin; Female; Fluorouracil; Hematologic Diseases; Humans; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Recurrence, Local; Patient Selection; Platinum Compounds; Salvage Therapy; Severity of Illness Index; Stomach Neoplasms; Taxoids; Treatment Outcome | 2007 |
Maintenance immunotherapy in recurrent or metastatic squamous cell carcinoma of the head and neck.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; CD4-CD8 Ratio; Cisplatin; Disease-Free Survival; Docetaxel; Female; Head and Neck Neoplasms; Humans; Ifosfamide; Immunotherapy; Killer Cells, Natural; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; T-Lymphocytes; Taxoids | 2008 |
Fixed-dose rate gemcitabine plus docetaxel as second-line therapy for metastatic uterine leiomyosarcoma: a Gynecologic Oncology Group phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease-Free Survival; Docetaxel; Female; Gemcitabine; Humans; Leiomyosarcoma; Middle Aged; Neoplasm Recurrence, Local; Taxoids; Uterine Neoplasms | 2008 |
Phase II study of docetaxel for recurrent or metastatic non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Docetaxel; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Survival Rate; Taxoids | 1994 |
[Late phase II clinical study of RP56976 (docetaxel) in patients with advanced/recurrent breast cancer].
Topics: Adult; Aged; Alopecia; Anorexia; Antineoplastic Agents, Phytogenic; Asthenia; Bone Neoplasms; Breast Neoplasms; Docetaxel; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Lung Neoplasms; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Taxoids; Treatment Outcome | 1994 |
A late phase II study of RP56976 (docetaxel) in patients with advanced or recurrent breast cancer.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Aged, 80 and over; Alopecia; Antineoplastic Agents, Phytogenic; Bone Neoplasms; Breast Neoplasms; Carcinoma, Medullary; Carcinoma, Papillary; Docetaxel; Female; Humans; Infusions, Intravenous; Leukopenia; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Middle Aged; Neoplasm Recurrence, Local; Neutropenia; Paclitaxel; Taxoids; Toxicity Tests | 1996 |
Docetaxel: an active drug for squamous cell carcinoma of the head and neck.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Carcinoma, Squamous Cell; Docetaxel; Female; Head and Neck Neoplasms; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Taxoids; Treatment Outcome | 1996 |
Preliminary report of the activity of docetaxel in advanced or recurrent squamous cell cancer of the cervix.
Topics: Adult; Antineoplastic Agents, Phytogenic; Carcinoma, Squamous Cell; Docetaxel; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Taxoids; Uterine Cervical Neoplasms | 1996 |
Phase II trial of docetaxel in patients with recurrent malignant glioma: a study of the National Cancer Institute of Canada Clinical Trials Group.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Brain Neoplasms; Docetaxel; Female; Glioma; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Taxoids | 1996 |
A phase I trial of docetaxel and 5-day continuous infusion of 5-fluorouracil in patients with advanced or recurrent breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Female; Fluorouracil; Humans; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Taxoids | 1998 |
[Late phase II clinical study of RP56976 (docetaxel) in patients with advanced/recurrent gastric cancer: a Japanese Cooperative Study Group trial (group A)].
Topics: Adult; Aged; Alopecia; Antineoplastic Agents, Phytogenic; Docetaxel; Female; Fever; Humans; Leukopenia; Liver Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Nausea; Neoplasm Recurrence, Local; Paclitaxel; Stomach Neoplasms; Taxoids; Vomiting | 1998 |
[Late phase II clinical study of RP56976 (docetaxel) in patients with advanced/recurrent head and neck cancer].
Topics: Adenocarcinoma; Adult; Aged; Anorexia; Antineoplastic Agents, Phytogenic; Carcinoma, Squamous Cell; Docetaxel; Drug Administration Schedule; Female; Head and Neck Neoplasms; Humans; Infusions, Intravenous; Leukopenia; Male; Middle Aged; Neoplasm Recurrence, Local; Neutropenia; Paclitaxel; Remission Induction; Taxoids | 1999 |
Docetaxel and cisplatin: an active regimen in patients with locally advanced, recurrent or metastatic squamous cell carcinoma of the head and neck. Results of a phase II study of the EORTC Early Clinical Studies Group.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Disease-Free Survival; Docetaxel; Female; Head and Neck Neoplasms; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Prognosis; Survival Rate; Taxoids; Treatment Outcome | 1999 |
[Efficacy of docetaxel for recurrent breast cancer: evaluation based on chemosensitivity test and clinical response].
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Docetaxel; Doxorubicin; Drug Administration Schedule; Drug Evaluation; Drug Screening Assays, Antitumor; Female; Humans; Neoplasm Recurrence, Local; Paclitaxel; Taxoids | 2000 |
Phase II study of docetaxel and cisplatin in patients with recurrent or disseminated squamous-cell carcinoma of the head and neck.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Docetaxel; Female; Head and Neck Neoplasms; Humans; Infusions, Intravenous; Male; Middle Aged; Neoplasm Recurrence, Local; Neutropenia; Paclitaxel; Survival Analysis; Taxoids | 2000 |
Second-line chemotherapy for non-small-cell lung cancer with monthly docetaxel and weekly gemcitabine: a phase II trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Disease Progression; Docetaxel; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Survival Analysis; Taxoids; Treatment Outcome | 2001 |
Second line chemotherapy with docetaxel in patients with recurrent malignant glioma: a phase II study.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Brain Neoplasms; Docetaxel; Female; Glioma; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Survival Rate; Taxoids; Time Factors; Treatment Outcome | 2000 |
Docetaxel and cisplatin in locally advanced or metastatic squamous-cell carcinoma of the head and neck: a phase II study of the Southern Italy Cooperative Oncology Group (SICOG).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Disease-Free Survival; Docetaxel; Female; Head and Neck Neoplasms; Humans; Italy; Male; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Prognosis; Survival Rate; Taxoids; Treatment Outcome | 2001 |
[Efficacy of weekly docetaxel therapy for advanced or recurrent breast cancer].
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Docetaxel; Drug Administration Schedule; Drug Tolerance; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Pilot Projects; Taxoids; Treatment Outcome | 2001 |
[A phase I study of docetaxel (TXT) and doxifluridine (5'-DFUR) combination therapy in patients with advanced and recurrent breast cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Drug Administration Schedule; Female; Floxuridine; Humans; Infusions, Intravenous; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Taxoids | 2001 |
[Effect of weekly docetaxel in patients with recurrent breast cancer].
Topics: Adult; Aged; Alopecia; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Docetaxel; Drug Administration Schedule; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Neutropenia; Paclitaxel; Pilot Projects; Taxoids | 2001 |
Phase II trial of weekly docetaxel in second-line therapy for nonsmall cell lung carcinoma.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Docetaxel; Drug Administration Schedule; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Survival Analysis; Taxoids | 2001 |
Docetaxel followed by hormone therapy after failure of definitive treatments for clinically localized/locally advanced prostate cancer: preliminary results.
Topics: Adenocarcinoma; Aged; Anilides; Antineoplastic Agents, Hormonal; Antineoplastic Agents, Phytogenic; Docetaxel; Finasteride; Goserelin; Humans; Leuprolide; Male; Middle Aged; Neoplasm Recurrence, Local; Nitriles; Paclitaxel; Pilot Projects; Prostate-Specific Antigen; Prostatic Neoplasms; Salvage Therapy; Taxoids; Tosyl Compounds | 2001 |
Docetaxel, estramustine, and short-term androgen withdrawal for patients with biochemical failure after definitive local therapy for prostate cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Estramustine; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Prostate-Specific Antigen; Prostatic Neoplasms; Taxoids | 2001 |
Docetaxel as rescue medication in anthracycline- and ifosfamide-resistant locally advanced or metastatic soft tissue sarcoma: results of a phase II trial.
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Child; Child, Preschool; Disease Progression; Docetaxel; Drug Resistance, Neoplasm; Female; Humans; Ifosfamide; Male; Neoplasm Metastasis; Neoplasm Recurrence, Local; Paclitaxel; Prognosis; Sarcoma; Soft Tissue Neoplasms; Taxoids; Treatment Outcome | 2001 |
Gemcitabine and docetaxel as second-line chemotherapy for patients with nonsmall cell lung carcinoma who fail prior paclitaxel plus platinum-based regimens.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Patient Compliance; Platinum; Survival Analysis; Taxoids; Treatment Outcome | 2001 |
Phase II Trial of docetaxel and cisplatin combination chemotherapy in patients with squamous cell carcinoma of the head and neck.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Disease Progression; Docetaxel; Female; Head and Neck Neoplasms; Humans; Infusions, Intravenous; Male; Middle Aged; Neoplasm Recurrence, Local; Neutropenia; Paclitaxel; Survival Rate; Taxoids; Treatment Outcome | 2002 |
Combined modality treatment of oral and oropharyngeal cancer including neoadjuvant intraarterial cisplatin and radical surgery followed by concurrent radiation and chemotherapy with weekly docetaxel - three year results of a pilot study.
Topics: Antineoplastic Agents; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Cisplatin; Cranial Irradiation; Docetaxel; Dose Fractionation, Radiation; Drug Tolerance; Feasibility Studies; Female; Humans; Injections, Intra-Arterial; Lymph Node Excision; Male; Middle Aged; Mouth Neoplasms; Neck; Neoplasm Recurrence, Local; Neoplasm Staging; Oropharyngeal Neoplasms; Paclitaxel; Patient Compliance; Pilot Projects; Prognosis; Radiotherapy, Adjuvant; Radiotherapy, Conformal; Survival Analysis; Taxoids | 2002 |
287 other study(ies) available for docetaxel anhydrous and Local Neoplasm Recurrence
| Article | Year |
|---|---|
Sequential Gemcitabine plus Docetaxel Is the Standard Second-line Intravesical Therapy for Bacillus Calmette-Guérin-unresponsive Non-muscle invasive Bladder Cancer: Con.
Topics: BCG Vaccine; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Urinary Bladder Neoplasms | 2022 |
Impact of previous nivolumab treatment on the response to taxanes in patients with recurrent/metastatic head and neck squamous cell carcinoma.
Topics: Aged; Bridged-Ring Compounds; Disease Progression; Docetaxel; Female; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Nivolumab; Paclitaxel; Retrospective Studies; Squamous Cell Carcinoma of Head and Neck; Taxoids; Treatment Outcome | 2021 |
Safety and effectiveness of ramucirumab and docetaxel: a single-arm, prospective, multicenter, non-interventional, observational, post-marketing safety study of NSCLC in Japan.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Docetaxel; Female; Humans; Japan; Lung Neoplasms; Male; Marketing; Neoplasm Recurrence, Local; Prospective Studies; Ramucirumab | 2022 |
Real-World Efficacy of Nintedanib Plus Docetaxel After Progression on Immune Checkpoint Inhibitors: Results From the Ongoing, Non-interventional VARGADO Study.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Docetaxel; Humans; Immune Checkpoint Inhibitors; Indoles; Lung Neoplasms; Neoplasm Recurrence, Local; Prospective Studies; Treatment Outcome | 2022 |
Analysis of Multiple Drug Resistance Mechanism in Different Types of Soft Tissue Sarcomas: Assessment of the Expression of ABC-Transporters, MVP, YB-1, and Analysis of Their Correlation with Chemosensitivity of Cancer Cells.
Topics: ATP-Binding Cassette Transporters; Docetaxel; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Humans; Neoplasm Recurrence, Local; Sarcoma; Soft Tissue Neoplasms | 2022 |
Single-nucleotide polymorphisms and the effectiveness of taxane-based chemotherapy in premenopausal breast cancer: a population-based cohort study in Denmark.
Topics: Breast Neoplasms; Bridged-Ring Compounds; Chemotherapy, Adjuvant; Cohort Studies; Cytochrome P-450 CYP3A; Denmark; Docetaxel; Female; Humans; Liver-Specific Organic Anion Transporter 1; Neoplasm Recurrence, Local; Polymorphism, Single Nucleotide; Taxoids | 2022 |
Efficacy of Androgen Receptor-targeted Drugs After Prostate Cancer Recurrence With Bone Metastases: PROSTAT-BSI Sub-analysis.
Topics: Bone Neoplasms; Docetaxel; Hormones; Humans; Male; Neoplasm Recurrence, Local; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Receptors, Androgen | 2022 |
Quality of Life, Efficacy, and Safety of Sequential Intravesical Gemcitabine + Docetaxel versus BCG for Non-Muscle Invasive Urinary Bladder Cancer: A Pilot Study.
Topics: Administration, Intravesical; BCG Vaccine; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Pilot Projects; Prospective Studies; Quality of Life; Urinary Bladder Neoplasms | 2022 |
New approaches in palliative systemic therapy of anal squamous cell carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carcinoma, Squamous Cell; Cisplatin; Docetaxel; Fluorouracil; Humans; Immunotherapy; Neoplasm Recurrence, Local; Palliative Care | 2022 |
Neoadjuvant chemotherapy for locally advanced esophageal cancer comparing cisplatin and 5-fluorouracil versus docetaxel plus cisplatin and 5-fluorouracil: a propensity score matching analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Fluorouracil; Humans; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Neoplasms, Second Primary; Propensity Score; Retrospective Studies; Taxoids | 2022 |
Sequential Intravesical Valrubicin and Docetaxel for the Salvage Treatment of Non-Muscle-Invasive Bladder Cancer.
Topics: Adjuvants, Immunologic; Administration, Intravesical; BCG Vaccine; Carcinoma in Situ; Docetaxel; Doxorubicin; Humans; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Retrospective Studies; Salvage Therapy; Urinary Bladder Neoplasms | 2022 |
Assessment of neoadjuvant chemotherapy with docetaxel, cisplatin, and fluorouracil in patients with oral cavity cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; Fluorouracil; Head and Neck Neoplasms; Humans; Induction Chemotherapy; Mouth Neoplasms; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Taxoids | 2023 |
Sequential Intravesical Gemcitabine and Docetaxel for bacillus Calmette-Guérin-Naïve High-Risk Nonmuscle-Invasive Bladder Cancer.
Topics: Adjuvants, Immunologic; Administration, Intravesical; Bacillus; BCG Vaccine; Carcinoma in Situ; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Retrospective Studies; Urinary Bladder Neoplasms | 2022 |
Re: Sequential Intravesical Gemcitabine and Docetaxel for Bacillus Calmette-Guérin-naïve High-risk Nonmuscle-invasive Bladder Cancer.
Topics: Adjuvants, Immunologic; Administration, Intravesical; Bacillus; BCG Vaccine; Docetaxel; Gemcitabine; Humans; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Urinary Bladder Neoplasms | 2022 |
Dual HER2 blockade with pertuzumab (P) and trastuzumab (T) in patients with HER2-positive metastatic breast cancer (mBC) relapsing after adjuvant treatment with T: results from a German non-interventional study (NIS) HELENA (NCT01777958).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Second Primary; Receptor, ErbB-2; Trastuzumab | 2022 |
Recurrence Pattern Comparing Preoperative Chemoradiotherapy and Preoperative Chemotherapy with Docetaxel plus 5-Fluorouracil and Cisplatin for Advanced Esophageal Cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplatin; Docetaxel; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Fluorouracil; Humans; Neoplasm Recurrence, Local | 2022 |
Two cases of anal squamous cell carcinoma achieving complete response after docetaxel + cisplatin + S-1 (DCS) induction chemotherapy followed by chemoradiation.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplatin; Docetaxel; Fluorouracil; Humans; Induction Chemotherapy; Neoplasm Recurrence, Local; Taxoids | 2023 |
Saikosaponin A enhances Docetaxel efficacy by selectively inducing death of dormant prostate cancer cells through excessive autophagy.
Topics: Apoptosis; Autophagy; Cell Line, Tumor; Cell Proliferation; Docetaxel; Humans; Male; Neoplasm Recurrence, Local; Prostate; Prostatic Neoplasms; Proto-Oncogene Proteins c-akt | 2023 |
Long-term follow-up of sequential intravesical gemcitabine and docetaxel salvage therapy for non-muscle invasive bladder cancer.
Topics: Adjuvants, Immunologic; Administration, Intravesical; Aged; BCG Vaccine; Docetaxel; Follow-Up Studies; Gemcitabine; Humans; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Non-Muscle Invasive Bladder Neoplasms; Retrospective Studies; Salvage Therapy; Urinary Bladder Neoplasms | 2023 |
Neoadjuvant Trastuzumab and Pertuzumab in Combination with Standard Chemotherapy for HER2-Positive Early Breast Cancer: Real-World Practice in Cuba.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Breast Neoplasms; Cuba; Docetaxel; Female; Humans; Middle Aged; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Prospective Studies; Receptor, ErbB-2; Trastuzumab | 2023 |
Significance of lymphovascular invasion in esophageal squamous cell carcinoma undergoing neoadjuvant chemotherapy followed by esophagectomy.
Topics: Cisplatin; Docetaxel; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Esophagectomy; Fluorouracil; Humans; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Retrospective Studies | 2023 |
A Multicenter Retrospective Chart Review of Clinical Outcomes Among Patients With KRAS G12C Mutant Non-Small Cell Lung Cancer.
Topics: Carcinoma, Non-Small-Cell Lung; Docetaxel; Humans; Kelch-Like ECH-Associated Protein 1; Lung Neoplasms; Mutation; Neoplasm Recurrence, Local; NF-E2-Related Factor 2; Platinum; Proto-Oncogene Proteins p21(ras); Retrospective Studies; Taxoids | 2023 |
Identification of a novel eighteen-gene signature of recurrent metastasis neuroblastoma.
Topics: Chronic Disease; DNA Copy Number Variations; Docetaxel; Gene Expression Profiling; Humans; Neoplasm Recurrence, Local; Neuroblastoma; Vinorelbine | 2023 |
Impact of adding pertuzumab to trastuzumab plus chemotherapy in neoadjuvant treatment of HER2 positive breast cancer patients: a multicenter real-life HER2PATH study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Female; Humans; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Paclitaxel; Receptor, ErbB-2; Retrospective Studies; Trastuzumab | 2023 |
Phase II Study of Docetaxel and Trametinib in Patients with KRAS Mutation Positive Recurrent Non-Small Cell Lung Cancer (NSCLC; SWOG S1507, NCT-02642042).
Topics: Carcinoma, Non-Small-Cell Lung; Docetaxel; Humans; Lung Neoplasms; Mutation; Neoplasm Recurrence, Local; Proto-Oncogene Proteins p21(ras) | 2023 |
Long-term Outcomes of Neoadjuvant Chemotherapy With Docetaxel, Cisplatin and S-1 for Stage III Gastric Cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Docetaxel; Humans; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Prognosis; Prospective Studies; Retrospective Studies; Stomach Neoplasms | 2023 |
Targeting KRAS-Mutated NSCLC: Novel TKIs and Beyond.
Topics: Carcinoma, Non-Small-Cell Lung; Docetaxel; Humans; Lung Neoplasms; Mutation; Neoplasm Recurrence, Local; Proto-Oncogene Proteins p21(ras) | 2023 |
Sequential intravesical gemcitabine/docetaxel provides a durable remission in recurrent high-risk NMIBC following BCG therapy.
Topics: Aged; BCG Vaccine; Docetaxel; Gemcitabine; Humans; Neoplasm Recurrence, Local; Non-Muscle Invasive Bladder Neoplasms; Prospective Studies; Retrospective Studies; Urinary Bladder Neoplasms | 2023 |
Benefit of postoperative regional nodal irradiation in patients receiving preoperative systemic therapy with docetaxel/carboplatin/trastuzumab/pertuzumab for HER2-positive breast cancer.
Topics: Breast Neoplasms; Carboplatin; Docetaxel; Female; Humans; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Retrospective Studies; Trastuzumab | 2023 |
Synergistic combination treatment to break cross talk between cancer cells and bone cells to inhibit progression of bone metastasis.
Topics: Animals; Bone Neoplasms; Cell Line, Tumor; Docetaxel; Humans; Male; Mice; Neoplasm Recurrence, Local; Prostatic Neoplasms; RANK Ligand; Tissue Distribution; Tumor Microenvironment | 2020 |
[Successful Administration of Alternate-Day, Low-Dose S-1 in a Patient with Recurrent Esophageal Cancer with a Poor Compliance Profile].
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Drug Combinations; Esophageal Neoplasms; Female; Humans; Lymph Nodes; Mediastinum; Neoplasm Recurrence, Local; Oxonic Acid; Tegafur | 2019 |
Clinical outcome and predictive factors for docetaxel and epirubicin neoadjuvant chemotherapy of locally advanced breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Epirubicin; Female; Humans; Middle Aged; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Retrospective Studies; Taxoids; Treatment Outcome; Young Adult | 2020 |
Preoperative intra-arterial chemotherapy with docetaxel, cisplatin, and peplomycin combined with intravenous chemotherapy using 5-fluorouracil for oral squamous cell carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Docetaxel; Fluorouracil; Humans; Mouth Neoplasms; Neoplasm Recurrence, Local; Peplomycin; Taxoids | 2020 |
Patient-Reported Cognitive Impairment Among Women With Early Breast Cancer Randomly Assigned to Endocrine Therapy Alone Versus Chemoendocrine Therapy: Results From TAILORx.
Topics: Aged; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Cognitive Dysfunction; Cyclophosphamide; Docetaxel; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Randomized Controlled Trials as Topic; Tamoxifen | 2020 |
Quality of Life With Pembrolizumab for Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma: KEYNOTE-040.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Cetuximab; Disease-Free Survival; Docetaxel; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Patient Reported Outcome Measures; Quality of Life; Squamous Cell Carcinoma of Head and Neck | 2021 |
Outcomes of concurrent radiotherapy with weekly docetaxel and platinum-based chemotherapy in stage III non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Chemoradiotherapy; Cisplatin; Docetaxel; Female; Follow-Up Studies; Humans; Induction Chemotherapy; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Radiotherapy Dosage; Retrospective Studies; Survival Rate; Time Factors; Treatment Outcome | 2020 |
Downstaging and Histological Effects Might Be Reliable Predictors of the Efficacy of DOC+CDDP+5-FU (DCF) as Neoadjuvant Therapy for Stage III or Borderline Resectable Esophageal Cancer: a Single Institute Experience.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Disease-Free Survival; Docetaxel; Drug Administration Schedule; Esophageal Mucosa; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Esophagectomy; Esophagoscopy; Feasibility Studies; Female; Fluorouracil; Follow-Up Studies; Humans; Japan; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Neoplasm Staging; Pyrimidines; Retrospective Studies | 2021 |
Topics: Deoxycytidine; Docetaxel; Gemcitabine; Humans; Neoplasm Recurrence, Local; Urinary Bladder Neoplasms | 2020 |
Recurrence patterns after bevacizumab in platinum-sensitive, recurrent epithelial ovarian cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Carboplatin; Carcinoma, Ovarian Epithelial; Cisplatin; Cohort Studies; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Retrospective Studies; Topotecan | 2020 |
Local and metastatic curative radiotherapy in patients with de novo oligometastatic prostate cancer.
Topics: Aged; Aged, 80 and over; Androgen Antagonists; Bone Neoplasms; Disease-Free Survival; Docetaxel; Follow-Up Studies; Humans; Kaplan-Meier Estimate; Magnetic Resonance Imaging; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Positron Emission Tomography Computed Tomography; Prognosis; Prostate-Specific Antigen; Prostatectomy; Prostatic Neoplasms; Radiotherapy; Recurrence; Retrospective Studies; Tumor Burden | 2020 |
Docetaxel-induced fluid retention during adjuvant chemotherapy with S-1 plus docetaxel.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Docetaxel; Humans; Japan; Neoplasm Recurrence, Local; Stomach Neoplasms | 2021 |
Docetaxel exposure and hematological toxicity in Chinese patients with locally advanced/metastatic nasopharyngeal carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; China; Docetaxel; Humans; Nasopharyngeal Carcinoma; Nasopharyngeal Neoplasms; Neoplasm Recurrence, Local; Taxoids | 2021 |
[Long-Term Follow-Up of Patients Who Received Chemotherapy with S-1 and Docetaxel after Relatively Curative Surgery for Advanced Gastric Cancer Including Non-Curative Factors].
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Docetaxel; Follow-Up Studies; Gastrectomy; Humans; Neoplasm Recurrence, Local; Patients; Stomach Neoplasms | 2020 |
[Docetaxel and Ramucirumab Combination Chemotherapy after Nivolumab Treatment for Pretreated Pulmonary Squamous Cell Carcinoma-A Successful Case].
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Docetaxel; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Nivolumab; Ramucirumab | 2021 |
Clinical Impact of the Prognostic Nutritional Index as a Predictor of Outcomes in Patients with Stage II/III Gastric Cancer: A Retrospective Cohort Study.
Topics: Aged; Aged, 80 and over; Chemotherapy, Adjuvant; Docetaxel; Drug Combinations; Female; Gastrectomy; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Nutrition Assessment; Oxonic Acid; Practice Guidelines as Topic; Prognosis; Retrospective Studies; Stomach Neoplasms; Survival Analysis; Tegafur; Treatment Outcome | 2021 |
Docetaxel and cisplatin induction chemotherapy with or without fluorouracil in locoregionally advanced nasopharyngeal carcinoma: A retrospective propensity score matching analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Cisplatin; Docetaxel; Fluorouracil; Humans; Induction Chemotherapy; Nasopharyngeal Carcinoma; Nasopharyngeal Neoplasms; Neoplasm Recurrence, Local; Propensity Score; Retrospective Studies | 2022 |
Intravesical sequential gemcitabine and docetaxel versus bacillus calmette-guerin (BCG) plus interferon in patients with recurrent non-muscle invasive bladder cancer following a single induction course of BCG.
Topics: Adjuvants, Immunologic; Administration, Intravesical; Adult; Aged; Antineoplastic Agents; BCG Vaccine; Cohort Studies; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Induction Chemotherapy; Interferon alpha-2; Male; Middle Aged; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Treatment Outcome; Urinary Bladder Neoplasms | 2022 |
Topical delivery of chemotherapeutic drugs using nano-hybrid hydrogels to inhibit post-surgical tumour recurrence.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cell-Penetrating Peptides; Docetaxel; Drug Delivery Systems; Humans; Hydrogels; Mice; Neoplasm Recurrence, Local | 2021 |
Overexpression of claspin promotes docetaxel resistance and is associated with prostate-specific antigen recurrence in prostate cancer.
Topics: Adaptor Proteins, Signal Transducing; Aged; Datasets as Topic; Disease-Free Survival; Docetaxel; Drug Resistance, Neoplasm; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; Humans; Kallikreins; Kaplan-Meier Estimate; Male; Neoplasm Grading; Neoplasm Recurrence, Local; PC-3 Cells; Prostate-Specific Antigen; Prostatic Neoplasms; Retrospective Studies; Up-Regulation | 2021 |
Synergistic Antitumor Activity of SH003 and Docetaxel via EGFR Signaling Inhibition in Non-Small Cell Lung Cancer.
Topics: A549 Cells; Angelica; Angiogenesis Inhibitors; Animals; Apoptosis; Astragalus Plant; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Docetaxel; ErbB Receptors; Humans; Lung Neoplasms; Mice; Neoplasm Recurrence, Local; Plant Extracts; Protein Kinase Inhibitors; Signal Transduction; STAT3 Transcription Factor; Trichosanthes; Xenograft Model Antitumor Assays | 2021 |
Multinucleated polyploidy drives resistance to Docetaxel chemotherapy in prostate cancer.
Topics: Animals; Apoptosis; Cell Line, Tumor; Docetaxel; Drug Resistance, Neoplasm; Humans; Hyaluronan Receptors; Male; Mice; Neoplasm Recurrence, Local; Polyploidy; Prostatic Neoplasms, Castration-Resistant; Taxoids; Xenograft Model Antitumor Assays | 2017 |
Efficacy and safety of gemcitabine plus docetaxel in Japanese patients with unresectable or recurrent bone and soft tissue sarcoma: Results from a single-institutional analysis.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents; Bone Neoplasms; Deoxycytidine; Disease-Free Survival; Docetaxel; Drug Administration Schedule; Drug Therapy, Combination; Female; Gemcitabine; Humans; Japan; Male; Middle Aged; Neoplasm Recurrence, Local; Neutropenia; Retrospective Studies; Sarcoma; Soft Tissue Neoplasms; Survival Rate; Taxoids; Treatment Outcome; Young Adult | 2017 |
A Pilot Trial of S-1 and Paclitaxel in Unresectable or Postoperative Recurrent Esophageal Squamous Cell Carcinoma Pretreated by Fluorouracil, Cisplatin, and Docetaxel Chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Cohort Studies; Disease-Free Survival; Docetaxel; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Esophagectomy; Fluorouracil; Humans; Japan; Kaplan-Meier Estimate; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Paclitaxel; Palliative Care; Pilot Projects; Prognosis; Retrospective Studies; Risk Assessment; Survival Analysis; Taxoids | 2018 |
Adjuvant gemcitabine-docetaxel chemotherapy for stage I uterine leiomyosarcoma: Trends and survival outcomes.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Deoxycytidine; Disease-Free Survival; Docetaxel; Female; Gemcitabine; Humans; Leiomyosarcoma; Middle Aged; Neoplasm Recurrence, Local; Proportional Hazards Models; Retrospective Studies; Taxoids; Uterine Neoplasms | 2017 |
Chemoradiation Therapy Followed by Surgery in the Treatment of Locoregionally Advanced Non-Small Cell Lung Cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Chemoradiotherapy, Adjuvant; Cisplatin; Disease Progression; Disease-Free Survival; Docetaxel; Feasibility Studies; Female; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Neoplasm Staging; Pneumonectomy; Proportional Hazards Models; Radiotherapy Dosage; Retrospective Studies; Risk Factors; Taxoids; Time Factors; Treatment Outcome | 2018 |
Taxane Followed by Anthracycline or Vice Versa: Impact of Sequential Order on Breast Cancer Recurrence?-Reply.
Topics: Anthracyclines; Breast Neoplasms; Bridged-Ring Compounds; Capecitabine; Cyclophosphamide; Docetaxel; Epirubicin; Humans; Neoplasm Recurrence, Local; Taxoids | 2018 |
Taxane Followed by Anthracycline or Vice Versa: Impact of Sequential Order on Breast Cancer Recurrence?
Topics: Anthracyclines; Breast Neoplasms; Bridged-Ring Compounds; Capecitabine; Cyclophosphamide; Docetaxel; Epirubicin; Humans; Neoplasm Recurrence, Local; Taxoids | 2018 |
Successful downstaging of locally recurrent penile squamous cell carcinoma with neoadjuvant nanosomal docetaxel lipid suspension (NDLS) based regimen followed by curative surgery.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Cisplatin; Docetaxel; Fluorouracil; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Penile Neoplasms; Penis; Taxoids; Tomography, X-Ray Computed | 2017 |
Gemcitabine and Taxane Adjuvant Therapy with Chemoradiation in Resected Pancreatic Cancer: A Novel Strategy for Improved Survival?
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy, Adjuvant; Deoxycytidine; Docetaxel; Female; Follow-Up Studies; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Pancreatic Neoplasms; Prognosis; Survival Rate | 2018 |
Safety and Efficacy of Prostatic Artery Chemoembolization for Prostate Cancer-Initial Experience.
Topics: Aged; Antineoplastic Agents; Chemoembolization, Therapeutic; Docetaxel; Humans; Male; Neoplasm Grading; Neoplasm Recurrence, Local; Prospective Studies; Prostate; Prostate-Specific Antigen; Prostatic Neoplasms; Taxoids; Treatment Outcome | 2018 |
Follicular dendritic cell sarcoma of the porta hepatis.
Topics: Abdominal Pain; Antineoplastic Combined Chemotherapy Protocols; Bilirubin; Biomarkers, Tumor; Cholangiopancreatography, Endoscopic Retrograde; Dendritic Cell Sarcoma, Follicular; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Liver Neoplasms; Magnetic Resonance Imaging; Male; Middle Aged; Neoplasm Recurrence, Local; Taxoids | 2018 |
Beau's lines in nails: An indicator of recent Docetaxel and 5-FU use.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Docetaxel; Fluorouracil; Gastrectomy; Humans; Lymph Node Excision; Male; Middle Aged; Nail Diseases; Nails; Neoplasm Recurrence, Local; Oxaloacetates; Stomach Neoplasms | 2018 |
[Neoadjuvant chemotherapy with concurrent chemoradiotherapy in the treatment of nasopharyngeal cancer: Southern Tunisian experience].
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Chemotherapy, Adjuvant; Cisplatin; Docetaxel; Female; Fluorouracil; Humans; Induction Chemotherapy; Male; Middle Aged; Nasopharyngeal Neoplasms; Neoplasm Recurrence, Local; Neutropenia; Radiotherapy Dosage; Retrospective Studies; Taxoids; Tunisia | 2018 |
In Vitro and In Vivo evaluation of a novel folate-targeted theranostic nanoemulsion of docetaxel for imaging and improved anticancer activity against ovarian cancers.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Disease Models, Animal; Docetaxel; Drug Carriers; Emulsions; Endocytosis; Female; Folate Receptor 1; Folic Acid; Gadolinium; Humans; Magnetic Resonance Imaging; Mice; Mice, Inbred C57BL; Mice, Transgenic; Molecular Imaging; Nanoparticles; Neoplasm Recurrence, Local; Ovarian Neoplasms; Theranostic Nanomedicine | 2018 |
[Pulmonary Pleomorphic Carcinoma Relapsed after Surgery Surviving Long-term by Chemotherapy and Nivolumab].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Carcinoma; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Nivolumab | 2018 |
Efficacy and safety of cisplatin and weekly docetaxel in patients with recurrent or metastatic squamous cell carcinoma of the head and neck.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Disease Progression; Docetaxel; Drug Administration Schedule; Female; Head and Neck Neoplasms; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Progression-Free Survival; Retrospective Studies; Squamous Cell Carcinoma of Head and Neck; Time Factors | 2019 |
Chemotherapy Sensitizes Therapy-Resistant Cells to Mild Hyperthermia by Suppressing Heat Shock Protein 27 Expression in Triple-Negative Breast Cancer.
Topics: Animals; Combined Modality Therapy; Docetaxel; Drug Resistance, Neoplasm; Female; Gold; HSP27 Heat-Shock Proteins; Humans; Hyperthermia, Induced; Metal Nanoparticles; Mice; Neoplasm Recurrence, Local; Neoplastic Stem Cells; Triple Negative Breast Neoplasms; Xenograft Model Antitumor Assays | 2018 |
Bevacizumab combined with platinum-taxane chemotherapy as first-line treatment for advanced ovarian cancer: a prospective observational study of safety and efficacy in Japanese patients (JGOG3022 trial).
Topics: Adenocarcinoma, Clear Cell; Adenocarcinoma, Mucinous; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Cystadenocarcinoma, Serous; Docetaxel; Endometrial Neoplasms; Female; Humans; Japan; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Prognosis; Prospective Studies; Safety; Survival Rate; Young Adult | 2019 |
Building evidence-based treatment recommendations for advanced anal cancer: the time is now.
Topics: Anus Neoplasms; Carcinoma, Squamous Cell; Cisplatin; Docetaxel; Epitopes; Fluorouracil; Humans; Neoplasm Recurrence, Local | 2018 |
Lobaplatin inhibits prostate cancer progression in part by impairing AR and ERG signal.
Topics: Androgen Antagonists; Androgen Receptor Antagonists; Androgens; Animals; Antineoplastic Agents; Cyclobutanes; Disease Progression; Docetaxel; Down-Regulation; Humans; Male; Mice; Neoplasm Recurrence, Local; Organoplatinum Compounds; Prostate; Prostatic Neoplasms; Receptors, Androgen; Taxoids; Transcriptional Regulator ERG | 2018 |
Pharmacogenetic variants and response to neoadjuvant single-agent doxorubicin or docetaxel: a study in locally advanced breast cancer patients participating in the NCT00123929 phase 2 randomized trial.
Topics: Adult; Aged; Breast Neoplasms; Cytochrome P-450 CYP1B1; Docetaxel; Doxorubicin; Female; Genetic Association Studies; Humans; Middle Aged; Multidrug Resistance-Associated Protein 2; Multidrug Resistance-Associated Proteins; Neoplasm Recurrence, Local; Polymorphism, Single Nucleotide; Randomized Controlled Trials as Topic | 2018 |
Prognostic significance of risk stratification in CHAARTED and LATITUDE studies among Japanese men with de novo metastatic prostate cancer.
Topics: Aged; Androgen Antagonists; Androstenes; Antineoplastic Agents; Biopsy, Large-Core Needle; Clinical Trials as Topic; Disease Progression; Docetaxel; Humans; Japan; Male; Neoplasm Recurrence, Local; Orchiectomy; Prognosis; Progression-Free Survival; Prostate; Prostatic Neoplasms; Retrospective Studies; Risk Assessment | 2019 |
Nivolumab therapy for lung cancer with tracheo-parenchymal fistula: A case report.
Topics: Adenocarcinoma; Antineoplastic Agents; Antineoplastic Agents, Immunological; Bevacizumab; Carboplatin; Chemoradiotherapy; Docetaxel; Fistula; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Nivolumab; Paclitaxel; Treatment Outcome | 2018 |
Liposomal paclitaxel versus docetaxel in induction chemotherapy using Taxanes, cisplatin and 5-fluorouracil for locally advanced nasopharyngeal carcinoma.
Topics: Adolescent; Adult; Aged; Cell Line, Tumor; Cisplatin; Disease-Free Survival; Docetaxel; Drug-Related Side Effects and Adverse Reactions; Female; Fluorouracil; Herpesvirus 4, Human; Humans; Liposomes; Male; Middle Aged; Nasopharyngeal Carcinoma; Neoplasm Recurrence, Local; Neutropenia; Paclitaxel; Taxoids | 2018 |
[Three Cases of Advanced Gastric Cancer with Peritoneal Dissemination Successfully Treated with S-1 and Docetaxel Combination Chemotherapy].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Drug Combinations; Female; Gastrectomy; Humans; Male; Neoplasm Recurrence, Local; Oxonic Acid; Peritoneal Neoplasms; Stomach Neoplasms; Tegafur | 2018 |
Adenosine triphosphate-based chemotherapy response assay predicts long-term survival of primary epithelial ovarian cancer.
Topics: Adenocarcinoma, Clear Cell; Adenocarcinoma, Mucinous; Adenosine Triphosphate; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cystadenocarcinoma, Serous; Docetaxel; Endometrial Neoplasms; Female; Follow-Up Studies; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Prognosis; Retrospective Studies; Survival Rate | 2019 |
Success of chemotherapy and a liver transplant in a pediatric patient with hepatic angiosarcoma: A case report.
Topics: Antineoplastic Agents; Biopsy; Child, Preschool; Docetaxel; Doxorubicin; Female; Hemangiosarcoma; Humans; Ifosfamide; Liver; Liver Neoplasms; Liver Transplantation; Neoplasm Recurrence, Local; Treatment Outcome | 2019 |
Degree of
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Proliferation; Combined Modality Therapy; Deoxycytidine; Docetaxel; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Gemcitabine; Gene Amplification; Humans; Liposarcoma; Mice; Neoplasm Recurrence, Local; Prognosis; Prospective Studies; Proto-Oncogene Proteins c-mdm2; Retrospective Studies; Surgical Procedures, Operative; Survival Rate; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2019 |
Prognostic significance of pathological tumor response and residual nodal metastasis in patients with esophageal squamous cell carcinoma after neoadjuvant chemotherapy followed by surgery.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Cisplatin; Docetaxel; Esophageal Neoplasms; Esophagectomy; Female; Fluorouracil; Humans; Lymph Node Excision; Lymph Nodes; Lymphatic Metastasis; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplasm, Residual; Prognosis; Retrospective Studies; Survival Rate | 2019 |
The combination of gemcitabine and docetaxel arrests a doxorubicin-resistant dedifferentiated liposarcoma in a patient-derived orthotopic xenograft model.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease Models, Animal; Docetaxel; Doxorubicin; Drug Resistance, Neoplasm; Gemcitabine; Heterografts; Humans; Indazoles; Liposarcoma; Male; Mice; Mice, Nude; Neoplasm Recurrence, Local; Pyrimidines; Sulfonamides; Tumor Burden; Xenograft Model Antitumor Assays | 2019 |
Predictive Factors for Completion of TPF Induction Chemotherapy in Patients With Locally Advanced Head and Neck Cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Disease-Free Survival; Docetaxel; Drug-Related Side Effects and Adverse Reactions; Female; Fluorouracil; Head and Neck Neoplasms; Humans; Induction Chemotherapy; Male; Middle Aged; Neoplasm Recurrence, Local; Prognosis | 2019 |
Single-agent chemotherapy compared with combination chemotherapy as second-line treatment in extensive-stage small cell lung cancer: a retrospective analysis.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Docetaxel; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Platinum; Prognosis; Retrospective Studies; Salvage Therapy; Small Cell Lung Carcinoma; Survival Rate; Taxoids; Topotecan | 2013 |
VEGF and TSP1 levels correlate with prognosis in advanced non-small cell lung cancer.
Topics: Adenocarcinoma; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Basic Helix-Loop-Helix Leucine Zipper Transcription Factors; Bevacizumab; Biomarkers, Tumor; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Case-Control Studies; Cisplatin; Docetaxel; Enzyme-Linked Immunosorbent Assay; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Prospective Studies; Survival Rate; Taxoids; Vascular Endothelial Growth Factor A | 2013 |
Survival impact of pulmonary metastasectomy for patients with head and neck cancer.
Topics: Adenoma; Antineoplastic Agents; Carcinoma; Cisplatin; Docetaxel; Female; Fluorouracil; Head and Neck Neoplasms; Histiocytoma, Malignant Fibrous; Humans; Lung Neoplasms; Male; Metastasectomy; Middle Aged; Multivariate Analysis; Neoplasm Recurrence, Local; Pneumonectomy; Prognosis; Retrospective Studies; Taxoids; Thoracotomy | 2013 |
Breast-conserving surgery after tumor downstaging by neoadjuvant chemotherapy is oncologically safe for stage III breast cancer patients.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Disease-Free Survival; Docetaxel; Doxorubicin; Female; Fluorouracil; Humans; Ki-67 Antigen; Lymphatic Metastasis; Mastectomy, Segmental; Methotrexate; Middle Aged; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Radiotherapy, Adjuvant; Retrospective Studies; Risk Factors; Survival Rate; Taxoids | 2013 |
Vitamin D receptor genetic variants are associated with chemotherapy response and prognosis in patients with advanced non-small-cell lung cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Deoxycytidine; DNA, Neoplasm; Docetaxel; Female; Follow-Up Studies; Gemcitabine; Genotype; Haplotypes; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Polymerase Chain Reaction; Polymorphism, Single Nucleotide; Prognosis; Receptors, Calcitriol; Survival Rate; Taxoids; Vinblastine; Vinorelbine | 2013 |
Pathologic complete response to neoadjuvant chemotherapy with trastuzumab predicts for improved survival in women with HER2-overexpressing breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease-Free Survival; Docetaxel; Female; Humans; Middle Aged; Neoadjuvant Therapy; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Receptor, ErbB-2; Survival; Taxoids; Trastuzumab; Treatment Outcome; Young Adult | 2013 |
The recurrence and survival of oral squamous cell carcinoma: a report of 275 cases.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Cisplatin; Docetaxel; Female; Fluorouracil; Follow-Up Studies; Humans; Lymphatic Metastasis; Male; Middle Aged; Mouth Neoplasms; Neck Dissection; Neoplasm Recurrence, Local; Neoplasm Staging; Radiotherapy, Adjuvant; Survival Rate; Taxoids; Young Adult | 2013 |
Should bevacizumab be continued after progression on bevacizumab in recurrent ovarian cancer?
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Cisplatin; Cyclophosphamide; Disease Progression; Docetaxel; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Humans; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Prognosis; Retrospective Studies; Survival Rate; Taxoids; Topotecan | 2013 |
Adjuvant trastuzumab for 6 months is effective in patients with HER2-positive stage II or III breast cancer.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Docetaxel; Epirubicin; Female; Fluorouracil; Follow-Up Studies; Humans; Immunoenzyme Techniques; In Situ Hybridization, Fluorescence; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Receptor, ErbB-2; Retrospective Studies; Survival Rate; Taxoids; Trastuzumab | 2013 |
Design of precise third-line therapy for gastric cancer: target or chemotherpy?
Topics: Adenocarcinoma; Antineoplastic Agents; Docetaxel; Female; Humans; Male; Neoplasm Recurrence, Local; Stomach Neoplasms; Taxoids | 2013 |
Analysis of the correlation between endorectal MRI response to neoadjuvant chemotherapy and biochemical recurrence in patients with high-risk localized prostate cancer.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Chemotherapy, Adjuvant; Clinical Trials, Phase II as Topic; Docetaxel; Humans; Kallikreins; Magnetic Resonance Imaging; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Prospective Studies; Prostate-Specific Antigen; Prostatectomy; Prostatic Neoplasms; Taxoids; Treatment Outcome | 2013 |
Is catheter rupture rare after totally implantable access port implantation via the right internal jugular vein? Report of a case.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Catheterization, Central Venous; Catheters, Indwelling; Docetaxel; Equipment Failure; Female; Humans; Jugular Veins; Middle Aged; Motion; Neck; Neoplasm Recurrence, Local; Stress, Mechanical; Surgery, Computer-Assisted; Taxoids; Ultrasonography, Interventional; Vinblastine; Vinorelbine | 2014 |
Inhibition of ABCB1 expression overcomes acquired docetaxel resistance in prostate cancer.
Topics: Antineoplastic Agents; Apigenin; Apoptosis; ATP Binding Cassette Transporter, Subfamily D, Member 1; ATP-Binding Cassette Transporters; Cell Line, Tumor; Docetaxel; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Humans; Male; Molecular Targeted Therapy; Neoplasm Recurrence, Local; Prostatic Neoplasms, Castration-Resistant; Taxoids | 2013 |
Comparative profiling of N-glycans isolated from serum samples of ovarian cancer patients and analyzed by microchip electrophoresis.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Benzamides; Biomarkers, Tumor; Case-Control Studies; Docetaxel; Electrophoresis, Microchip; Female; Glycoproteins; Glycosylation; Humans; Imatinib Mesylate; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Piperazines; Polysaccharides; Principal Component Analysis; Protein Processing, Post-Translational; Pyrimidines; ROC Curve; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization; Taxoids | 2013 |
Single institutional experience of the treatment of angiosarcoma of the face and scalp.
Topics: Aged; Antineoplastic Agents; Chemoradiotherapy; Combined Modality Therapy; Docetaxel; Facial Neoplasms; Female; Hemangiosarcoma; Humans; Interleukin-2; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Retrospective Studies; Scalp; Skin Neoplasms; Taxoids; Treatment Outcome | 2013 |
Does adjuvant chemotherapy improve survival for women with early-stage uterine leiomyosarcoma?
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Leiomyosarcoma; Middle Aged; Neoplasm Grading; Neoplasm Recurrence, Local; Neoplasm Staging; Radiotherapy, Adjuvant; Retrospective Studies; Taxoids; Uterine Neoplasms | 2013 |
Time to prostate specific antigen (PSA) nadir may predict rapid relapse in men with metastatic castration-resistant prostate cancer (CRPC) receiving docetaxel chemotherapy.
Topics: Aged; Aged, 80 and over; Castration; Disease Progression; Disease-Free Survival; Docetaxel; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Prostate-Specific Antigen; Prostatic Neoplasms; Retrospective Studies; Taxoids | 2013 |
The effectiveness of chemoradiation therapy and salvage surgery for hypopharyngeal squamous cell carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiotherapy, Adjuvant; Cisplatin; Disease-Free Survival; Docetaxel; Dose Fractionation, Radiation; Female; Fluorouracil; Head and Neck Neoplasms; Humans; Hypopharyngeal Neoplasms; Induction Chemotherapy; Kaplan-Meier Estimate; Magnetic Resonance Imaging; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Positron-Emission Tomography; Prognosis; Retrospective Studies; Salvage Therapy; Squamous Cell Carcinoma of Head and Neck; Taxoids; Tomography, X-Ray Computed; Treatment Failure; Treatment Outcome | 2013 |
ERCC1 expression does not predict survival and treatment response in advanced stage non-small cell lung cancer cases treated with platinum based chemotherapy.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; DNA-Binding Proteins; Docetaxel; Endonucleases; Female; Follow-Up Studies; Glutamates; Guanine; Humans; Ifosfamide; Immunoenzyme Techniques; Lung Neoplasms; Male; Middle Aged; Mitomycin; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Pemetrexed; Prognosis; Retrospective Studies; Survival Rate; Taxoids | 2013 |
DCF (docetaxel, cisplatin and 5-fluorouracil) chemotherapy is a promising treatment for recurrent advanced squamous cell anal carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Cisplatin; Disease-Free Survival; Docetaxel; Female; Fluorouracil; Human papillomavirus 16; Humans; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Squamous Cell; Papillomavirus Infections; Prospective Studies; Retrospective Studies; Taxoids; Treatment Outcome | 2013 |
TPF induction chemotherapy and concomitant irradiation with cisplatin and cetuximab in unresectable squamous cell carcinoma of the head and neck.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cetuximab; Chemoradiotherapy; Cisplatin; Cohort Studies; Combined Modality Therapy; Disease-Free Survival; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fluorouracil; Head and Neck Neoplasms; Humans; Immunotherapy; Induction Chemotherapy; Infusions, Intravenous; Kaplan-Meier Estimate; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Prognosis; Squamous Cell Carcinoma of Head and Neck; Statistics, Nonparametric; Survival Analysis; Taxoids; Treatment Outcome | 2014 |
Outcome data of patients with peritoneal carcinomatosis from gastric origin treated by a strategy of bidirectional chemotherapy prior to cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in a single specialized center in Japan.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Cancer, Regional Perfusion; Cisplatin; Combined Modality Therapy; Docetaxel; Drug Combinations; Female; Follow-Up Studies; Gastrectomy; Humans; Hyperthermia, Induced; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Oxonic Acid; Peritoneal Neoplasms; Prognosis; Prospective Studies; Stomach Neoplasms; Survival Rate; Taxoids; Tegafur | 2014 |
PI3K/PTEN/AKT/mTOR polymorphisms: association with clinical outcome in patients with head and neck squamous cell carcinoma receiving cetuximab-docetaxel.
Topics: Aged; Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Squamous Cell; Cetuximab; Class I Phosphatidylinositol 3-Kinases; Docetaxel; Female; Genotype; Head and Neck Neoplasms; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Phosphatidylinositol 3-Kinases; Polymorphism, Single Nucleotide; Proto-Oncogene Proteins c-akt; PTEN Phosphohydrolase; Squamous Cell Carcinoma of Head and Neck; Taxoids; TOR Serine-Threonine Kinases; Treatment Outcome | 2015 |
Local control and prognostic significance of transarterial treatment for limited recurrence of ovarian cancer as third-line and beyond therapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; Female; Humans; Infusions, Intra-Arterial; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Prognosis; Quality of Life; Retrospective Studies; Taxoids | 2014 |
A nomogram for predicting locoregional recurrence in primary breast cancer patients who received breast-conserving surgery after neoadjuvant chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Combined Modality Therapy; Cyclophosphamide; Docetaxel; Epirubicin; Female; Fluorouracil; Follow-Up Studies; Humans; Lymphatic Metastasis; Mastectomy, Segmental; Middle Aged; Neoadjuvant Therapy; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Neoplasm Staging; Nomograms; Prognosis; Radiotherapy, Adjuvant; Retrospective Studies; ROC Curve; Survival Rate; Taxoids | 2014 |
Cost-effectiveness of prophylaxis treatment strategies for febrile neutropenia in patients with recurrent ovarian cancer.
Topics: Antineoplastic Agents; Carcinoma, Ovarian Epithelial; Chemotherapy-Induced Febrile Neutropenia; Cost-Benefit Analysis; Docetaxel; Drug Costs; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Humans; Markov Chains; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Polyethylene Glycols; Quality-Adjusted Life Years; Recombinant Proteins; Taxoids; Topotecan | 2014 |
Epithelial-to-mesenchymal transition mediates docetaxel resistance and high risk of relapse in prostate cancer.
Topics: Aged; Antineoplastic Agents; Cell Line, Tumor; Cluster Analysis; Docetaxel; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Homeodomain Proteins; Humans; Hyaluronan Receptors; Male; Middle Aged; Neoplasm Grading; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Prostatic Neoplasms; Taxoids; Transcription Factors; Treatment Outcome; Zinc Finger E-box-Binding Homeobox 1 | 2014 |
Taxane and anthracycline based neoadjuvant chemotherapy for locally advanced breast cancer: institutional experience.
Topics: Adult; Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Bridged-Ring Compounds; Docetaxel; Epirubicin; Female; Humans; Middle Aged; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Retrospective Studies; Taxoids; Treatment Outcome; Young Adult | 2014 |
Chemoradiotherapy with taxane is superior to conventional surgery and radiotherapy in the management of cutaneous angiosarcoma: a multicentre, retrospective study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bridged-Ring Compounds; Chemoradiotherapy; Combined Modality Therapy; Docetaxel; Drug Administration Schedule; Female; Head and Neck Neoplasms; Hemangiosarcoma; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Retrospective Studies; Scalp; Skin Neoplasms; Taxoids; Treatment Outcome | 2014 |
A pyriform sinus cancer organ preservation strategy comprising induction chemotherapy with docetaxel, cisplatin, and 5-fluorouracil, followed by potentiated radiotherapy: a multicenter, retrospective study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therapy; Disease-Free Survival; Docetaxel; Female; Fluorouracil; Humans; Induction Chemotherapy; Male; Middle Aged; Neoplasm Recurrence, Local; Organ Sparing Treatments; Paranasal Sinus Neoplasms; Pyriform Sinus; Retrospective Studies; Taxoids | 2014 |
Relationship between chemotherapy and prognosis in different subtypes of node-negative breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Female; Humans; Immunohistochemistry; Kaplan-Meier Estimate; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Prognosis; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Retrospective Studies; Taxoids; Treatment Outcome; Young Adult | 2014 |
Docetaxel rechallenge after an initial good response in patients with metastatic castration-resistant prostate cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Docetaxel; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Prostatic Neoplasms, Castration-Resistant; Remission Induction; Retreatment; Retrospective Studies; Taxoids | 2015 |
Adjuvant chemotherapy after esophagectomy: is there a role in the treatment of the lymph node positive thoracic esophageal squamous cell carcinoma?
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Cisplatin; Combined Modality Therapy; Docetaxel; Esophageal Neoplasms; Esophagectomy; Female; Fluorouracil; Follow-Up Studies; Humans; Male; Middle Aged; Neoplasm Grading; Neoplasm Recurrence, Local; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Prognosis; Retrospective Studies; Survival Rate; Taxoids; Thoracic Neoplasms | 2014 |
Induction chemotherapy with docetaxel, cisplatin and fluorouracil followed by surgery and concurrent chemoradiotherapy improves outcome of recurrent advanced head and neck squamous cell carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplatin; Docetaxel; Female; Fluorouracil; Head and Neck Neoplasms; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Retrospective Studies; Squamous Cell Carcinoma of Head and Neck; Taxoids | 2014 |
Survival and recurrence patterns after neoadjuvant docetaxel, cisplatin, and 5-fluorouracil (DCF) for locally advanced esophagogastric adenocarcinoma.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Docetaxel; Esophageal Neoplasms; Esophagogastric Junction; Female; Fluorouracil; Follow-Up Studies; Humans; Male; Middle Aged; Neoplasm Grading; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Prospective Studies; Retrospective Studies; Stomach Neoplasms; Survival Rate; Taxoids | 2015 |
Efficacy of taxane-based regimens in a first-line setting for recurrent and/or metastatic Chinese patients with esophageal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Asian People; Disease-Free Survival; Docetaxel; Esophageal Neoplasms; Female; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Retrospective Studies; Taxoids | 2014 |
Risk and predictors for early radiation pneumonitis in patients with stage III non-small cell lung cancer treated with concurrent or sequential chemoradiotherapy.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplatin; Docetaxel; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Radiation Pneumonitis; Radiotherapy Dosage; Radiotherapy, Conformal; Radiotherapy, Intensity-Modulated; Risk Factors; Taxoids; Vinblastine; Vinorelbine | 2014 |
Taxane-induced hedgehog signaling is linked to expansion of breast cancer stem-like populations after chemotherapy.
Topics: Apoptosis; Breast Neoplasms; Bridged-Ring Compounds; Cell Line, Tumor; Cell Proliferation; Docetaxel; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Neoplastic; Hedgehog Proteins; Humans; MCF-7 Cells; Neoplasm Recurrence, Local; Neoplastic Stem Cells; Signal Transduction; Taxoids | 2015 |
A retrospective study of docetaxel or paclitaxel in patients with advanced or recurrent esophageal squamous cell carcinoma who previously received fluoropyrimidine- and platinum-based chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Carcinoma, Squamous Cell; Disease-Free Survival; Docetaxel; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Female; Humans; Male; Middle Aged; Multivariate Analysis; Neoplasm Recurrence, Local; Neutropenia; Paclitaxel; Platinum; Prognosis; Pyrimidines; Retrospective Studies; Survival Rate; Taxoids; Treatment Outcome | 2014 |
Carcinoma of the salivary glands: guidelines and case report of sustained remission with docetaxel.
Topics: Antineoplastic Agents; Carcinoma, Mucoepidermoid; Docetaxel; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Remission Induction; Salivary Gland Neoplasms; Sialography; Taxoids; Tomography, X-Ray Computed | 2015 |
ATP-based chemotherapy response assay in primary or recurrent ovarian and peritoneal cancer.
Topics: Adenocarcinoma, Clear Cell; Adenosine Triphosphate; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma, Ovarian Epithelial; Cisplatin; Docetaxel; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Female; Humans; Ifosfamide; Irinotecan; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Predictive Value of Tests; Sensitivity and Specificity; Taxoids | 2014 |
[Efficacy and safety of fixed dose rate gemcitabine infusion in combination with docetaxel in patients with relapsed/refractory soft tissue sarcoma].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease-Free Survival; Docetaxel; Gemcitabine; Humans; Leiomyosarcoma; Neoplasm Recurrence, Local; Neutropenia; Retrospective Studies; Sarcoma; Taxoids; Treatment Outcome | 2014 |
BRCA2-associated therapy-related acute myeloid leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma in Situ; Carcinoma, Ductal, Breast; Cyclophosphamide; Docetaxel; Epirubicin; Female; Fluorouracil; Genes, BRCA2; Humans; Leukemia, Myeloid, Acute; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Second Primary; Taxoids | 2015 |
Salvage surgery after local recurrence in patients with head and neck carcinoma treated with chemoradiotherapy or bioradiotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; Cetuximab; Chemoradiotherapy; Cisplatin; Cohort Studies; Docetaxel; Female; Fluorouracil; Head and Neck Neoplasms; Humans; Laryngeal Neoplasms; Male; Middle Aged; Mouth Neoplasms; Neoplasm Recurrence, Local; Pharyngeal Neoplasms; Retrospective Studies; Salvage Therapy; Squamous Cell Carcinoma of Head and Neck; Taxoids | 2015 |
[Recurrence sites following definitive intensity-modulated conformational radiotherapy of squamous-cell carcinomas of the upper aerodigestive tract].
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; Cetuximab; Cisplatin; Combined Modality Therapy; Docetaxel; Female; Fluorouracil; Head and Neck Neoplasms; Humans; Kaplan-Meier Estimate; Lymph Node Excision; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Radiotherapy Dosage; Radiotherapy, Intensity-Modulated; Retrospective Studies; Taxoids | 2015 |
Docetaxel, cisplatin, and fluorouracil for patients with inoperable recurrent or metastatic head and neck squamous cell carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Carcinoma, Squamous Cell; Cisplatin; Cohort Studies; Docetaxel; Female; Fluorouracil; Head and Neck Neoplasms; Humans; Liver Neoplasms; Lung Neoplasms; Lymph Nodes; Male; Middle Aged; Neoplasm Recurrence, Local; Retrospective Studies; Taxoids | 2015 |
Long-term Efficacy and Safety Results: Can Enzalutamide Challenge the Dogma of Androgen Deprivation Therapy in Hormone-naïve Prostate Cancer?
Topics: Androgen Receptor Antagonists; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Benzamides; Bone Neoplasms; Docetaxel; Humans; Male; Neoplasm Recurrence, Local; Nitriles; Phenylthiohydantoin; Prostatectomy; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Taxoids | 2015 |
[Therapeutic option after failure of first-line chemotherapy].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Docetaxel; Evidence-Based Medicine; Humans; Indoles; Lung Neoplasms; Neoplasm Recurrence, Local; Taxoids; Treatment Outcome | 2015 |
Long-term remission of locally recurrent oropharyngeal cancer after docetaxel-based chemotherapy plus cetuximab.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cetuximab; Cisplatin; Disease-Free Survival; Docetaxel; Fluorouracil; Head and Neck Neoplasms; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Positron Emission Tomography Computed Tomography; Quality of Life; Remission Induction; Taxoids; Time Factors; Tonsillar Neoplasms; Treatment Outcome | 2016 |
What is an appropriate second-line regimen for recurrent endometrial cancer? Ancillary analysis of the SGSG012/GOTIC004/Intergroup study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Docetaxel; Doxorubicin; Drug Resistance, Neoplasm; Endometrial Neoplasms; Female; Humans; Kaplan-Meier Estimate; Neoplasm Recurrence, Local; Paclitaxel; Retrospective Studies; Taxoids | 2015 |
Impact of docetaxel in addition to cisplatin and fluorouracil as neoadjuvant treatment for resectable stage III or T3 esophageal cancer: a propensity score-matched analysis.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; Esophageal Neoplasms; Female; Fluorouracil; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Grading; Neoplasm Recurrence, Local; Neoplasm Staging; Propensity Score; Retrospective Studies; Taxoids | 2015 |
Pertuzumab, trastuzumab and docetaxel reduced the recurrence of brain metastasis from breast cancer: a case report.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Breast Neoplasms; Docetaxel; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Taxoids; Trastuzumab | 2016 |
Serial blood-based analysis of AR-V7 in men with advanced prostate cancer.
Topics: Aged; Aged, 80 and over; Androstenes; Antineoplastic Agents; Benzamides; Biomarkers, Tumor; Docetaxel; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplastic Cells, Circulating; Nitriles; Phenylthiohydantoin; Prospective Studies; Prostatic Neoplasms, Castration-Resistant; Protein Isoforms; Receptors, Androgen; Reverse Transcriptase Polymerase Chain Reaction; Taxoids; Treatment Outcome | 2015 |
Preparation and therapeutic application of docetaxel-loaded poly(d,l-lactide) nanofibers in preventing breast cancer recurrence.
Topics: Animals; Antineoplastic Agents; Biocompatible Materials; Breast Neoplasms; Cell Line, Tumor; Docetaxel; Drug Carriers; Female; Mice; Mice, Inbred BALB C; Nanofibers; Neoplasm Recurrence, Local; Polyesters; Taxoids; X-Ray Diffraction | 2016 |
Prognostic significance of nodal involvement region in clinical stage IIIc breast cancer patients who received primary systemic treatment, surgery, and radiotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Chemotherapy, Adjuvant; Clavicle; Combined Modality Therapy; Cyclophosphamide; Disease-Free Survival; Docetaxel; Dose Fractionation, Radiation; Doxorubicin; Female; Follow-Up Studies; Humans; Lymph Node Excision; Lymph Nodes; Lymphatic Metastasis; Mammary Glands, Human; Mastectomy; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Radiotherapy, Adjuvant; Survival Rate; Taxoids | 2015 |
Prognostic factors modifying the treatment-free interval in recurrent ovarian cancer.
Topics: Age Factors; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemotherapy, Adjuvant; Cisplatin; Cytoreduction Surgical Procedures; Deoxycytidine; Disease-Free Survival; Docetaxel; Doxorubicin; Female; Gemcitabine; Humans; Middle Aged; Multivariate Analysis; Neoplasm Grading; Neoplasm Recurrence, Local; Neoplasm, Residual; Neoplasms, Cystic, Mucinous, and Serous; Ovarian Neoplasms; Paclitaxel; Prognosis; Proportional Hazards Models; Retrospective Studies; Survival Analysis; Taxoids; Time Factors; Topotecan | 2015 |
Induction Chemotherapy and Sequential Concomitant Chemo-radiation in Locally Advanced Head and Neck Cancers: How Induction-phase Intensity and Treatment Breaks May Impact on Clinical Outcomes.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplatin; Docetaxel; Female; Fluorouracil; Follow-Up Studies; Head and Neck Neoplasms; Humans; Induction Chemotherapy; Male; Middle Aged; Neoplasm Grading; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Radiotherapy, Intensity-Modulated; Remission Induction; Retrospective Studies; Survival Rate; Taxoids; Time Factors | 2015 |
Nedaplatin: a new platinum for squamous lung cancer?
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Docetaxel; Female; Humans; Lung Neoplasms; Male; Neoplasm Recurrence, Local; Organoplatinum Compounds; Taxoids | 2015 |
Prognostic implication of serum hepatocyte growth factor in stage II/III breast cancer patients who received neoadjuvant chemotherapy.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease-Free Survival; Docetaxel; Doxorubicin; Female; Hepatocyte Growth Factor; Humans; Lymphatic Metastasis; Middle Aged; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Taxoids | 2016 |
[Characteristics of recurrence in patients with gastric cancer after radical gastrectomy and adjuvant chemotherapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Docetaxel; Fluorouracil; Gastrectomy; Humans; Leucovorin; Lymph Node Excision; Lymphatic Metastasis; Neoplasm Recurrence, Local; Neoplasms, Second Primary; Organoplatinum Compounds; Prognosis; Retrospective Studies; Stomach Neoplasms; Taxoids; Time Factors | 2015 |
Gemcitabine and Docetaxel Compared With Observation, Radiation, or Other Chemotherapy Regimens as Adjuvant Treatment for Stage I-to-IV Uterine Leiomyosarcoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Deoxycytidine; Docetaxel; Female; Follow-Up Studies; Gemcitabine; Humans; Leiomyosarcoma; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Radiotherapy, Adjuvant; Retrospective Studies; Survival Rate; Taxoids; Uterine Neoplasms | 2016 |
Docetaxel-based adjuvant therapy for breast cancer patients in Asia-Pacific region: Results from 5 years follow-up on Asia-Pacific Breast Initiative-I.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Asia; Breast Neoplasms; Chemotherapy, Adjuvant; Cohort Studies; Docetaxel; Female; Follow-Up Studies; Humans; Longitudinal Studies; Middle Aged; Neoplasm Recurrence, Local; Neutropenia; Prospective Studies; Taxoids | 2016 |
Safety Analysis of Adjuvant Chemotherapy with Docetaxel Administered with or without Anthracyclines to Early Stage Breast Cancer Patients: Combined Results from the Asia- Pacific Breast Initiatives I and II.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Docetaxel; Doxorubicin; Epirubicin; Female; Follow-Up Studies; Humans; Longitudinal Studies; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Prospective Studies; Safety; Survival Rate; Taxoids; Young Adult | 2016 |
Efficacy of docetaxel, cisplatin, and 5-fluorouracil chemotherapy for superficial esophageal squamous cell carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Disease-Free Survival; Docetaxel; Early Detection of Cancer; Endoscopy, Digestive System; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Female; Fluorouracil; Follow-Up Studies; Head and Neck Neoplasms; Humans; Lymph Nodes; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplasms, Multiple Primary; Retrospective Studies; Taxoids; Treatment Outcome | 2017 |
Retrograde intra-arterial chemotherapy and daily concurrent proton beam therapy for recurrent oral cavity squamous cell carcinoma: Analysis of therapeutic results in 46 cases.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiotherapy, Adjuvant; Cisplatin; Cohort Studies; Computed Tomography Angiography; Disease-Free Survival; Docetaxel; Drug Administration Schedule; Female; Head and Neck Neoplasms; Humans; Imaging, Three-Dimensional; Infusions, Intra-Arterial; Kaplan-Meier Estimate; Male; Middle Aged; Mouth Neoplasms; Neoplasm Recurrence, Local; Prognosis; Proton Therapy; Retrospective Studies; Risk Assessment; Squamous Cell Carcinoma of Head and Neck; Statistics, Nonparametric; Survival Analysis; Taxoids; Treatment Outcome | 2016 |
Retrospective Analysis on the Feasibility and Efficacy of Docetaxel-Cisplatin Therapy for Recurrent Endometrial Cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bridged-Ring Compounds; Cisplatin; Disease-Free Survival; Docetaxel; Endometrial Neoplasms; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Prognosis; Retrospective Studies; Taxoids; Treatment Outcome | 2016 |
Gemcitabine and docetaxel in relapsed and unresectable high-grade osteosarcoma and spindle cell sarcoma of bone.
Topics: Adolescent; Adult; Aged; Child; Deoxycytidine; Disease-Free Survival; Docetaxel; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Grading; Neoplasm Recurrence, Local; Osteosarcoma; Recurrence; Sarcoma; Taxoids; Treatment Outcome | 2016 |
Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy with lobaplatin and docetaxel to treat synchronous peritoneal carcinomatosis from gastric cancer: Results from a Chinese center.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Chemotherapy, Cancer, Regional Perfusion; China; Cyclobutanes; Cytoreduction Surgical Procedures; Databases, Factual; Docetaxel; Female; Follow-Up Studies; Humans; Hyperthermia, Induced; Kaplan-Meier Estimate; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplasms, Multiple Primary; Organoplatinum Compounds; Peritoneal Neoplasms; Prognosis; Retrospective Studies; Sample Size; Stomach Neoplasms; Taxoids; Treatment Outcome | 2016 |
Prognostic Value of 68Ga-NOTA-RGD PET/CT for Predicting Disease-Free Survival for Patients With Breast Cancer Undergoing Neoadjuvant Chemotherapy and Surgery: A Comparison Study With Dynamic Contrast Enhanced MRI.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Contrast Media; Coordination Complexes; Cyclophosphamide; Disease-Free Survival; Docetaxel; Doxorubicin; Epirubicin; Female; Fluorodeoxyglucose F18; Gallium Radioisotopes; Humans; Kaplan-Meier Estimate; Lymph Node Excision; Magnetic Resonance Imaging; Mastectomy; Mastectomy, Segmental; Middle Aged; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Neovascularization, Pathologic; Oligopeptides; Organometallic Compounds; Positron Emission Tomography Computed Tomography; Prognosis; Proportional Hazards Models; Prospective Studies; Radiopharmaceuticals; Taxoids | 2016 |
RANK Signaling Blockade Reduces Breast Cancer Recurrence by Inducing Tumor Cell Differentiation.
Topics: Animals; Apoptosis; Ataxin-1; Cell Differentiation; Docetaxel; Female; Humans; Lung Neoplasms; Mammary Neoplasms, Experimental; Mammary Tumor Virus, Mouse; Mice; Mice, Inbred C57BL; Neoplasm Recurrence, Local; Neoplastic Stem Cells; RANK Ligand; Receptor Activator of Nuclear Factor-kappa B; Signal Transduction; Taxoids; Transcription Factor AP-2 | 2016 |
The Utility of Serum CA9 for Prognostication in Prostate Cancer.
Topics: Aged; Antigens, Neoplasm; Antineoplastic Agents; Biomarkers, Tumor; Carbonic Anhydrase IX; Docetaxel; Gene Expression Regulation, Neoplastic; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Phenotype; Prognosis; Prostate-Specific Antigen; Prostatectomy; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Taxoids; Treatment Outcome | 2016 |
Achieved good response of S-1 and docetaxel combination chemotherapy in two patients with metastatic extramammary Paget's disease.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Drug Combinations; Fatal Outcome; Humans; Liver Neoplasms; Male; Neoplasm Recurrence, Local; Oxonic Acid; Paget Disease, Extramammary; Prognosis; Spinal Neoplasms; Tegafur | 2017 |
Induction chemotherapy for the treatment of non-endemic locally advanced nasopharyngeal carcinoma.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Chemoradiotherapy; Cisplatin; Deoxycytidine; Disease Progression; Disease-Free Survival; Docetaxel; Female; Gemcitabine; Humans; Induction Chemotherapy; Kaplan-Meier Estimate; Lymphatic Metastasis; Male; Middle Aged; Multivariate Analysis; Nasopharyngeal Carcinoma; Nasopharyngeal Neoplasms; Neoplasm Recurrence, Local; Neoplasm Staging; Proportional Hazards Models; Retrospective Studies; Risk Factors; Taxoids; Time Factors; Treatment Outcome; Young Adult | 2017 |
Personalized Medicine Approach for an Exceptional Response to Multiple-recurrent and Metastatic HER2-positive Oropharyngeal Squamous Cell Carcinoma.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cetuximab; Chemoradiotherapy; Cisplatin; Docetaxel; Fluorouracil; Humans; Induction Chemotherapy; Lung Neoplasms; Lymph Nodes; Magnetic Resonance Imaging; Male; Mediastinum; Middle Aged; Molecular Targeted Therapy; Neoplasm Recurrence, Local; Oropharyngeal Neoplasms; Positron Emission Tomography Computed Tomography; Precision Medicine; Radiotherapy, Intensity-Modulated; Receptor, ErbB-2; Taxoids; Tomography, X-Ray Computed; Trastuzumab | 2017 |
Successful management of synchronous recurrent breast carcinoma with chronic myelogenous leukemia: a case report.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Chemotherapy, Adjuvant; Docetaxel; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Neoplasm Recurrence, Local; Taxoids; Treatment Outcome | 2017 |
Clinical benefit of nanoparticle albumin-bound-paclitaxel in recurrent/metastatic head and neck squamous cell carcinoma resistant to cremophor-based paclitaxel or docetaxel.
Topics: Adult; Aged; Albumin-Bound Paclitaxel; Antineoplastic Agents; Carcinoma, Squamous Cell; Docetaxel; Drug Resistance, Neoplasm; Female; Head and Neck Neoplasms; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Paclitaxel; Polyethylene Glycols; Retrospective Studies; Squamous Cell Carcinoma of Head and Neck; Taxoids | 2017 |
Prognostic Advantage of Docetaxel/Cisplatin/ 5-Fluorouracil Neoadjuvant Chemotherapy in Clinical Stage II/III Esophageal Squamous Cell Carcinoma due to Excellent Control of Preoperative Disease and Postoperative Lymph Node Recurrence.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Docetaxel; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Esophagectomy; Female; Fluorouracil; Humans; Lymphatic Metastasis; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Neoplasm Staging; Postoperative Period; Preoperative Care; Prognosis; Prospective Studies; Taxoids; Treatment Outcome | 2017 |
Case of angiosarcoma of the scalp successfully controlled by eribulin.
Topics: Aged; Chemoradiotherapy; Docetaxel; Furans; Head and Neck Neoplasms; Hemangiosarcoma; Humans; Ketones; Male; Neoplasm Recurrence, Local; Scalp; Skin; Skin Neoplasms; Treatment Outcome | 2018 |
Current Status of Uterine Leiomyosarcoma in the Tohoku Region: Results of the Tohoku Translational Center Development Network Survey.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Deoxycytidine; Disease-Free Survival; Docetaxel; Female; Gemcitabine; Health Surveys; Humans; Japan; Leiomyosarcoma; Lymph Node Excision; Middle Aged; Neoplasm Recurrence, Local; Prognosis; Retrospective Studies; Taxoids; Uterine Neoplasms | 2017 |
Contrasting roles of the ABCG2 Q141K variant in prostate cancer.
Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily G, Member 2; Docetaxel; Folic Acid; Gene Expression Regulation, Neoplastic; Humans; Male; MicroRNAs; Neoplasm Proteins; Neoplasm Recurrence, Local; Polymorphism, Single Nucleotide; Prostatic Neoplasms; Taxoids | 2017 |
Estrogen receptor expression and efficacy of docetaxel-containing adjuvant chemotherapy in patients with node-positive breast cancer: results from a pooled analysis.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Docetaxel; Female; Follow-Up Studies; Humans; Menopause; Middle Aged; Neoplasm Recurrence, Local; Randomized Controlled Trials as Topic; Receptors, Estrogen; Taxoids | 2008 |
[Adjuvant chemotherapy for breast cancer and targeted therapies].
Topics: Antibiotics, Antineoplastic; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Docetaxel; Doxorubicin; Female; Humans; Neoplasm Recurrence, Local; Paclitaxel; Proportional Hazards Models; Randomized Controlled Trials as Topic; Receptor, ErbB-2; Survival Analysis; Taxoids; Trastuzumab | 2008 |
Tumor heterogeneity in ovarian cancer as demonstrated by in vitro chemoresistance assays.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Docetaxel; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Prospective Studies; Taxoids; Topotecan | 2008 |
Evaluation of combined docetaxel and nedaplatin chemotherapy for recurrent esophageal cancer compared with conventional chemotherapy using cisplatin and 5-fluorouracil: a retrospective study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Cisplatin; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Esophageal Neoplasms; Esophagectomy; Female; Fluorouracil; Follow-Up Studies; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Recurrence, Local; Organoplatinum Compounds; Probability; Retrospective Studies; Risk Assessment; Survival Analysis; Taxoids; Treatment Outcome | 2008 |
[Docetaxel-Cisplatin-5-Fu Combination Chemotherapy as a First-line Treatment in Patients with Metastatic or Recurred Gastric Cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; Fluorouracil; Humans; Neoplasm Metastasis; Neoplasm Recurrence, Local; Stomach Neoplasms; Taxoids; Treatment Outcome | 2007 |
[Combination of docetaxel and capecitabine for the treatment of anthracycline-resistant advanced breast carcinoma].
Topics: Adult; Aged; Agranulocytosis; Anthracyclines; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Docetaxel; Drug Resistance, Neoplasm; Female; Fluorouracil; Follow-Up Studies; Humans; Liver Neoplasms; Lung Neoplasms; Mastectomy; Middle Aged; Neoplasm Recurrence, Local; Quality of Life; Remission Induction; Survival Rate; Taxoids; Vomiting | 2008 |
Docetaxel-cisplatin-radiotherapy in adenoid cystic carcinoma with high-grade transformation.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Adenoid Cystic; Cisplatin; Combined Modality Therapy; Docetaxel; Female; Humans; Magnetic Resonance Imaging; Maxillary Sinus Neoplasms; Middle Aged; Mouth Neoplasms; Neoplasm Recurrence, Local; Radiotherapy, Conformal; Taxoids; Tomography, X-Ray Computed | 2009 |
Second-line combination chemotherapy with docetaxel and nedaplatin for Cisplatin-pretreated refractory metastatic/recurrent esophageal squamous cell carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Docetaxel; Drug Resistance, Neoplasm; Esophageal Neoplasms; Female; Humans; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Organoplatinum Compounds; Prognosis; Salvage Therapy; Survival Rate; Taxoids; Treatment Outcome | 2009 |
Docetaxel for the adjuvant treatment of early node-positive breast cancer: a single technology appraisal.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cost-Benefit Analysis; Cyclophosphamide; Docetaxel; Doxorubicin; Female; Humans; Lymphatic Metastasis; Neoplasm Recurrence, Local; Quality of Life; Randomized Controlled Trials as Topic; Taxoids; Technology Assessment, Biomedical | 2009 |
Safety and efficacy of bidirectional chemotherapy for treatment of patients with peritoneal dissemination from gastric cancer: Selection for cytoreductive surgery.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Cancer, Regional Perfusion; Cisplatin; Combined Modality Therapy; Docetaxel; Female; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Patient Selection; Peritoneal Neoplasms; Prognosis; Stomach Neoplasms; Survival Rate; Taxoids | 2009 |
Successful treatment of syncope with chemotherapy irresponsive to cardiac pacemaker in head and neck cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Docetaxel; Head and Neck Neoplasms; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Pacemaker, Artificial; Radiography; Syncope; Taxoids; Tonsillar Neoplasms | 2009 |
[A case of recurrence gastric cancer patient who was post operated and multi drug chemotherapy was effective for administration of S-1 and docetaxel combination therapy].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Drug Combinations; Gastrectomy; Humans; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Recurrence, Local; Oxonic Acid; Stomach Neoplasms; Taxoids; Tegafur | 2009 |
Re-challenge chemotherapy for relapsed non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Child; Cisplatin; Docetaxel; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Middle Aged; Mitomycin; Neoplasm Recurrence, Local; Retrospective Studies; Survival Rate; Taxoids; Treatment Outcome | 2010 |
Triplet chemotherapy with cisplatin, docetaxel, and irinotecan for patients with recurrent or refractory non-small cell lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Signet Ring Cell; Carcinoma, Squamous Cell; Cisplatin; Docetaxel; Female; Follow-Up Studies; Gefitinib; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Quinazolines; Retrospective Studies; Survival Analysis; Taxoids | 2010 |
Reirradiation with alternating docetaxel-based chemotherapy for recurrent head and neck squamous cell carcinoma: update of a single-center prospective phase II protocol.
Topics: Adolescent; Adult; Aged; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therapy; Docetaxel; Female; Head and Neck Neoplasms; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Radiation-Sensitizing Agents; Radiotherapy; Radiotherapy Dosage; Survival Analysis; Taxoids | 2010 |
Combination therapy with docetaxel and S-1 as a first-line treatment in patients with advanced or recurrent gastric cancer: a retrospective analysis.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Drug Combinations; Female; Follow-Up Studies; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neoplasm Staging; Oxonic Acid; Retrospective Studies; Stomach Neoplasms; Survival Rate; Taxoids; Tegafur; Treatment Outcome | 2010 |
[An elderly hemodialytic case of recurrent esophageal cancer given combination chemotherapy with docetaxel and nedaplatin who showed temporal relief of swallowing disturbance].
Topics: Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Deglutition; Docetaxel; Esophageal Neoplasms; Fatal Outcome; Humans; Male; Myocardial Infarction; Neoplasm Recurrence, Local; Organoplatinum Compounds; Quality of Life; Renal Dialysis; Taxoids; Tomography, X-Ray Computed; Treatment Outcome | 2010 |
Multidrug resistance gene (MDR-1) and risk of brain metastasis in epithelial ovarian, fallopian tube, and peritoneal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Biomarkers, Tumor; Brachytherapy; Brain Neoplasms; Carboplatin; Carcinoma, Ovarian Epithelial; Cisplatin; Cohort Studies; Combined Modality Therapy; Docetaxel; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Fallopian Tube Neoplasms; Female; Follow-Up Studies; Humans; Immunoenzyme Techniques; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Retrospective Studies; Risk Factors; Survival Rate; Taxoids; Treatment Outcome | 2011 |
A cost-effectiveness analysis of docetaxel versus pemetrexed in second-line chemotherapy for stage IIIb or IV non-small cell lung cancer in China.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cost-Benefit Analysis; Disease-Free Survival; Docetaxel; Glutamates; Guanine; Humans; Lung Neoplasms; Neoplasm Recurrence, Local; Neoplasm Staging; Pemetrexed; Platinum Compounds; Retrospective Studies; Taxoids | 2010 |
Potential role of platelet-derived growth factor receptor inhibition using imatinib in combination with docetaxel in the treatment of recurrent non-small cell lung cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Docetaxel; Female; Follow-Up Studies; Humans; Imatinib Mesylate; Immunoenzyme Techniques; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Piperazines; Pyrimidines; Receptors, Platelet-Derived Growth Factor; Survival Rate; Taxoids; Treatment Outcome | 2011 |
Persistent Krüppel-like factor 4 expression predicts progression and poor prognosis of head and neck squamous cell carcinoma.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Blotting, Western; Carcinoma, Squamous Cell; Cell Adhesion; Cell Movement; Cell Proliferation; Cisplatin; Disease Progression; Docetaxel; Drug Resistance, Neoplasm; Female; Fluorouracil; Head and Neck Neoplasms; Humans; Immunoenzyme Techniques; Kruppel-Like Factor 4; Kruppel-Like Transcription Factors; Male; Mice; Mice, Nude; Middle Aged; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Survival Rate; Taxoids; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2011 |
[Docetaxel with concurrent radiotherapy in patients with inoperable or relapsed oesophageal cancer].
Topics: Aged; Antineoplastic Agents; Combined Modality Therapy; Docetaxel; Esophageal Neoplasms; Female; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Taxoids | 2010 |
[A case of recurrent esophageal cancer with tracheal invasion treated by chemo-radiotherapy (CRT) after placement of tracheal stent that maintained complete response (CR) for two years].
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Docetaxel; Esophageal Neoplasms; Fluorouracil; Humans; Male; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Remission Induction; Stents; Taxoids; Trachea; Tracheal Neoplasms; Tracheal Stenosis | 2010 |
[A long-term survival case of local recurrence of breast cancer treated with combined modality therapy].
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Combined Modality Therapy; Docetaxel; Female; Humans; Lymph Node Excision; Mastectomy; Neoplasm Recurrence, Local; Paclitaxel; Tamoxifen; Taxoids; Tegafur; Trastuzumab; Uracil | 2010 |
Adjuvant docetaxel for node-negative breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Disease-Free Survival; Docetaxel; Female; Humans; Intention to Treat Analysis; Neoplasm Recurrence, Local; Recurrence; Taxoids | 2011 |
Successful multimodal treatment of a breast cancer patient with a recurrence invading the chest wall.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Docetaxel; Doxorubicin; Female; Humans; Neoplasm Invasiveness; Neoplasm Metastasis; Neoplasm Recurrence, Local; Plastic Surgery Procedures; Polyethylene Glycols; Ribs; Taxoids; Thoracic Wall | 2011 |
CYP3A4 expression to predict treatment response to docetaxel for metastasis and recurrence of primary breast cancer.
Topics: Adult; Aged; Antineoplastic Agents; Breast Neoplasms; Carcinoma; Cytochrome P-450 CYP3A; Disease Progression; Docetaxel; Drug Screening Assays, Antitumor; Female; Humans; Immunohistochemistry; Lymphatic Metastasis; Middle Aged; Neoplasm Recurrence, Local; Taxoids; Treatment Outcome | 2011 |
Neoadjuvant intraperitoneal and systemic chemotherapy for gastric cancer patients with peritoneal dissemination.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Docetaxel; Feasibility Studies; Female; Fluorouracil; Follow-Up Studies; Gastrectomy; Humans; Lymph Node Excision; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Neoplasm Staging; Peritoneal Neoplasms; Postoperative Complications; Prognosis; Prospective Studies; Stomach Neoplasms; Survival Rate; Taxoids | 2011 |
Proof of activity of anti-epidermal growth factor receptor-targeted therapy for relapsed squamous cell carcinoma of the penis.
Topics: Amputation, Surgical; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Cisplatin; Docetaxel; Drug Administration Schedule; ErbB Receptors; Fluorouracil; Humans; Lymph Node Excision; Lymphatic Metastasis; Male; Middle Aged; Molecular Targeted Therapy; Neoplasm Recurrence, Local; Neoplasm Staging; Panitumumab; Penile Neoplasms; Positron-Emission Tomography; Sentinel Lymph Node Biopsy; Taxoids; Tomography, X-Ray Computed; Treatment Outcome | 2011 |
Evaluating the value of number of cycles of docetaxel and prednisone in men with metastatic castration-resistant prostate cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Clinical Trials as Topic; Disease-Free Survival; Docetaxel; Gossypol; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Prednisone; Prostate-Specific Antigen; Prostatic Neoplasms; Retrospective Studies; Taxoids; Treatment Outcome | 2012 |
Case report: responses to cabazitaxel in metastatic castration-resistant prostate cancer after extensive docetaxel treatment.
Topics: Adenocarcinoma; Androgen Antagonists; Antineoplastic Agents; Combined Modality Therapy; Docetaxel; Drug Resistance, Neoplasm; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Prostatic Neoplasms; Radiotherapy; Taxoids | 2011 |
Retrospective analysis of third-line and fourth-line chemotherapy for advanced non-small-cell lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Docetaxel; Drug Combinations; Female; Follow-Up Studies; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Oxonic Acid; Quinazolines; Retrospective Studies; Taxoids; Tegafur; Treatment Outcome | 2012 |
Long-term results of radiochemotherapy for solitary lymph node metastasis after curative resection of esophageal cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Docetaxel; Esophageal Neoplasms; Esophagectomy; Female; Fluorouracil; Humans; Japan; Lymph Node Excision; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Recurrence, Local; Organoplatinum Compounds; Radiotherapy Dosage; Retrospective Studies; Salvage Therapy; Survival Analysis; Taxoids | 2012 |
A retrospective comparison of docetaxel and paclitaxel for patients with advanced or recurrent esophageal cancer who previously received platinum-based chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Disease-Free Survival; Docetaxel; Esophageal Neoplasms; Female; Follow-Up Studies; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Organoplatinum Compounds; Paclitaxel; Retrospective Studies; Taxoids | 2011 |
Predictive value of peripheral blood lymphocyte count in breast cancer patients treated with primary chemotherapy.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Docetaxel; Doxorubicin; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Lymphocyte Count; Mastectomy; Middle Aged; Multivariate Analysis; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Retrospective Studies; Survival Analysis; Taxoids; Trastuzumab; Treatment Outcome | 2012 |
Salvage chemotherapy for recurrent or persistent clear cell carcinoma of the ovary: a single-institution experience for a series of 20 patients.
Topics: Adenocarcinoma, Clear Cell; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Ovarian Epithelial; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Irinotecan; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Retrospective Studies; Salvage Therapy; Survival Rate; Taxoids | 2013 |
Impact of prophylactic cranial irradiation timing on brain relapse rates in patients with stage IIIB non-small-cell lung carcinoma treated with two different chemoradiotherapy regimens.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Chemoradiotherapy; Cisplatin; Cranial Irradiation; Docetaxel; Female; Humans; Induction Chemotherapy; Lung Neoplasms; Male; Middle Aged; Multivariate Analysis; Neoplasm Recurrence, Local; Retrospective Studies; Taxoids; Time Factors; Turkey; Vinblastine; Vinorelbine | 2012 |
Adjuvant chemoradiotherapy with or without intraoperative radiotherapy for the treatment of resectable locally advanced gastric adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Chi-Square Distribution; Cisplatin; Docetaxel; Female; Fluorouracil; Gastrectomy; Humans; Intraoperative Care; Leucovorin; Male; Middle Aged; Neoplasm Grading; Neoplasm Recurrence, Local; Neoplasm Staging; Postoperative Care; Prognosis; Radiotherapy Dosage; Radiotherapy, Adjuvant; Stomach Neoplasms; Survival Rate; Taxoids; Treatment Outcome | 2012 |
Short-term clinicopathological outcome of neoadjuvant chemohormonal therapy comprising complete androgen blockade, followed by treatment with docetaxel and estramustine phosphate before radical prostatectomy in Japanese patients with high-risk localized p
Topics: Aged; Androgens; Anilides; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Docetaxel; Estramustine; Female; Follow-Up Studies; Humans; Leuprolide; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Neoplasm Staging; Nitriles; Prostate-Specific Antigen; Prostatectomy; Prostatic Neoplasms; Survival Rate; Taxoids; Tosyl Compounds; Treatment Outcome | 2012 |
Gemcitabine with or without docetaxel and resection for recurrent osteosarcoma: the experience at Children's Memorial Hospital.
Topics: Adolescent; Antineoplastic Agents; Bone Neoplasms; Child; Combined Modality Therapy; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Male; Neoplasm Recurrence, Local; Neurosurgical Procedures; Osteosarcoma; Retrospective Studies; Taxoids; Treatment Outcome | 2012 |
Failure patterns and survival in patients with nasopharyngeal carcinoma treated with intensity modulated radiation in Northwest China: a pilot study.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Child; Cisplatin; Docetaxel; Dose-Response Relationship, Radiation; Female; Fluorouracil; Follow-Up Studies; Humans; Lymphatic Metastasis; Male; Middle Aged; Nasopharyngeal Neoplasms; Neoplasm Recurrence, Local; Neoplasm Staging; Radiotherapy Planning, Computer-Assisted; Radiotherapy, Conformal; Radiotherapy, Intensity-Modulated; Retrospective Studies; Survival Rate; Taxoids; Treatment Failure; Young Adult | 2012 |
The role of chemoradiotherapy in patients with unresectable T4 breast tumors.
Topics: Adenocarcinoma, Mucinous; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Chemoradiotherapy; Deoxycytidine; Docetaxel; Female; Fluorouracil; Follow-Up Studies; Humans; Lymphatic Metastasis; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Prognosis; Remission Induction; Survival Rate; Taxoids | 2013 |
Adjuvant chemotherapy decreases and postpones distant metastasis in extremity stage IIB/III synovial sarcoma patients.
Topics: Adult; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Dacarbazine; Deoxycytidine; Disease-Free Survival; Docetaxel; Doxorubicin; Drug Administration Schedule; Extremities; Female; Gemcitabine; Humans; Ifosfamide; Kaplan-Meier Estimate; Male; Mesna; Middle Aged; Neoplasm Grading; Neoplasm Recurrence, Local; Neoplasm Staging; Radiotherapy, Adjuvant; Remission Induction; Sarcoma, Synovial; Soft Tissue Neoplasms; Taxoids | 2012 |
Cutis verticis gyrata secondary to infiltrating ductal carcinoma breast.
Topics: Breast Neoplasms; Carcinoma, Ductal, Breast; Chemotherapy, Adjuvant; Combined Modality Therapy; Docetaxel; Female; Follow-Up Studies; Humans; Hypertrophy; Lung Neoplasms; Mastectomy; Middle Aged; Neoplasm Recurrence, Local; Radiotherapy, Adjuvant; Scalp Dermatoses; Severity of Illness Index; Skin; Taxoids | 2012 |
Long-term outcome of induction chemoradiotherapy with docetaxel and cisplatin followed by surgery for non-small-cell lung cancer with mediastinal lymph node metastasis.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Chemoradiotherapy, Adjuvant; Cisplatin; Disease-Free Survival; Docetaxel; Feasibility Studies; Female; Humans; Japan; Kaplan-Meier Estimate; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Pneumonectomy; Taxoids; Time Factors; Treatment Outcome | 2012 |
Clinical correlates of 'BRCAness' in triple-negative breast cancer of patients receiving adjuvant chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; BRCA1 Protein; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Disease-Free Survival; Docetaxel; Epirubicin; Female; Fluorouracil; Follow-Up Studies; Humans; Kaplan-Meier Estimate; Methotrexate; Middle Aged; Neoplasm Recurrence, Local; Proportional Hazards Models; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Taxoids; Treatment Outcome; Young Adult | 2012 |
Adjuvant chemotherapy for stage I clear cell carcinoma of the ovary: an analysis of fully staged patients.
Topics: Adenocarcinoma, Clear Cell; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Chemotherapy, Adjuvant; Cisplatin; Docetaxel; Female; Follow-Up Studies; Humans; Irinotecan; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Postoperative Care; Prognosis; Retrospective Studies; Survival Rate; Taxoids | 2012 |
Cabazitaxel rechallenge at prostate-specific antigen relapse after previous cabazitaxel and docetaxel chemotherapy: case report.
Topics: Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Docetaxel; Drug Resistance, Neoplasm; Fatal Outcome; Humans; Male; Neoplasm Recurrence, Local; Prednisolone; Prostate-Specific Antigen; Prostatic Neoplasms; Taxoids; Treatment Outcome | 2012 |
Efficacy and safety of gemcitabine-docetaxel combination therapy for recurrent or refractory high-grade osteosarcoma in China: a retrospective study of 18 patients.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; China; Deoxycytidine; Disease Progression; Docetaxel; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Grading; Neoplasm Recurrence, Local; Osteosarcoma; Retrospective Studies; Salvage Therapy; Taxoids; Treatment Outcome | 2012 |
Experience with combination of docetaxel, cisplatin plus 5-fluorouracil chemotherapy, and intensity-modulated radiotherapy for locoregionally advanced nasopharyngeal carcinoma.
Topics: Adult; Aged; Carcinoma; Cisplatin; Combined Modality Therapy; Disease-Free Survival; Docetaxel; Drug-Related Side Effects and Adverse Reactions; Female; Fluorouracil; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Nasopharyngeal Carcinoma; Nasopharyngeal Neoplasms; Neoplasm Recurrence, Local; Radiotherapy, Intensity-Modulated; Taxoids; Treatment Outcome | 2013 |
A combined therapy with docetaxel and nedaplatin for relapsed and metastatic esophageal carcinoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Esophageal Neoplasms; Female; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Organoplatinum Compounds; Taxoids | 2012 |
Malignant fibrous histiocytoma of the ovary: a case report.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Deoxycytidine; Docetaxel; Fatal Outcome; Female; Gemcitabine; Histiocytoma, Malignant Fibrous; Humans; Lung Neoplasms; Neoplasm Recurrence, Local; Ovarian Neoplasms; Taxoids | 2012 |
Failure event types and prognostic factors after node-positive breast cancer in patients treated by adjuvant chemotherapy: impact on follow-up.
Topics: Adult; Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Disease-Free Survival; Docetaxel; Epirubicin; Female; Fluorouracil; Follow-Up Studies; Humans; Lymph Nodes; Melphalan; Middle Aged; Mitoxantrone; Neoplasm Recurrence, Local; Prognosis; Randomized Controlled Trials as Topic; Taxoids; Treatment Failure | 2012 |
An immunohistochemical signature comprising PTEN, MYC, and Ki67 predicts progression in prostate cancer patients receiving adjuvant docetaxel after prostatectomy.
Topics: Aged; Antineoplastic Agents; Biomarkers, Tumor; Combined Modality Therapy; Disease Progression; Disease-Free Survival; Docetaxel; Follow-Up Studies; Humans; Immunoenzyme Techniques; Ki-67 Antigen; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Prospective Studies; Prostatectomy; Prostatic Neoplasms; Proto-Oncogene Proteins c-myc; PTEN Phosphohydrolase; Survival Rate; Taxoids; Tumor Suppressor Protein p53 | 2012 |
Case involving long-term survival after esophageal cancer with liver and lung metastases treated by multidisciplinary therapy: report of a case.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Catheter Ablation; Chemotherapy, Adjuvant; Cisplatin; Combined Modality Therapy; Docetaxel; Esophageal Neoplasms; Esophagectomy; Fluorouracil; Hepatectomy; Humans; Liver Neoplasms; Lung Neoplasms; Lymph Node Excision; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Pneumonectomy; Taxoids; Time Factors | 2013 |
Aldehyde dehydrogenase 1 expression is associated with poor prognosis in patients with esophageal squamous cell carcinoma.
Topics: Aged; Aldehyde Dehydrogenase 1 Family; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Squamous Cell; Case-Control Studies; Chi-Square Distribution; Cisplatin; Disease-Free Survival; Docetaxel; Esophageal Neoplasms; Esophagectomy; Female; Fluorouracil; Humans; Hyaluronan Receptors; Isoenzymes; Kaplan-Meier Estimate; Male; Middle Aged; Multivariate Analysis; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Proportional Hazards Models; Retinal Dehydrogenase; Retrospective Studies; Taxoids | 2013 |
Leiomyosarcoma of the sigmoid colon with multiple liver metastases and gastric cancer: a case report.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Docetaxel; Drug Combinations; Fatal Outcome; Female; Humans; Immunohistochemistry; Leiomyosarcoma; Liver Neoplasms; Neoplasm Recurrence, Local; Oxonic Acid; Sigmoid Neoplasms; Stomach Neoplasms; Taxoids; Tegafur | 2012 |
Selective small molecule Stat3 inhibitor reduces breast cancer tumor-initiating cells and improves recurrence free survival in a human-xenograft model.
Topics: Adipose Tissue; Animals; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Disease Models, Animal; Disease-Free Survival; Docetaxel; Drug Resistance, Neoplasm; Female; Humans; Kaplan-Meier Estimate; Mice; Mice, SCID; Neoplasm Recurrence, Local; Neoplastic Stem Cells; Small Molecule Libraries; STAT3 Transcription Factor; Taxoids; Time Factors; Tumor Burden; Xenograft Model Antitumor Assays | 2012 |
Induction chemoradiotherapy is superior to induction chemotherapy for the survival of non-small-cell lung cancer patients with pathological mediastinal lymph node metastasis.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Chemoradiotherapy, Adjuvant; Chemotherapy, Adjuvant; Cisplatin; Disease-Free Survival; Docetaxel; Female; Humans; Induction Chemotherapy; Irinotecan; Kaplan-Meier Estimate; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Multivariate Analysis; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Neoplasm Staging; Pneumonectomy; Proportional Hazards Models; Radiation Dosage; Risk Factors; Taxoids; Time Factors; Treatment Outcome | 2012 |
A patient with simultaneously appearing adenocarcinoma and small-cell lung carcinoma harbouring an identical EGFR exon 19 mutation.
Topics: Adenocarcinoma; Adult; Antineoplastic Agents; Cisplatin; Deoxycytidine; Docetaxel; ErbB Receptors; Erlotinib Hydrochloride; Female; Gemcitabine; Humans; Lung Neoplasms; Mutation; Neoplasm Recurrence, Local; Quinazolines; Small Cell Lung Carcinoma; Taxoids | 2012 |
Successful response to docetaxel treatment in recurrent ovarian granulosa cell tumor: a case report.
Topics: Aged; Antineoplastic Agents; Docetaxel; Female; Granulosa Cell Tumor; Humans; Neoplasm Recurrence, Local; Ovarian Neoplasms; Taxoids | 2012 |
Clinical usefulness of human epidermal growth factor receptor-2 extracellular domain as a biomarker for monitoring cancer status and predicting the therapeutic efficacy in breast cancer.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Capecitabine; Carcinoma, Ductal, Breast; Deoxycytidine; Disease-Free Survival; Docetaxel; Drug Resistance, Neoplasm; Female; Fluorouracil; Humans; Kaplan-Meier Estimate; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Protein Structure, Tertiary; Receptor, ErbB-2; Taxoids; Trastuzumab; Treatment Outcome | 2013 |
Long-term survival outcomes with intravesical docetaxel for recurrent nonmuscle invasive bladder cancer after previous bacillus Calmette-Guérin therapy.
Topics: Adjuvants, Immunologic; Administration, Intravesical; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; BCG Vaccine; Docetaxel; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Humans; Incidence; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Prospective Studies; Survival Rate; Taxoids; Time Factors; Treatment Outcome; United States; Urinary Bladder; Urinary Bladder Neoplasms | 2013 |
MEK inhibition as a strategy for targeting residual breast cancer cells with low DUSP4 expression.
Topics: Antineoplastic Agents; Benzimidazoles; Breast Neoplasms; Cell Proliferation; Docetaxel; Drug Resistance, Neoplasm; Drug Synergism; Dual-Specificity Phosphatases; Extracellular Signal-Regulated MAP Kinases; Female; Humans; MAP Kinase Signaling System; Mitogen-Activated Protein Kinase Phosphatases; Mitogen-Activated Protein Kinases; Neoplasm Recurrence, Local; Neoplasm, Residual; Protein Kinase Inhibitors; Proto-Oncogene Proteins p21(ras); RNA Interference; Taxoids | 2012 |
Neoadjuvant chemotherapy with docetaxel-cisplatin in patients with stage III N2 non-small-cell lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Cisplatin; Docetaxel; Female; Follow-Up Studies; Humans; Lung Neoplasms; Lymphatic Metastasis; Male; Mediastinum; Middle Aged; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Retrospective Studies; Survival Rate; Taxoids | 2013 |
Results of chemoselection with short induction chemotherapy followed by chemoradiation or surgery in the treatment of functionally inoperable carcinomas of the pharynx and larynx.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma; Chemoradiotherapy; Cisplatin; Disease-Free Survival; Docetaxel; Endoscopy; Feasibility Studies; Female; Humans; Induction Chemotherapy; Laryngeal Neoplasms; Male; Middle Aged; Multimodal Imaging; Neoplasm Recurrence, Local; Neoplasm Staging; Organ Sparing Treatments; Pharyngeal Neoplasms; Positron-Emission Tomography; Remission Induction; Salvage Therapy; Survival Rate; Taxoids; Time Factors; Tomography, X-Ray Computed; Treatment Outcome | 2013 |
Effectiveness of doxifluridine (5'-DFUR)/docetaxel against advanced/recurrent gastric cancer showing resistance to various anticancer drug regimens.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Drug Resistance, Neoplasm; Fatal Outcome; Floxuridine; Gastrectomy; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Stomach Neoplasms; Taxoids | 2002 |
A retrospective analysis of the outcome of patients who have received two prior chemotherapy regimens including platinum and docetaxel for recurrent non-small-cell lung cancer.
Topics: Adult; Aged; Carcinoma, Non-Small-Cell Lung; Disease Progression; Docetaxel; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Platinum; Retrospective Studies; Survival Rate; Taxoids; Time Factors; Treatment Outcome | 2003 |
Docetaxel and carboplatin combination chemotherapy for recurrent endometrial cancer.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Docetaxel; Endometrial Neoplasms; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Taxoids; Tomography, X-Ray Computed | 2003 |
[Combined usage of taxotere in induction chemotherapy of head and neck neoplasms].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; Female; Fluorouracil; Head and Neck Neoplasms; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Taxoids | 2003 |
Extraorbital sebaceous carcinoma with rapidly developing visceral metastases.
Topics: Aged; Antineoplastic Agents, Phytogenic; Docetaxel; Fatal Outcome; Female; Humans; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neoplasms, Glandular and Epithelial; Orbit; Paclitaxel; Sebaceous Gland Neoplasms; Taxoids; Viscera | 2003 |
A primary retroperitoneal serous cystadenocarcinoma with clinically aggressive behavior.
Topics: Adult; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; CA-125 Antigen; CA-19-9 Antigen; Carboplatin; Cystadenocarcinoma, Serous; Docetaxel; Female; Humans; Liver Neoplasms; Magnetic Resonance Imaging; Mesentery; Neoplasm Recurrence, Local; Pelvic Neoplasms; Retroperitoneal Neoplasms; Taxoids; Tomography, X-Ray Computed | 2004 |
[Cryoimmunological therapy with local injection of OK-432 against advance or recurrent breast cancer].
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cisplatin; Combined Modality Therapy; Cryosurgery; Docetaxel; Drug Administration Schedule; Epirubicin; Female; Fluorouracil; Humans; Injections, Intralesional; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Picibanil; Taxoids | 2003 |
[Preliminary evaluation of chemotherapy with docetaxel, 5-FU, CDDP for recurrent esophageal cancer--a pilot study].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; Drug Administration Schedule; Esophageal Neoplasms; Fluorouracil; Humans; Leukopenia; Lymph Nodes; Lymphatic Metastasis; Male; Middle Aged; Nausea; Neoplasm Recurrence, Local; Neoplastic Cells, Circulating; Pilot Projects; Prognosis; Taxoids | 2003 |
Effect of re-treatment with gefitinib ('Iressa', ZD1839) after acquisition of resistance.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Disease Progression; Docetaxel; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; Humans; Irinotecan; Lung Neoplasms; Male; Neoplasm Metastasis; Neoplasm Recurrence, Local; Protein-Tyrosine Kinases; Quinazolines; Retreatment; Taxoids | 2004 |
The use of contrast-enhanced computed tomography before neoadjuvant chemotherapy to identify patients likely to be treated safely with breast-conserving surgery.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Doxorubicin; Female; Humans; Mammography; Mastectomy, Segmental; Middle Aged; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Taxoids; Tomography, X-Ray Computed | 2004 |
A case of radiation recall mucositis associated with docetaxel.
Topics: Antineoplastic Agents, Phytogenic; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Combined Modality Therapy; Docetaxel; Humans; Inflammation; Male; Middle Aged; Mucous Membrane; Neoplasm Recurrence, Local; Radiation-Sensitizing Agents; Radiodermatitis; Radiotherapy, Adjuvant; Taxoids; Tongue Neoplasms | 2004 |
Preoperative concurrent chemoradiotherapy with cisplatin and docetaxel in patients with locally advanced non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Combined Modality Therapy; Docetaxel; Feasibility Studies; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Pleural Effusion; Postoperative Complications; Preoperative Care; Survival Rate; Taxoids | 2004 |
Weekly taxanes--a leap forward or a minute progress?
Topics: Adult; Aged; Breast Neoplasms; Chemotherapy, Adjuvant; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Mastectomy; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Prognosis; Randomized Controlled Trials as Topic; Risk Assessment; Survival Analysis; Taxoids; Treatment Outcome | 2004 |
[Retrospective analysis on efficacy and toxicity of paclitaxel-containing treatments in patients with advanced or recurrent breast cancer].
Topics: Adult; Aged; Aged, 80 and over; Anthracyclines; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Docetaxel; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Humans; Liver Neoplasms; Middle Aged; Nausea; Neoplasm Recurrence, Local; Paclitaxel; Peripheral Nervous System Diseases; Proportional Hazards Models; Retrospective Studies; Survival Rate; Taxoids; Trastuzumab; Vomiting, Anticipatory | 2004 |
Successful treatment of pulmonary metastasis and local recurrence of angiosarcoma with docetaxel.
Topics: Diagnosis, Differential; Docetaxel; Hemangiosarcoma; Humans; Lung Neoplasms; Magnetic Resonance Imaging; Male; Middle Aged; Neoplasm Recurrence, Local; Scalp; Skin Neoplasms; Taxoids; Tomography, X-Ray Computed | 2004 |
Treatment issues in pediatric gastric adenocarcinoma.
Topics: Anastomosis, Roux-en-Y; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Signet Ring Cell; Catheter Ablation; Chemotherapy, Adjuvant; Child; Cisplatin; Combined Modality Therapy; Docetaxel; Female; Fluorouracil; Gastrectomy; Gastritis; Helicobacter Infections; Helicobacter pylori; Humans; Irinotecan; Liver Neoplasms; Lymph Node Excision; Neoplasm Recurrence, Local; Neoplastic Syndromes, Hereditary; Pancreatectomy; Prognosis; Radiation-Sensitizing Agents; Radiotherapy, Adjuvant; Remission Induction; Reoperation; Splenectomy; Stomach Neoplasms; Taxoids | 2004 |
[A case of recurrent gastric cancer tolerant to TS-1 therapy successfully treated by TS-1 combined with docetaxel].
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Docetaxel; Drug Administration Schedule; Drug Combinations; Drug Resistance, Neoplasm; Gastrectomy; Humans; Lymph Nodes; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Recurrence, Local; Oxonic Acid; Pancreatectomy; Pyridines; Splenectomy; Stomach Neoplasms; Taxoids; Tegafur | 2004 |
Efficacy of docetaxel as a second-line chemotherapy for thymic carcinoma.
Topics: Antineoplastic Agents, Phytogenic; Carcinoma, Squamous Cell; Cervical Vertebrae; Docetaxel; Female; Humans; Mediastinal Neoplasms; Mediastinum; Middle Aged; Neoplasm Recurrence, Local; Salvage Therapy; Spinal Neoplasms; Taxoids; Thymoma; Thymus Neoplasms; Tomography, X-Ray Computed; Treatment Outcome | 2004 |
Prediction of response to docetaxel by immunohistochemical analysis of CYP3A4 expression in human breast cancers.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Docetaxel; Female; Humans; Immunohistochemistry; Middle Aged; Neoplasm Recurrence, Local; Predictive Value of Tests; Taxoids | 2005 |
[Multi-target tumor therapy].
Topics: Antimetabolites, Antineoplastic; Asbestosis; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase III as Topic; Docetaxel; Enzyme Inhibitors; Glutamates; Guanine; Humans; Lung Neoplasms; Mesothelioma; Neoplasm Recurrence, Local; Pemetrexed; Pleural Neoplasms; Survival Rate; Taxoids; Treatment Outcome | 2005 |
A pilot study of weekly docetaxel therapy for recurrent ovarian cancer, tubal cancer, and primary peritoneal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Biomarkers, Tumor; CA-125 Antigen; Docetaxel; Drug Administration Schedule; Fallopian Tube Neoplasms; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Pilot Projects; Platinum Compounds; Taxoids; Treatment Outcome | 2005 |
Combined-modality treatment for isolated recurrences of breast carcinoma: update on 30 years of experience at the University of Texas M.D. Anderson Cancer Center and assessment of prognostic factors.
Topics: Adult; Aged; Aged, 80 and over; Breast Neoplasms; Clinical Trials as Topic; Combined Modality Therapy; Docetaxel; Doxorubicin; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Proportional Hazards Models; Receptors, Estrogen; Taxoids | 2005 |
Sphingosine kinase-1 as a chemotherapy sensor in prostate adenocarcinoma cell and mouse models.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents, Phytogenic; Apoptosis; Blotting, Western; Camptothecin; Ceramides; Disease Models, Animal; Docetaxel; Flow Cytometry; Green Fluorescent Proteins; Humans; Lysophospholipids; Male; Mice; Mice, Nude; Microscopy, Fluorescence; Neoplasm Recurrence, Local; Neoplasms, Hormone-Dependent; Phosphotransferases (Alcohol Group Acceptor); Prostatic Neoplasms; RNA Interference; Sphingosine; Taxoids; Tumor Cells, Cultured | 2005 |
Neoadjuvant interstitial high-dose-rate (HDR) brachytherapy combined with systemic chemotherapy in patients with breast cancer.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; Breast; Breast Neoplasms; Carcinoma, Ductal; Carcinoma, Lobular; Cisplatin; Combined Modality Therapy; Cyclophosphamide; Docetaxel; Dose Fractionation, Radiation; Doxorubicin; Epirubicin; Female; Fluorouracil; Follow-Up Studies; Humans; Lymphatic Metastasis; Mastectomy, Segmental; Methotrexate; Middle Aged; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Neoplasm Staging; Radiotherapy Dosage; Radiotherapy Planning, Computer-Assisted; Retrospective Studies; Risk Factors; Taxoids; Time Factors; Tomography, X-Ray Computed; Treatment Outcome | 2006 |
Radiation therapy for T2N0 laryngeal cancer: A retrospective analysis for the impact of concurrent chemotherapy on local control.
Topics: Aged; Aged, 80 and over; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therapy; Disease-Free Survival; Docetaxel; Female; Glottis; Humans; Laryngeal Neoplasms; Male; Middle Aged; Multivariate Analysis; Neoplasm Recurrence, Local; Radiotherapy Dosage; Remission Induction; Retrospective Studies; Survival Rate; Taxoids; Voice Quality | 2006 |
Bevacizumab and weekly taxane chemotherapy demonstrates activity in refractory ovarian cancer.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Bevacizumab; Combined Modality Therapy; Docetaxel; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Taxoids | 2006 |
[First observations of the dose-dense weekly docetaxel therapy in relapsed ovarian cancer].
Topics: Aged; Antineoplastic Agents, Phytogenic; Disease-Free Survival; Docetaxel; Drug Administration Schedule; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Retrospective Studies; Taxoids; Treatment Outcome | 2006 |
Predictive value of D-dimer plasma levels in response and progressive disease in patients with lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Bridged-Ring Compounds; Camptothecin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Deoxycytidine; Disease Progression; Docetaxel; Female; Fibrin Fibrinogen Degradation Products; Gemcitabine; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Patient Compliance; Predictive Value of Tests; Prospective Studies; Survival Analysis; Taxoids; Treatment Outcome; Vinblastine | 2006 |
Efficacy of taxotere in the post-prostatectomy setting.
Topics: Docetaxel; Humans; Male; Neoplasm Recurrence, Local; Prostatic Neoplasms; Randomized Controlled Trials as Topic; Taxoids | 2006 |
[AUO study in hormone-refractory prostate cancer. Phase III study on treatment of hormone-refractory prostate cancer (HRPC) with docetaxel: continuous treatment vs. intermittent repetition of treatment after renewed progression--PRINCE].
Topics: Androgen Antagonists; Antineoplastic Agents; Clinical Trials, Phase III as Topic; Disease Progression; Docetaxel; Drug Administration Schedule; Drug Resistance, Neoplasm; Humans; Male; Neoplasm Recurrence, Local; Prostatic Neoplasms; Taxoids | 2006 |
[Examination of the safety of docetaxel/cyclophosphamide combination therapy for advanced recurrent breast cancer].
Topics: Adult; Alopecia; Anemia; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Cyclophosphamide; Docetaxel; Drug Administration Schedule; Female; Granulocyte Colony-Stimulating Factor; Humans; Lung Neoplasms; Lymph Nodes; Lymphatic Metastasis; Middle Aged; Neoplasm Recurrence, Local; Neutropenia; Retrospective Studies; Skin Neoplasms; Stomatitis; Taxoids | 2006 |
Combination chemotherapy with docetaxel and nedaplatin for recurrent esophageal cancer in an outpatient setting.
Topics: Aged; Aged, 80 and over; Ambulatory Care; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Docetaxel; Esophageal Neoplasms; Esophagectomy; Feasibility Studies; Female; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Organoplatinum Compounds; Taxoids | 2006 |
Basal cell carcinoma metastatic to cervical lymph nodes and lungs.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biopsy, Fine-Needle; Carboplatin; Carcinoma, Basal Cell; Carcinoma, Papillary; Deoxycytidine; Diagnostic Errors; Docetaxel; Gemcitabine; Head and Neck Neoplasms; Humans; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Neck Dissection; Neoplasm Recurrence, Local; Neoplasms, Second Primary; Radiotherapy; Seminoma; Skin Neoplasms; Taxoids; Testicular Neoplasms; Thyroid Neoplasms; Thyroidectomy; Unnecessary Procedures | 2006 |
Dose escalation study of docetaxel and nedaplatin in patients with relapsed or refractory squamous cell carcinoma of the esophagus pretreated using cisplatin, 5-fluorouracil, and radiation.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Docetaxel; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Esophageal Neoplasms; Female; Fluorouracil; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Organoplatinum Compounds; Remission Induction; Salvage Therapy; Taxoids | 2006 |
Late recurrence of a prostatic adenocarcinoma as a solitary splenic metastasis.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Diagnosis, Differential; Docetaxel; Follow-Up Studies; Humans; Male; Neoplasm Recurrence, Local; Prostatectomy; Prostatic Neoplasms; Radiation-Sensitizing Agents; Splenectomy; Splenic Neoplasms; Taxoids; Tomography, X-Ray Computed | 2007 |
[A case report of small cell carcinoma of the esophagus successfully treated by irinotecan and cisplatin].
Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Small Cell; Cisplatin; Docetaxel; Esophageal Neoplasms; Humans; Irinotecan; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Recurrence, Local; Taxoids | 2006 |
Lack of effective systemic therapy for recurrent clear cell carcinoma of the ovary.
Topics: Adenocarcinoma, Clear Cell; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Cyclophosphamide; Docetaxel; Drug Resistance, Neoplasm; Female; Humans; Melphalan; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Taxoids | 2007 |
[A feasible study of docetaxel/nedaplatin combined chemotherapy for relapsed or refractory esophageal cancer patients as a 2nd-line chemotherapy].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Combined Modality Therapy; Docetaxel; Drug Administration Schedule; Esophageal Neoplasms; Feasibility Studies; Humans; Infusions, Intravenous; Lymph Nodes; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Recurrence, Local; Organoplatinum Compounds; Taxoids | 2007 |
Melanoma-associated antigen-A1 expression predicts resistance to docetaxel and paclitaxel in advanced and recurrent gastric cancer.
Topics: Antigens, Neoplasm; Antineoplastic Agents; Blotting, Western; Cell Line, Tumor; Cell Proliferation; DNA Methylation; Docetaxel; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Humans; Immunohistochemistry; Melanoma-Specific Antigens; Neoplasm Proteins; Neoplasm Recurrence, Local; Paclitaxel; Polymerase Chain Reaction; Predictive Value of Tests; Prognosis; Stomach Neoplasms; Taxoids; Transfection | 2007 |
Single-agent docetaxel in patients with platinum-refractory metastatic or recurrent squamous cell carcinoma of the head and neck (SCCHN).
Topics: Antineoplastic Agents; Carcinoma, Squamous Cell; Docetaxel; Drug Tolerance; Head and Neck Neoplasms; Humans; Neoplasm Metastasis; Neoplasm Recurrence, Local; Platinum; Retrospective Studies; Taxoids; Treatment Outcome | 2007 |
[Docetaxel-cisplatin-5-FU combination chemotherapy as a first-line treatment in patients with metastatic or recurred gastric cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; Female; Fluorouracil; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Retrospective Studies; Stomach Neoplasms; Survival Analysis; Taxoids | 2007 |
Progression of disease despite good endoscopic local control of upper tract urothelial carcinoma.
Topics: Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Papillary; Carcinoma, Transitional Cell; Chemotherapy, Adjuvant; Combined Modality Therapy; Deoxycytidine; Disease Progression; Docetaxel; Electrocoagulation; Gemcitabine; Humans; Kidney Neoplasms; Kidney Pelvis; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Neoplasm Recurrence, Local; Nephrectomy; Paclitaxel; Taxoids; Ureteroscopy | 2007 |
Erlotinib, docetaxel, and gefitinib in sequential cohorts with relapsed non-small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Docetaxel; ErbB Receptors; Erlotinib Hydrochloride; Female; Follow-Up Studies; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Protein Kinase Inhibitors; Quinazolines; Radiation-Sensitizing Agents; Retrospective Studies; Survival Rate; Taxoids; Treatment Outcome | 2008 |
Weekly epirubicin plus docetaxel as first-line treatment in metastatic breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Epirubicin; Female; Humans; Kaplan-Meier Estimate; Middle Aged; Neoplasm Recurrence, Local; Taxoids | 2007 |
Second-line combination chemotherapy with docetaxel for cisplatin-pretreated refractory metastatic esophageal cancer: a preliminary report of initial experience.
Topics: Adrenal Gland Neoplasms; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Cisplatin; Docetaxel; Esophageal Neoplasms; Feasibility Studies; Female; Fluorouracil; Humans; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Recurrence, Local; Salvage Therapy; Survival Rate; Taxoids; Treatment Outcome | 2007 |
Death of a clinical trial: a speculative inclusion criterion gone wrong.
Topics: Antineoplastic Agents; Australia; Chemotherapy, Adjuvant; Diphosphonates; Docetaxel; Humans; Imidazoles; Male; Multicenter Studies as Topic; Neoplasm Recurrence, Local; Prostate-Specific Antigen; Prostatectomy; Prostatic Neoplasms; Randomized Controlled Trials as Topic; Reverse Transcriptase Polymerase Chain Reaction; Taxoids; Zoledronic Acid | 2007 |
Comparison among different classification systems regarding the pathological response of preoperative chemotherapy in relation to the long-term outcome.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Combined Modality Therapy; Cyclophosphamide; Disease-Free Survival; Docetaxel; Doxorubicin; Drug Monitoring; Estrogens; Female; Fluorouracil; Follow-Up Studies; Humans; Japan; Lymphatic Metastasis; Mastectomy; Methotrexate; Middle Aged; Neoadjuvant Therapy; Neoplasm Proteins; Neoplasm Recurrence, Local; Neoplasms, Hormone-Dependent; Paclitaxel; Progesterone; Prognosis; Retrospective Studies; Taxoids; Trastuzumab; Treatment Outcome | 2009 |
Biological therapy of salivary duct carcinoma.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Ductal; Combined Modality Therapy; Docetaxel; Humans; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Recurrence, Local; Parotid Neoplasms; Taxoids; Trastuzumab; Treatment Outcome | 2009 |
Pathological lymph node involvement at surgery is a significant predictive factor of recurrence in locally advanced breast cancer treated with concomitant epirubicin-docetaxel neoadjuvant chemotherapy: a cohort study.
Topics: Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Axilla; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Cohort Studies; Disease-Free Survival; Docetaxel; Epirubicin; Female; Humans; Lymphatic Metastasis; Middle Aged; Multivariate Analysis; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Retrospective Studies; Taxoids | 2009 |
CA 125: a misleading tumor marker?
Topics: Antineoplastic Agents, Phytogenic; CA-125 Antigen; Cystadenocarcinoma, Mucinous; Docetaxel; Female; Humans; Lymphatic Metastasis; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Taxoids | 1996 |
Activity and toxicity of docetaxel (Taxotere) in women with previously treated metastatic breast cancer.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Ascites; Breast Neoplasms; Docetaxel; Edema; Female; Humans; Infusions, Intravenous; Middle Aged; Neoplasm Recurrence, Local; Neutropenia; Paclitaxel; Pleural Effusion; Taxoids; Treatment Failure; Treatment Outcome | 1997 |
[Breast cancer with liver metastasis responsive to docetaxel: case report].
Topics: Alopecia; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Docetaxel; Drug Administration Schedule; Female; Humans; Leukopenia; Liver Neoplasms; Lymphatic Metastasis; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Taxoids | 1998 |
[Pharmacological study of weekly docetaxel in patients with metastatic breast cancer].
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Docetaxel; Drug Administration Schedule; Feasibility Studies; Female; Humans; Infusions, Intravenous; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Taxoids | 1999 |
[Effective alendronate therapy against a bone metastasis occurring during docetaxel therapy for breast cancer--a case report].
Topics: Aged; Alendronate; Antineoplastic Agents, Phytogenic; Bone Neoplasms; Breast Neoplasms; Docetaxel; Female; Humans; Neoplasm Recurrence, Local; Paclitaxel; Taxoids | 1999 |
[Administration of docetaxel in cases of recurrent breast carcinoma with malignant pleural effusion controlled by intrapleural administration of OK-432].
Topics: Adenocarcinoma; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Docetaxel; Drug Administration Schedule; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Picibanil; Pleura; Pleural Effusion, Malignant; Taxoids | 1999 |
[A case of recurrent breast cancer with carcinoma erysipeloides responding to sequential therapy with docetaxel (TXT) and doxifluridine (5'-DFUR) accompanied by leucovorin (LV)].
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma; Cyclophosphamide; Docetaxel; Doxorubicin; Drug Administration Schedule; Female; Floxuridine; Fluorouracil; Humans; Injections, Intra-Arterial; Leucovorin; Mastectomy; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Skin Neoplasms; Taxoids | 2000 |
Concurrent radiation therapy and paclitaxel or docetaxel chemotherapy in high-risk breast cancer.
Topics: Adult; Aged; Analysis of Variance; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Docetaxel; Drug Administration Schedule; Feasibility Studies; Female; Follow-Up Studies; Humans; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Radiation-Sensitizing Agents; Radiotherapy Dosage; Retrospective Studies; Taxoids | 2000 |
[Refractory non-small-cell lung cancer responding to combination chemotherapy with docetaxel, gemcitabine and cisplatin].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Deoxycytidine; Docetaxel; Drug Administration Schedule; Drug Resistance, Neoplasm; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Taxoids | 2001 |
[Two cases of advanced and metastatic breast cancers treated by docetaxel in combination with intra-arterial infusion of adriamycin].
Topics: Adult; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Doxorubicin; Female; Humans; Infusions, Intra-Arterial; Infusions, Intravenous; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Taxoids | 2001 |
Prediction of chemotherapeutic response by collagen gel droplet embedded culture-drug sensitivity test in human breast cancers.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Biopsy; Breast Neoplasms; Collagen; Cyclophosphamide; Docetaxel; Drug Screening Assays, Antitumor; Epirubicin; Female; Gels; Humans; Immunoenzyme Techniques; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Predictive Value of Tests; Taxoids | 2002 |